[CLS]
Approximately
60
%
of
the
treated
patients
were
male
,
with
a
mean
age
of
55
.
1
years
.
[SEP]
[CLS]
The
table
below
lists
the
adverse
drug
reactions
that
occurred
in
at
least
1
%
of
patients
treated
with
Fe
##rri
##p
##ro
##x
in
clinical
trials
.
[SEP]
[CLS]
5
.
9
Progressive
Multi
##fo
##cal
Le
##uk
##oe
##nce
##pha
##lop
##athy
J
##C
virus
infection
resulting
in
PM
##L
and
death
has
been
reported
in
AD
##CE
##TR
##IS
-
treated
patients
.
[SEP]
[CLS]
If
a
patient
develops
skin
disco
##lora
##tion
,
serious
consideration
should
be
given
to
changing
to
an
alternate
medication
.
[SEP]
[CLS]
5
.
8
He
##pa
##to
##to
##xi
##city
Ser
##ious
cases
of
he
##pa
##to
##to
##xi
##city
,
including
fatal
outcomes
,
have
occurred
in
patients
receiving
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
*
T
##iss
##ue
inflammation
as
well
as
pro
##static
h
##yper
##p
##lasia
have
been
associated
with
false
positive
11
C
-
ch
##olin
##e
P
##ET
images
.
[SEP]
[CLS]
Inter
##rup
##t
or
disco
##ntin
##ue
Z
##yd
##eli
##g
as
recommended
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
These
data
reflect
exposure
of
92
##3
patients
to
T
##AN
##Z
##E
##UM
and
a
mean
duration
of
exposure
to
T
##AN
##Z
##E
##UM
of
93
weeks
.
[SEP]
[CLS]
Table
2
:
Se
##vere
to
Fat
##al
I
##mm
##une
-
mediated
Ad
##verse
Re
##actions
in
Study
1
a
Including
fatal
outcome
.
[SEP]
[CLS]
(
5
.
1
)
item
{
Cat
##ara
##cts
-
Use
of
co
##rt
##ico
##ster
##oids
may
result
in
posterior
sub
##cap
##sul
##ar
cat
##ara
##ct
formation
.
[SEP]
[CLS]
5
.
4
Tu
##mor
L
##ys
##is
S
##yn
##drome
Tu
##mor
l
##ys
##is
syndrome
(
T
##LS
)
,
which
may
be
life
-
threatening
or
fatal
,
has
been
observed
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
*
He
##pa
##tic
toxicity
[
see
Do
##sa
##ge
and
Administration
(
2
.
5
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Pat
##ients
received
G
##IL
##OT
##RI
##F
40
mg
daily
until
documented
disease
progression
or
into
##ler
##ance
to
the
therapy
.
[SEP]
[CLS]
5
.
8
Contact
Len
##s
We
##ar
D
##UR
##E
##Z
##OL
should
not
be
ins
##til
##led
while
wearing
contact
lenses
.
[SEP]
[CLS]
(
5
.
1
)
*
He
##mor
##r
##hage
:
Se
##vere
,
sometimes
fatal
,
hem
##or
##r
##hage
including
hem
##op
##ty
##sis
and
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
occurred
in
3
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
of
Volume
De
##ple
##tion
##V
##ol
##ume
de
##ple
##tion
includes
reports
of
de
##hy
##dra
##tion
,
h
##y
##po
##vo
##lem
##ia
,
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
or
h
##y
##pot
##ens
##ion
.
[SEP]
[CLS]
To
adjust
for
normal
growth
,
z
-
scores
were
derived
(
measured
in
standard
de
##viation
##s
[
SD
]
)
,
which
normal
##ize
for
the
natural
growth
of
p
##ediatric
patients
by
comparisons
[SEP]
[CLS]
to
age
-
and
sex
-
matched
population
standards
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
[SEP]
[CLS]
exposure
.
[SEP]
[CLS]
Pat
##ients
with
MC
##L
who
develop
l
##ymph
##oc
##yt
##osis
greater
than
400
,
000
/
m
##c
##L
have
developed
in
##tra
##c
##rani
##al
hem
##or
##r
##hage
,
let
##har
##gy
,
g
##ait
instability
,
and
headache
.
[SEP]
[CLS]
The
median
age
of
patients
treated
with
D
##AL
##VA
##NC
##E
was
47
years
,
ranging
between
16
and
93
years
old
.
[SEP]
[CLS]
Ce
##r
##vic
##al
D
##ys
##ton
##ia
About
3
%
of
subjects
developed
antibodies
(
binding
or
neutral
##izing
)
over
time
with
D
##Y
##SP
##OR
##T
(
r
)
treatment
.
[SEP]
[CLS]
(
6
.
2
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Jan
##ssen
Products
,
LP
at
1
-
800
-
J
##AN
##SS
##EN
(
1
-
800
-
52
##6
-
77
##36
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
laboratory
abnormal
##ity
(
incidence
>
=
3
%
)
was
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Ser
##ious
,
life
-
threatening
events
of
her
##pes
simple
##x
infections
,
including
cases
of
en
##ce
##pha
##lit
##is
and
multi
##or
##gan
failure
,
have
occurred
with
G
##IL
##EN
##Y
##A
0
.
5
mg
in
the
post
##market
##ing
setting
.
[SEP]
[CLS]
In
general
,
limiting
the
dose
injected
into
the
stern
##oc
##le
##ido
##mas
##to
##id
muscle
may
decrease
the
occurrence
of
d
##ys
##pha
##gia
.
[SEP]
[CLS]
Use
of
S
##IM
##PO
##NI
ARIA
in
patients
under
18
years
of
age
has
not
been
established
.
[SEP]
[CLS]
5
.
3
Inter
##st
##iti
##al
Lu
##ng
Disease
(
IL
##D
)
IL
##D
or
IL
##D
-
like
adverse
reactions
(
e
.
g
.
,
lung
in
##fi
##ltration
,
p
##ne
##um
##oni
##tis
,
acute
respiratory
distress
syndrome
,
or
al
##ve
##oli
##tis
all
##ergic
)
occurred
[SEP]
[CLS]
in
1
.
5
%
of
the
38
##65
patients
who
received
G
##IL
##OT
##RI
##F
across
clinical
trials
;
of
these
,
0
.
4
%
were
fatal
.
[SEP]
[CLS]
The
incidence
of
adverse
reactions
associated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
is
shown
in
Table
2
.
[SEP]
[CLS]
These
metabolic
changes
include
h
##yper
##gly
##ce
##mia
,
d
##ys
##lip
##ide
##mia
,
and
weight
gain
.
[SEP]
[CLS]
P
##ul
##mona
##ry
em
##bol
##ism
was
fatal
in
2
%
(
1
/
55
)
of
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
The
median
time
to
onset
of
card
##io
##my
##op
##athy
in
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
was
86
days
(
range
:
27
to
253
days
)
.
[SEP]
[CLS]
For
U
##L
##OR
##IC
40
mg
,
55
##9
patients
were
treated
for
>
=
6
months
.
[SEP]
[CLS]
J
##E
##V
##TA
##NA
is
con
##tra
##ind
##ica
##ted
in
patients
with
ne
##ut
##rop
##hil
counts
of
<
=
1
,
500
cells
/
mm
3
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
proportion
of
subjects
who
received
a
trans
##fusion
for
the
management
of
an
##emia
was
3
%
of
subjects
treated
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
to
less
than
[SEP]
[CLS]
1
%
in
subjects
who
received
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
*
Per
##form
test
for
late
##nt
T
##B
;
if
positive
,
start
treatment
for
T
##B
prior
to
starting
S
##IM
##PO
##NI
ARIA
(
5
.
1
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
*
The
most
frequently
reported
adverse
reactions
(
>
=
5
%
)
in
clinical
trials
were
h
##yper
##sen
##si
##ti
##vity
reactions
and
included
:
an
##aph
##yla
##xi
##s
,
[SEP]
[CLS]
r
##ash
,
p
##yre
##xia
,
flush
##ing
/
feeling
hot
,
u
##rt
##ica
##ria
,
headache
,
h
##yper
##hi
##dr
##osis
,
nausea
,
cough
,
decreased
oxygen
sat
##uration
,
ta
##chy
##card
##ia
,
ta
##chy
##p
##nea
,
chest
discomfort
,
di
##zzi
##ness
,
[SEP]
[CLS]
muscle
twitch
##ing
,
agitation
,
c
##yan
##osis
,
er
##yt
##hem
##a
,
h
##yper
##tens
##ion
/
increased
blood
pressure
,
p
##allo
##r
,
rig
##ors
,
t
##rem
##or
,
vomit
##ing
,
fatigue
,
and
my
##al
##gia
(
6
.
1
)
.
[SEP]
[CLS]
5
.
2
Con
##com
##ita
##nt
Use
of
C
##YP
##3
##A
##4
In
##hibit
##ors
ST
##EN
##DR
##A
metabolism
is
principally
mediated
by
the
C
##YP
##45
##0
is
##of
##orm
3
##A
##4
(
C
##YP
##3
##A
##4
)
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
End
##op
##ht
##hal
##mit
##is
and
re
##tina
##l
detachment
##s
may
occur
following
in
##tra
##vi
##tre
##al
injection
##s
.
[SEP]
[CLS]
Skin
and
Sub
##cut
##aneous
T
##iss
##ue
Di
##sor
##ders
:
al
##ope
##cia
,
an
##gio
-
ed
##ema
,
der
##mat
##itis
,
der
##mo
##graph
##ism
,
e
##cc
##hy
##mos
##is
,
e
##cz
##ema
,
hair
color
changes
,
hair
growth
abnormal
,
h
##yper
##hi
##dr
##osis
,
[SEP]
[CLS]
p
##eel
##ing
skin
,
pet
##ech
##iae
,
photos
##ens
##iti
##vity
,
p
##ru
##rit
##us
,
pu
##rp
##ura
,
skin
disco
##lora
##tion
,
skin
les
##ion
,
skin
odor
abnormal
,
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Call
your
doctor
for
medical
advice
about
side
effects
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
In
addition
,
one
D
##AL
##VA
##NC
##E
-
treated
subject
in
a
Phase
1
trial
had
post
-
base
##line
AL
##T
elevations
greater
than
20
times
U
##L
##N
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
art
##hr
##itis
,
joint
stiff
##ness
,
joint
swelling
,
muscle
spa
##sm
##s
,
m
##us
##cu
##los
##kel
##etal
pain
,
my
##al
##gia
.
[SEP]
[CLS]
If
such
a
reaction
occurs
,
therapy
with
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
should
be
stopped
at
once
and
alternative
treatments
should
be
considered
.
[SEP]
[CLS]
There
were
no
differences
in
efficacy
or
safety
between
patients
with
or
without
im
##mu
##nor
##ea
##ct
##ivity
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
Risk
of
T
##hy
##roid
C
-
cell
Tu
##mor
##s
Car
##cin
##ogenic
##ity
of
al
##bi
##g
##lut
##ide
could
not
be
assessed
in
rode
##nts
due
to
the
rapid
development
of
drug
-
clearing
,
anti
-
drug
antibodies
[
see
[SEP]
[CLS]
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
Higher
than
recommended
dos
##ing
or
repeated
dos
##ing
appears
to
increase
the
risk
(
5
.
1
)
*
h
##yper
##sen
##si
##ti
##vity
reactions
with
cut
##aneous
manifest
##ations
,
ranging
from
mild
to
severe
,
including
[SEP]
[CLS]
death
,
have
occurred
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
,
and
treat
promptly
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Most
commonly
reported
adverse
reactions
were
flush
##ing
(
2
%
)
,
headache
(
1
%
)
,
increased
blood
pressure
(
2
%
)
[SEP]
[CLS]
,
nausea
(
1
%
)
,
and
di
##zzi
##ness
(
1
%
)
.
[SEP]
[CLS]
Have
an
##aph
##yla
##ctic
and
h
##yper
##sen
##si
##ti
##vity
treatment
measures
available
prior
to
Da
##T
##sca
##n
administration
.
[SEP]
[CLS]
No
neutral
##izing
antibodies
were
detected
.
[SEP]
[CLS]
Pat
##ients
were
between
the
ages
of
18
and
69
on
the
date
of
the
first
dose
of
CE
##RD
##EL
##GA
,
and
included
87
females
and
72
males
.
[SEP]
[CLS]
P
##sor
##ias
##is
Clinical
Trials
The
safety
of
O
##TE
##Z
##LA
(
r
)
was
assessed
in
142
##6
subjects
in
3
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trials
in
adult
subjects
with
moderate
to
severe
[SEP]
[CLS]
plaque
ps
##oria
##sis
who
were
candidates
for
photo
##ther
##ap
##y
or
systemic
therapy
.
[SEP]
[CLS]
The
incidence
of
IL
##D
appeared
to
be
higher
in
patients
of
Asian
ethnicity
(
2
.
1
%
)
as
compared
to
non
-
Asian
##s
(
1
.
2
%
)
.
[SEP]
[CLS]
Monitor
patients
during
and
for
an
appropriate
period
of
time
after
administration
of
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Use
with
caution
in
patients
at
risk
for
gas
##tro
##int
##est
##inal
per
##fo
##ration
or
fist
##ula
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
in
P
##ediatric
Pat
##ients
During
clinical
trials
,
141
p
##ediatric
patients
(
7
aged
<
24
months
,
33
aged
2
-
5
years
,
58
aged
6
-
[SEP]
[CLS]
11
years
and
43
aged
12
-
17
)
received
D
##OT
##AR
##EM
.
[SEP]
[CLS]
(
5
.
14
,
8
.
1
)
5
.
1
Card
##iac
To
##xi
##ci
##ties
worse
##ning
of
pre
-
existing
cardiac
failure
(
e
.
g
.
,
con
##ges
##tive
heart
failure
,
pulmonary
ed
##ema
,
decreased
e
##jection
fraction
)
,
[SEP]
[CLS]
restrict
##ive
card
##io
##my
##op
##athy
,
my
##oc
##ard
##ial
is
##che
##mia
,
and
my
##oc
##ard
##ial
in
##far
##ction
including
fatalities
have
occurred
following
administration
of
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
In
some
cases
,
h
##yper
##gly
##ce
##mia
has
resolved
when
the
at
##y
##pical
anti
##psy
##cho
##tic
was
discontinued
;
however
,
some
patients
required
continuation
of
anti
-
di
##abe
##tic
treatment
despite
disco
##ntin
##uation
of
the
anti
##psy
##cho
##tic
drug
.
[SEP]
[CLS]
Pat
##ients
with
unstable
or
poorly
controlled
h
##yper
##tens
##ion
,
a
recent
history
of
card
##iovascular
or
c
##ere
##bro
##vas
##cular
events
may
be
at
an
increased
risk
of
adverse
card
##iovascular
effects
.
[SEP]
[CLS]
In
the
patients
with
AP
C
##ML
and
BP
C
##ML
,
the
median
duration
of
B
##OS
##U
##L
##IF
treatment
was
10
months
and
3
months
,
respectively
.
[SEP]
[CLS]
Administration
of
cab
##azi
##ta
##xe
##l
to
patients
with
mild
and
moderate
he
##pa
##tic
imp
##air
##ment
should
be
undertaken
with
caution
and
close
monitoring
of
safety
.
[SEP]
[CLS]
Pat
##ients
treated
with
D
##AL
##VA
##NC
##E
were
predominantly
male
(
60
%
)
and
Caucasian
(
78
%
)
.
[SEP]
[CLS]
Pat
##ients
with
acute
respiratory
illness
may
be
at
risk
of
serious
acute
ex
##ace
##rb
##ation
of
their
respiratory
compromise
due
to
h
##yper
##sen
##si
##ti
##vity
reactions
,
and
require
additional
monitoring
[
see
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
The
population
was
almost
entirely
Caucasian
(
99
%
)
with
a
median
age
of
51
years
(
range
18
-
82
years
)
.
[SEP]
[CLS]
Although
there
were
few
non
-
Caucasian
patients
,
no
differences
in
the
incidence
##s
of
adverse
reactions
compared
to
Caucasian
patients
were
observed
.
[SEP]
[CLS]
5
.
7
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
T
##R
##U
##L
##IC
##IT
##Y
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
*
XI
##AF
##LE
##X
is
available
for
the
treatment
of
P
##ey
##ron
##ie
'
s
disease
only
through
a
restricted
program
called
the
XI
##AF
##LE
##X
R
##EM
##S
Program
(
5
.
3
)
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
##ap
##p
##rov
##al
use
of
Y
##ER
##VO
##Y
.
[SEP]
[CLS]
A
##pp
##rop
##ria
##te
prop
##hyl
##actic
measures
,
including
pre
##tre
##at
##ment
non
##to
##xi
##c
c
##yt
##ored
##uction
and
on
-
treatment
h
##yd
##ration
,
should
be
used
for
the
prevention
of
T
##LS
during
B
##L
##IN
##C
##Y
##TO
treatment
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
Anti
##bo
##dies
directed
against
the
be
##lat
##ace
##pt
molecule
were
assessed
in
39
##8
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
in
Studies
1
and
2
(
212
of
these
patients
were
treated
[SEP]
[CLS]
for
at
least
2
years
)
.
[SEP]
[CLS]
If
this
product
is
used
for
10
days
or
longer
,
I
##OP
should
be
monitored
.
[SEP]
[CLS]
(
5
.
5
)
*
Q
##T
pro
##long
##ation
:
Q
##T
interval
should
be
monitored
in
patients
taking
con
##com
##ita
##nt
medications
known
to
increase
the
Q
##T
interval
or
with
certain
heart
conditions
.
[SEP]
[CLS]
Beta
-
ago
##nist
medications
may
produce
trans
##ient
h
##yper
##gly
##ce
##mia
in
some
patients
.
[SEP]
[CLS]
Amy
##vid
caused
no
serious
adverse
reactions
in
the
studies
and
the
reported
adverse
reactions
were
predominantly
mild
to
moderate
in
severity
.
[SEP]
[CLS]
However
,
an
earlier
onset
can
not
be
ruled
out
,
and
it
is
possible
that
re
##tina
##l
abnormal
##ities
were
present
earlier
in
the
course
of
exposure
to
P
##OT
##IG
##A
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
from
NO
##RT
##H
##ER
##A
were
h
##yper
##tens
##ion
or
increased
blood
pressure
and
nausea
.
[SEP]
[CLS]
5
.
6
Effects
on
A
##bility
to
Drive
and
Use
Machine
##s
Due
to
the
potential
for
ne
##uro
##log
##ic
events
,
including
seizure
##s
,
patients
receiving
B
##L
##IN
##C
##Y
##TO
are
at
risk
for
[SEP]
[CLS]
loss
of
consciousness
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
6
.
3
I
##mm
##uno
##genic
##ity
During
clinical
studies
in
Du
##pu
##yt
##ren
'
s
contract
##ure
and
P
##ey
##ron
##ie
'
s
disease
,
patients
were
tested
at
multiple
time
points
for
antibodies
to
the
protein
components
of
XI
##AF
##LE
##X
(
[SEP]
[CLS]
AU
##X
-
I
and
AU
##X
-
II
)
.
[SEP]
[CLS]
With
##hold
then
dose
reduce
,
or
permanently
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
The
most
common
reasons
for
interrupt
##ion
or
disco
##ntin
##uations
were
di
##ar
##r
##hea
(
11
%
)
,
pneumonia
(
11
%
)
,
and
elevated
trans
##ami
##nas
##es
(
10
%
)
.
[SEP]
[CLS]
First
onset
of
symptoms
occurred
at
various
times
from
initiation
of
AD
##CE
##TR
##IS
therapy
,
with
some
cases
occurring
within
3
months
of
initial
exposure
.
[SEP]
[CLS]
Among
patients
in
whom
the
status
of
both
m
##uc
##ous
membrane
disco
##lora
##tion
and
re
##tina
##l
pig
##mentary
abnormal
##ities
are
reported
,
approximately
a
quarter
of
those
with
m
##uc
##ous
membrane
disco
##lora
##tion
had
concurrent
[SEP]
[CLS]
re
##tina
##l
pig
##mentary
abnormal
##ities
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
who
have
been
previously
maintained
on
20
mg
or
more
of
pre
##dn
##ison
##e
(
or
its
equivalent
)
may
be
most
susceptible
,
particularly
when
their
systemic
co
##rt
##ico
##ster
##oids
have
been
[SEP]
[CLS]
almost
completely
withdrawn
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
connect
##ive
tissue
disorders
:
my
##os
##itis
,
ch
##ond
##rop
##athy
,
t
##rism
##us
.
[SEP]
[CLS]
Monitor
lip
##ase
and
am
##yla
##se
prior
to
treatment
and
periodically
thereafter
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Consider
the
diagnosis
of
PM
##L
in
any
patient
presenting
with
new
-
onset
signs
and
symptoms
of
central
nervous
system
abnormal
##ities
.
[SEP]
[CLS]
Live
##r
Fun
##ction
Test
A
##b
##nor
##mal
##ities
:
Among
patients
with
Grade
0
or
1
AL
##T
levels
at
base
##line
,
18
%
of
H
##AL
##AV
##EN
-
treated
patients
experienced
Grade
2
or
greater
AL
##T
elevation
.
[SEP]
[CLS]
R
##E
-
CO
##VE
##R
and
R
##E
-
CO
##VE
##R
II
studies
compared
PR
##AD
##A
##X
##A
150
mg
twice
daily
and
war
##fari
##n
for
the
treatment
of
deep
vein
th
##rom
##bos
##is
and
pulmonary
em
##bol
##ism
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
##are
discussed
elsewhere
in
the
label
##ing
:
*
N
##ep
##hr
##ogenic
systemic
fi
##bro
##sis
(
N
##SF
)
[
see
Box
##ed
Warning
and
Warning
##s
and
Pre
##ca
##ution
##s
(
[SEP]
[CLS]
5
.
1
)
]
*
H
##yper
##sen
##si
##ti
##vity
reactions
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
incidence
>
=
[SEP]
[CLS]
0
.
5
%
)
are
nausea
,
headache
,
feeling
hot
,
di
##zzi
##ness
,
and
back
pain
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Bay
##er
Health
##C
##are
Ph
##arma
##ce
##utical
##s
Inc
.
[SEP]
[CLS]
at
1
-
88
##8
-
84
-
BA
##Y
##ER
(
1
-
88
##8
-
84
##2
-
29
##37
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Monitor
patients
for
signs
and
symptoms
of
infection
and
treat
appropriately
.
[SEP]
[CLS]
Monitor
laboratory
parameters
(
including
,
but
not
limited
to
,
white
blood
cell
count
and
absolute
ne
##ut
##rop
##hil
count
)
during
B
##L
##IN
##C
##Y
##TO
in
##fusion
.
[SEP]
[CLS]
Three
of
these
6
patients
tested
positive
for
neutral
##izing
antibodies
.
[SEP]
[CLS]
The
mean
age
of
participants
was
55
years
,
1
%
of
participants
were
75
years
or
older
and
53
%
of
participants
were
male
.
[SEP]
[CLS]
The
median
time
to
onset
of
any
ne
##uro
##logical
toxicity
was
7
days
.
[SEP]
[CLS]
Sign
##s
and
symptoms
of
h
##y
##po
##nat
##rem
##ia
include
headache
,
difficulty
concentrating
,
memory
imp
##air
##ment
,
confusion
,
weakness
,
and
un
##stead
##iness
,
which
can
lead
to
falls
.
[SEP]
[CLS]
(
5
.
6
)
*
Extra
##vas
##ation
:
As
##sure
good
ve
##nous
access
and
monitor
in
##fusion
site
during
and
after
administration
.
[SEP]
[CLS]
Table
6
:
Weight
Change
Results
Cat
##ego
##riz
##ed
by
B
##MI
at
Basel
##ine
:
Co
##mp
##ara
##tor
-
Control
##led
52
-
Week
Study
in
Adults
with
Sc
##hi
##zophrenia
B
##MI
<
23
SA
##P
##H
##RI
##S
N
=
295
B
##MI
23
-
<
=
27
SA
##P
##H
##RI
##S
[SEP]
[CLS]
N
=
290
B
##MI
>
27
SA
##P
##H
##RI
##S
N
=
302
Mean
change
from
Basel
##ine
(
kg
)
1
.
7
1
0
%
with
>
=
7
%
increase
in
body
weight
22
%
13
%
9
[SEP]
[CLS]
%
P
##ediatric
Pat
##ients
:
Data
on
mean
changes
in
body
weight
and
the
proportion
of
p
##ediatric
patients
meeting
a
weight
gain
criterion
of
>
=
7
%
of
body
weight
from
[SEP]
[CLS]
the
short
-
term
,
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
trial
are
presented
in
Table
7
.
[SEP]
[CLS]
5
.
5
Gen
##ital
My
##cot
##ic
In
##fect
##ions
IN
##VO
##KA
##NA
increases
the
risk
of
g
##eni
##tal
my
##cot
##ic
infections
.
[SEP]
[CLS]
Table
1
In
##ves
##ti
##gat
##or
Assessment
of
Maxim
##al
Local
Skin
Re
##actions
in
the
Treatment
Area
during
the
57
Days
Post
Treatment
Period
(
face
/
scalp
trials
)
Face
and
Sc
##al
##p
(
n
=
54
##5
)
[SEP]
[CLS]
Pi
##cat
##o
(
r
)
gel
,
0
.
01
##5
%
once
daily
for
3
days
Skin
reactions
Any
Grade
##a
>
Basel
##ine
Grade
4
87
(
32
%
)
3
(
1
%
[SEP]
[CLS]
)
1
(
0
%
)
0
(
0
%
)
a
Mi
##ld
(
grade
1
)
,
Mode
##rate
(
grade
2
-
3
)
or
Se
##vere
(
grade
4
)
.
[SEP]
[CLS]
The
median
daily
dose
of
T
##AF
##IN
##LA
##R
was
300
mg
(
range
:
118
to
300
mg
)
.
[SEP]
[CLS]
5
.
5
Met
##ab
##olic
Changes
At
##y
##pical
anti
##psy
##cho
##tic
drugs
have
been
associated
with
metabolic
changes
that
may
increase
card
##iovascular
/
c
##ere
##bro
##vas
##cular
risk
.
[SEP]
[CLS]
Pain
increases
occurring
during
patch
application
usually
began
to
resolve
after
patch
removal
.
[SEP]
[CLS]
5
.
4
Ta
##rdi
##ve
D
##ys
##kin
##esi
##a
A
syndrome
of
potentially
i
##rre
##versible
,
in
##vo
##lu
##ntary
,
d
##ys
##kin
##etic
movements
can
develop
in
patients
treated
with
anti
##psy
##cho
##tic
drugs
.
[SEP]
[CLS]
Inc
##rease
##s
in
Low
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
(
L
##D
##L
-
C
)
and
non
-
High
-
Den
##sity
Li
##pop
##rote
##in
Cho
##les
##tero
##l
(
non
-
HD
##L
-
C
)
In
the
pool
of
four
place
##bo
-
controlled
trials
,
dose
-
related
increases
in
L
##D
##L
-
C
with
IN
##VO
##KA
##NA
were
[SEP]
[CLS]
observed
.
[SEP]
[CLS]
Upper
Lim
##b
Spa
##stic
##ity
From
230
subjects
treated
with
D
##Y
##SP
##OR
##T
(
r
)
and
tested
for
the
presence
of
binding
antibodies
,
5
subjects
were
positive
at
base
##line
and
17
developed
[SEP]
[CLS]
antibodies
after
treatment
.
[SEP]
[CLS]
*
Use
with
caution
in
patients
with
compromised
respiratory
function
or
d
##ys
##pha
##gia
(
5
.
4
)
.
[SEP]
[CLS]
All
other
ch
##em
##otherapy
was
continued
according
to
the
patient
'
s
prescribed
treatment
regime
##n
[
see
Clinical
Studies
(
14
)
]
.
Study
2
enrolled
30
patients
[
29
were
being
[SEP]
[CLS]
treated
for
AL
##L
and
one
for
l
##ymph
##ob
##lastic
l
##ymph
##oma
(
L
##BL
)
]
following
all
##er
##gy
to
native
E
.
co
##li
as
##par
##agi
##nas
##e
or
p
##eg
##as
##par
##gas
##e
.
[SEP]
[CLS]
The
risk
of
developing
ta
##rdi
##ve
d
##ys
##kin
##esi
##a
and
the
likelihood
that
it
will
become
i
##rre
##versible
are
believed
to
increase
as
the
duration
of
treatment
and
the
total
cumulative
dose
of
anti
##psy
##cho
##tic
[SEP]
[CLS]
administered
increases
.
[SEP]
[CLS]
One
of
these
events
was
fatal
.
[SEP]
[CLS]
In
un
##ap
##p
##roved
uses
,
including
spa
##stic
##ity
in
children
and
adults
,
and
in
approved
indication
##s
,
symptoms
consistent
with
spread
of
to
##xin
effect
have
been
reported
at
doses
comparable
to
[SEP]
[CLS]
or
lower
than
doses
used
to
treat
c
##er
##vic
##al
d
##ys
##ton
##ia
.
[SEP]
[CLS]
5
.
3
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
(
N
##MS
)
A
potentially
fatal
s
##ym
##pt
##om
complex
sometimes
referred
to
as
N
##eur
##ole
##ptic
Mali
##gnant
S
##yn
##drome
(
N
##MS
)
has
been
reported
in
association
with
administration
of
[SEP]
[CLS]
anti
##psy
##cho
##tic
drugs
,
including
FA
##NA
##P
##T
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
during
evaluation
of
patients
with
suspected
IL
##D
,
and
disco
##ntin
##ue
G
##IL
##OT
##RI
##F
in
patients
with
confirmed
IL
##D
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
be
##lim
##uma
##b
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
6
.
2
I
##mm
##uno
##genic
##ity
Across
repeated
treatment
in
the
controlled
trials
,
4
patients
tested
positive
for
anti
-
i
##cat
##iba
##nt
antibodies
.
[SEP]
[CLS]
In
addition
,
the
incidence
of
Grade
1
-
3
palm
##ar
-
plant
##ar
er
##yt
##hr
##ody
##ses
##the
##sia
syndrome
was
7
%
.
[SEP]
[CLS]
Two
percent
(
4
of
183
)
of
subjects
had
a
Grade
3
to
4
treatment
-
emerge
##nt
hem
##ato
##logy
laboratory
abnormal
##ity
,
with
ne
##ut
##rop
##enia
(
2
%
[
3
of
183
]
[SEP]
[CLS]
)
being
the
most
frequently
reported
.
[SEP]
[CLS]
5
.
9
In
##fusion
Re
##actions
In
##fusion
reactions
,
including
life
-
threatening
reactions
,
have
occurred
in
patients
receiving
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
5
.
2
Effects
on
Ser
##um
Live
##r
B
##io
##chemist
##ries
in
Pat
##ients
with
He
##pa
##titis
B
or
C
Co
-
infection
Pat
##ients
with
underlying
he
##pa
##titis
B
or
C
may
be
at
increased
risk
for
worse
##ning
or
development
[SEP]
[CLS]
of
trans
##ami
##nas
##e
elevations
with
use
of
T
##I
##VI
##CA
##Y
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
(
6
)
S
##J
##IA
:
The
most
common
adverse
drug
reactions
greater
than
10
%
reported
by
patients
with
S
##J
##IA
treated
with
IL
##AR
##IS
are
infections
(
na
##so
##pha
##ryn
##git
##is
and
[SEP]
[CLS]
upper
respiratory
tract
infections
)
,
abdominal
pain
and
injection
site
reactions
.
[SEP]
[CLS]
The
most
frequently
observed
adverse
drug
reactions
in
subjects
receiving
N
##eur
##ace
##q
were
injection
site
reactions
.
[SEP]
[CLS]
For
these
patients
,
a
reduction
in
the
quantity
of
concurrently
administered
lip
##ids
may
be
necessary
to
compensate
for
the
amount
of
lip
##id
in
##fused
as
part
of
the
C
##lev
##ip
##re
##x
formulation
[SEP]
[CLS]
.
[SEP]
[CLS]
The
majority
of
these
reports
have
occurred
in
patients
who
received
con
##com
##ita
##nt
im
##mu
##nos
##up
##press
##ants
.
[SEP]
[CLS]
Some
patients
with
h
##yper
##sen
##si
##ti
##vity
reactions
also
reported
a
history
of
all
##er
##gy
to
other
mac
##rol
##ides
.
[SEP]
[CLS]
For
cases
of
Grade
3
non
-
infectious
p
##ne
##um
##oni
##tis
interrupt
A
##FI
##NI
##TO
##R
until
resolution
to
less
than
or
equal
to
Grade
1
.
[SEP]
[CLS]
*
Inc
##reased
risk
for
developing
post
-
transplant
l
##ymph
##op
##rol
##ifer
##ative
disorder
(
PT
##LD
)
,
predominantly
involving
the
central
nervous
system
(
C
##NS
)
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
E
##L
##I
##Q
##UI
##S
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
(
B
)
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
For
U
##L
##OR
##IC
80
mg
,
137
##7
subjects
were
treated
for
>
=
6
months
,
67
##4
patients
were
treated
for
>
=
1
year
and
51
##5
patients
were
treated
for
>
=
2
[SEP]
[CLS]
years
.
[SEP]
[CLS]
*
He
##pa
##to
##to
##xi
##city
:
Monitor
liver
enzymes
and
bi
##li
##ru
##bin
(
5
.
8
)
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Gen
##zy
##me
at
1
-
800
-
74
##5
-
44
##47
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
[SEP]
[CLS]
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
[SEP]
[CLS]
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Re
##fer
to
the
pre
##s
##cribing
information
for
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
for
additional
information
regarding
dose
reduction
or
disco
##ntin
##uation
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
greater
than
or
equal
to
2
%
)
include
headache
,
flush
##ing
,
nasal
congestion
,
na
##so
##pha
##ryn
##git
##is
,
and
[SEP]
[CLS]
back
pain
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
1
-
87
##7
-
66
##3
-
04
##12
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
*
Talk
with
your
healthcare
provider
regularly
about
whether
you
should
continue
taking
D
##U
##AV
##EE
.
[SEP]
[CLS]
R
##iba
##vir
##in
dose
reduction
is
recommended
for
the
initial
management
of
an
##emia
.
[SEP]
[CLS]
Pat
##ients
should
be
instructed
about
non
-
p
##har
##ma
##co
##log
##ic
interventions
that
help
to
reduce
the
occurrence
of
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
(
e
.
g
.
,
sitting
on
the
edge
of
the
bed
for
several
minutes
before
[SEP]
[CLS]
attempting
to
stand
in
the
morning
and
slowly
rising
from
a
seated
position
)
.
[SEP]
[CLS]
If
bi
##li
##ru
##bin
is
elevated
,
perform
fraction
##ation
.
[SEP]
[CLS]
Laboratory
Para
##meter
##s
:
activated
partial
th
##rom
##bo
##p
##last
##in
time
prolonged
,
c
##rea
##tine
increased
,
bi
##car
##bon
##ate
decreased
,
sodium
increased
,
E
##EG
abnormal
,
glucose
increased
,
ch
##ole
##ster
##ol
increased
,
t
##rig
##ly
##cer
##ides
increased
,
[SEP]
[CLS]
am
##yla
##se
increased
,
potassium
increased
,
T
##S
##H
increased
,
plate
##let
count
decreased
,
hem
##ato
##c
##rit
decreased
,
hem
##og
##lo
##bin
decreased
,
MC
##V
increased
,
RB
##C
decreased
,
c
##rea
##tin
##ine
increased
,
[SEP]
[CLS]
blood
u
##rea
increased
,
B
##UN
/
c
##rea
##tin
##ine
ratio
increased
,
CP
##K
)
increased
,
al
##kal
##ine
p
##hos
##pha
##tase
increased
,
L
##D
##H
increased
,
PS
##A
increased
,
urine
output
increased
,
l
##ymph
##oc
##yte
count
decreased
,
[SEP]
[CLS]
ne
##ut
##rop
##hil
count
decreased
,
W
##BC
increased
,
co
##agu
##lation
test
abnormal
,
L
##D
##L
)
increased
,
pro
##th
##rom
##bin
time
prolonged
,
u
##rina
##ry
casts
,
urine
positive
for
white
blood
cells
.
[SEP]
[CLS]
Se
##vere
h
##yper
##sen
##si
##ti
##vity
reactions
require
immediate
disco
##ntin
##uation
of
the
J
##E
##V
##TA
##NA
in
##fusion
and
appropriate
therapy
.
[SEP]
[CLS]
Do
not
use
D
##U
##AV
##EE
for
a
condition
for
which
it
was
not
prescribed
.
[SEP]
[CLS]
Ad
##verse
reactions
led
to
treatment
disco
##ntin
##uation
in
32
%
of
AD
##CE
##TR
##IS
-
treated
patients
in
Study
3
.
[SEP]
[CLS]
In
a
3
-
week
,
bi
##pol
##ar
man
##ia
p
##ediatric
trial
,
the
incidence
of
adverse
events
related
to
abnormal
pro
##la
##ct
##in
levels
were
0
%
in
the
SA
##P
##H
##RI
##S
2
.
5
mg
twice
daily
treatment
[SEP]
[CLS]
group
,
2
%
in
the
SA
##P
##H
##RI
##S
5
mg
twice
daily
treatment
group
,
and
1
%
in
the
SA
##P
##H
##RI
##S
10
mg
twice
daily
treatment
group
versus
to
1
%
[SEP]
[CLS]
for
patients
treated
with
place
##bo
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Po
##tas
##sium
levels
should
be
within
the
normal
range
prior
to
administration
of
M
##U
##LT
##A
##Q
and
maintained
in
the
normal
range
during
administration
of
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
5
.
2
B
##lee
##ding
E
##L
##I
##Q
##UI
##S
increases
the
risk
of
bleeding
and
can
cause
serious
,
potentially
fatal
,
bleeding
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
and
##A
##d
##verse
Re
##actions
(
6
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
5
.
3
H
##y
##po
##gly
##ce
##mia
with
Con
##com
##ita
##nt
Use
of
In
##sul
##in
Secret
##ago
##gues
or
In
##sul
##in
The
risk
of
h
##y
##po
##gly
##ce
##mia
is
increased
when
T
##AN
##Z
##E
##UM
is
used
in
combination
with
insulin
secret
##ago
##gues
(
e
.
g
.
,
su
##lf
##ony
##lu
##rea
##s
)
[SEP]
[CLS]
or
insulin
.
[SEP]
[CLS]
The
risk
of
these
events
may
be
increased
by
the
post
##oper
##ative
use
of
in
##d
##well
##ing
e
##pid
##ural
cat
##he
##ters
or
the
con
##com
##ita
##nt
use
of
medicinal
products
affecting
hem
##ost
##asis
.
[SEP]
[CLS]
*
The
risk
for
N
##SF
appears
highest
among
patients
with
:
o
##C
##hr
##onic
,
severe
kidney
disease
(
G
##F
##R
<
30
m
##L
/
min
/
1
.
73
##m
##2
)
,
or
##o
##A
##cute
kidney
injury
.
[SEP]
[CLS]
Rapid
in
##tra
##ven
##ous
in
##fusion
##s
of
D
##AL
##VA
##NC
##E
can
cause
reactions
that
resemble
`
`
Red
-
Man
S
##yn
##drome
,
'
'
including
flush
##ing
of
the
upper
body
,
u
##rt
##ica
##ria
,
p
##ru
##rit
##us
,
and
/
or
r
##ash
.
[SEP]
[CLS]
This
trial
involved
SA
##P
##H
##RI
##S
doses
of
5
mg
,
10
mg
,
15
mg
,
and
20
mg
twice
daily
,
and
place
##bo
,
and
was
conducted
in
151
clinical
##ly
[SEP]
[CLS]
stable
patients
with
s
##chi
##zophrenia
,
with
electro
##card
##io
##graphic
assessments
throughout
the
dos
##ing
interval
at
base
##line
and
steady
state
.
[SEP]
[CLS]
*
Tu
##mor
l
##ys
##is
syndrome
:
Close
##ly
monitor
patients
with
rapidly
pro
##life
##rating
tumor
or
high
tumor
burden
(
5
.
5
)
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Neo
##nat
##al
toxicity
:
Risk
of
gasping
syndrome
if
ben
##zy
##l
alcohol
is
used
in
neon
##ates
.
[SEP]
[CLS]
Laboratory
,
EC
##G
and
vital
sign
changes
observed
in
MD
##D
clinical
studies
The
following
changes
were
observed
in
pre
-
marketing
place
##bo
-
controlled
,
short
-
term
MD
##D
studies
with
PR
##IS
##TI
##Q
.
[SEP]
[CLS]
The
incidence
and
severity
of
p
##yre
##xia
are
increased
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
compared
with
T
##AF
##IN
##LA
##R
as
a
single
agent
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
6
.
[SEP]
[CLS]
5
.
4
V
##eno
##us
T
##hr
##omb
##oe
##mbo
##lis
##m
V
##eno
##us
th
##rom
##boe
##mbo
##lis
##m
can
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Given
the
similarity
in
h
##yper
##sen
##si
##ti
##vity
symptoms
and
acute
H
##A
##E
symptoms
,
patients
should
be
monitored
closely
in
the
event
of
a
h
##yper
##sen
##si
##ti
##vity
reaction
.
[SEP]
[CLS]
N
##er
##vous
system
disorders
-
S
##ync
##ope
,
con
##vu
##ls
##ion
,
d
##ys
##ton
##ia
.
[SEP]
[CLS]
All
patients
should
be
tested
for
H
##B
##V
infection
before
in
##iti
##ating
T
##NF
-
block
##er
therapy
.
[SEP]
[CLS]
The
proportion
of
subjects
who
discontinued
treatment
with
ST
##RI
##BI
##LD
(
el
##vi
##te
##gra
##vir
150
mg
/
co
##bic
##ista
##t
150
mg
/
em
##tric
##ita
##bine
200
mg
/
ten
##of
##ov
##ir
D
##F
300
mg
)
;
AT
##RI
##PL
##A
(
e
##fa
##vir
##en
##z
600
mg
/
em
##tric
##ita
##bine
200
mg
/
ten
##of
##ov
##ir
D
##F
[SEP]
[CLS]
300
mg
)
;
or
at
##az
##ana
##vir
(
AT
##V
)
+
r
##ito
##na
##vir
(
R
##TV
)
+
T
##R
##U
##VA
##DA
(
em
##tric
##ita
##bine
200
mg
/
ten
##of
##ov
##ir
D
##F
300
mg
)
due
to
adverse
events
,
regardless
[SEP]
[CLS]
of
severity
,
was
6
.
0
%
,
7
.
4
%
and
8
.
5
%
,
respectively
.
[SEP]
[CLS]
T
##I
##VI
##CA
##Y
is
con
##tra
##ind
##ica
##ted
in
patients
who
have
experienced
a
previous
h
##yper
##sen
##si
##ti
##vity
reaction
to
do
##lut
##eg
##ra
##vir
.
[SEP]
[CLS]
FA
##NA
##P
##T
is
not
approved
for
the
treatment
of
patients
with
De
##ment
##ia
-
Re
##lated
P
##sy
##cho
##sis
.
[SEP]
[CLS]
Monitor
weight
.
[SEP]
[CLS]
Grade
2
AD
##R
##s
reported
in
at
least
1
subject
were
r
##ash
(
n
=
1
)
,
abdominal
pain
(
n
=
1
)
,
and
di
##ar
##r
##hea
(
n
=
[SEP]
[CLS]
1
)
.
[SEP]
[CLS]
In
Study
1
,
the
overall
incidence
of
cut
##aneous
reactions
consisting
of
r
##ash
,
er
##yt
##hem
##a
,
and
a
##c
##ne
##iform
r
##ash
was
90
%
,
and
the
incidence
of
Grade
3
[SEP]
[CLS]
cut
##aneous
reactions
was
16
%
.
[SEP]
[CLS]
The
600
-
mg
dose
was
studied
in
2
of
the
3
studies
.
[SEP]
[CLS]
In
this
trial
,
the
safety
profile
of
F
##IR
##A
##Z
##Y
##R
in
patients
who
self
-
administered
F
##IR
##A
##Z
##Y
##R
was
similar
in
nature
and
frequency
to
that
of
patients
whose
therapy
was
administered
by
healthcare
[SEP]
[CLS]
professionals
.
[SEP]
[CLS]
These
reactions
were
more
likely
to
occur
with
higher
in
##fusion
rates
.
[SEP]
[CLS]
Mac
##ular
Ed
##ema
in
Pat
##ients
with
History
of
U
##ve
##itis
or
Di
##abe
##tes
Mel
##lit
##us
Pat
##ients
with
a
history
of
u
##ve
##itis
and
patients
with
diabetes
me
##lli
##tus
are
at
increased
risk
of
mac
##ular
ed
##ema
during
[SEP]
[CLS]
G
##IL
##EN
##Y
##A
therapy
.
[SEP]
[CLS]
V
##Z
##V
v
##ac
##cin
##ation
of
anti
##body
-
negative
patients
is
recommended
prior
to
com
##men
##cing
treatment
with
G
##IL
##EN
##Y
##A
,
following
which
initiation
of
treatment
with
G
##IL
##EN
##Y
##A
should
be
postponed
for
1
month
to
allow
the
[SEP]
[CLS]
full
effect
of
v
##ac
##cin
##ation
to
occur
.
[SEP]
[CLS]
In
the
controlled
portions
of
clinical
trials
of
T
##NF
-
block
##ers
including
the
sub
##cut
##aneous
formulation
of
go
##lim
##uma
##b
more
cases
of
l
##ymph
##oma
have
been
observed
among
patients
receiving
anti
-
T
##NF
treatment
compared
with
patients
[SEP]
[CLS]
in
the
control
groups
.
[SEP]
[CLS]
Fourteen
(
24
%
)
patients
stopped
therapy
prior
to
completion
;
seven
due
to
all
##ergic
reactions
,
five
due
to
physician
or
patient
choice
,
one
due
to
disease
[SEP]
[CLS]
progression
,
and
one
due
to
disco
##ntin
##uation
during
front
##line
protocol
.
[SEP]
[CLS]
Monitor
re
##nal
function
with
regular
measurement
of
the
serum
c
##rea
##tin
##ine
and
/
or
estimated
c
##rea
##tin
##ine
clearance
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##tens
##ion
including
h
##yper
##tensive
crisis
has
been
observed
.
[SEP]
[CLS]
Although
the
prevalence
of
the
syndrome
appears
to
be
highest
among
the
elderly
,
especially
elderly
women
,
it
is
impossible
to
rely
upon
prevalence
estimates
to
predict
,
at
[SEP]
[CLS]
the
inception
of
anti
##psy
##cho
##tic
treatment
,
which
patients
are
likely
to
develop
the
syndrome
.
[SEP]
[CLS]
These
metabolic
changes
include
h
##yper
##gly
##ce
##mia
,
d
##ys
##lip
##ide
##mia
,
and
body
weight
gain
.
[SEP]
[CLS]
The
median
dose
intensity
was
48
##3
mg
/
day
,
and
500
mg
/
day
,
in
the
AP
C
##ML
and
BP
C
##ML
co
##hor
##ts
,
respectively
.
[SEP]
[CLS]
Monitor
liver
-
related
laboratory
tests
.
[SEP]
[CLS]
Inc
##rease
##s
in
c
##rea
##tin
##ine
1
.
5
to
3
times
the
upper
limit
of
normal
occurred
in
9
%
of
patients
.
[SEP]
[CLS]
The
most
frequent
adverse
reaction
leading
to
treatment
disco
##ntin
##uation
was
sub
##du
##ral
hem
##ato
##ma
(
1
.
8
%
)
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Report
##ed
in
>
=
4
%
Pat
##ients
T
##reate
##d
with
NE
##SI
##NA
25
mg
and
More
Fr
##e
##quent
##ly
Than
in
Pat
##ients
Given
Place
##bo
in
Poole
##d
Studies
Number
of
Pat
##ients
(
%
)
[SEP]
[CLS]
NE
##SI
##NA
##25
mg
Place
##bo
Active
Co
##mp
##ara
##tor
N
=
59
##0
##2
N
=
29
##26
N
=
225
##7
Na
##so
##pha
##ryn
##git
##is
257
(
4
.
4
)
89
(
3
.
0
)
113
(
5
.
0
)
Head
##ache
247
(
4
.
2
)
72
(
2
.
5
)
[SEP]
[CLS]
121
(
5
.
4
)
Upper
Re
##sp
##ira
##tory
T
##rac
##t
In
##fect
##ion
247
(
4
.
2
)
61
(
2
.
1
)
113
(
5
.
0
)
Pan
##cre
##ati
##tis
In
the
clinical
trial
program
,
pan
##cre
##ati
##tis
was
reported
[SEP]
[CLS]
in
11
of
59
##0
##2
(
0
.
2
%
)
patients
receiving
NE
##SI
##NA
25
mg
daily
compared
to
five
of
51
##8
##3
(
<
0
.
1
%
)
patients
receiving
all
com
##par
##ators
.
[SEP]
[CLS]
(
5
.
2
,
5
.
3
,
5
.
4
)
*
H
##y
##po
##nat
##rem
##ia
:
Monitor
sodium
levels
in
patients
at
risk
or
patients
experiencing
h
##y
##po
##nat
##rem
##ia
symptoms
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
PR
##IS
##TI
##Q
should
be
considered
in
patients
with
s
##ym
##pt
##oma
##tic
h
##y
##po
##nat
##rem
##ia
and
appropriate
medical
intervention
should
be
instituted
.
[SEP]
[CLS]
Monitor
re
##nal
function
in
patients
with
re
##nal
imp
##air
##ment
reporting
severe
adverse
gas
##tro
##int
##est
##inal
reactions
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
,
Use
in
S
##pecific
Population
##s
(
8
.
7
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
P
##OT
##IG
##A
causes
m
##uc
##ous
membrane
disco
##lora
##tion
and
it
is
not
clear
whether
this
disco
##lora
##tion
is
related
to
re
##tina
##l
abnormal
##ities
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
In
healthy
subjects
,
large
doses
of
inhaled
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
(
4
times
the
recommended
dose
of
v
##ila
##nter
##ol
,
representing
a
12
-
or
10
-
fold
higher
systemic
exposure
than
seen
in
[SEP]
[CLS]
subjects
with
CO
##PD
or
as
##th
##ma
,
respectively
)
have
been
associated
with
clinical
##ly
significant
pro
##long
##ation
of
the
Q
##T
##c
interval
,
which
has
the
potential
for
producing
vent
##ric
##ular
a
##rr
##hy
##th
##mia
##s
.
[SEP]
[CLS]
Eight
(
2
%
)
patients
developed
antibodies
during
treatment
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
.
[SEP]
[CLS]
5
.
6
T
##hy
##roid
A
##cc
##um
##ulation
F
##ail
##ure
to
block
thy
##roid
up
##take
of
i
##od
##ine
123
may
result
in
an
increased
long
term
risk
for
thy
##roid
neo
##p
##lasia
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
Part
##icular
care
should
be
taken
in
observing
patients
post
##oper
##ative
##ly
or
during
periods
of
stress
for
evidence
of
inadequate
ad
##rena
##l
response
.
[SEP]
[CLS]
Del
##ay
in
stopping
IN
##TE
##LE
##NC
##E
(
r
)
treatment
after
the
onset
of
severe
r
##ash
may
result
in
a
life
-
threatening
reaction
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
AG
##RA
##NU
##L
##OC
##Y
##TO
##SI
##S
/
NE
##UT
##RO
##P
##EN
##IA
WA
##R
##NI
##NG
:
AG
##RA
##NU
##L
##OC
##Y
##TO
##SI
##S
/
NE
##UT
##RO
##P
##EN
##IA
*
Fe
##rri
##p
##ro
##x
can
cause
a
##gra
##nu
##loc
##yt
##osis
that
can
lead
to
serious
infections
and
death
.
[SEP]
[CLS]
Pat
##ients
with
unstable
cardiac
disease
,
narrow
-
angle
g
##lau
##com
##a
,
or
s
##ym
##pt
##oma
##tic
pro
##static
h
##yper
##tro
##phy
or
bladder
outlet
o
##bs
##truction
were
excluded
from
these
trials
.
[SEP]
[CLS]
There
was
fatal
pneumonia
in
1
subject
receiving
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
and
in
7
subjects
receiving
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
(
less
than
1
%
for
each
treatment
group
)
.
[SEP]
[CLS]
Data
from
this
safety
study
indicate
that
the
greatest
risk
of
V
##TE
is
present
after
initially
starting
a
CO
##C
or
restart
##ing
(
following
a
4
week
or
greater
pill
-
free
interval
[SEP]
[CLS]
)
the
same
or
a
different
CO
##C
.
[SEP]
[CLS]
One
published
report
of
18
F
-
met
##hyl
##cho
##line
P
##ET
imaging
indicated
that
disco
##ntin
##uation
of
co
##l
##chi
##cine
for
two
weeks
resolved
the
co
##l
##chi
##cine
effect
.
[SEP]
[CLS]
R
##out
##ine
monitoring
of
serum
ca
##l
##ci
##ton
##in
or
using
thy
##roid
ultra
##sound
is
of
uncertain
value
for
early
detection
of
M
##TC
in
patients
treated
with
T
##R
##U
##L
##IC
##IT
##Y
.
[SEP]
[CLS]
Reports
of
pen
##ile
`
`
popping
'
'
sounds
or
sensations
A
popping
sensation
in
the
penis
'
'
,
and
sometimes
accompanied
by
de
##tum
##es
##cence
,
hem
##ato
##ma
and
/
or
pain
,
were
reported
in
[SEP]
[CLS]
73
/
55
##1
(
13
.
2
%
)
XI
##AF
##LE
##X
-
treated
patients
and
1
/
281
(
0
.
3
%
)
place
##bo
-
treated
patients
.
[SEP]
[CLS]
A
total
of
74
##1
patients
have
been
treated
with
AM
##P
##Y
##RA
for
over
six
months
,
501
for
over
one
year
and
35
##2
for
over
two
years
.
[SEP]
[CLS]
If
such
effects
occur
,
BR
##E
##O
E
##LL
##IP
##TA
may
need
to
be
discontinued
.
[SEP]
[CLS]
(
5
.
8
,
8
.
1
,
8
.
7
)
5
.
1
Se
##vere
or
Per
##sist
##ent
Gas
##tro
##int
##est
##inal
To
##xi
##city
Di
##ar
##r
##hea
,
nausea
,
vomit
##ing
,
or
abdominal
pain
occurred
in
96
%
of
255
patients
including
[SEP]
[CLS]
severe
cases
in
14
%
of
patients
treated
with
Z
##Y
##KA
##DI
##A
in
Study
1
.
[SEP]
[CLS]
Monitor
liver
enzymes
and
bi
##li
##ru
##bin
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Inter
##rup
##t
Fe
##rri
##p
##ro
##x
if
infection
develops
,
and
monitor
the
AN
##C
more
frequently
.
[SEP]
[CLS]
The
most
frequent
(
>
=
2
%
)
serious
adverse
reactions
reported
for
subjects
treated
with
Z
##yd
##eli
##g
were
pneumonia
(
17
%
)
,
p
##yre
##xia
(
9
%
)
,
[SEP]
[CLS]
se
##psis
(
8
%
)
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
(
5
%
)
and
di
##ar
##r
##hea
(
5
%
)
.
[SEP]
[CLS]
The
safety
evaluation
of
G
##IL
##OT
##RI
##F
is
based
on
the
data
from
more
than
380
##0
patients
,
including
213
##5
N
##SC
##LC
patients
receiving
G
##IL
##OT
##RI
##F
mon
##otherapy
at
or
above
the
recommended
dose
.
[SEP]
[CLS]
5
.
5
Ren
##al
I
##mp
##air
##ment
In
patients
treated
with
G
##LP
-
1
receptor
ago
##nist
##s
,
there
have
been
post
##market
##ing
reports
of
acute
re
##nal
failure
and
worse
##ning
of
chronic
re
##nal
failure
,
which
may
sometimes
[SEP]
[CLS]
require
hem
##od
##ial
##ys
##is
.
[SEP]
[CLS]
In
many
cases
,
this
h
##y
##po
##nat
##rem
##ia
appears
to
be
the
result
of
the
syndrome
of
inappropriate
anti
##di
##ure
##tic
hormone
secret
##ion
(
S
##IA
##D
##H
)
.
[SEP]
[CLS]
(
5
.
1
)
*
Corporal
r
##up
##ture
(
pen
##ile
fracture
)
or
other
serious
injury
to
the
penis
:
A
##vo
##id
in
##ject
##ing
into
the
u
##ret
##hra
,
nerves
,
blood
vessels
,
co
##rp
##ora
[SEP]
[CLS]
cavern
##osa
or
other
co
##lla
##gen
-
containing
structures
of
the
penis
.
[SEP]
[CLS]
In
general
,
disco
##ntin
##uation
events
occurred
more
frequently
with
longer
duration
of
therapy
.
[SEP]
[CLS]
If
signs
and
symptoms
fail
to
improve
after
2
days
,
the
patient
should
be
re
-
evaluated
.
[SEP]
[CLS]
Grade
3
or
higher
(
severe
,
life
-
threatening
,
or
fatal
)
ne
##uro
##logical
toxic
##ities
following
initiation
of
B
##L
##IN
##C
##Y
##TO
administration
occurred
in
approximately
15
%
of
patients
and
included
en
##ce
##pha
##lop
##athy
,
[SEP]
[CLS]
con
##vu
##ls
##ions
,
speech
disorders
,
disturbance
##s
in
consciousness
,
confusion
and
di
##sor
##ient
##ation
,
and
balance
disorders
.
[SEP]
[CLS]
In
clinical
studies
,
55
##5
patients
were
exposed
to
Amy
##vid
.
[SEP]
[CLS]
*
Ren
##al
toxicity
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
All
patients
treated
with
V
##im
##iz
##im
2
mg
/
kg
once
per
week
tested
positive
for
neutral
##izing
antibodies
capable
of
in
##hibit
##ing
the
drug
from
binding
to
the
man
##nose
-
6
-
phosphate
receptor
at
least
once
during
[SEP]
[CLS]
the
trial
.
[SEP]
[CLS]
The
increased
risk
of
su
##icidal
thoughts
with
A
##ED
##s
was
observed
as
early
as
one
week
after
starting
treatment
with
A
##ED
##s
and
persisted
for
the
duration
of
treatment
assessed
.
[SEP]
[CLS]
The
proportion
of
patients
with
elevations
in
t
##rig
##ly
##cer
##ides
>
=
200
mg
/
d
##L
(
at
End
##point
)
was
15
.
2
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
11
.
4
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Skin
reactions
including
S
##J
##S
and
T
##EN
have
occurred
when
T
##RE
##AN
##DA
was
administered
con
##com
##ita
##ntly
with
all
##op
##uri
##no
##l
and
other
medications
known
to
cause
these
syndrome
##s
.
[SEP]
[CLS]
(
2
.
6
,
5
.
7
)
*
Drug
In
##duced
Live
##r
In
##ju
##ry
:
Disco
##ntin
##ue
AP
##TI
##OM
in
patients
with
j
##au
##ndi
##ce
or
evidence
of
significant
liver
injury
.
[SEP]
[CLS]
The
safety
population
(
received
at
least
1
dose
of
B
##OS
##U
##L
##IF
)
included
54
##6
C
##ML
patients
:
*
287
patients
with
CP
C
##ML
previously
treated
with
im
##ati
##ni
##b
only
who
had
[SEP]
[CLS]
a
median
duration
of
B
##OS
##U
##L
##IF
treatment
of
24
months
,
and
a
median
dose
intensity
of
48
##4
mg
/
day
.
[SEP]
[CLS]
The
safety
data
described
below
reflect
exposure
to
K
##AL
##BI
##TO
##R
in
255
patients
with
H
##A
##E
treated
with
either
in
##tra
##ven
##ous
or
sub
##cut
##aneous
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
Of
these
6
AD
##A
positive
patients
,
one
experienced
a
h
##yper
##sen
##si
##ti
##vity
reaction
during
Study
1
(
2
%
,
1
of
56
)
.
[SEP]
[CLS]
*
Using
est
##rogen
##s
may
increase
your
chance
of
getting
cancer
of
the
u
##ter
##us
(
w
##omb
)
.
[SEP]
[CLS]
En
##sure
that
patients
are
well
h
##yd
##rated
before
administration
of
K
##y
##p
##rol
##is
in
Cycle
1
,
and
in
subsequent
cycles
as
needed
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
who
are
treated
with
at
##y
##pical
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
and
[SEP]
[CLS]
c
##ere
##bro
##vas
##cular
-
related
adverse
events
,
including
stroke
.
[SEP]
[CLS]
5
.
7
H
##yper
##tens
##ion
H
##yper
##tens
##ion
,
including
h
##yper
##tensive
crisis
and
h
##yper
##tensive
emergency
,
has
been
observed
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
If
su
##pine
h
##yper
##tens
##ion
can
not
be
managed
by
elevation
of
the
head
of
the
bed
,
reduce
or
disco
##ntin
##ue
NO
##RT
##H
##ER
##A
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
O
##bt
##ain
periodic
liver
testing
in
patients
during
treatment
with
G
##IL
##OT
##RI
##F
.
[SEP]
[CLS]
6
.
2
Clinical
Trials
Experience
in
P
##ediatric
Sub
##jects
I
##MP
##AA
##CT
P
##10
##9
##3
is
an
ongoing
multi
##cent
##er
,
open
-
label
,
non
-
comparative
trial
of
approximately
160
HIV
-
1
-
infected
p
##ediatric
subjects
aged
6
weeks
to
less
than
[SEP]
[CLS]
18
years
,
of
which
23
treatment
-
experienced
,
IN
##ST
##I
-
naive
subjects
aged
12
to
less
than
18
years
were
enrolled
[
see
Use
in
S
##pecific
Population
##s
(
8
.
4
)
,
Clinical
[SEP]
[CLS]
Studies
(
14
.
2
)
]
.
[SEP]
[CLS]
Treatment
of
c
##er
##vic
##al
d
##ys
##ton
##ia
with
b
##ot
##ulin
##um
to
##xin
##s
may
weaken
neck
muscles
that
serve
as
access
##ory
muscles
of
ventilation
.
[SEP]
[CLS]
Mac
##ular
ed
##ema
occurred
predominantly
during
the
first
3
to
4
months
of
therapy
.
[SEP]
[CLS]
Counsel
patients
regarding
the
potential
risk
of
M
##TC
with
the
use
of
T
##AN
##Z
##E
##UM
and
inform
them
of
the
symptoms
of
thy
##roid
tumors
(
e
.
g
.
,
mass
in
the
neck
,
[SEP]
[CLS]
d
##ys
##pha
##gia
,
d
##ys
##p
##nea
,
persistent
hoarse
##ness
)
.
[SEP]
[CLS]
Heart
Rate
Inc
##rease
In
the
pool
of
place
##bo
-
controlled
trials
,
mean
heart
rate
in
patients
treated
with
T
##AN
##Z
##E
##UM
was
higher
by
an
average
of
1
to
2
b
##pm
compared
with
[SEP]
[CLS]
mean
heart
rate
in
patients
treated
with
place
##bo
across
study
visits
.
[SEP]
[CLS]
To
aid
in
the
management
of
such
patients
,
consider
consultation
with
a
physician
with
expertise
in
the
diagnosis
and
treatment
of
invasive
fun
##gal
infections
.
[SEP]
[CLS]
In
the
post
##market
##ing
experience
,
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
.
[SEP]
[CLS]
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
He
##pa
##to
##to
##xi
##city
:
Monitor
liver
function
before
and
during
therapy
.
[SEP]
[CLS]
Blood
and
l
##ymph
##atic
system
disorders
:
f
##eb
##ril
##e
ne
##ut
##rop
##enia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
*
Do
not
place
D
##U
##AV
##EE
in
pill
boxes
or
pill
organizers
.
[SEP]
[CLS]
Overall
,
a
higher
rate
of
AP
##TC
events
was
observed
in
U
##L
##OR
##IC
than
in
all
##op
##uri
##no
##l
-
treated
patients
.
[SEP]
[CLS]
*
Per
##form
test
for
late
##nt
T
##B
;
if
positive
,
start
treatment
for
T
##B
prior
to
starting
C
##IM
##Z
##IA
(
5
.
1
)
.
[SEP]
[CLS]
5
.
3
W
##orse
##ning
of
Na
##rrow
-
Ang
##le
G
##lau
##com
##a
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
should
be
used
with
caution
in
patients
with
narrow
-
angle
g
##lau
##com
##a
.
[SEP]
[CLS]
Pat
##ients
with
abnormal
L
##VE
##F
,
history
of
acute
co
##rona
##ry
syndrome
within
6
months
,
current
evidence
of
Class
II
or
greater
con
##ges
##tive
heart
failure
(
New
York
Heart
Association
)
[SEP]
[CLS]
,
history
R
##VO
or
R
##P
##ED
,
Q
##T
##c
interval
>
=
480
m
##se
##c
,
treatment
re
##fra
##ctor
##y
h
##yper
##tens
##ion
,
un
##con
##tro
##lled
a
##rr
##hy
##th
##mia
##s
,
history
of
p
##ne
##um
##oni
##tis
or
inter
##st
##iti
##al
lung
disease
,
or
a
known
[SEP]
[CLS]
history
of
G
##6
##PD
deficiency
were
excluded
.
[SEP]
[CLS]
Disco
##ntin
##ue
E
##L
##I
##Q
##UI
##S
in
patients
with
active
path
##ological
hem
##or
##r
##hage
.
[SEP]
[CLS]
The
effects
of
ten
##of
##ov
##ir
D
##F
-
associated
changes
in
B
##MD
and
bio
##chemical
markers
on
long
-
term
bone
health
and
future
fracture
risk
are
unknown
.
[SEP]
[CLS]
Treatment
of
late
##nt
tuberculosis
infection
prior
to
therapy
with
T
##NF
-
blocking
agents
has
been
shown
to
reduce
the
risk
of
tuberculosis
react
##ivation
during
therapy
.
[SEP]
[CLS]
The
incidence
of
reported
th
##rom
##boe
##mbo
##lic
events
in
wet
AM
##D
studies
during
the
first
year
was
1
.
8
%
(
32
out
of
1824
)
in
the
combined
group
of
patients
treated
[SEP]
[CLS]
with
E
##Y
##LE
##A
.
[SEP]
[CLS]
Op
##tic
at
##rop
##hy
and
op
##tic
nerve
disorder
have
been
reported
as
potential
causes
of
vision
loss
.
[SEP]
[CLS]
5
.
6
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
trials
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
T
##AN
##Z
##E
##UM
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
Other
clinical
##ly
important
adverse
reactions
observed
in
<
10
%
of
patients
(
N
=
58
##6
)
treated
with
T
##AF
##IN
##LA
##R
were
:
Gas
##tro
##int
##est
##inal
Di
##sor
##ders
:
Pan
##cre
##ati
##tis
.
[SEP]
[CLS]
*
C
##IM
##Z
##IA
should
be
discontinued
if
a
patient
develops
a
serious
infection
or
se
##psis
(
5
.
1
)
.
[SEP]
[CLS]
In
the
long
-
term
extension
studies
,
the
incidence
##s
of
ad
##ju
##dicated
AP
##TC
events
were
:
U
##L
##OR
##IC
80
mg
0
.
97
(
95
%
C
##I
0
.
57
-
1
.
56
)
,
and
all
##op
##uri
##no
##l
0
.
58
(
95
[SEP]
[CLS]
%
C
##I
0
.
02
-
3
.
24
)
.
[SEP]
[CLS]
Report
any
diagnosis
of
N
##SF
following
E
##O
##VI
##ST
administration
to
Bay
##er
Health
##C
##are
(
1
-
88
##8
-
84
##2
-
29
##37
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
)
.
[SEP]
[CLS]
6
.
1
Clinical
Study
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Consul
##tation
with
a
physician
with
expertise
in
the
treatment
of
tuberculosis
is
recommended
to
aid
in
the
decision
whether
in
##iti
##ating
anti
-
tuberculosis
therapy
is
appropriate
for
an
individual
patient
.
[SEP]
[CLS]
Beta
-
block
##ers
should
be
withdrawn
only
after
a
gradual
reduction
in
dose
.
[SEP]
[CLS]
Re
##com
##men
##ded
doses
of
im
##mu
##nos
##up
##press
##ants
should
not
be
exceeded
.
[SEP]
[CLS]
Physicians
and
patients
should
be
aware
of
the
increased
risk
of
infection
with
A
##FI
##NI
##TO
##R
.
[SEP]
[CLS]
The
long
-
term
clinical
effects
of
the
increase
in
heart
rate
have
not
been
established
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
6
)
]
.
[SEP]
[CLS]
Ren
##al
function
should
be
evaluated
prior
to
in
##iti
##ating
J
##AR
##DI
##AN
##CE
and
periodically
thereafter
.
[SEP]
[CLS]
For
patients
who
develop
prolonged
Grade
2
di
##ar
##r
##hea
lasting
more
than
48
hours
or
greater
than
or
equal
to
Grade
3
di
##ar
##r
##hea
,
with
##hold
G
##IL
##OT
##RI
##F
until
di
##ar
##r
##hea
resolve
##s
to
Grade
[SEP]
[CLS]
1
or
less
,
and
resume
G
##IL
##OT
##RI
##F
with
appropriate
dose
reduction
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Table
6
compares
the
incidence
of
treatment
-
emerge
##nt
adverse
reactions
reported
with
an
incidence
of
>
=
10
%
for
patients
receiving
A
##FI
##NI
##TO
##R
10
mg
daily
versus
place
##bo
.
[SEP]
[CLS]
In
clinical
trials
where
ethnicity
was
recorded
the
ethnic
distribution
was
74
%
Caucasian
,
12
%
Asian
,
4
%
Black
,
and
10
%
others
.
[SEP]
[CLS]
No
cases
of
transmission
of
viral
diseases
or
C
##J
##D
have
ever
been
reported
for
album
##in
.
[SEP]
[CLS]
Disco
##ntin
##ue
K
##y
##p
##rol
##is
if
PR
##ES
is
suspected
and
evaluate
.
[SEP]
[CLS]
Table
7
:
Key
Laboratory
A
##b
##nor
##mal
##ities
Report
##ed
in
Pat
##ients
with
RC
##C
at
a
Higher
Rate
in
the
A
##FI
##NI
##TO
##R
Arm
than
the
Place
##bo
Arm
G
##rading
according
to
CT
##CA
##E
Version
3
.
0
a
[SEP]
[CLS]
Re
##fle
##cts
corresponding
adverse
drug
reaction
reports
of
an
##emia
,
le
##uk
##ope
##nia
,
l
##ymph
##ope
##nia
,
ne
##ut
##rop
##enia
,
and
th
##rom
##bo
##cy
##top
##enia
(
collectively
pan
##cy
##top
##enia
)
,
which
occurred
at
lower
frequency
.
[SEP]
[CLS]
5
.
3
Is
##che
##mic
Heart
Disease
,
A
##rr
##hy
##th
##mia
##s
,
and
Con
##ges
##tive
Heart
F
##ail
##ure
NO
##RT
##H
##ER
##A
may
ex
##ace
##rb
##ate
existing
is
##che
##mic
heart
disease
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
characterized
by
r
##ash
,
constitutional
findings
,
and
sometimes
organ
d
##ys
##function
,
including
liver
injury
,
have
been
reported
.
[SEP]
[CLS]
Of
these
136
##8
patients
,
safety
data
were
received
for
94
##0
patients
with
a
median
age
of
9
years
(
0
to
76
years
)
,
63
%
were
male
[SEP]
[CLS]
,
91
%
with
le
##uke
##mia
,
3
%
with
l
##ymph
##oma
,
and
6
%
with
unknown
disease
information
.
[SEP]
[CLS]
While
adequate
h
##yd
##ration
is
required
prior
to
each
dose
in
Cycle
1
,
all
patients
should
also
be
monitored
for
evidence
of
volume
over
##load
,
especially
patients
at
risk
for
[SEP]
[CLS]
cardiac
failure
.
[SEP]
[CLS]
One
patient
developed
PM
##L
after
taking
G
##IL
##EN
##Y
##A
for
approximately
2
.
5
years
.
[SEP]
[CLS]
Death
##s
as
a
com
##plication
of
severe
d
##ys
##pha
##gia
have
been
reported
after
treatment
with
b
##ot
##ulin
##um
to
##xin
.
[SEP]
[CLS]
They
are
not
interchange
##able
with
other
preparations
of
b
##ot
##ulin
##um
to
##xin
products
and
,
therefore
,
units
of
biological
activity
of
D
##Y
##SP
##OR
##T
(
r
)
can
not
be
compared
to
or
[SEP]
[CLS]
converted
into
units
of
any
other
b
##ot
##ulin
##um
to
##xin
products
assessed
with
any
other
specific
ass
##ay
method
[
see
##D
##es
##cription
(
11
)
]
.
[SEP]
[CLS]
5
.
5
Skin
Re
##actions
Skin
reactions
have
been
reported
with
T
##RE
##AN
##DA
treatment
in
clinical
trials
and
post
##market
##ing
safety
reports
,
including
r
##ash
,
toxic
skin
reactions
and
bull
##ous
ex
##ant
##hem
##a
.
[SEP]
[CLS]
A
RCA
##P
##TA
NE
##OH
##AL
##ER
is
not
indicated
for
the
treatment
of
as
##th
##ma
.
[SEP]
[CLS]
Ser
##ious
In
##fect
##ions
Re
##ceptor
act
##iva
##tor
of
nuclear
factor
ka
##ppa
-
B
l
##igan
##d
(
RA
##N
##K
##L
)
is
expressed
on
activated
T
and
B
l
##ymph
##ocytes
and
in
l
##ymph
nodes
.
[SEP]
[CLS]
There
were
four
suicide
##s
in
drug
-
treated
patients
in
the
trials
and
none
in
place
##bo
-
treated
patients
,
but
the
number
of
events
is
too
small
to
allow
any
conclusion
about
drug
[SEP]
[CLS]
effect
on
suicide
.
[SEP]
[CLS]
He
##pa
##tic
Trans
##ami
##nas
##es
An
increased
incidence
of
elevations
of
he
##pa
##tic
trans
##ami
##nas
##es
in
patients
treated
with
T
##EC
##FI
##DE
##RA
was
seen
primarily
during
the
first
six
months
of
treatment
,
and
most
patients
with
[SEP]
[CLS]
elevations
had
levels
<
3
times
the
upper
limit
of
normal
(
U
##L
##N
)
.
[SEP]
[CLS]
However
,
some
of
these
cases
were
in
the
setting
of
disease
progression
.
[SEP]
[CLS]
However
,
e
##pid
##em
##iol
##ogical
studies
suggest
an
increased
risk
of
treatment
-
emerge
##nt
h
##yper
##gly
##ce
##mia
-
related
adverse
events
in
patients
treated
with
the
at
##y
##pical
anti
##psy
##cho
##tics
included
in
these
studies
.
[SEP]
[CLS]
In
##jection
into
these
structures
may
result
in
possible
permanent
injury
,
such
as
tend
##on
r
##up
##ture
or
l
##iga
##ment
damage
,
or
skin
lace
##ration
.
[SEP]
[CLS]
The
proportion
of
patients
who
discontinued
treatment
due
to
adverse
reactions
in
the
controlled
phase
of
Trial
1
through
Week
24
was
3
.
5
%
for
S
##IM
##PO
##NI
ARIA
-
treated
patients
and
0
.
5
[SEP]
[CLS]
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
demographic
characteristics
were
similar
among
the
4
pivotal
studies
and
between
the
treatment
groups
within
these
studies
.
[SEP]
[CLS]
I
##mm
##une
system
disorders
:
an
##aph
##yla
##ctic
shock
,
h
##yper
##sen
##si
##ti
##vity
.
[SEP]
[CLS]
If
chicken
##pox
develops
,
treatment
with
anti
##vir
##al
agents
may
be
considered
.
[SEP]
[CLS]
Table
2
:
Laboratory
A
##b
##nor
##mal
##ities
of
Interest
in
Study
1
A
##bir
##ater
##one
(
N
=
79
##1
)
Place
##bo
(
N
=
39
##4
)
Laboratory
A
##b
##nor
##mal
##ity
All
Grades
(
%
)
Grade
3
-
4
(
%
)
[SEP]
[CLS]
All
Grades
(
%
)
Grade
3
-
4
(
%
)
H
##yper
##tri
##gly
##cer
##ide
##mia
62
.
5
0
.
4
53
.
0
0
High
AS
##T
30
.
6
2
.
1
36
.
3
1
.
5
H
##y
##po
##kal
##emia
28
.
3
5
.
3
19
.
8
1
.
0
H
##y
##pop
##hos
##phate
##mia
23
.
8
7
.
2
15
.
7
[SEP]
[CLS]
5
.
8
High
AL
##T
11
.
1
1
.
4
10
.
4
0
.
8
High
Total
B
##ili
##ru
##bin
6
.
6
0
.
1
4
.
6
0
Study
2
:
Met
##ast
##atic
CR
##PC
Prior
to
Ch
##em
##otherapy
Study
2
enrolled
108
##8
patients
with
meta
##static
CR
##PC
[SEP]
[CLS]
who
had
not
received
prior
c
##yt
##oto
##xi
##c
ch
##em
##otherapy
.
[SEP]
[CLS]
Such
monitoring
may
increase
the
risk
of
unnecessary
procedures
,
due
to
the
low
test
specific
##ity
for
serum
ca
##l
##ci
##ton
##in
and
a
high
background
incidence
of
thy
##roid
disease
.
[SEP]
[CLS]
The
most
frequent
(
>
=
0
.
5
%
)
adverse
reactions
associated
with
the
use
of
E
##O
##VI
##ST
were
nausea
,
headache
,
feeling
hot
,
di
##zzi
##ness
,
and
[SEP]
[CLS]
back
pain
.
[SEP]
[CLS]
Re
##sp
##ira
##tory
,
Thor
##ac
##ic
and
Media
##st
##inal
Di
##sor
##ders
:
non
-
infectious
p
##ne
##um
##oni
##tis
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Ad
##vise
patients
taking
Fe
##rri
##p
##ro
##x
to
report
immediately
any
symptoms
in
##dicative
of
infection
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
CO
##RP
##OR
##AL
R
##UP
##TU
##RE
(
P
##EN
##IL
##E
F
##RA
##CT
##UR
##E
)
OR
O
##TH
##ER
SE
##RI
##O
##US
P
##EN
##IL
##E
IN
##J
##UR
##Y
IN
THE
T
##RE
##AT
##ME
##NT
OF
P
##E
##Y
##RO
##NI
##E
'
S
D
##IS
##EA
##SE
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
[SEP]
[CLS]
*
Corporal
r
##up
##ture
(
pen
##ile
fracture
)
was
reported
as
an
adverse
reaction
in
5
of
104
##4
(
0
.
5
%
)
XI
##AF
##LE
##X
-
treated
patients
in
clinical
studies
.
[SEP]
[CLS]
Pre
##ex
##ist
##ing
liver
disease
,
elevated
base
##line
liver
enzymes
,
and
con
##com
##ita
##nt
medications
may
also
increase
the
risk
.
[SEP]
[CLS]
Ad
##verse
reactions
during
exposure
were
obtained
by
general
inquiry
and
recorded
by
clinical
investigators
using
their
own
terminology
.
[SEP]
[CLS]
Investigation
##s
:
blood
bi
##li
##ru
##bin
increased
,
blood
c
##rea
##tin
##ine
p
##hos
##ph
##oki
##nas
##e
increased
.
[SEP]
[CLS]
Also
,
patients
taking
di
##ure
##tics
or
who
are
otherwise
volume
depleted
can
be
at
greater
risk
[
see
Use
in
S
##pecific
Population
##s
(
8
.
5
)
and
Clinical
Ph
##arma
##cology
(
12
.
6
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
All
infections
,
and
other
organisms
.
[SEP]
[CLS]
There
was
no
apparent
pattern
with
respect
to
the
an
##ato
##mic
site
of
fracture
.
[SEP]
[CLS]
Ren
##al
and
u
##rina
##ry
disorders
:
N
##ep
##hr
##otic
syndrome
and
re
##nal
failure
.
[SEP]
[CLS]
(
5
.
4
)
*
H
##yper
##tens
##ion
:
Monitor
blood
pressure
regularly
.
[SEP]
[CLS]
The
clinical
impact
of
anti
-
be
##lat
##ace
##pt
antibodies
(
including
neutral
##izing
anti
-
be
##lat
##ace
##pt
antibodies
)
could
not
be
determined
in
the
studies
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Rule
out
infectious
et
##iol
##ogies
of
di
##ar
##r
##hea
before
starting
c
##ro
##fe
##lem
##er
.
[SEP]
[CLS]
The
clinical
significance
of
small
changes
in
B
##MD
with
regard
to
long
-
term
consequences
such
as
fracture
is
unknown
.
[SEP]
[CLS]
5
.
15
Co
##ex
##ist
##ing
Con
##ditions
BR
##E
##O
E
##LL
##IP
##TA
,
like
all
medicines
containing
s
##ym
##path
##omi
##met
##ic
am
##ines
,
should
be
used
with
caution
in
patients
with
con
##vu
##lsive
disorders
or
thy
##rot
##ox
##ico
##sis
and
in
those
who
are
[SEP]
[CLS]
unusually
re
##sp
##ons
##ive
to
s
##ym
##path
##omi
##met
##ic
am
##ines
.
[SEP]
[CLS]
(
5
.
4
)
*
Art
##hra
##l
##gia
:
Se
##vere
and
di
##sa
##bling
art
##hra
##l
##gia
has
been
reported
in
patients
taking
D
##PP
-
4
inhibitor
##s
.
[SEP]
[CLS]
Before
in
##iti
##ating
IN
##VO
##KA
##NA
in
patients
with
one
or
more
of
these
characteristics
,
volume
status
should
be
assessed
and
corrected
.
[SEP]
[CLS]
5
.
3
H
##yper
##kal
##emia
IN
##VO
##KA
##NA
can
lead
to
h
##yper
##kal
##emia
.
[SEP]
[CLS]
5
.
2
My
##elo
##su
##pp
##ression
T
##hr
##omb
##oc
##yt
##ope
##nia
,
an
##emia
and
ne
##ut
##rop
##enia
occur
with
B
##OS
##U
##L
##IF
treatment
.
[SEP]
[CLS]
(
5
.
2
)
A
##vo
##ida
##nce
of
Contact
Len
##ses
.
[SEP]
[CLS]
Pat
##ients
with
RA
and
other
chronic
inflammatory
diseases
,
particularly
patients
with
highly
active
disease
and
/
or
chronic
exposure
to
im
##mu
##nos
##up
##press
##ant
the
##rap
##ies
,
may
be
at
higher
risk
(
up
to
[SEP]
[CLS]
several
fold
)
than
the
general
population
for
the
development
of
l
##ymph
##oma
,
even
in
the
absence
of
T
##NF
-
blocking
therapy
.
[SEP]
[CLS]
Is
##olate
##d
delayed
onset
events
,
including
trans
##ient
as
##ys
##to
##le
and
une
##x
##plain
##ed
death
,
have
occurred
within
24
hours
of
the
first
dose
.
[SEP]
[CLS]
These
exclusion
criteria
included
a
history
of
seizure
,
underlying
brain
injury
with
loss
of
consciousness
,
trans
##ient
is
##che
##mic
attack
within
the
past
12
months
,
cerebral
vascular
accident
,
[SEP]
[CLS]
brain
meta
##sta
##ses
,
and
brain
art
##eri
##ove
##nous
ma
##lf
##orm
##ation
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
frequency
or
establish
a
ca
##usal
relationship
to
drug
exposure
[SEP]
[CLS]
:
acute
pan
##cre
##ati
##tis
,
ch
##ole
##cy
##st
##itis
,
ch
##ole
##lit
##hia
##sis
,
art
##erial
th
##rom
##bot
##ic
events
and
reflex
sympathetic
d
##ys
##tro
##phy
.
[SEP]
[CLS]
Pat
##ients
with
multiple
my
##elo
##ma
and
a
high
tumor
burden
should
be
considered
to
be
at
greater
risk
for
T
##LS
.
[SEP]
[CLS]
The
overall
exposure
in
the
controlled
trials
was
equivalent
to
171
##6
person
-
years
.
[SEP]
[CLS]
The
significance
of
this
finding
is
unknown
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
Post
##market
##ing
reports
indicate
that
the
effects
of
D
##Y
##SP
##OR
##T
(
r
)
and
all
[SEP]
[CLS]
b
##ot
##ulin
##um
to
##xin
products
may
spread
from
the
area
of
injection
to
produce
symptoms
consistent
with
b
##ot
##ulin
##um
to
##xin
effects
.
[SEP]
[CLS]
*
You
and
your
healthcare
provider
should
talk
regularly
about
whether
you
still
need
treatment
with
D
##U
##AV
##EE
.
[SEP]
[CLS]
Death
due
to
cardiac
arrest
has
occurred
within
a
day
of
K
##y
##p
##rol
##is
administration
.
[SEP]
[CLS]
c
The
1
,
200
-
mg
dose
of
H
##OR
##I
##Z
##AN
##T
was
a
treatment
arm
in
each
of
the
3
double
-
blind
,
place
##bo
-
controlled
,
12
-
week
clinical
trials
.
[SEP]
[CLS]
(
5
.
1
)
*
Ser
##ious
an
##aph
##yla
##ctic
)
reactions
have
been
reported
with
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
drugs
.
[SEP]
[CLS]
If
a
patient
experiences
anti
##cho
##liner
##gic
C
##NS
effects
,
dose
reduction
or
drug
disco
##ntin
##uation
should
be
considered
.
[SEP]
[CLS]
Monitor
re
##nal
function
,
blood
glucose
,
lip
##ids
,
and
hem
##ato
##log
##ic
parameters
prior
to
treatment
and
periodically
thereafter
.
[SEP]
[CLS]
(
2
.
2
)
(
4
)
*
Se
##vere
h
##yper
##sen
##si
##ti
##vity
can
occur
and
may
include
generalized
r
##ash
/
er
##yt
##hem
##a
,
h
##y
##pot
##ens
##ion
and
br
##on
##cho
##sp
##as
##m
.
[SEP]
[CLS]
Prior
to
in
##iti
##ating
S
##IM
##PO
##NI
ARIA
,
assess
if
treatment
for
late
##nt
tuberculosis
is
needed
;
An
in
##du
##ration
of
5
mm
or
greater
is
a
positive
tube
##rc
##ulin
skin
test
,
even
[SEP]
[CLS]
for
patients
previously
v
##ac
##cin
##ated
with
Ba
##ci
##lle
Cal
##mett
##e
-
G
##uer
##in
(
BC
##G
)
.
[SEP]
[CLS]
Do
not
use
N
##U
##L
##O
##J
##IX
in
transplant
recipients
who
are
E
##B
##V
se
##rone
##gat
##ive
or
with
unknown
se
##ros
##tat
##us
.
[SEP]
[CLS]
5
.
7
Ph
##eo
##ch
##rom
##oc
##yt
##oma
There
is
no
information
to
guide
use
of
C
##lev
##ip
##re
##x
in
treating
h
##yper
##tens
##ion
associated
with
p
##he
##och
##rom
##oc
##yt
##oma
.
[SEP]
[CLS]
In
##vasive
Fun
##gal
In
##fect
##ions
If
patients
develop
a
serious
systemic
illness
and
they
reside
or
travel
in
regions
where
my
##cos
##es
are
endemic
,
consider
invasive
fun
##gal
infection
in
the
differential
diagnosis
[SEP]
[CLS]
.
[SEP]
[CLS]
In
the
event
of
re
##c
##rud
##es
##cent
P
.
f
##al
##ci
##par
##um
infection
after
treatment
with
Co
##arte
##m
Table
##ts
,
patients
should
be
treated
with
a
different
anti
##mal
##aria
##l
drug
.
[SEP]
[CLS]
Most
cases
occurred
in
association
with
se
##psis
,
de
##hy
##dra
##tion
,
or
o
##bs
##truct
##ive
u
##rop
##athy
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
The
most
common
cause
of
deaths
occurring
in
patients
(
%
)
in
the
two
arms
(
K
##R
##d
versus
Rd
)
included
[SEP]
[CLS]
re
##nal
0
(
0
%
)
versus
1
(
<
1
%
)
,
and
other
adverse
events
9
(
2
%
)
versus
10
(
3
%
)
.
[SEP]
[CLS]
Gala
##ctor
##r
##hea
,
am
##eno
##rr
##hea
,
g
##yne
##com
##ast
##ia
,
and
imp
##ote
##nce
have
been
reported
in
patients
receiving
pro
##la
##ct
##in
-
el
##eva
##ting
compounds
.
[SEP]
[CLS]
Such
monitoring
may
increase
the
risk
of
unnecessary
procedures
,
due
to
the
low
specific
##ity
of
serum
ca
##l
##ci
##ton
##in
testing
for
M
##TC
and
a
high
background
incidence
of
thy
##roid
disease
.
[SEP]
[CLS]
In
clinical
trials
,
the
most
common
adverse
reactions
(
>
=
5
%
)
following
al
##g
##lu
##cos
##idas
##e
al
##fa
treatment
were
h
##yper
##sen
##si
##ti
##vity
reactions
,
and
included
an
##aph
##yla
##xi
##s
,
r
##ash
,
[SEP]
[CLS]
p
##yre
##xia
,
flush
##ing
/
feeling
hot
,
u
##rt
##ica
##ria
,
headache
,
h
##yper
##hi
##dr
##osis
,
nausea
,
cough
,
decreased
oxygen
sat
##uration
,
ta
##chy
##card
##ia
,
ta
##chy
##p
##nea
,
chest
discomfort
,
di
##zzi
##ness
,
[SEP]
[CLS]
muscle
twitch
##ing
,
agitation
,
c
##yan
##osis
,
er
##yt
##hem
##a
,
h
##yper
##tens
##ion
/
increased
blood
pressure
,
p
##allo
##r
,
rig
##ors
,
t
##rem
##or
,
vomit
##ing
,
fatigue
,
and
my
##al
##gia
.
[SEP]
[CLS]
There
is
no
experience
with
anti
##fi
##bri
##no
##ly
##tic
agents
(
t
##rane
##xa
##mic
acid
,
amino
##cap
##roi
##c
acid
)
in
individuals
receiving
a
##pi
##xa
##ban
.
[SEP]
[CLS]
Two
of
the
patients
(
1
%
)
with
persistent
##ly
positive
antibodies
experienced
adverse
reactions
consistent
with
in
##fusion
reactions
that
led
to
disco
##ntin
##uation
of
treatment
.
[SEP]
[CLS]
5
.
10
Women
of
Child
##be
##aring
Po
##ten
##tial
Pre
##men
##op
##aus
##al
women
who
have
not
undergone
a
h
##yster
##ec
##tom
##y
or
o
##op
##hore
##ct
##omy
must
use
effective
con
##tra
##ception
while
using
M
##U
##LT
##A
##Q
.
[SEP]
[CLS]
Overall
,
a
higher
incidence
of
in
##fusion
related
reactions
was
observed
in
patients
who
developed
persistent
##ly
positive
antibodies
.
[SEP]
[CLS]
The
median
age
was
54
years
,
57
%
were
male
,
and
>
99
%
were
white
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
Evaluation
of
erect
##ile
d
##ys
##function
(
E
##D
)
should
include
an
appropriate
medical
assessment
to
identify
potential
underlying
causes
,
as
well
as
treatment
options
.
[SEP]
[CLS]
If
liver
injury
is
found
,
institute
appropriate
treatment
and
investigate
the
probable
cause
.
[SEP]
[CLS]
Pre
##med
##ica
##te
all
patients
prior
to
the
initiation
of
the
in
##fusion
of
J
##E
##V
##TA
##NA
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
5
.
4
Pan
##cy
##top
##enia
(
Use
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
Alfa
)
Ser
##ious
cases
of
pan
##cy
##top
##enia
have
been
reported
post
##market
##ing
in
patients
receiving
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
*
He
##pa
##to
##to
##xi
##city
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
*
See
you
healthcare
provider
right
away
if
you
get
v
##agi
##nal
bleeding
while
taking
D
##U
##AV
##EE
.
[SEP]
[CLS]
In
two
controlled
clinical
trials
in
patients
with
chronic
he
##pa
##titis
C
and
th
##rom
##bo
##cy
##top
##enia
,
as
##cite
##s
and
en
##ce
##pha
##lop
##athy
occurred
more
frequently
on
the
arm
receiving
treatment
with
PR
##OM
##AC
##TA
plus
anti
##vir
##als
(
[SEP]
[CLS]
7
%
)
than
the
place
##bo
plus
anti
##vir
##als
arm
(
4
%
)
.
[SEP]
[CLS]
5
.
4
Ren
##al
F
##ail
##ure
In
the
random
##ized
clinical
trial
,
re
##nal
failure
of
any
grade
occurred
in
4
%
of
the
patients
being
treated
with
J
##E
##V
##TA
##NA
,
including
four
cases
with
[SEP]
[CLS]
fatal
outcome
.
[SEP]
[CLS]
T
##hr
##omb
##oe
##mbo
##lic
events
were
reported
in
clinical
trials
with
VI
##CT
##RE
##L
##IS
among
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
,
and
among
those
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
,
regardless
of
E
##SA
use
[SEP]
[CLS]
.
[SEP]
[CLS]
Given
the
similarity
in
h
##yper
##sen
##si
##ti
##vity
symptoms
and
acute
H
##A
##E
symptoms
,
monitor
patients
closely
for
h
##yper
##sen
##si
##ti
##vity
reactions
(
5
)
.
[SEP]
[CLS]
AM
##PL
##IF
##Y
Study
The
mean
duration
of
exposure
to
E
##L
##I
##Q
##UI
##S
was
154
days
and
to
en
##ox
##apa
##rin
/
war
##fari
##n
was
152
days
in
the
AM
##PL
##IF
##Y
study
.
[SEP]
[CLS]
N
##eu
##tro
##pen
##ic
deaths
have
been
reported
.
[SEP]
[CLS]
Disco
##ntin
##ue
J
##E
##V
##TA
##NA
immediately
if
severe
reactions
occur
and
administer
appropriate
therapy
.
[SEP]
[CLS]
In
clinical
studies
,
there
were
uncommon
reports
of
is
##che
##mic
cardiac
adverse
reactions
,
including
my
##oc
##ard
##ial
is
##che
##mia
,
my
##oc
##ard
##ial
in
##far
##ction
,
and
co
##rona
##ry
o
##cc
##lusion
requiring
re
##vas
##cular
##ization
;
these
patients
had
[SEP]
[CLS]
multiple
underlying
cardiac
risk
factors
.
[SEP]
[CLS]
6
.
3
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
##ap
##p
##rov
##al
use
of
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Consider
interrupting
therapy
with
B
##EN
##L
##Y
##ST
##A
if
patients
develop
a
new
infection
during
treatment
with
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
Di
##ar
##r
##hea
Di
##ar
##r
##hea
has
resulted
in
de
##hy
##dra
##tion
with
or
without
re
##nal
imp
##air
##ment
;
some
of
these
cases
were
fatal
.
[SEP]
[CLS]
b
The
600
-
mg
dose
of
H
##OR
##I
##Z
##AN
##T
was
a
treatment
arm
in
2
of
the
3
double
-
blind
,
place
##bo
-
controlled
,
12
-
week
clinical
trials
.
[SEP]
[CLS]
The
proportion
of
patients
with
ps
##oria
##tic
art
##hr
##itis
who
discontinued
treatment
due
to
any
adverse
reaction
was
4
.
6
%
for
patients
taking
O
##TE
##Z
##LA
30
mg
twice
daily
and
1
.
2
%
for
[SEP]
[CLS]
place
##bo
-
treated
patients
.
[SEP]
[CLS]
In
clinical
studies
with
K
##y
##p
##rol
##is
,
these
events
typically
occurred
early
in
the
course
of
K
##y
##p
##rol
##is
therapy
(
<
5
cycles
)
.
[SEP]
[CLS]
In
the
presence
of
binding
and
neutral
##izing
antibodies
to
D
##Y
##SP
##OR
##T
(
r
)
some
patients
continue
to
experience
clinical
benefit
.
[SEP]
[CLS]
During
the
controlled
portion
of
the
Phase
3
trial
in
RA
for
S
##IM
##PO
##NI
ARIA
,
the
incidence
of
ma
##li
##gna
##ncies
other
than
l
##ymph
##oma
and
N
##MS
##C
per
100
-
patient
-
years
of
follow
-
up
was
0
.
56
[SEP]
[CLS]
(
95
%
C
##I
:
0
.
01
,
3
.
11
)
in
the
S
##IM
##PO
##NI
ARIA
group
compared
with
an
incidence
of
0
(
95
%
C
##I
:
0
.
00
,
3
.
79
)
in
[SEP]
[CLS]
the
place
##bo
group
.
[SEP]
[CLS]
Table
1
presents
adverse
reactions
reported
in
>
=
10
%
patients
who
received
IN
##L
##Y
##TA
or
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Table
9
:
Ad
##verse
Re
##actions
Report
##ed
in
2
%
or
More
of
Adult
Pat
##ients
in
Any
SA
##P
##H
##RI
##S
Do
##se
Group
and
Which
O
##cc
##ur
##red
at
Greater
Inc
##iden
##ce
Than
in
the
Place
##bo
Group
[SEP]
[CLS]
in
3
-
Week
B
##ip
##olar
Man
##ia
Trials
*
SA
##P
##H
##RI
##S
5
mg
to
10
mg
twice
daily
with
flexible
dos
##ing
.
[SEP]
[CLS]
These
events
were
con
##founded
by
con
##com
##ita
##nt
medications
and
/
or
pre
##ex
##ist
##ing
disease
,
and
the
relationship
to
G
##IL
##EN
##Y
##A
is
uncertain
.
[SEP]
[CLS]
V
##agi
##nal
bleeding
after
men
##op
##aus
##e
may
be
a
warning
sign
of
cancer
of
the
u
##ter
##us
(
w
##omb
)
.
[SEP]
[CLS]
IN
##L
##Y
##TA
has
not
been
studied
in
patients
with
severe
he
##pa
##tic
imp
##air
##ment
.
[SEP]
[CLS]
Pat
##ients
with
pre
-
existing
swallowing
or
breathing
difficulties
may
be
more
susceptible
to
these
complications
.
[SEP]
[CLS]
Pat
##ients
who
are
carriers
of
H
##B
##V
and
require
treatment
with
T
##NF
-
block
##ers
should
be
closely
monitored
for
clinical
and
laboratory
signs
of
active
H
##B
##V
infection
throughout
therapy
and
for
several
months
[SEP]
[CLS]
following
termination
of
therapy
.
[SEP]
[CLS]
Se
##vere
h
##y
##po
##gly
##ce
##mia
was
defined
as
an
event
consistent
with
h
##y
##po
##gly
##ce
##mia
where
the
patient
required
the
assistance
of
another
person
to
recover
,
lost
consciousness
,
or
experienced
a
seizure
(
[SEP]
[CLS]
regardless
of
whether
bio
##chemical
documentation
of
a
low
glucose
value
was
obtained
)
.
[SEP]
[CLS]
In
the
pool
of
four
place
##bo
-
controlled
clinical
trials
,
male
g
##eni
##tal
my
##cot
##ic
infections
(
e
.
g
.
,
can
##di
##dal
b
##alan
##itis
,
b
##alan
##op
##ost
##hit
##is
)
occurred
in
0
.
6
%
,
4
.
2
%
,
and
[SEP]
[CLS]
3
.
7
%
of
males
treated
with
place
##bo
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
S
Includes
subjects
treated
with
flexible
dose
of
SA
##P
##H
##RI
##S
5
or
10
mg
twice
daily
(
N
=
90
)
.
[SEP]
[CLS]
Four
place
##bo
-
controlled
and
one
active
-
controlled
trials
of
16
weeks
up
through
two
years
in
duration
were
conducted
in
combination
with
met
##form
##in
,
in
combination
with
p
##io
##gli
##ta
##zone
and
with
p
##io
##gli
##ta
##zone
added
[SEP]
[CLS]
to
a
background
of
met
##form
##in
therapy
.
[SEP]
[CLS]
The
frequency
of
2
+
protein
##uria
was
similar
between
the
two
treatment
groups
between
one
and
three
years
after
transplant
##ation
(
<
10
%
in
both
studies
)
.
[SEP]
[CLS]
The
data
reflect
the
percentage
of
patients
whose
test
results
were
positive
for
antibodies
to
be
##lat
##ace
##pt
in
specific
ass
##ays
.
[SEP]
[CLS]
5
.
13
Red
##uction
in
Bone
Mine
##ral
Den
##sity
Dec
##rease
##s
in
bone
mineral
density
)
have
been
observed
with
long
-
term
administration
of
products
containing
inhaled
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
The
need
for
continued
treatment
should
be
re
##ass
##essed
periodically
.
[SEP]
[CLS]
The
safety
evaluation
of
NO
##RT
##H
##ER
##A
is
based
on
two
place
##bo
-
controlled
studies
1
to
2
weeks
in
duration
(
Studies
301
and
302
)
,
one
8
-
week
place
##bo
-
controlled
study
(
Study
[SEP]
[CLS]
306
)
,
and
two
long
-
term
,
open
-
label
extension
studies
(
Studies
303
and
304
)
.
[SEP]
[CLS]
P
##sy
##chia
##tric
disorders
:
An
##xi
##ety
,
bi
##pol
##ar
disorder
,
and
suicide
attempt
.
[SEP]
[CLS]
(
5
.
3
)
*
W
##ou
##nd
Co
##mp
##lication
##s
:
With
##hold
CO
##ME
##TR
##I
##Q
for
de
##his
##cence
or
complications
requiring
medical
intervention
.
[SEP]
[CLS]
For
infectious
adverse
reactions
,
the
ca
##usa
##tive
organism
is
reported
if
specified
by
the
physician
in
the
clinical
trials
.
[SEP]
[CLS]
Per
##io
##per
##ative
H
##yper
##tens
##ion
The
place
##bo
-
controlled
experience
with
C
##lev
##ip
##re
##x
in
the
per
##io
##per
##ative
setting
was
both
small
and
brief
(
about
30
minutes
)
.
[SEP]
[CLS]
Met
##ab
##olis
##m
and
nutrition
disorders
:
metabolic
acid
##osis
,
de
##hy
##dra
##tion
.
[SEP]
[CLS]
If
a
patient
is
exposed
to
chicken
##pox
,
prop
##hyl
##ax
##is
with
var
##ice
##lla
z
##ost
##er
immune
g
##lo
##bul
##in
(
V
##Z
##IG
)
may
be
indicated
.
[SEP]
[CLS]
Overall
,
4
%
of
subjects
reported
one
or
more
adverse
reactions
following
E
##O
##VI
##ST
administration
.
[SEP]
[CLS]
5
.
2
All
##ergic
Re
##actions
As
with
any
in
##ject
##able
drug
product
,
all
##ergic
reactions
and
an
##aph
##yla
##xi
##s
may
occur
.
[SEP]
[CLS]
If
pan
##cre
##ati
##tis
is
suspected
,
promptly
disco
##ntin
##ue
T
##R
##U
##L
##IC
##IT
##Y
.
[SEP]
[CLS]
Table
4
provides
the
adverse
reactions
occurring
in
at
least
10
%
of
subjects
receiving
Z
##yd
##eli
##g
mon
##otherapy
,
and
Table
5
provides
the
treatment
-
emerge
##nt
laboratory
abnormal
##ities
.
[SEP]
[CLS]
In
Study
1
,
p
##ne
##um
##oni
##tis
was
reported
in
4
%
of
255
patients
treated
with
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
He
##mat
##olo
##gic
To
##xi
##city
Bel
##eo
##da
##q
can
cause
th
##rom
##bo
##cy
##top
##enia
,
le
##uk
##ope
##nia
(
ne
##ut
##rop
##enia
and
l
##ymph
##ope
##nia
)
,
and
/
or
an
##emia
;
monitor
blood
counts
weekly
during
treatment
,
and
modify
[SEP]
[CLS]
dos
##age
as
necessary
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
3
Live
##r
Disease
Disco
##ntin
##ue
Nat
##azi
##a
if
j
##au
##ndi
##ce
develops
.
[SEP]
[CLS]
One
(
0
.
2
%
)
patient
died
as
a
result
of
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
and
one
additional
patient
required
hospital
##ization
for
severe
der
##mat
##itis
.
[SEP]
[CLS]
The
increased
risk
of
su
##icidal
thoughts
with
A
##ED
##s
was
observed
as
early
as
one
week
after
starting
drug
treatment
with
A
##ED
##s
and
persisted
for
the
duration
of
treatment
assessed
.
[SEP]
[CLS]
5
.
5
G
##all
##bla
##dder
Disease
Studies
suggest
a
small
increased
relative
risk
of
developing
gal
##l
##bla
##dder
disease
among
CO
##C
users
.
[SEP]
[CLS]
Ad
##verse
reactions
of
Grade
3
or
higher
were
reported
in
80
%
of
patients
.
[SEP]
[CLS]
Pro
##tamine
su
##lf
##ate
and
vitamin
K
are
not
expected
to
affect
the
anti
##coa
##gu
##lant
activity
of
da
##bi
##gat
##ran
.
[SEP]
[CLS]
(
5
.
1
)
*
Some
patients
with
re
##tina
##l
abnormal
##ities
have
been
found
to
have
abnormal
visual
a
##cu
##ity
.
[SEP]
[CLS]
(
5
.
1
,
6
.
1
)
*
I
##mp
##air
##ment
in
re
##nal
function
:
Monitor
re
##nal
function
during
therapy
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Me
##rz
Ph
##arma
##ce
##utical
##s
,
LLC
at
88
##8
-
49
##3
-
66
##46
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
All
patients
taking
P
##OT
##IG
##A
should
have
base
##line
and
periodic
(
every
6
months
)
systematic
visual
monitoring
by
an
op
##ht
##hal
##mic
professional
.
[SEP]
[CLS]
In
this
study
,
76
%
(
44
of
58
)
completed
all
planned
therapy
.
[SEP]
[CLS]
*
N
##eur
##ological
toxic
##ities
,
which
may
be
severe
,
life
-
threatening
,
or
fatal
,
occurred
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
Alternatively
,
administration
of
non
-
enter
##ic
coated
as
##pi
##rin
(
up
to
a
dose
of
325
mg
)
30
minutes
prior
to
T
##EC
##FI
##DE
##RA
dos
##ing
may
reduce
the
incidence
or
severity
of
[SEP]
[CLS]
flush
##ing
[
see
Do
##sing
and
Administration
(
2
.
1
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
The
most
frequent
second
primary
ma
##li
##gna
##ncy
was
non
-
me
##lan
##oma
skin
cancer
(
range
,
4
to
11
%
)
.
[SEP]
[CLS]
5
.
2
H
##yper
##sen
##si
##ti
##vity
Clinical
##ly
significant
h
##yper
##sen
##si
##ti
##vity
including
an
##aph
##yla
##xi
##s
has
been
reported
with
Pro
##lia
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
V
##ert
##ex
Ph
##arma
##ce
##utical
##s
Incorporated
at
1
-
87
##7
-
63
##4
-
87
##8
##9
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Events
related
to
visual
changes
were
also
observed
in
mon
##otherapy
trials
.
[SEP]
[CLS]
The
impact
of
treatment
with
C
##IM
##Z
##IA
on
the
development
and
course
of
ma
##li
##gna
##ncies
,
as
well
as
active
and
/
or
chronic
infections
,
is
not
fully
understood
[
see
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
,
5
.
5
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Fat
##al
pulmonary
em
##bol
##ism
was
reported
in
1
/
35
##9
patients
(
<
1
%
)
receiving
IN
##L
##Y
##TA
and
none
of
the
patients
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
In
most
cases
the
reactions
were
of
mild
or
moderate
intensity
.
[SEP]
[CLS]
The
sudden
drop
in
est
##rogen
levels
causes
`
`
surgical
men
##op
##aus
##e
.
[SEP]
[CLS]
Monitor
patients
periodically
.
[SEP]
[CLS]
The
most
frequently
reported
of
these
adverse
reactions
were
headache
,
na
##so
##pha
##ryn
##git
##is
,
injection
site
pain
,
sin
##us
##itis
,
U
##RI
,
injection
site
br
##ui
##sing
,
and
injection
site
reaction
)
[SEP]
[CLS]
.
[SEP]
[CLS]
6
.
2
I
##mm
##uno
##genic
##ity
As
with
all
therapeutic
proteins
,
there
is
a
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
Ad
##verse
reactions
with
G
##IL
##EN
##Y
##A
0
.
5
mg
in
Study
2
,
the
1
-
year
active
-
controlled
(
versus
inter
##fer
##on
beta
-
1
##a
)
study
were
generally
similar
to
those
in
Studies
1
and
3
.
[SEP]
[CLS]
Screen
all
patients
for
re
##nal
imp
##air
##ment
by
obtaining
a
history
and
/
or
laboratory
tests
.
[SEP]
[CLS]
Grade
3
and
higher
adverse
reactions
were
reported
among
47
%
of
X
##TA
##ND
##I
-
treated
patients
and
53
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
adverse
events
occurring
in
>
=
5
%
of
X
##E
##OM
##IN
-
treated
patients
and
greater
than
place
##bo
in
the
Phase
3
study
were
eye
##lid
p
##tosis
,
dry
eye
,
dry
mouth
,
[SEP]
[CLS]
di
##ar
##r
##hea
,
headache
,
visual
imp
##air
##ment
,
d
##ys
##p
##nea
,
na
##so
##pha
##ryn
##git
##is
,
and
respiratory
tract
infection
.
[SEP]
[CLS]
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
(
5
.
2
)
*
To
##via
##z
,
like
other
anti
##mus
##car
##ini
##c
drugs
,
should
be
used
with
caution
in
patients
with
decreased
gas
##tro
##int
##est
##inal
m
##ot
##ility
,
such
as
those
with
severe
con
##st
##ip
##ation
.
[SEP]
[CLS]
A
##ED
##s
increase
the
risk
of
su
##icidal
thoughts
in
patients
taking
these
drugs
for
any
indication
.
[SEP]
[CLS]
5
.
2
Ser
##ious
In
##fect
##ions
Ser
##ious
and
sometimes
fatal
infections
have
been
reported
in
patients
receiving
im
##mu
##nos
##up
##pressive
agents
,
including
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
Analysis
of
seventeen
place
##bo
-
controlled
trials
(
m
##oda
##l
duration
10
weeks
)
,
largely
in
patients
taking
at
##y
##pical
anti
##psy
##cho
##tic
drugs
,
revealed
a
risk
of
death
in
the
drug
-
treated
patients
of
[SEP]
[CLS]
between
1
.
6
to
1
.
7
times
the
risk
of
death
in
place
##bo
-
treated
patients
.
[SEP]
[CLS]
5
.
6
Other
I
##mm
##une
-
mediated
Ad
##verse
Re
##actions
,
Including
O
##cular
Man
##ife
##sta
##tions
The
following
clinical
##ly
significant
immune
-
mediated
adverse
reactions
were
seen
in
less
than
1
%
of
Y
##ER
##VO
##Y
-
treated
patients
in
Study
1
:
[SEP]
[CLS]
ne
##ph
##rit
##is
,
p
##ne
##um
##oni
##tis
,
men
##ing
##itis
,
per
##ica
##rdi
##tis
,
u
##ve
##itis
,
i
##rit
##is
,
and
hem
##oly
##tic
an
##emia
.
[SEP]
[CLS]
The
majority
of
the
most
common
adverse
reactions
presented
in
##T
##able
2
##oc
##cu
##rred
within
the
first
2
weeks
of
treatment
and
tended
to
resolve
over
time
with
continued
dos
##ing
.
[SEP]
[CLS]
5
.
2
H
##y
##pot
##ens
##ion
and
Re
##fle
##x
Ta
##chy
##card
##ia
C
##lev
##ip
##re
##x
may
produce
systemic
h
##y
##pot
##ens
##ion
and
reflex
ta
##chy
##card
##ia
.
[SEP]
[CLS]
Ad
##vise
patients
to
contact
their
healthcare
provider
if
they
become
pregnant
,
or
if
pregnancy
is
suspected
,
while
taking
T
##AF
##IN
##LA
##R
[
see
Drug
Inter
##actions
(
7
.
2
)
,
Use
[SEP]
[CLS]
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
B
##lee
##ding
was
assessed
in
each
study
beginning
with
the
first
dose
of
double
-
blind
study
drug
.
[SEP]
[CLS]
For
patients
receiving
C
##lev
##ip
##re
##x
and
all
active
com
##par
##ators
the
incidence
of
serious
adverse
events
within
one
hour
of
drug
in
##fusion
disco
##ntin
##uation
was
similar
.
[SEP]
[CLS]
5
.
11
F
##lu
##id
Re
##ten
##tion
E
##stro
##gens
may
cause
some
degree
of
fluid
retention
.
[SEP]
[CLS]
For
patients
with
SE
##GA
and
severe
he
##pa
##tic
imp
##air
##ment
,
reduce
the
starting
dose
of
A
##FI
##NI
##TO
##R
Table
##ts
or
A
##FI
##NI
##TO
##R
D
##IS
##P
##ER
##Z
by
approximately
50
%
and
adjust
subsequent
doses
based
on
therapeutic
[SEP]
[CLS]
drug
monitoring
[
see
Do
##sa
##ge
and
Administration
(
2
.
4
,
2
.
5
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reaction
leading
to
treatment
disco
##ntin
##uation
in
the
J
##E
##V
##TA
##NA
group
was
ne
##ut
##rop
##enia
(
2
%
)
.
[SEP]
[CLS]
Since
many
of
the
patients
in
the
Phase
3
trial
were
also
taking
medications
that
cause
liver
enzyme
elevations
(
e
.
g
.
,
non
##ster
##oid
##al
anti
-
inflammatory
drugs
[
NSA
##ID
##s
]
,
met
##hot
##re
##xa
##te
[SEP]
[CLS]
[
M
##T
##X
]
,
or
is
##onia
##zi
##d
prop
##hyl
##ax
##is
)
,
the
relationship
between
S
##IM
##PO
##NI
ARIA
and
liver
enzyme
elevation
is
not
clear
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
(
2
.
1
,
5
.
3
)
5
.
1
H
##yper
##sen
##si
##ti
##vity
Re
##actions
H
##yper
##sen
##si
##ti
##vity
reactions
such
as
flush
##ing
and
d
##ys
##p
##nea
have
[SEP]
[CLS]
been
observed
within
minutes
following
V
##iza
##my
##l
administration
.
[SEP]
[CLS]
O
##bs
##erve
patients
for
signs
and
symptoms
of
h
##yper
##sen
##si
##ti
##vity
reactions
during
and
following
E
##O
##VI
##ST
administration
.
[SEP]
[CLS]
Pat
##ients
who
demonstrate
hem
##ody
##nam
##ic
instability
on
alpha
-
block
##er
therapy
alone
are
at
increased
risk
of
s
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
with
con
##com
##ita
##nt
use
of
PD
##E
##5
inhibitor
##s
.
[SEP]
[CLS]
Skin
bio
##psy
in
one
patient
demonstrated
deposition
of
anti
-
r
##h
##GA
##A
antibodies
in
the
les
##ion
.
[SEP]
[CLS]
Case
##s
of
chronic
le
##uke
##mia
have
been
reported
in
association
with
post
-
marketing
T
##NF
-
block
##er
use
in
RA
and
other
indication
##s
.
[SEP]
[CLS]
Therefore
,
patients
should
be
monitored
for
decreased
efficacy
and
food
consumption
should
be
encouraged
while
taking
Co
##arte
##m
Table
##ts
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
,
Drug
Inter
##actions
[SEP]
[CLS]
(
7
.
4
)
,
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
(
5
.
1
,
12
.
6
)
*
Hal
##of
##ant
##rine
and
Co
##arte
##m
Table
##ts
should
not
be
administered
within
one
month
of
each
other
due
to
potential
add
##itive
effects
on
the
Q
##T
interval
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
greater
than
or
equal
to
20
%
)
were
nausea
,
fatigue
,
cough
,
di
##ar
##r
##hea
,
and
headache
.
[SEP]
[CLS]
e
Includes
the
following
terms
:
brain
stem
hem
##or
##r
##hage
,
cerebral
hem
##or
##r
##hage
,
gas
##tric
hem
##or
##r
##hage
,
e
##pis
##ta
##xi
##s
,
g
##ing
##ival
hem
##or
##r
##hage
,
hem
##at
##uria
,
v
##agi
##nal
hem
##or
##r
##hage
,
hem
##or
##r
##hage
in
##tra
##c
##rani
##al
,
[SEP]
[CLS]
eye
hem
##or
##r
##hage
,
and
v
##it
##re
##ous
hem
##or
##r
##hage
.
[SEP]
[CLS]
6
.
2
I
##mm
##uno
##genic
##ity
In
the
K
##AL
##BI
##TO
##R
H
##A
##E
program
,
patients
developed
antibodies
to
K
##AL
##BI
##TO
##R
.
[SEP]
[CLS]
If
used
in
combination
with
tram
##eti
##ni
##b
,
no
dose
modification
of
tram
##eti
##ni
##b
is
required
for
patients
who
develop
non
-
cut
##aneous
ma
##li
##gna
##ncies
.
[SEP]
[CLS]
G
##I
bleed
includes
re
##ct
##al
bleeding
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
led
to
withdrawal
in
<
1
%
of
patients
receiving
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
compared
with
2
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
incidence
>
=
30
%
)
were
s
##tom
##ati
##tis
,
infections
,
r
##ash
,
fatigue
,
di
##ar
##r
##hea
,
and
decreased
appetite
.
[SEP]
[CLS]
Pat
##ients
may
present
with
fatigue
,
headache
,
mental
status
changes
,
abdominal
pain
,
unusual
bow
##el
habits
,
and
h
##y
##pot
##ens
##ion
,
or
non
##sp
##ec
##ific
symptoms
which
may
resemble
other
causes
[SEP]
[CLS]
such
as
brain
meta
##sta
##sis
or
underlying
disease
.
[SEP]
[CLS]
In
a
3
-
week
,
place
##bo
-
controlled
p
##ediatric
trial
with
bi
##pol
##ar
I
disorder
,
the
mean
increases
(
at
End
##point
)
in
pro
##la
##ct
##in
levels
were
3
.
2
ng
/
m
##L
for
patients
treated
with
SA
##P
##H
##RI
##S
[SEP]
[CLS]
2
.
5
mg
twice
daily
,
2
.
1
ng
/
m
##L
for
patients
treated
with
SA
##P
##H
##RI
##S
5
mg
twice
daily
,
and
6
.
4
ng
/
m
##L
for
patients
treated
with
SA
##P
##H
##RI
##S
10
mg
twice
daily
compared
[SEP]
[CLS]
to
an
increase
of
2
.
5
ng
/
m
##L
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
(
2
.
3
,
5
.
3
)
*
He
##pa
##tic
toxicity
:
Fat
##al
he
##pa
##tic
imp
##air
##ment
occurs
in
0
.
18
%
of
patients
.
[SEP]
[CLS]
5
.
4
Su
##icidal
Be
##ha
##vior
and
I
##dea
##tion
H
##OR
##I
##Z
##AN
##T
(
g
##aba
##pent
##in
en
##aca
##rb
##il
)
is
a
pro
##dr
##ug
of
g
##aba
##pent
##in
,
an
anti
##ep
##ile
##ptic
drug
(
A
##ED
)
.
[SEP]
[CLS]
All
9
patients
had
h
##y
##pop
##it
##uit
##aris
##m
and
some
had
additional
con
##com
##ita
##nt
end
##oc
##rino
##path
##ies
such
as
ad
##rena
##l
ins
##uff
##iciency
,
h
##y
##po
##gon
##adi
##sm
,
and
h
##y
##pot
##hy
##roid
##ism
.
[SEP]
[CLS]
Re
##current
reactions
consisting
of
flu
-
like
illness
or
a
combination
of
events
such
as
p
##yre
##xia
,
chill
##s
,
my
##al
##gia
,
art
##hra
##l
##gia
,
pain
,
or
fatigue
occurring
after
completion
of
in
##fusion
##s
[SEP]
[CLS]
and
lasting
usually
for
1
-
3
days
have
been
observed
in
some
patients
treated
with
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
Several
patients
had
a
prior
history
of
pan
##cre
##ati
##tis
.
[SEP]
[CLS]
The
higher
risk
of
falls
for
patients
treated
with
IN
##VO
##KA
##NA
was
observed
within
the
first
few
weeks
of
treatment
.
[SEP]
[CLS]
Ad
##vise
females
of
reproductive
potential
of
the
potential
risk
to
a
f
##etus
and
use
of
effective
con
##tra
##ception
.
[SEP]
[CLS]
Care
##ful
consideration
should
be
given
to
the
patient
'
s
clinical
status
prior
to
administration
of
V
##im
##iz
##im
and
consider
delay
##ing
the
V
##im
##iz
##im
in
##fusion
(
5
.
2
)
.
[SEP]
[CLS]
5
.
6
Tu
##mor
L
##ys
##is
S
##yn
##drome
Tu
##mor
l
##ys
##is
syndrome
has
been
reported
with
I
##MB
##R
##U
##VI
##CA
therapy
.
[SEP]
[CLS]
Pat
##ients
experienced
relief
of
symptoms
upon
disco
##ntin
##uation
of
the
medication
.
[SEP]
[CLS]
The
safety
profile
for
patients
in
study
AS
-
1
treated
with
C
##IM
##Z
##IA
was
similar
to
the
safety
profile
seen
in
patients
with
RA
.
[SEP]
[CLS]
Heart
Rate
Inc
##rease
and
Ta
##chy
##card
##ia
Re
##lated
Ad
##verse
Re
##actions
.
[SEP]
[CLS]
All
were
serious
and
one
G
##I
fist
##ula
was
fatal
(
<
1
%
)
.
[SEP]
[CLS]
These
hem
##ato
##mas
may
result
in
permanent
para
##lysis
(
5
.
3
)
.
[SEP]
[CLS]
Ad
##verse
reactions
related
to
re
##nal
function
can
occur
after
in
##iti
##ating
FA
##R
##X
##IG
##A
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
[
See
Do
##sa
##ge
and
Administration
(
2
.
2
)
.
]
[SEP]
[CLS]
Ra
##sh
was
reported
more
frequently
in
female
subjects
than
in
male
subjects
(
r
##ash
>
=
Grade
2
was
reported
in
13
/
64
[
20
.
3
%
]
females
versus
2
/
37
[
[SEP]
[CLS]
5
.
4
%
]
males
;
disco
##ntin
##uations
due
to
r
##ash
were
reported
in
4
/
64
[
6
.
3
%
]
females
versus
0
/
37
[
0
%
]
males
)
.
[SEP]
[CLS]
Ad
##re
##V
##ie
##w
imaging
should
not
be
performed
if
disco
##ntin
##uation
of
these
medications
would
involve
risks
which
out
##wei
##gh
the
value
of
Ad
##re
##V
##ie
##w
imaging
.
[SEP]
[CLS]
These
findings
were
generally
observed
within
the
first
12
weeks
of
treatment
and
were
re
##versible
with
dose
interrupt
##ion
.
[SEP]
[CLS]
The
safety
of
Z
##Y
##TI
##GA
in
patients
with
left
vent
##ric
##ular
e
##jection
fraction
<
50
%
or
New
York
Heart
Association
(
NY
##HA
)
Class
III
or
IV
heart
failure
(
in
[SEP]
[CLS]
Study
1
)
or
NY
##HA
Class
II
to
IV
heart
failure
(
in
Study
2
)
was
not
established
because
these
patients
were
excluded
from
these
random
##ized
clinical
trials
[
[SEP]
[CLS]
see
##C
##lini
##cal
Studies
(
14
)
]
.
[SEP]
[CLS]
The
patient
demographic
##s
were
similar
to
Studies
1
and
2
.
[SEP]
[CLS]
5
.
3
I
##mm
##une
-
mediated
Der
##mat
##itis
In
Study
1
,
severe
,
life
-
threatening
,
or
fatal
immune
-
mediated
der
##mat
##itis
(
e
##g
,
Stevens
-
Johnson
syndrome
,
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
,
or
r
##ash
complicated
by
full
[SEP]
[CLS]
thickness
der
##mal
ul
##cer
##ation
;
Grade
3
-
5
)
occurred
in
13
(
2
.
5
%
)
Y
##ER
##VO
##Y
-
treated
patients
.
[SEP]
[CLS]
He
##pa
##tic
ad
##eno
##mas
are
associated
with
CO
##C
use
.
[SEP]
[CLS]
Laboratory
abnormal
##ities
considered
AD
##R
##s
are
included
in
Table
2
.
[SEP]
[CLS]
In
some
incidence
##s
these
pneumonia
events
were
fatal
.
[SEP]
[CLS]
5
.
5
Gas
##tro
##int
##est
##inal
To
##xi
##city
Na
##use
##a
,
vomit
##ing
and
di
##ar
##r
##hea
occur
with
Bel
##eo
##da
##q
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
and
may
require
the
use
of
anti
##em
##etic
and
anti
##dia
##rr
##hea
##l
medications
.
[SEP]
[CLS]
G
##RA
##NI
##X
clinical
trials
safety
data
are
based
upon
the
results
of
three
random
##ized
clinical
trials
in
patients
receiving
my
##elo
##ab
##lative
ch
##em
##otherapy
for
breast
cancer
(
N
=
34
##8
)
,
lung
cancer
(
[SEP]
[CLS]
N
=
240
)
and
non
-
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
(
N
=
92
)
.
[SEP]
[CLS]
When
medical
##ly
feasible
,
stop
these
drugs
before
Ad
##re
##V
##ie
##w
administration
and
monitor
patients
for
the
occurrence
of
clinical
##ly
significant
withdrawal
symptoms
,
especially
patients
with
elevated
levels
of
circulating
cat
##ech
##ola
##mine
##s
[SEP]
[CLS]
and
their
meta
##bol
##ites
.
[SEP]
[CLS]
Neo
##vas
##cular
(
Wet
)
Age
-
Re
##lated
Mac
##ular
De
##gene
##ration
(
AM
##D
)
The
data
described
below
reflect
exposure
to
E
##Y
##LE
##A
in
1824
patients
with
wet
AM
##D
,
including
122
##3
patients
treated
with
[SEP]
[CLS]
the
2
-
mg
dose
,
in
2
double
-
masked
,
active
-
controlled
clinical
studies
(
VI
##E
##W
##1
and
VI
##E
##W
##2
)
for
12
months
[
see
##C
##lini
##cal
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
C
##IM
##Z
##IA
should
be
discontinued
if
a
patient
develops
a
serious
infection
or
se
##psis
.
[SEP]
[CLS]
5
.
2
I
##mp
##air
##ment
in
Ren
##al
Fun
##ction
FA
##R
##X
##IG
##A
increases
serum
c
##rea
##tin
##ine
and
decreases
e
##G
##F
##R
.
[SEP]
[CLS]
Ad
##verse
reactions
which
occurred
in
>
=
25
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
occurring
more
frequently
in
the
CO
##ME
##TR
##I
##Q
arm
with
a
between
-
arm
difference
of
>
=
5
%
included
,
[SEP]
[CLS]
in
order
of
decreasing
frequency
:
di
##ar
##r
##hea
,
s
##tom
##ati
##tis
,
palm
##ar
-
plant
##ar
er
##yt
##hr
##ody
##ses
##the
##sia
syndrome
(
PP
##ES
)
,
decreased
weight
,
decreased
appetite
,
nausea
,
fatigue
,
oral
pain
,
[SEP]
[CLS]
hair
color
changes
,
d
##ys
##ge
##us
##ia
,
h
##yper
##tens
##ion
,
abdominal
pain
,
and
con
##st
##ip
##ation
.
[SEP]
[CLS]
Ad
##vise
women
of
potential
risk
to
a
f
##etus
.
[SEP]
[CLS]
The
most
common
non
-
hem
##ato
##log
##ic
adverse
reactions
(
>
=
30
%
)
were
nausea
(
75
%
)
,
fatigue
(
57
%
)
,
vomit
##ing
(
40
%
)
,
[SEP]
[CLS]
di
##ar
##r
##hea
(
37
%
)
and
p
##yre
##xia
(
34
%
)
.
[SEP]
[CLS]
If
abnormal
##ities
are
detected
,
monitoring
of
these
parameters
should
be
continued
to
ensure
that
further
de
##ter
##ior
##ation
does
not
occur
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reaction
is
discussed
in
greater
detail
in
other
sections
of
the
label
:
*
Trans
##ami
##nas
##e
El
##eva
##tions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
[SEP]
[CLS]
]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
drug
reactions
to
K
##AL
##Y
##DE
##CO
(
occurring
in
>
=
8
%
of
patients
with
CF
who
have
a
G
##55
##1
##D
mutation
in
the
CF
##TR
gene
[SEP]
[CLS]
)
were
headache
,
or
##op
##har
##yn
##ge
##al
pain
,
upper
respiratory
tract
infection
,
nasal
congestion
,
abdominal
pain
,
na
##so
##pha
##ryn
##git
##is
,
di
##ar
##r
##hea
,
r
##ash
,
nausea
,
and
di
##zzi
##ness
.
[SEP]
[CLS]
Some
patients
required
hospital
##ization
and
disco
##ntin
##uation
of
AP
##TI
##OM
.
[SEP]
[CLS]
If
a
serious
h
##yper
##sen
##si
##ti
##vity
reaction
is
suspected
,
disco
##ntin
##ue
NE
##SI
##NA
,
assess
for
other
potential
causes
for
the
event
and
institute
alternative
treatment
for
diabetes
[
see
##A
##d
##verse
Re
##actions
(
6
.
2
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
10
%
in
V
##im
##iz
##im
patients
and
occurring
at
a
higher
incidence
than
place
##bo
-
treated
patients
)
were
p
##yre
##xia
,
vomit
##ing
,
[SEP]
[CLS]
headache
,
nausea
,
abdominal
pain
,
chill
##s
,
and
fatigue
(
6
.
1
)
.
[SEP]
[CLS]
The
percentage
of
patients
who
withdrew
from
the
study
due
to
adverse
events
was
4
.
2
%
and
0
.
8
%
for
the
place
##bo
and
Pro
##lia
groups
,
respectively
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
and
Fat
##ig
##ue
AP
##TI
##OM
causes
dose
-
dependent
increases
in
so
##m
##no
##len
##ce
and
fatigue
-
related
adverse
reactions
(
fatigue
,
as
##the
##nia
,
ma
##lai
##se
,
h
##yper
##so
##m
##nia
,
se
##dation
,
and
let
##har
##gy
)
.
[SEP]
[CLS]
(
5
.
3
)
*
Ta
##rdi
##ve
D
##ys
##kin
##esi
##a
:
Disco
##ntin
##ue
if
clinical
##ly
appropriate
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
Se
##iz
##ure
occurred
in
0
.
9
%
of
patients
receiving
X
##TA
##ND
##I
who
previously
received
do
##ce
##ta
##xe
##l
and
in
0
.
1
%
of
patients
who
were
ch
##em
##otherapy
-
naive
.
[SEP]
[CLS]
2
##I
##nc
##lude
##s
the
preferred
terms
oral
h
##y
##po
##est
##hesia
,
oral
par
##est
##hesia
,
and
oral
d
##ys
##est
##hesia
.
[SEP]
[CLS]
Ad
##verse
reactions
that
occurred
after
repeated
injection
##s
in
2
-
3
%
of
the
population
included
br
##on
##chi
##tis
,
in
##fluenza
,
p
##har
##yn
##gol
##ary
##nge
##al
pain
,
cough
,
contact
der
##mat
##itis
,
injection
site
swelling
,
[SEP]
[CLS]
and
injection
site
discomfort
.
[SEP]
[CLS]
This
study
showed
a
statistical
##ly
significant
reduction
in
heart
rate
compared
to
base
##line
,
averaging
about
three
beats
per
minute
,
observed
thirty
minutes
after
injection
.
[SEP]
[CLS]
5
.
2
I
##mm
##une
-
Media
##ted
Re
##actions
I
##mm
##une
-
mediated
cut
##aneous
reactions
have
been
reported
with
al
##g
##lu
##cos
##idas
##e
al
##fa
including
ne
##c
##rot
##izing
skin
lesions
[
see
##A
##d
##verse
Re
##actions
(
6
.
3
)
]
.
[SEP]
[CLS]
In
##form
patients
of
the
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
,
h
##yper
##sen
##si
##ti
##vity
reactions
,
and
immune
-
mediated
reactions
and
have
them
seek
immediate
medical
care
should
signs
and
symptoms
occur
[
see
[SEP]
[CLS]
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
,
5
.
2
)
]
.
[SEP]
[CLS]
*
If
you
take
too
much
D
##U
##AV
##EE
,
call
your
healthcare
provider
.
[SEP]
[CLS]
In
addition
to
the
h
##yper
##sen
##si
##ti
##vity
reactions
reported
in
clinical
trials
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
,
the
following
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
reported
in
at
least
2
patients
[SEP]
[CLS]
and
included
:
an
##aph
##yla
##ctic
shock
,
respiratory
failure
,
respiratory
arrest
,
cardiac
arrest
,
h
##y
##pox
##ia
,
d
##ys
##p
##nea
,
w
##hee
##zing
,
con
##vu
##ls
##ions
,
peripheral
cold
##ness
,
restless
##ness
,
nervous
##ness
,
[SEP]
[CLS]
back
pain
,
s
##tri
##dor
,
p
##har
##yn
##ge
##al
ed
##ema
,
abdominal
pain
,
a
##p
##nea
,
muscle
spa
##sm
,
and
con
##junct
##iv
##itis
.
[SEP]
[CLS]
Risk
factors
for
PM
##L
include
treatment
with
im
##mu
##nos
##up
##press
##ant
the
##rap
##ies
and
imp
##air
##ment
of
immune
function
.
[SEP]
[CLS]
Ang
##io
##ede
##ma
associated
with
upper
air
##way
swelling
may
be
life
-
threatening
.
[SEP]
[CLS]
T
##it
##ration
was
used
over
the
first
5
days
[
see
Do
##sa
##ge
and
Administration
(
2
.
1
)
]
.
[SEP]
[CLS]
Across
the
clinical
development
program
for
Y
##ER
##VO
##Y
,
the
following
likely
immune
-
mediated
adverse
reactions
were
also
reported
with
less
than
1
%
incidence
:
my
##oc
##ard
##itis
,
an
##gio
##pathy
,
[SEP]
[CLS]
temporal
art
##eri
##tis
,
v
##as
##cu
##lit
##is
,
p
##oly
##my
##al
##gia
r
##he
##umatic
##a
,
con
##junct
##iv
##itis
,
b
##le
##pha
##rit
##is
,
e
##pis
##cle
##rit
##is
,
s
##cle
##rit
##is
,
le
##uk
##oc
##yt
##oc
##lastic
v
##as
##cu
##lit
##is
,
er
##yt
##hem
##a
multi
##form
##e
,
ps
##oria
##sis
,
pan
##cre
##ati
##tis
,
art
##hr
##itis
,
[SEP]
[CLS]
auto
##im
##mu
##ne
thy
##roid
##itis
,
sa
##rc
##oid
##osis
,
ne
##uro
##sen
##sor
##y
h
##y
##po
##ac
##us
##is
,
auto
##im
##mu
##ne
central
ne
##uro
##pathy
(
en
##ce
##pha
##lit
##is
)
,
my
##os
##itis
,
p
##oly
##my
##os
##itis
,
and
o
##cular
my
##os
##itis
.
[SEP]
[CLS]
period
##ont
##al
and
/
or
other
pre
-
existing
dental
disease
,
an
##emia
,
co
##agu
##lop
##athy
,
infection
,
ill
-
fitting
den
##tures
)
.
[SEP]
[CLS]
Prior
to
initiation
of
therapy
with
IL
##AR
##IS
,
patients
should
receive
all
recommended
v
##ac
##cin
##ations
.
[SEP]
[CLS]
Drugs
that
affect
the
immune
system
by
blocking
T
##NF
have
been
associated
with
an
increased
risk
of
new
tuberculosis
and
react
##ivation
of
late
##nt
tuberculosis
(
T
##B
)
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
In
the
pool
of
place
##bo
-
controlled
trials
,
gas
##tro
##int
##est
##inal
complaints
occurred
more
frequently
among
patients
receiving
T
##AN
##Z
##E
##UM
(
39
%
)
than
patients
receiving
place
##bo
(
33
%
[SEP]
[CLS]
)
.
[SEP]
[CLS]
5
.
6
Po
##ten
##tial
for
Tu
##mor
Growth
St
##im
##ulatory
Effects
on
Mali
##gnant
Cell
##s
The
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factor
(
G
-
CS
##F
)
receptor
through
which
G
##RA
##NI
##X
acts
has
been
found
on
tumor
cell
lines
.
[SEP]
[CLS]
Because
CE
##RD
##EL
##GA
is
predicted
to
cause
increases
in
EC
##G
intervals
(
PR
)
at
substantially
elevated
el
##ig
##lus
##tat
plasma
concentrations
,
use
of
CE
##RD
##EL
##GA
is
not
recommended
in
patients
with
pre
-
existing
[SEP]
[CLS]
cardiac
disease
(
con
##ges
##tive
heart
failure
,
recent
acute
my
##oc
##ard
##ial
in
##far
##ction
,
bra
##dy
##card
##ia
,
heart
block
,
vent
##ric
##ular
a
##rr
##hy
##th
##mia
)
,
long
Q
##T
syndrome
,
and
in
combination
with
Class
[SEP]
[CLS]
I
##A
(
e
.
g
.
,
q
##uin
##id
##ine
,
pro
##ca
##ina
##mi
##de
)
and
Class
III
(
e
.
g
.
,
am
##io
##dar
##one
,
so
##tal
##ol
)
anti
##ar
##r
##hy
##th
##mic
medications
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
Anti
##body
t
##iter
##s
were
determined
using
a
br
##id
##ging
enzyme
-
linked
im
##mu
##nos
##or
##bent
ass
##ay
(
E
##L
##IS
##A
)
for
anti
-
g
##lu
##car
##pid
##ase
antibodies
.
[SEP]
[CLS]
The
incidence
of
u
##rina
##ry
tract
infections
in
female
patients
random
##ized
to
place
##bo
,
J
##AR
##DI
##AN
##CE
10
mg
,
and
J
##AR
##DI
##AN
##CE
25
mg
was
16
.
6
%
,
18
.
4
%
,
and
17
.
0
[SEP]
[CLS]
%
,
respectively
.
[SEP]
[CLS]
Del
##ay
##ed
reactions
can
occur
up
to
several
days
after
administration
.
[SEP]
[CLS]
P
##sy
##chia
##tric
Di
##sor
##ders
:
ps
##ych
##otic
behavior
including
aggressive
thoughts
.
[SEP]
[CLS]
Inc
##reased
risk
of
th
##rom
##bot
##ic
events
after
premature
disco
##ntin
##uation
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
?
[SEP]
[CLS]
*
I
##mm
##une
Re
##con
##st
##itution
S
##yn
##drome
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
8
)
]
.
[SEP]
[CLS]
The
median
time
to
first
onset
of
any
grade
was
14
weeks
(
range
,
0
.
1
-
47
)
,
of
Grade
2
was
27
weeks
(
range
,
0
.
4
-
52
)
and
[SEP]
[CLS]
of
Grade
3
was
34
weeks
(
range
,
7
-
106
)
.
[SEP]
[CLS]
Pro
##phy
##la
##ctic
therapy
(
i
.
e
.
,
non
-
s
##tero
##idal
anti
-
inflammatory
drug
[
NSA
##ID
]
or
co
##l
##chi
##cine
upon
initiation
of
treatment
)
may
be
beneficial
for
up
to
six
months
.
[SEP]
[CLS]
A
##cute
card
##ior
##es
##pi
##rator
##y
failure
has
been
observed
in
infant
##ile
-
onset
Po
##mp
##e
disease
patients
with
underlying
cardiac
h
##yper
##tro
##phy
,
possibly
associated
with
fluid
over
##load
with
in
##tra
##ven
##ous
administration
of
al
##g
##lu
##cos
##idas
##e
al
##fa
[
see
##D
##osa
##ge
and
[SEP]
[CLS]
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
System
##ic
immune
-
mediated
reactions
,
including
possible
type
III
immune
-
mediated
reactions
have
been
observed
with
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
In
some
patients
,
con
##com
##ita
##nt
use
of
these
two
drug
classes
can
lower
blood
pressure
significantly
leading
to
s
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
(
e
.
g
.
,
di
##zzi
##ness
,
light
##headed
##ness
,
faint
##ing
)
.
[SEP]
[CLS]
Mu
##s
##cu
##los
##kel
##etal
and
Con
##nect
##ive
T
##iss
##ue
Di
##sor
##ders
:
r
##hab
##dom
##yo
##lysis
.
[SEP]
[CLS]
Most
studies
show
no
significant
increased
risk
associated
with
use
of
est
##rogen
##s
for
less
than
1
year
.
[SEP]
[CLS]
Extra
##vas
##ation
into
tissues
during
G
##ada
##vist
administration
may
result
in
moderate
irritation
[
see
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
2
)
]
.
[SEP]
[CLS]
M
##U
##LT
##A
##Q
offers
no
benefit
in
subjects
in
permanent
A
##F
.
[SEP]
[CLS]
Most
of
these
events
were
not
specific
to
the
injection
site
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Pro
##phy
##lax
##is
for
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
is
recommended
after
transplant
##ation
.
[SEP]
[CLS]
5
.
3
He
##mor
##r
##hage
He
##mor
##r
##hage
##s
,
including
major
hem
##or
##r
##hage
##s
defined
as
s
##ym
##pt
##oma
##tic
bleeding
in
a
critical
area
or
organ
,
can
occur
when
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
.
[SEP]
[CLS]
Includes
13
subjects
with
major
bleeding
events
that
occurred
before
the
first
dose
of
a
##pi
##xa
##ban
(
administered
12
to
24
hours
post
surgery
)
.
[SEP]
[CLS]
Inc
##reased
incidence
of
seizure
##s
has
been
observed
at
20
mg
twice
daily
in
controlled
clinical
studies
of
9
-
14
weeks
duration
with
da
##lf
##amp
##rid
##ine
in
patients
with
MS
.
[SEP]
[CLS]
In
addition
to
the
examination
of
the
fund
##us
including
the
mac
##ula
prior
to
treatment
and
at
3
-
4
months
after
starting
treatment
,
MS
patients
with
diabetes
me
##lli
##tus
or
a
history
[SEP]
[CLS]
of
u
##ve
##itis
should
have
regular
follow
-
up
examinations
.
[SEP]
[CLS]
Treatment
disco
##ntin
##uations
due
to
adverse
drug
reactions
occurred
in
18
%
of
patients
who
received
J
##E
##V
##TA
##NA
and
8
%
of
patients
who
received
mit
##ox
##ant
##rone
.
[SEP]
[CLS]
In
a
limited
number
of
patients
,
h
##y
##pop
##hy
##si
##tis
was
diagnosed
by
imaging
studies
through
en
##lar
##gement
of
the
pit
##uit
##ary
g
##land
.
[SEP]
[CLS]
Clinical
trials
of
G
##IL
##OT
##RI
##F
excluded
patients
with
an
abnormal
left
vent
##ric
##ular
e
##jection
fraction
(
L
##VE
##F
)
,
i
.
e
.
,
below
the
institutional
lower
limit
of
normal
.
[SEP]
[CLS]
Re
##actions
already
listed
for
either
adults
or
p
##ediatric
patients
in
other
parts
of
Ad
##verse
Re
##actions
(
6
)
,
or
those
considered
in
Con
##tra
##ind
##ica
##tions
(
4
)
,
Warning
##s
and
[SEP]
[CLS]
Pre
##ca
##ution
##s
(
5
)
or
Over
##dos
##age
(
10
)
are
not
included
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
for
severe
and
prolonged
di
##ar
##r
##hea
not
re
##sp
##ons
##ive
to
anti
-
di
##ar
##r
##hea
##l
agents
.
[SEP]
[CLS]
No
single
cause
of
death
pre
##dom
##inated
.
[SEP]
[CLS]
(
5
.
1
)
.
[SEP]
[CLS]
In
##fant
##ile
-
onset
Po
##mp
##e
disease
patients
with
compromised
cardiac
or
respiratory
function
may
be
at
risk
of
serious
acute
ex
##ace
##rb
##ation
of
their
cardiac
or
respiratory
compromise
due
to
fluid
over
##load
,
and
[SEP]
[CLS]
require
additional
monitoring
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
While
subjects
aged
12
to
17
years
were
included
in
this
trial
,
BR
##E
##O
E
##LL
##IP
##TA
is
not
approved
for
use
in
this
age
-
group
[
see
Use
in
S
##pecific
Population
##s
(
[SEP]
[CLS]
8
.
4
)
]
.
[SEP]
[CLS]
5
.
3
A
##cute
Kid
##ney
In
##ju
##ry
In
patients
with
chronic
##ally
reduced
re
##nal
function
,
acute
kidney
injury
requiring
dial
##ys
##is
has
occurred
with
the
use
of
GB
##CA
##s
.
[SEP]
[CLS]
*
Classical
H
##L
post
-
auto
-
H
##SC
##T
consolidation
:
ne
##ut
##rop
##enia
,
peripheral
sensory
ne
##uro
##pathy
,
th
##rom
##bo
##cy
##top
##enia
,
an
##emia
,
upper
respiratory
tract
infection
,
fatigue
,
peripheral
motor
ne
##uro
##pathy
,
nausea
,
[SEP]
[CLS]
cough
,
and
di
##ar
##r
##hea
(
6
.
1
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
leading
to
disco
##ntin
##uation
of
C
##IM
##Z
##IA
were
tuberculosis
infections
(
0
.
5
%
)
;
and
p
##yre
##xia
,
u
##rt
##ica
##ria
,
pneumonia
,
and
r
##ash
(
0
.
3
%
[SEP]
[CLS]
)
.
[SEP]
[CLS]
In
a
controlled
clinical
study
with
IN
##L
##Y
##TA
for
the
treatment
of
patients
with
RC
##C
,
ve
##nous
th
##rom
##boe
##mbo
##lic
events
were
reported
in
11
/
35
##9
patients
(
3
%
)
receiving
IN
##L
##Y
##TA
and
[SEP]
[CLS]
2
/
35
##5
patients
(
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
Table
10
:
Ad
##verse
Re
##actions
Report
##ed
in
2
%
or
More
of
P
##ediatric
Pat
##ients
(
Ages
10
to
17
Years
)
in
Any
SA
##P
##H
##RI
##S
Do
##se
Group
and
Which
O
##cc
##ur
##red
at
[SEP]
[CLS]
Greater
Inc
##iden
##ce
Than
in
the
Place
##bo
Group
in
a
3
-
Week
B
##ip
##olar
Man
##ia
Trial
1
##I
##nc
##lude
##s
the
preferred
terms
ta
##chy
##card
##ia
and
heart
rate
increased
.
[SEP]
[CLS]
If
you
have
or
have
had
cancer
,
talk
with
your
healthcare
provider
about
whether
you
should
use
D
##U
##AV
##EE
.
[SEP]
[CLS]
The
clinical
significance
of
this
is
unknown
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
in
>
=
13
%
of
patients
are
:
In
##fect
##ions
,
vomit
##ing
,
abdominal
pain
,
p
##yre
##xia
,
tons
##ili
##tis
,
an
##emia
,
[SEP]
[CLS]
ear
infection
,
di
##ar
##r
##hea
,
na
##so
##pha
##ryn
##git
##is
,
and
headache
.
[SEP]
[CLS]
The
types
and
frequency
of
common
adverse
reactions
observed
in
the
pool
of
eight
clinical
trials
were
consistent
with
those
listed
in
Table
1
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
in
>
=
10
%
of
Pro
##lia
-
treated
patients
receiving
AD
##T
for
pro
##state
cancer
or
ad
##ju
##vant
AI
therapy
for
breast
cancer
,
and
more
frequently
than
in
the
[SEP]
[CLS]
place
##bo
-
treated
patients
were
:
art
##hra
##l
##gia
(
13
.
0
%
place
##bo
vs
.
14
.
3
%
Pro
##lia
)
and
back
pain
(
10
.
5
%
place
##bo
vs
.
11
.
5
%
Pro
##lia
)
.
[SEP]
[CLS]
Inc
##rea
##sing
the
daily
dos
##age
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
beyond
the
recommended
dose
is
not
appropriate
in
this
situation
.
[SEP]
[CLS]
Across
clinical
trials
,
32
of
156
##0
patients
(
2
.
1
%
)
had
Q
##T
##c
##F
(
corrected
Q
##T
by
the
Fr
##ider
##ici
##a
method
)
greater
than
or
equal
to
500
m
##s
and
[SEP]
[CLS]
76
of
152
##0
patients
(
5
.
0
%
)
had
an
increase
from
base
##line
Q
##T
##c
##F
greater
than
or
equal
to
60
m
##s
by
automated
machine
-
read
evaluation
of
EC
##G
.
[SEP]
[CLS]
Red
blood
cell
trans
##fusion
##s
were
administered
to
20
%
of
patients
receiving
T
##RE
##AN
##DA
compared
with
6
%
of
patients
receiving
ch
##lora
##mb
##uc
##il
.
[SEP]
[CLS]
Ser
##ious
,
life
-
threatening
complications
were
reported
with
AP
##TI
##OM
-
associated
h
##y
##po
##nat
##rem
##ia
(
as
low
as
112
m
##E
##q
/
L
)
including
seizure
##s
,
severe
nausea
/
vomit
##ing
leading
to
de
##hy
##dra
##tion
,
severe
g
##ait
instability
,
and
[SEP]
[CLS]
injury
.
[SEP]
[CLS]
Non
-
Ho
##d
##g
##kin
L
##ymph
##oma
The
data
described
below
reflect
exposure
to
T
##RE
##AN
##DA
in
176
patients
with
in
##do
##lent
B
-
cell
NHL
treated
in
two
single
-
arm
studies
.
[SEP]
[CLS]
AP
##TI
##OM
should
be
discontinued
in
patients
with
j
##au
##ndi
##ce
or
other
evidence
of
significant
liver
injury
(
e
.
g
.
,
laboratory
evidence
)
.
[SEP]
[CLS]
The
kidney
transplant
recipient
was
treated
with
the
N
##U
##L
##O
##J
##IX
regime
##n
of
higher
cumulative
dose
and
more
frequent
dos
##ing
than
recommended
,
my
##co
##phe
##no
##late
m
##of
##eti
##l
(
M
##MF
)
,
and
co
##rt
##ico
##ster
##oids
for
[SEP]
[CLS]
2
years
.
[SEP]
[CLS]
In
##ves
##ti
##gat
##ors
graded
the
severity
of
gas
##tro
##int
##est
##inal
adverse
reactions
occurring
on
0
.
75
mg
and
1
.
5
mg
of
T
##R
##U
##L
##IC
##IT
##Y
as
`
`
mild
'
'
in
58
%
and
48
%
of
cases
,
[SEP]
[CLS]
respectively
,
`
`
moderate
'
'
in
35
%
and
42
%
of
cases
,
respectively
,
or
`
`
severe
'
'
in
7
%
and
11
%
of
cases
,
respectively
[SEP]
[CLS]
.
[SEP]
[CLS]
The
population
exposed
to
CO
##ME
##TR
##I
##Q
was
70
%
male
,
90
%
white
,
and
had
a
median
age
of
55
years
.
[SEP]
[CLS]
The
most
frequently
reported
g
##eni
##tal
my
##cot
##ic
infections
were
v
##ul
##vo
##va
##gin
##al
my
##cot
##ic
infections
in
females
and
b
##alan
##itis
in
males
.
[SEP]
[CLS]
Elder
##ly
patients
and
patients
with
impaired
re
##nal
function
may
be
more
susceptible
to
these
changes
.
[SEP]
[CLS]
The
following
adverse
reactions
have
been
identified
during
post
approval
use
of
PR
##AD
##A
##X
##A
:
an
##gio
##ede
##ma
,
th
##rom
##bo
##cy
##top
##enia
,
es
##op
##hage
##al
ul
##cer
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
H
##yper
##tens
##ion
,
H
##y
##po
##kal
##emia
and
F
##lu
##id
Re
##ten
##tion
Due
to
Mine
##ral
##oc
##ort
##ico
##id
Ex
##cess
Z
##Y
##TI
##GA
may
cause
h
##yper
##tens
##ion
,
h
##y
##po
##kal
##emia
,
and
fluid
retention
as
a
consequence
of
[SEP]
[CLS]
increased
mineral
##oc
##ort
##ico
##id
levels
resulting
from
C
##YP
##17
in
##hibition
[
see
##C
##lini
##cal
Ph
##arma
##cology
(
12
.
1
)
]
.
[SEP]
[CLS]
The
data
described
below
are
based
on
two
identical
,
pool
##ed
,
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
multi
-
center
trials
through
Day
365
in
patients
with
P
##ey
##ron
##ie
'
s
disease
(
[SEP]
[CLS]
Studies
1
and
2
)
.
[SEP]
[CLS]
(
5
.
2
)
*
Ad
##re
##V
##ie
##w
contains
ben
##zy
##l
alcohol
(
10
.
3
mg
/
m
##L
)
which
may
cause
serious
reactions
in
premature
or
low
birth
-
weight
infants
.
[SEP]
[CLS]
CO
##Cs
also
increase
the
risk
for
stroke
in
women
with
other
underlying
risk
factors
.
[SEP]
[CLS]
A
##cute
or
chronic
disturbance
##s
of
liver
function
may
ne
##cess
##itate
the
disco
##ntin
##uation
of
CO
##C
use
until
markers
of
liver
function
return
to
normal
and
CO
##C
ca
##usa
##tion
has
been
excluded
.
[SEP]
[CLS]
No
association
was
seen
between
anti
##body
development
and
the
development
of
adverse
events
.
[SEP]
[CLS]
A
p
##har
##ma
##co
##kin
##etic
analysis
suggested
that
Z
##Y
##KA
##DI
##A
causes
concentration
-
dependent
increases
in
the
Q
##T
##c
interval
.
[SEP]
[CLS]
[
See
Ad
##verse
Re
##actions
(
6
)
.
]
[SEP]
[CLS]
El
##eva
##tions
in
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
(
AL
##T
)
greater
than
5
times
the
upper
limit
of
normal
(
U
##L
##N
)
occurred
in
27
%
of
255
patients
in
Study
1
.
[SEP]
[CLS]
The
incidence
of
serious
infections
during
the
controlled
clinical
studies
was
3
%
per
patient
-
year
for
C
##IM
##Z
##IA
-
treated
patients
and
1
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
In
the
pool
of
place
##bo
-
and
active
-
controlled
trials
,
the
types
and
frequency
of
common
adverse
reactions
,
excluding
h
##y
##po
##gly
##ce
##mia
,
were
similar
to
those
listed
in
Table
1
.
[SEP]
[CLS]
5
.
12
Monitor
##ing
A
woman
who
is
taking
CO
##Cs
should
have
a
yearly
visit
with
her
healthcare
provider
for
a
blood
pressure
check
and
for
other
indicated
healthcare
.
[SEP]
[CLS]
Studies
also
do
not
suggest
a
te
##rato
##genic
effect
,
particularly
in
so
far
as
cardiac
an
##oma
##lies
and
limb
-
reduction
defects
are
concerned
,
when
taken
inadvertently
during
early
pregnancy
.
[SEP]
[CLS]
(
5
.
1
)
*
The
rate
of
progression
of
re
##tina
##l
abnormal
##ities
and
their
re
##vers
##ibility
are
unknown
.
[SEP]
[CLS]
Common
Ad
##verse
Re
##actions
(
>
=
2
%
)
:
headache
(
including
mi
##gra
##ines
)
(
12
.
7
%
)
,
breast
pain
(
7
.
0
%
)
,
men
##st
##ru
##al
disorders
(
[SEP]
[CLS]
metro
##rr
##ha
##gia
,
men
##st
##ru
##ation
irregular
,
men
##or
##r
##ha
##gia
,
v
##agi
##nal
hem
##or
##r
##hage
,
d
##ys
##function
##al
u
##ter
##ine
bleeding
,
g
##eni
##tal
hem
##or
##r
##hage
,
abnormal
withdrawal
bleeding
,
u
##ter
##ine
hem
##or
##r
##hage
)
(
6
.
9
%
)
,
[SEP]
[CLS]
nausea
or
vomit
##ing
(
6
.
0
%
)
,
a
##c
##ne
(
3
.
9
%
)
,
mood
changes
(
depression
,
mood
swings
,
depressed
mood
,
mood
altered
,
[SEP]
[CLS]
affect
lab
##ility
,
d
##ys
##thy
##mic
disorder
,
crying
)
(
3
.
0
%
)
and
increased
weight
(
2
.
9
%
)
.
[SEP]
[CLS]
In
##form
patients
of
the
signs
and
symptoms
of
an
##aph
##yla
##xi
##s
,
and
ins
##truct
them
to
seek
immediate
medical
care
should
signs
and
symptoms
occur
.
[SEP]
[CLS]
(
5
.
9
)
*
Se
##iz
##ures
:
Use
cautiously
in
patients
with
a
history
of
seizure
##s
or
with
conditions
that
lower
the
seizure
threshold
.
[SEP]
[CLS]
(
5
.
3
)
*
Brady
##card
##ia
:
X
##AL
##KO
##RI
can
cause
bra
##dy
##card
##ia
.
[SEP]
[CLS]
5
.
6
Em
##b
##ryo
##fe
##tal
To
##xi
##city
There
are
no
adequate
and
well
controlled
studies
of
B
##OS
##U
##L
##IF
in
pregnant
women
.
[SEP]
[CLS]
(
5
.
5
)
*
Em
##b
##ryo
##fe
##tal
To
##xi
##city
:
Can
cause
f
##etal
harm
.
[SEP]
[CLS]
In
the
controlled
ad
##junct
##ive
e
##pile
##psy
trials
,
these
events
were
reported
in
1
%
of
place
##bo
patients
,
4
%
of
patients
random
##ized
to
receive
800
mg
/
day
AP
##TI
##OM
,
and
[SEP]
[CLS]
7
%
of
patients
random
##ized
to
receive
1200
mg
/
day
AP
##TI
##OM
.
[SEP]
[CLS]
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
with
rates
in
the
[SEP]
[CLS]
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
5
.
1
Ana
##phy
##lax
##is
and
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Ana
##phy
##lax
##is
and
h
##yper
##sen
##si
##ti
##vity
reactions
have
been
observed
in
patients
during
and
up
to
3
hours
after
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
.
[SEP]
[CLS]
Grade
1
-
4
elevations
in
AL
##T
occurred
in
10
%
of
patients
treated
with
X
##TA
##ND
##I
(
0
.
2
%
Grade
3
-
4
)
and
16
%
of
patients
treated
with
place
##bo
(
0
.
2
[SEP]
[CLS]
%
Grade
3
-
4
)
.
[SEP]
[CLS]
E
##st
##imated
c
##rea
##tin
##ine
clearance
,
urine
glucose
and
urine
protein
should
be
documented
in
all
patients
prior
to
in
##iti
##ating
therapy
.
[SEP]
[CLS]
(
1
.
2
,
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
LA
##BA
increase
the
risk
of
as
##th
##ma
-
related
death
and
as
##th
##ma
-
related
hospital
##izations
.
[SEP]
[CLS]
Ser
##ious
adverse
drug
reactions
reported
in
2
%
or
more
of
patients
in
Study
1
were
con
##vu
##ls
##ion
,
pneumonia
,
IL
##D
/
p
##ne
##um
##oni
##tis
,
d
##ys
##p
##nea
,
de
##hy
##dra
##tion
,
h
##yper
##gly
##ce
##mia
,
and
[SEP]
[CLS]
nausea
.
[SEP]
[CLS]
Some
patients
(
13
%
)
received
pre
##med
##ica
##tion
,
which
may
have
mit
##igate
##d
or
masked
an
in
##fusion
reaction
;
however
,
there
is
insufficient
evidence
to
determine
whether
pre
##med
##ica
##tion
dim
##ini
##shes
[SEP]
[CLS]
the
frequency
or
severity
of
in
##fusion
reactions
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Pat
##ients
receiving
any
therapy
for
chronic
infection
should
not
begin
therapy
with
B
##EN
##L
##Y
##ST
##A
.
[SEP]
[CLS]
A
##cute
card
##ior
##es
##pi
##rator
##y
failure
,
possibly
associated
with
fluid
over
##load
,
has
been
reported
in
infant
##ile
-
onset
Po
##mp
##e
disease
patients
with
pre
-
existing
h
##yper
##tro
##phic
card
##io
##my
##op
##athy
[
see
##B
##ox
##ed
Warning
##and
##W
##ar
##ning
and
Pre
##ca
##ution
##s
(
5
.
3
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
E
##NT
##ER
##EG
is
available
only
through
a
program
under
a
R
##EM
##S
that
restrict
##s
use
to
enrolled
hospitals
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
*
Disco
##ntin
##uation
S
##yn
##drome
:
Ta
##per
dose
when
possible
and
monitor
for
disco
##ntin
##uation
symptoms
(
5
.
7
)
.
[SEP]
[CLS]
(
5
.
4
)
5
.
1
Ser
##ious
In
##fect
##ions
IL
##AR
##IS
has
been
associated
with
an
increased
risk
of
serious
infections
.
[SEP]
[CLS]
Phi
##mos
##is
occurred
more
frequently
in
male
patients
treated
with
J
##AR
##DI
##AN
##CE
10
mg
(
less
than
0
.
1
%
)
and
J
##AR
##DI
##AN
##CE
25
mg
(
0
.
1
%
)
than
place
##bo
(
0
[SEP]
[CLS]
%
)
.
[SEP]
[CLS]
Because
they
are
reported
from
a
population
of
unknown
size
,
precise
estimates
of
frequency
can
not
be
made
.
[SEP]
[CLS]
history
of
h
##y
##pop
##ara
##thy
##roid
##ism
,
thy
##roid
surgery
,
para
##thy
##roid
surgery
,
ma
##la
##bs
##or
##ption
syndrome
##s
,
ex
##cision
of
small
in
##test
##ine
,
severe
re
##nal
imp
##air
##ment
[
c
##rea
##tin
##ine
clearance
<
30
m
##L
/
min
]
or
receiving
[SEP]
[CLS]
dial
##ys
##is
)
,
clinical
monitoring
of
calcium
and
mineral
levels
(
p
##hos
##phorus
and
ma
##gnesium
)
is
highly
recommended
within
14
days
of
Pro
##lia
injection
.
[SEP]
[CLS]
In
total
,
11
%
of
the
patients
treated
with
E
##L
##I
##Q
##UI
##S
2
.
5
mg
twice
daily
experienced
adverse
reactions
.
[SEP]
[CLS]
Ad
##verse
reactions
of
the
hem
##ato
##log
##ic
system
,
including
medical
##ly
significant
c
##yt
##ope
##nia
(
e
.
g
.
,
le
##uk
##ope
##nia
,
pan
##cy
##top
##enia
,
th
##rom
##bo
##cy
##top
##enia
)
have
been
in
##f
##re
##quent
##ly
reported
with
C
##IM
##Z
##IA
[
see
Ad
##verse
Re
##actions
[SEP]
[CLS]
(
6
.
1
)
]
.
[SEP]
[CLS]
For
patients
receiving
hem
##od
##ial
##ys
##is
,
physicians
may
consider
the
pro
##mpt
initiation
of
hem
##od
##ial
##ys
##is
following
the
administration
of
a
GB
##CA
in
order
to
enhance
the
contrast
agent
'
s
elimination
[
see
[SEP]
[CLS]
Use
in
S
##pecific
Population
##s
(
8
.
6
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
2
%
)
associated
with
in
##fusion
-
related
reactions
were
nausea
(
4
%
)
,
chill
##s
(
4
%
)
,
d
##ys
##p
##nea
(
2
[SEP]
[CLS]
%
)
,
headache
(
2
%
)
,
p
##ru
##rit
##us
(
2
%
)
,
r
##ash
(
2
%
)
,
back
pain
(
2
%
)
,
and
[SEP]
[CLS]
vomit
##ing
(
2
%
)
.
[SEP]
[CLS]
5
.
5
G
##all
##bla
##dder
Disease
A
2
-
to
4
-
fold
increase
in
the
risk
of
gal
##l
##bla
##dder
disease
requiring
surgery
in
post
##men
##op
##aus
##al
women
receiving
est
##rogen
##s
has
been
reported
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
20
%
)
,
regardless
of
ca
##usal
##ity
,
were
ne
##ut
##rop
##enia
,
an
##emia
,
peripheral
sensory
ne
##uro
##pathy
,
fatigue
,
nausea
,
p
##yre
##xia
,
[SEP]
[CLS]
r
##ash
,
di
##ar
##r
##hea
,
and
pain
.
[SEP]
[CLS]
5
.
5
Inter
##ference
with
Laboratory
Tests
Ser
##um
iron
determination
using
complex
##ometric
methods
(
for
example
,
f
##er
##ro
##cene
complex
##ation
method
)
may
result
in
falsely
high
or
low
values
for
up
to
[SEP]
[CLS]
24
hours
after
the
examination
with
E
##O
##VI
##ST
because
of
the
ca
##lo
##xe
##tate
t
##ris
##od
##ium
ex
##ci
##pie
##nts
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
some
instances
,
H
##B
##V
react
##ivation
occurring
in
conjunction
with
T
##NF
block
##er
therapy
has
been
fatal
.
[SEP]
[CLS]
Table
4
Selected
He
##mat
##ological
Para
##meter
##s
Previously
Un
##tre
##ated
(
SP
##RI
##NT
-
1
and
SP
##RI
##NT
-
2
)
Previous
Treatment
F
##ail
##ures
(
R
##ES
##PO
##ND
-
2
)
Per
##cent
##age
of
Sub
##jects
Report
##ing
Selected
He
##mat
##ological
Para
##meter
##s
Per
##cent
##age
of
Sub
##jects
Report
##ing
Selected
[SEP]
[CLS]
He
##mat
##ological
Para
##meter
##s
He
##mat
##ological
Para
##meter
##s
VI
##CT
##RE
##L
##IS
+
P
##eg
##I
##nt
##ron
+
R
##E
##BE
##TO
##L
(
n
=
122
##5
)
P
##eg
##I
##nt
##ron
+
R
##E
##BE
##TO
##L
(
n
=
46
##7
)
VI
##CT
##RE
##L
##IS
+
P
##eg
##I
##nt
##ron
+
R
##E
##BE
##TO
##L
(
n
=
32
##3
)
P
##eg
##I
##nt
##ron
+
R
##E
##BE
##TO
##L
(
[SEP]
[CLS]
n
=
80
)
He
##mo
##g
##lo
##bin
(
g
/
d
##L
)
6
3
10
1
N
##eu
##tro
##phi
##ls
(
*
10
9
/
L
)
8
4
7
4
Plate
##lets
(
*
10
9
/
L
)
<
1
[SEP]
[CLS]
0
0
0
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
post
-
approval
use
of
VI
##CT
##RE
##L
##IS
in
combination
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
.
[SEP]
[CLS]
No
serious
in
##fusion
reactions
were
reported
.
[SEP]
[CLS]
f
Includes
the
following
terms
:
re
##nal
failure
and
re
##nal
failure
acute
.
[SEP]
[CLS]
Before
administer
##ing
V
##iza
##my
##l
,
ask
patients
about
prior
reactions
to
drugs
,
especially
those
containing
p
##oly
##sor
##bate
80
.
[SEP]
[CLS]
Have
re
##sus
##citation
equipment
and
trained
personnel
immediately
available
at
the
time
of
V
##iza
##my
##l
administration
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
During
adult
pre
-
marketing
clinical
trials
with
SA
##P
##H
##RI
##S
,
including
long
-
term
trials
without
comparison
to
place
##bo
,
so
##m
##no
##len
##ce
was
reported
in
18
%
(
35
##8
/
1953
)
of
patients
treated
with
SA
##P
##H
##RI
##S
[SEP]
[CLS]
.
[SEP]
[CLS]
V
##as
##cular
Di
##sor
##ders
:
H
##yper
##tens
##ion
.
[SEP]
[CLS]
*
with
a
family
history
of
con
##gen
##ital
pro
##long
##ation
of
the
Q
##T
interval
or
sudden
death
.
[SEP]
[CLS]
O
##var
##ian
Cancer
In
some
e
##pid
##em
##iol
##ogical
studies
,
the
use
of
est
##rogen
-
only
products
,
in
particular
for
5
or
more
years
,
has
been
associated
with
an
increased
risk
of
[SEP]
[CLS]
o
##var
##ian
cancer
.
[SEP]
[CLS]
Table
7
.
[SEP]
[CLS]
If
liver
injury
is
detected
,
promptly
interrupt
U
##L
##OR
##IC
and
assess
patient
for
probable
cause
,
then
treat
cause
if
possible
,
to
resolution
or
stab
##ilization
.
[SEP]
[CLS]
Ad
##verse
reactions
that
led
to
dose
modifications
of
any
drug
(
primarily
P
##eg
##I
##nt
##ron
and
R
##E
##BE
##TO
##L
)
occurred
in
39
%
of
subjects
receiving
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
[SEP]
[CLS]
to
24
%
of
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
.
[SEP]
[CLS]
C
##aut
##ion
is
advised
when
PD
##E
##5
inhibitor
##s
are
co
-
administered
with
alpha
-
block
##ers
.
[SEP]
[CLS]
B
##lee
##ding
results
during
the
treatment
period
in
the
Phase
III
studies
are
shown
in
Table
3
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
call
87
##7
-
37
##7
-
37
##8
##4
or
contact
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
S
##UI
##CI
##DA
##L
T
##H
##O
##U
##G
##HT
##S
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
Disco
##ntin
##ue
G
##RA
##NI
##X
in
patients
undergoing
a
sick
##le
cell
crisis
.
[SEP]
[CLS]
Take
the
next
dose
at
your
regular
time
.
[SEP]
[CLS]
Four
(
0
.
6
%
)
subjects
who
received
ST
##RI
##BI
##LD
developed
laboratory
findings
consistent
with
pro
##ximal
re
##nal
tub
##ular
d
##ys
##function
leading
to
disco
##ntin
##uation
of
ST
##RI
##BI
##LD
during
the
first
48
weeks
of
treatment
[SEP]
[CLS]
.
[SEP]
[CLS]
Due
to
overlap
in
signs
and
symptoms
,
it
was
not
possible
to
distinguish
between
h
##yper
##sen
##si
##ti
##vity
reactions
and
in
##fusion
reactions
in
all
cases
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
The
most
serious
adverse
reactions
were
:
*
Ser
##ious
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
Mali
##gna
##ncies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
[SEP]
[CLS]
(
5
.
2
)
]
*
Heart
F
##ail
##ure
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
Because
clinical
studies
are
conducted
under
widely
varying
and
controlled
conditions
,
adverse
reaction
[SEP]
[CLS]
rates
observed
in
clinical
studies
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
studies
of
another
drug
,
and
may
not
predict
the
rates
observed
[SEP]
[CLS]
in
a
broader
patient
population
in
clinical
practice
.
[SEP]
[CLS]
Other
adverse
reactions
with
incidence
##s
of
less
than
5
%
in
the
D
##Y
##SP
##OR
##T
(
r
)
500
Units
group
in
the
double
-
blind
phase
of
clinical
trials
included
di
##zzi
##ness
in
3
.
5
[SEP]
[CLS]
%
of
D
##Y
##SP
##OR
##T
(
r
)
-
treated
patients
and
1
%
of
place
##bo
-
treated
patients
,
and
muscle
at
##rop
##hy
in
1
%
of
D
##Y
##SP
##OR
##T
(
r
)
-
treated
patients
and
in
[SEP]
[CLS]
none
of
the
place
##bo
-
treated
patients
.
[SEP]
[CLS]
The
##rap
##eu
##tic
In
##fect
##ious
Agents
Other
uses
of
therapeutic
infectious
agents
such
as
live
at
##ten
##uated
bacteria
(
e
.
g
.
,
BC
##G
bladder
ins
##til
##lation
for
the
treatment
of
cancer
)
could
result
in
clinical
[SEP]
[CLS]
infections
,
including
di
##sse
##minated
infections
.
[SEP]
[CLS]
Table
1
shows
adverse
reactions
reported
in
Study
1
that
occurred
at
a
>
=
2
%
higher
frequency
in
the
X
##TA
##ND
##I
arm
compared
to
the
place
##bo
arm
.
[SEP]
[CLS]
For
events
of
aka
##thi
##sia
,
incidence
##s
were
2
%
,
2
%
,
and
1
%
for
patients
treated
with
SA
##P
##H
##RI
##S
2
.
5
mg
,
5
mg
,
and
10
mg
[SEP]
[CLS]
twice
daily
,
respectively
,
as
compared
to
0
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Some
of
the
reactions
were
life
-
threatening
and
included
an
##aph
##yla
##ctic
shock
,
cardiac
arrest
,
respiratory
arrest
,
respiratory
distress
,
h
##y
##pox
##ia
,
a
##p
##nea
,
d
##ys
##p
##nea
,
bra
##dy
##card
##ia
,
ta
##chy
##card
##ia
,
[SEP]
[CLS]
br
##on
##cho
##sp
##as
##m
,
throat
tight
##ness
,
h
##y
##pot
##ens
##ion
,
an
##gio
##ede
##ma
(
including
lip
swelling
,
per
##ior
##bit
##al
ed
##ema
,
and
face
ed
##ema
)
,
and
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Table
1
sum
##mar
##izes
adverse
reactions
occurring
in
2
or
more
patients
treated
with
Car
##bag
##lu
in
the
retrospective
case
series
.
[SEP]
[CLS]
The
three
factors
associated
with
the
largest
increase
in
volume
de
##ple
##tion
-
related
adverse
reactions
were
the
use
of
loop
di
##ure
##tics
,
moderate
re
##nal
imp
##air
##ment
(
e
##G
##F
##R
30
to
less
than
60
[SEP]
[CLS]
m
##L
/
min
/
1
.
73
m
2
)
,
and
age
75
years
and
older
(
Table
2
)
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
[SEP]
[CLS]
,
and
Use
in
S
##pecific
Population
##s
(
8
.
5
and
8
.
6
)
]
.
[SEP]
[CLS]
Eye
events
were
serious
in
0
.
7
%
of
AP
##TI
##OM
-
treated
patients
(
and
0
place
##bo
patients
)
and
led
to
disco
##ntin
##uation
in
4
%
of
AP
##TI
##OM
-
treated
patients
(
and
0
.
2
%
[SEP]
[CLS]
of
place
##bo
-
treated
patients
)
.
[SEP]
[CLS]
The
use
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
in
this
setting
is
inappropriate
.
[SEP]
[CLS]
I
##mp
##aire
##d
glucose
tolerance
.
[SEP]
[CLS]
New
Mali
##gna
##ncies
The
overall
incidence
of
new
ma
##li
##gna
##ncies
was
4
.
3
%
in
the
place
##bo
and
4
.
8
%
in
the
Pro
##lia
groups
.
[SEP]
[CLS]
5
.
2
Ser
##ious
Der
##mat
##olo
##gic
Re
##actions
Ser
##ious
der
##mat
##olo
##gic
reactions
including
Stevens
-
Johnson
S
##yn
##drome
(
S
##J
##S
)
have
been
reported
in
association
with
AP
##TI
##OM
use
.
[SEP]
[CLS]
5
.
3
Drug
Re
##action
with
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
/
Multi
##or
##gan
H
##yper
##sen
##si
##ti
##vity
Drug
Re
##action
with
E
##os
##ino
##phi
##lia
and
System
##ic
S
##ym
##pt
##oms
(
DR
##ES
##S
)
,
also
known
as
Multi
##or
##gan
H
##yper
##sen
##si
##ti
##vity
,
[SEP]
[CLS]
has
been
reported
in
patients
taking
AP
##TI
##OM
.
[SEP]
[CLS]
A
##b
##nor
##mal
thy
##roid
function
tests
should
be
clinical
##ly
evaluated
.
[SEP]
[CLS]
Di
##zzi
##ness
and
disturbance
in
g
##ait
were
also
observed
in
mon
##otherapy
trials
.
[SEP]
[CLS]
Pat
##ients
receiving
Pro
##lia
should
not
receive
X
##ge
##va
.
[SEP]
[CLS]
Monitor
for
symptoms
(
5
.
4
)
*
At
##y
##pical
f
##em
##oral
fracture
##s
:
Have
been
reported
.
[SEP]
[CLS]
No
fatal
adverse
events
occurred
on
treatment
among
patients
in
re
##mission
.
[SEP]
[CLS]
Act
##ivated
pro
##th
##rom
##bin
complex
concentrate
##s
(
a
##PC
##Cs
,
e
.
g
.
,
F
##EI
##BA
)
,
or
re
##comb
##ina
##nt
Factor
VII
##a
,
or
concentrate
##s
of
co
##agu
##lation
factors
II
,
IX
or
X
may
be
considered
[SEP]
[CLS]
but
their
use
has
not
been
evaluated
in
clinical
trials
.
[SEP]
[CLS]
Pro
##mpt
##ly
evaluate
any
signs
or
symptoms
of
blood
loss
(
e
.
g
.
,
a
drop
in
hem
##og
##lo
##bin
and
/
or
hem
##ato
##c
##rit
or
h
##y
##pot
##ens
##ion
)
.
[SEP]
[CLS]
More
patients
receiving
T
##R
##U
##L
##IC
##IT
##Y
0
.
75
mg
(
1
.
3
%
)
and
T
##R
##U
##L
##IC
##IT
##Y
1
.
5
mg
(
3
.
5
%
)
discontinued
treatment
due
to
gas
##tro
##int
##est
##inal
adverse
reactions
than
patients
receiving
place
##bo
(
[SEP]
[CLS]
0
.
2
%
)
.
[SEP]
[CLS]
With
##hold
dose
for
moderate
immune
-
mediated
adverse
reactions
until
return
to
base
##line
,
improvement
to
mild
severity
,
or
complete
resolution
,
and
patient
is
receiving
less
than
7
.
5
mg
pre
##dn
##ison
##e
[SEP]
[CLS]
or
equivalent
per
day
.
[SEP]
[CLS]
(
5
.
7
)
*
Pro
##tein
##uria
:
Monitor
urine
protein
.
[SEP]
[CLS]
Higher
proportions
of
patients
with
marked
laboratory
abnormal
##ities
of
h
##yper
##ph
##os
##phate
##mia
(
>
=
5
.
6
mg
/
d
##L
for
age
17
-
65
years
or
>
=
5
.
1
mg
/
d
##L
for
age
>
=
66
years
)
were
reported
[SEP]
[CLS]
on
FA
##R
##X
##IG
##A
at
Week
24
(
0
.
9
%
versus
1
.
7
%
for
place
##bo
and
FA
##R
##X
##IG
##A
10
mg
,
respectively
)
.
[SEP]
[CLS]
5
.
3
T
##hr
##omb
##otic
Events
CO
##ME
##TR
##I
##Q
treatment
results
in
an
increased
incidence
of
th
##rom
##bot
##ic
events
(
ve
##nous
th
##rom
##boe
##mbo
##lis
##m
:
6
%
vs
.
3
%
and
art
##erial
th
##rom
##boe
##mbo
##lis
##m
:
2
%
vs
.
0
[SEP]
[CLS]
%
in
CO
##ME
##TR
##I
##Q
-
treated
and
place
##bo
-
treated
patients
,
respectively
)
.
[SEP]
[CLS]
Ad
##vise
women
of
potential
harm
to
the
f
##etus
and
to
avoid
pregnancy
while
receiving
Bel
##eo
##da
##q
.
[SEP]
[CLS]
Table
4
shows
the
incidence
of
adverse
reactions
that
were
reported
in
greater
than
or
equal
to
5
%
of
XI
##AF
##LE
##X
-
treated
patients
after
two
concurrent
injection
##s
of
XI
##AF
##LE
##X
in
the
[SEP]
[CLS]
same
hand
through
Day
60
in
Study
3
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
WA
##R
##NI
##NG
:
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
PR
##AD
##A
##X
##A
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
,
and
(
B
)
EP
##ID
##UR
##AL
See
full
pre
##s
##cribing
information
for
complete
box
##ed
[SEP]
[CLS]
warning
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
PR
##AD
##A
##X
##A
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
:
Pre
##mat
##ure
disco
##ntin
##uation
of
any
oral
anti
##coa
##gu
##lant
,
including
PR
##AD
##A
##X
##A
,
increases
the
risk
of
th
##rom
##bot
##ic
[SEP]
[CLS]
events
.
[SEP]
[CLS]
Disco
##ntin
##ue
Z
##yd
##eli
##g
for
re
##current
he
##pa
##to
##to
##xi
##city
.
[SEP]
[CLS]
This
includes
cases
of
Stevens
-
Johnson
syndrome
,
h
##yper
##sen
##si
##ti
##vity
reaction
,
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
and
er
##yt
##hem
##a
multi
##form
##e
.
[SEP]
[CLS]
Generally
mild
##er
withdrawal
symptoms
(
e
.
g
.
,
d
##ys
##ph
##oria
,
anxiety
,
and
ins
##om
##nia
)
have
been
reported
following
abrupt
disco
##ntin
##uan
##ce
of
ben
##zo
##dia
##ze
##pine
##s
taken
continuously
at
therapeutic
doses
for
several
months
[SEP]
[CLS]
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
the
[SEP]
[CLS]
f
##etus
[
See
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Monitor
blood
pressure
,
serum
potassium
and
symptoms
of
fluid
retention
at
least
monthly
.
[SEP]
[CLS]
Inter
##rup
##t
or
disco
##ntin
##ue
Z
##yd
##eli
##g
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
adverse
reactions
are
discussed
in
greater
detail
in
the
Warning
##s
and
Pre
##ca
##ution
##s
(
5
)
section
of
the
label
##ing
:
*
End
##op
##ht
##hal
##mit
##is
and
[SEP]
[CLS]
re
##tina
##l
detachment
##s
*
Inc
##reased
in
##tra
##oc
##ular
pressure
*
T
##hr
##omb
##oe
##mbo
##lic
events
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
5
%
)
reported
in
patients
receiving
E
##Y
##LE
##A
were
con
##junct
##ival
hem
##or
##r
##hage
,
[SEP]
[CLS]
eye
pain
,
cat
##ara
##ct
,
v
##it
##re
##ous
float
##ers
,
in
##tra
##oc
##ular
pressure
increased
,
and
v
##it
##re
##ous
detachment
.
[SEP]
[CLS]
The
underlying
path
##ology
was
not
as
##cer
##tain
##ed
in
all
patients
but
in
some
instances
included
immune
-
mediated
he
##pa
##titis
.
[SEP]
[CLS]
I
##mple
##ment
a
plan
to
monitor
for
and
to
manage
a
##gra
##nu
##loc
##yt
##osis
/
ne
##ut
##rop
##enia
prior
to
in
##iti
##ating
Fe
##rri
##p
##ro
##x
treatment
.
[SEP]
[CLS]
Eva
##lu
##ate
for
re
##tina
##l
vein
th
##rom
##bos
##is
immediately
.
[SEP]
[CLS]
One
patient
(
0
.
4
%
)
required
permanent
disco
##ntin
##uation
due
to
elevated
trans
##ami
##nas
##es
,
and
j
##au
##ndi
##ce
.
[SEP]
[CLS]
R
##E
-
ME
##D
##Y
was
an
active
-
controlled
study
(
war
##fari
##n
)
in
which
143
##0
patients
received
PR
##AD
##A
##X
##A
150
mg
twice
daily
following
3
to
12
months
of
oral
anti
##coa
##gu
##lant
regime
##n
.
[SEP]
[CLS]
If
this
drug
is
used
during
pregnancy
,
or
if
the
patient
becomes
pregnant
while
taking
this
drug
,
the
patient
should
be
app
##rise
##d
of
the
potential
hazard
to
a
[SEP]
[CLS]
f
##etus
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
]
.
[SEP]
[CLS]
Oral
con
##tra
##ceptive
use
should
be
discontinued
if
pregnancy
is
confirmed
.
[SEP]
[CLS]
If
PR
##AD
##A
##X
##A
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
,
consider
coverage
with
another
anti
##coa
##gu
##lant
[
see
Do
##sa
##ge
and
Administration
(
[SEP]
[CLS]
2
.
4
,
2
.
5
,
2
.
6
)
]
.
[SEP]
[CLS]
Inc
##rease
##s
in
AS
##T
of
Grade
3
or
4
were
limited
to
1
%
and
3
%
of
patients
,
respectively
.
[SEP]
[CLS]
Len
##ses
may
be
reins
##ert
##ed
after
10
minutes
following
administration
of
B
##EP
##RE
##VE
.
[SEP]
[CLS]
DR
##ES
##S
typically
,
although
not
exclusively
,
presents
with
fever
,
r
##ash
,
and
/
or
l
##ymph
##ade
##no
##pathy
,
in
association
with
other
organ
system
involvement
,
such
as
he
##pa
##titis
,
ne
##ph
##rit
##is
,
[SEP]
[CLS]
hem
##ato
##logical
abnormal
##ities
,
my
##oc
##ard
##itis
,
or
my
##os
##itis
sometimes
resembling
an
acute
viral
infection
.
[SEP]
[CLS]
A
CBC
including
l
##ymph
##oc
##yte
count
should
also
be
obtained
after
6
months
of
treatment
,
every
6
to
12
months
thereafter
,
and
as
clinical
##ly
indicated
.
[SEP]
[CLS]
Fifty
-
eight
percent
(
58
%
)
of
the
population
was
male
and
73
%
were
Caucasian
,
16
%
were
Asian
,
and
4
%
were
Black
or
African
American
[SEP]
[CLS]
.
[SEP]
[CLS]
In
the
pool
of
eight
clinical
trials
,
h
##yper
##sen
##si
##ti
##vity
-
related
adverse
reactions
(
including
er
##yt
##hem
##a
,
r
##ash
,
p
##ru
##rit
##us
,
u
##rt
##ica
##ria
,
and
an
##gio
##ede
##ma
)
occurred
in
3
.
0
%
,
3
.
8
[SEP]
[CLS]
%
,
and
4
.
2
%
of
patients
receiving
com
##par
##ator
,
IN
##VO
##KA
##NA
100
mg
,
and
IN
##VO
##KA
##NA
300
mg
,
respectively
.
[SEP]
[CLS]
(
5
.
4
)
*
Se
##vere
Visual
Loss
:
Report
##ed
in
0
.
2
%
of
patients
.
[SEP]
[CLS]
So
##m
##no
##len
##ce
and
fatigue
-
related
events
were
serious
in
0
.
3
%
of
AP
##TI
##OM
-
treated
patients
(
and
0
place
##bo
patients
)
and
led
to
disco
##ntin
##uation
in
3
%
of
AP
##TI
##OM
-
treated
patients
(
and
[SEP]
[CLS]
0
.
7
%
of
place
##bo
-
treated
patients
)
.
[SEP]
[CLS]
Monitor
electro
##ly
##tes
if
Q
##T
pro
##long
##ation
is
detected
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
and
Drug
Inter
##actions
(
7
.
4
)
]
.
[SEP]
[CLS]
5
.
2
Det
##eri
##oration
of
Disease
and
A
##cute
Episode
##s
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
should
not
be
initiated
in
patients
with
acute
##ly
de
##ter
##ior
##ating
CO
##PD
,
which
may
be
a
life
-
threatening
condition
.
[SEP]
[CLS]
En
##sure
safe
handling
to
protect
patients
and
health
care
workers
from
un
##int
##ent
##ional
radiation
exposure
(
2
.
1
,
5
.
2
)
.
[SEP]
[CLS]
Pre
##s
##cribe
only
for
recommended
patient
populations
.
[SEP]
[CLS]
Ser
##ious
depression
was
reported
in
0
.
4
%
(
6
/
1
,
45
##8
)
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
0
.
1
%
(
1
/
67
##5
)
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Fat
##al
cardiac
failure
was
reported
in
2
/
35
##9
patients
(
1
%
)
receiving
IN
##L
##Y
##TA
and
1
/
35
##5
patients
(
<
1
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
(
5
.
6
)
*
accumulation
of
body
fat
:
O
##bs
##erve
##d
in
patients
receiving
anti
##ret
##rov
##ira
##l
therapy
.
[SEP]
[CLS]
Se
##vere
acute
ex
##ace
##rb
##ations
of
he
##pa
##titis
B
have
been
reported
in
patients
coin
##fected
with
HIV
-
1
and
H
##B
##V
who
have
discontinued
E
##MT
##RI
##VA
or
VI
##RE
##AD
,
two
of
the
components
of
ST
##RI
##BI
##LD
.
[SEP]
[CLS]
A
variety
of
C
##NS
anti
##cho
##liner
##gic
effects
have
been
reported
,
including
headache
,
di
##zzi
##ness
,
and
so
##m
##no
##len
##ce
.
[SEP]
[CLS]
*
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
7
)
]
.
[SEP]
[CLS]
5
.
3
Lac
##k
of
Inter
##chang
##ea
##bility
With
G
##aba
##pent
##in
H
##OR
##I
##Z
##AN
##T
is
not
interchange
##able
with
other
g
##aba
##pent
##in
products
because
of
differing
p
##har
##ma
##co
##kin
##etic
profiles
.
[SEP]
[CLS]
The
proportion
of
patients
with
pro
##la
##ct
##in
elevations
>
=
4
times
U
##L
##N
(
at
End
##point
)
were
2
.
6
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
0
.
6
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Laboratory
A
##b
##nor
##mal
##ities
Treatment
-
naive
Sub
##jects
:
Selected
laboratory
abnormal
##ities
(
Grades
2
to
4
)
with
a
worse
##ning
grade
from
base
##line
and
representing
the
worst
-
grade
toxicity
in
at
least
2
%
[SEP]
[CLS]
of
subjects
are
presented
in
Table
3
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
incidence
of
antibodies
to
V
##OR
##A
##X
##A
##Z
##E
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
All
patients
should
be
instructed
to
seek
medical
advice
if
signs
,
symptoms
,
or
high
risk
exposure
suggest
##ive
of
tuberculosis
(
e
.
g
.
,
persistent
cough
,
weight
loss
,
[SEP]
[CLS]
sub
##fe
##bri
##le
temperature
)
appear
during
or
after
IL
##AR
##IS
therapy
.
[SEP]
[CLS]
The
changes
in
F
##E
##V
##1
appear
to
be
re
##versible
after
treatment
disco
##ntin
##uation
.
[SEP]
[CLS]
T
##3
re
##sin
up
##take
is
decreased
,
reflecting
the
elevated
T
##B
##G
.
[SEP]
[CLS]
The
range
of
time
to
diagnosis
of
basal
cell
car
##cin
##oma
was
28
to
249
days
in
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
was
197
days
for
the
patient
[SEP]
[CLS]
receiving
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
(
5
.
4
)
*
C
##lev
##ip
##re
##x
gives
no
protection
against
the
effects
of
abrupt
beta
-
block
##er
withdrawal
.
[SEP]
[CLS]
S
##ym
##pt
##oms
of
PR
##ES
are
usually
re
##versible
but
may
evolve
into
is
##che
##mic
stroke
or
cerebral
hem
##or
##r
##hage
.
[SEP]
[CLS]
5
.
5
He
##pa
##titis
B
V
##ir
##us
Re
##act
##ivation
Use
of
T
##NF
block
##ers
,
including
C
##IM
##Z
##IA
,
has
been
associated
with
react
##ivation
of
he
##pa
##titis
B
virus
)
in
patients
who
are
chronic
carriers
of
[SEP]
[CLS]
this
virus
.
[SEP]
[CLS]
The
effect
of
treatment
with
D
##U
##AV
##EE
on
the
risk
of
o
##var
##ian
cancer
is
unknown
.
[SEP]
[CLS]
When
v
##as
##od
##ila
##tors
are
used
in
combination
,
an
add
##itive
effect
on
blood
pressure
may
be
anticipated
.
[SEP]
[CLS]
Therefore
,
patients
receiving
al
##g
##lu
##cos
##idas
##e
al
##fa
should
undergo
periodic
u
##rina
##lysis
[
see
##A
##d
##verse
Re
##actions
(
6
.
3
)
]
.
[SEP]
[CLS]
5
.
6
Visual
A
##b
##nor
##mal
##ities
Re
##tina
##l
vascular
th
##rom
##bos
##is
has
been
reported
in
patients
receiving
est
##rogen
##s
.
[SEP]
[CLS]
The
useful
##ness
of
hem
##od
##ial
##ys
##is
in
the
prevention
of
N
##SF
is
unknown
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
General
Di
##sor
##ders
and
Administration
Site
Con
##ditions
:
As
##the
##nia
.
[SEP]
[CLS]
The
ma
##li
##gna
##ncies
occurred
after
a
median
of
30
months
of
therapy
(
range
1
to
84
months
)
.
[SEP]
[CLS]
M
##U
##LT
##A
##Q
doubles
the
risk
of
death
in
these
patients
(
4
,
5
.
1
,
14
.
3
)
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
(
>
=
3
%
)
with
a
Higher
Inc
##iden
##ce
for
PR
##OM
##AC
##TA
versus
Place
##bo
from
Two
Place
##bo
-
controlled
Trials
in
P
##ediatric
Pat
##ients
6
Years
and
Older
with
Ch
##ronic
I
##mm
##une
(
[SEP]
[CLS]
I
##dio
##pathic
)
T
##hr
##omb
##oc
##yt
##ope
##nia
PR
##OM
##AC
##TA
Place
##bo
n
=
82
n
=
40
Ad
##verse
Re
##action
(
%
)
(
%
)
Upper
respiratory
tract
infection
16
5
Na
##so
##pha
##ryn
##git
##is
12
5
R
##hin
##itis
11
[SEP]
[CLS]
8
Abd
##omi
##nal
pain
9
5
Co
##ugh
9
0
Oro
##pha
##ryn
##ge
##al
pain
9
3
Too
##tha
##che
6
0
AS
##T
increased
5
0
Di
##ar
##r
##hea
5
3
Ra
##sh
5
3
AL
##T
increased
##a
6
0
[SEP]
[CLS]
Vita
##min
D
deficiency
4
0
*
a
Includes
adverse
reactions
or
laboratory
abnormal
##ities
>
3
x
U
##L
##N
.
[SEP]
[CLS]
He
##pa
##to
##bil
##iary
Di
##sor
##ders
:
he
##pa
##tic
failure
(
some
fatal
)
,
j
##au
##ndi
##ce
,
serious
cases
of
abnormal
liver
function
test
results
,
liver
disorder
.
[SEP]
[CLS]
No
reports
involved
the
administration
of
met
##hyl
##ene
blue
by
other
routes
(
such
as
oral
tablets
or
local
tissue
injection
)
or
at
lower
doses
.
[SEP]
[CLS]
Families
and
care
##gi
##vers
of
patients
being
treated
with
anti
##de
##press
##ants
for
major
de
##pressive
disorder
or
other
indication
##s
,
both
psychiatric
and
non
##psy
##chia
##tric
,
should
be
alerted
about
the
need
to
monitor
[SEP]
[CLS]
patients
for
the
emergence
of
agitation
,
i
##rri
##ta
##bility
,
unusual
changes
in
behavior
,
and
the
other
symptoms
described
above
,
as
well
as
the
emergence
of
su
##icidal
##ity
,
and
[SEP]
[CLS]
to
report
such
symptoms
immediately
to
healthcare
providers
.
[SEP]
[CLS]
Do
not
restart
U
##L
##OR
##IC
if
liver
injury
is
confirmed
and
no
alternate
et
##iology
can
be
found
.
[SEP]
[CLS]
5
.
4
Extra
##vas
##ation
and
In
##jection
Site
Re
##actions
.
[SEP]
[CLS]
5
.
9
Effects
on
B
##lee
##ding
The
safety
of
ST
##EN
##DR
##A
is
unknown
in
patients
with
bleeding
disorders
and
patients
with
active
p
##ept
##ic
ul
##cer
##ation
.
[SEP]
[CLS]
AS
##T
greater
than
or
equal
to
3
x
U
##L
##N
was
reported
in
34
%
and
38
%
of
patients
for
PR
##OM
##AC
##TA
and
place
##bo
,
respectively
.
[SEP]
[CLS]
In
patients
receiving
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
four
cases
of
non
-
cut
##aneous
ma
##li
##gna
##ncies
were
identified
:
K
##RA
##S
mutation
-
positive
pan
##cre
##atic
ad
##eno
##car
##cin
##oma
(
n
=
1
)
,
[SEP]
[CLS]
re
##current
N
##RA
##S
mutation
-
positive
color
##ec
##tal
car
##cin
##oma
(
n
=
1
)
,
head
and
neck
car
##cin
##oma
(
n
=
1
)
,
and
g
##lio
##blast
##oma
(
n
=
1
)
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
in
Pat
##ients
with
Se
##vere
or
Essential
H
##yper
##tens
##ion
Ad
##verse
reactions
that
were
reported
in
<
1
%
of
patients
with
severe
or
essential
h
##yper
##tens
##ion
included
:
Card
##iac
[SEP]
[CLS]
:
my
##oc
##ard
##ial
in
##far
##ction
,
cardiac
arrest
##N
##er
##vous
system
:
s
##ync
##ope
##R
##es
##pi
##rator
##y
:
d
##ys
##p
##nea
6
.
2
Post
-
Marketing
and
Other
Clinical
Experience
Because
adverse
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
[SEP]
[CLS]
it
is
not
always
possible
to
estimate
re
##lia
##bly
their
frequency
or
to
establish
a
ca
##usal
relationship
to
drug
exposure
.
[SEP]
[CLS]
Monitor
heart
failure
patients
carefully
.
[SEP]
[CLS]
The
incidence
of
h
##y
##po
##gly
##ce
##mia
increased
when
J
##AR
##DI
##AN
##CE
was
administered
with
insulin
or
su
##lf
##ony
##lu
##rea
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
In
these
trials
,
93
%
of
patients
treated
with
B
##EN
##L
##Y
##ST
##A
reported
an
adverse
reaction
compared
with
92
%
treated
with
place
##bo
.
[SEP]
[CLS]
The
administration
of
anti
##his
##tamine
##s
,
s
##tero
##ids
,
br
##on
##cho
##di
##lator
##s
,
and
/
or
e
##pine
##ph
##rine
may
reduce
the
severity
of
the
reactions
.
[SEP]
[CLS]
Among
subjects
aged
12
to
17
years
,
as
##th
##ma
-
related
hospital
##izations
occurred
in
4
subjects
(
2
.
6
%
)
treated
with
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
(
n
=
151
)
compared
with
[SEP]
[CLS]
0
subjects
treated
with
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
(
n
=
130
)
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Take
##da
Ph
##arma
##ce
##utical
##s
at
1
-
87
##7
-
T
##A
##KE
##DA
-
7
(
1
-
87
##7
-
82
##5
-
33
##27
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Grade
3
-
4
re
##nal
failure
occurred
in
six
patients
in
the
ever
##oli
##mus
arm
and
three
patients
in
the
place
##bo
arm
.
[SEP]
[CLS]
5
.
5
Central
N
##er
##vous
System
Effects
To
##via
##z
is
associated
with
anti
##cho
##liner
##gic
central
nervous
s
##yte
##m
(
C
##NS
)
effects
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Across
the
3
studies
,
there
were
149
##3
patients
random
##ized
equally
to
place
##bo
,
O
##TE
##Z
##LA
20
mg
twice
daily
or
O
##TE
##Z
##LA
30
mg
twice
daily
.
[SEP]
[CLS]
In
short
-
term
place
##bo
-
controlled
trials
(
4
-
to
6
-
weeks
)
,
there
were
1
.
0
%
(
13
/
134
##2
)
il
##oper
##ido
##ne
-
treated
patients
with
[SEP]
[CLS]
hem
##ato
##c
##rit
at
least
one
time
below
the
extended
normal
range
during
post
-
random
##ization
treatment
,
compared
to
0
.
3
%
(
2
/
58
##5
)
on
place
##bo
.
[SEP]
[CLS]
5
.
3
New
On
##set
or
W
##orse
##ning
Ren
##al
I
##mp
##air
##ment
Ren
##al
imp
##air
##ment
,
including
cases
of
acute
re
##nal
failure
and
Fan
##con
##i
syndrome
(
re
##nal
tub
##ular
injury
with
severe
h
##y
##pop
##hos
##phate
##mia
)
,
has
been
[SEP]
[CLS]
reported
with
the
use
of
ten
##of
##ov
##ir
D
##F
,
a
component
of
ST
##RI
##BI
##LD
,
and
with
the
use
of
ST
##RI
##BI
##LD
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
(
5
.
1
)
*
E
##NT
##ER
##EG
is
available
only
through
a
restricted
program
for
short
-
term
use
(
15
doses
)
called
the
E
##NT
##ER
##EG
Access
Support
and
Education
(
E
.
A
.
S
.
E
.
[SEP]
[CLS]
There
were
no
new
clinical
##ly
relevant
A
##Es
that
emerged
in
the
later
treatment
cycles
.
[SEP]
[CLS]
The
Pro
##lia
Post
##market
##ing
Active
Safety
Sur
##ve
##illa
##nce
Program
is
available
to
collect
information
from
pre
##s
##cribe
##rs
on
specific
adverse
events
.
[SEP]
[CLS]
In
addition
,
patients
taking
Ed
##ar
##bi
who
had
moderate
to
severe
re
##nal
imp
##air
##ment
at
base
##line
or
who
were
>
75
years
of
age
were
more
likely
to
report
[SEP]
[CLS]
serum
c
##rea
##tin
##ine
increases
.
[SEP]
[CLS]
Approximately
61
%
of
X
##E
##OM
##IN
-
treated
patients
had
previously
received
another
b
##ot
##ulin
##um
to
##xin
type
A
product
.
[SEP]
[CLS]
The
relationship
to
G
##IL
##EN
##Y
##A
remains
uncertain
.
[SEP]
[CLS]
In
the
controlled
ad
##junct
##ive
e
##pile
##psy
trials
,
these
events
were
reported
in
16
%
of
patients
random
##ized
to
receive
AP
##TI
##OM
compared
to
6
%
of
place
##bo
patients
.
[SEP]
[CLS]
E
##pile
##psy
and
many
other
illness
##es
for
which
A
##ED
##s
are
prescribed
are
themselves
associated
with
m
##or
##bid
##ity
and
mortality
and
an
increased
risk
of
su
##icidal
thoughts
and
behavior
.
[SEP]
[CLS]
Inc
##reased
plasma
high
-
density
lip
##op
##rote
##in
,
reduced
low
-
density
lip
##op
##rote
##in
(
L
##D
##L
)
ch
##ole
##ster
##ol
concentrations
,
increased
t
##rig
##ly
##cer
##ide
levels
.
[SEP]
[CLS]
In
a
place
##bo
-
controlled
clinical
trial
of
patients
with
r
##he
##uma
##to
##id
art
##hr
##itis
,
no
difference
was
detected
in
anti
##body
response
to
vaccine
between
C
##IM
##Z
##IA
and
place
##bo
treatment
groups
when
the
p
##ne
##um
##oc
##oc
##cal
p
##oly
##sa
##cc
##hari
##de
[SEP]
[CLS]
vaccine
and
in
##fluenza
vaccine
were
administered
concurrently
with
C
##IM
##Z
##IA
.
[SEP]
[CLS]
Other
important
serious
adverse
reactions
reported
in
clinical
trials
and
/
or
post
##market
##ing
experience
were
acute
re
##nal
failure
,
cardiac
failure
,
h
##yper
##sen
##si
##ti
##vity
,
skin
reactions
,
pulmonary
fi
##bro
##sis
,
and
[SEP]
[CLS]
my
##elo
##dy
##sp
##lastic
syndrome
.
[SEP]
[CLS]
Due
to
the
potential
for
an
##aph
##yla
##xi
##s
,
appropriate
medical
support
should
be
readily
available
when
V
##im
##iz
##im
is
administered
.
[SEP]
[CLS]
Consider
disco
##ntin
##uing
Pro
##lia
if
severe
symptoms
develop
(
5
.
7
)
*
Se
##vere
Mu
##s
##cle
Pain
may
occur
.
[SEP]
[CLS]
[
See
Drug
Inter
##actions
(
7
.
1
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
.
]
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
h
##y
##pot
##ens
##ion
after
in
##iti
##ating
therapy
.
[SEP]
[CLS]
(
5
.
5
)
*
B
##lad
##der
Cancer
:
An
im
##bal
##ance
in
bladder
cancer
##s
was
observed
in
clinical
trials
.
[SEP]
[CLS]
Se
##vere
p
##ria
##pis
##m
may
require
surgical
intervention
.
[SEP]
[CLS]
(
5
.
1
)
*
All
patients
taking
P
##OT
##IG
##A
should
have
base
##line
and
periodic
(
every
6
months
)
systematic
visual
monitoring
by
an
op
##ht
##hal
##mic
professional
.
[SEP]
[CLS]
Twenty
-
nine
patients
(
85
%
)
with
Grade
3
-
5
enter
##oc
##oli
##tis
were
treated
with
high
-
dose
(
>
=
40
mg
pre
##dn
##ison
##e
equivalent
per
day
)
co
##rt
##ico
##ster
##oids
,
with
a
median
dose
of
[SEP]
[CLS]
80
mg
/
day
of
pre
##dn
##ison
##e
or
equivalent
;
the
median
duration
of
treatment
was
2
.
3
weeks
(
ranging
up
to
13
.
9
weeks
)
followed
by
co
##rt
##ico
##ster
##oid
tape
##r
.
[SEP]
[CLS]
The
population
in
these
studies
was
71
%
White
,
7
%
Black
or
African
American
,
11
%
Asian
;
32
%
were
of
Hispanic
or
Latino
ethnicity
.
[SEP]
[CLS]
I
##dela
##lis
##ib
is
te
##rato
##genic
in
rats
,
at
systemic
exposure
##s
12
times
those
reported
in
patients
at
the
recommended
dose
of
150
mg
twice
daily
.
[SEP]
[CLS]
All
patients
who
tested
positive
for
binding
antibodies
also
tested
positive
for
neutral
##izing
anti
-
b
##lina
##tum
##oma
##b
antibodies
.
[SEP]
[CLS]
Of
these
7
patients
,
6
had
complete
resolution
;
time
to
resolution
ranged
up
to
15
.
6
weeks
.
[SEP]
[CLS]
If
at
any
time
AS
##T
or
AL
##T
rise
above
five
times
the
U
##L
##N
,
or
the
bi
##li
##ru
##bin
rises
above
three
times
the
U
##L
##N
,
interrupt
Z
##Y
##TI
##GA
treatment
and
closely
monitor
[SEP]
[CLS]
liver
function
.
[SEP]
[CLS]
Stop
Nat
##azi
##a
if
there
is
une
##x
##plain
##ed
loss
of
vision
,
prop
##tosis
,
dip
##lop
##ia
,
p
##ap
##ille
##de
##ma
,
or
re
##tina
##l
vascular
lesions
.
[SEP]
[CLS]
These
patients
were
managed
without
surgical
intervention
,
but
the
long
-
term
consequences
are
unknown
.
[SEP]
[CLS]
P
##las
##ma
Z
##in
##c
Con
##cent
##ration
Dec
##reased
plasma
zinc
concentrations
have
been
observed
on
Fe
##rri
##p
##ro
##x
therapy
.
[SEP]
[CLS]
If
adequate
h
##yper
##gly
##ce
##mic
control
can
not
be
achieved
with
optimal
medical
management
,
permanently
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
5
.
3
Laboratory
Tests
Ser
##um
Live
##r
En
##zy
##me
Activities
In
clinical
studies
,
7
.
5
%
of
64
##2
subjects
treated
with
Fe
##rri
##p
##ro
##x
developed
increased
AL
##T
values
.
[SEP]
[CLS]
In
cases
of
s
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
that
is
not
life
-
threatening
,
with
##hold
Z
##Y
##KA
##DI
##A
until
recovery
to
as
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
or
to
a
heart
rate
of
60
b
##pm
or
above
,
evaluate
the
[SEP]
[CLS]
use
of
con
##com
##ita
##nt
medications
,
and
adjust
the
dose
of
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
5
.
1
Risk
for
Image
Mi
##sin
##ter
##p
##reta
##tion
and
Other
E
##rro
##rs
E
##rro
##rs
may
occur
in
the
N
##eur
##ace
##q
est
##imation
of
brain
ne
##uri
##tic
beta
-
am
##yl
##oid
plaque
density
during
image
interpretation
[
see
Clinical
Studies
(
14
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
Table
5
:
Inc
##iden
##ce
of
Major
##M
##aj
##or
episodes
of
h
##y
##po
##gly
##ce
##mia
were
defined
as
s
##ym
##pt
##oma
##tic
episodes
requiring
external
(
third
party
)
assistance
due
to
severe
imp
##air
##ment
in
consciousness
with
a
[SEP]
[CLS]
plasma
glucose
value
<
54
mg
/
d
##L
and
pro
##mpt
recovery
after
glucose
or
g
##lu
##ca
##gon
administration
.
[SEP]
[CLS]
Overall
,
the
rate
of
PT
##LD
in
94
##9
patients
treated
with
any
of
the
N
##U
##L
##O
##J
##IX
regime
##ns
was
9
-
fold
higher
in
those
who
were
E
##B
##V
se
##rone
##gat
##ive
or
E
##B
##V
se
##ros
##tat
##us
unknown
(
[SEP]
[CLS]
8
/
139
)
compared
to
those
who
were
E
##B
##V
se
##rop
##os
##itive
(
5
/
81
##0
patients
)
.
[SEP]
[CLS]
The
overall
percentage
of
patients
with
antibodies
to
c
##ert
##oli
##zu
##ma
##b
p
##ego
##l
detect
##able
on
at
least
one
occasion
was
7
%
(
105
of
1
,
50
##9
)
in
the
r
##he
##uma
##to
##id
art
##hr
##itis
place
##bo
-
controlled
trials
[SEP]
[CLS]
.
[SEP]
[CLS]
In
this
clinical
context
,
if
the
patient
is
found
to
have
clinical
##ly
significant
liver
enzyme
elevations
and
if
abnormal
liver
tests
per
##sist
or
worse
##n
,
NE
##SI
##NA
should
be
interrupted
[SEP]
[CLS]
and
investigation
done
to
establish
the
probable
cause
.
[SEP]
[CLS]
Keep
bottle
tightly
closed
when
not
in
use
.
[SEP]
[CLS]
Pat
##ients
with
a
prior
an
##aph
##yla
##ctic
-
type
reaction
with
either
o
##x
##car
##ba
##ze
##pine
or
AP
##TI
##OM
should
not
be
treated
with
AP
##TI
##OM
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
There
was
an
increased
risk
of
these
adverse
reactions
during
the
t
##it
##ration
period
(
compared
to
the
maintenance
period
)
and
there
also
may
be
an
increased
risk
of
these
[SEP]
[CLS]
adverse
reactions
in
patients
60
years
of
age
and
older
compared
to
younger
adults
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
Pan
##cre
##ati
##tis
There
have
been
post
##market
##ing
reports
of
acute
pan
##cre
##ati
##tis
in
patients
taking
NE
##SI
##NA
.
[SEP]
[CLS]
The
data
combined
eight
clinical
trials
[
see
Clinical
Studies
(
14
)
]
and
reflect
exposure
of
61
##7
##7
patients
to
IN
##VO
##KA
##NA
.
[SEP]
[CLS]
The
most
frequent
adverse
reactions
that
led
to
disco
##ntin
##uation
of
X
##AL
##KO
##RI
were
IL
##D
(
1
.
7
%
)
,
AS
##T
elevation
(
1
.
2
%
)
,
d
##ys
##p
##nea
(
1
.
2
%
)
[SEP]
[CLS]
,
and
pulmonary
em
##bol
##ism
(
1
.
2
%
)
.
[SEP]
[CLS]
The
following
may
increase
the
risk
for
Q
##T
pro
##long
##ation
when
patients
are
receiving
S
##IR
##TU
##RO
:
*
use
with
other
Q
##T
pro
##long
##ing
drugs
including
flu
##oro
##quin
##olo
##nes
and
mac
##rol
##ide
anti
##ba
##cter
##ial
drugs
and
the
[SEP]
[CLS]
anti
##my
##co
##ba
##cter
##ial
drug
,
c
##lo
##fa
##zi
##mine
*
a
history
of
Tor
##sad
##e
de
Point
##es
*
a
history
of
con
##gen
##ital
long
Q
##T
syndrome
*
a
history
of
or
ongoing
h
##y
##pot
##hy
##roid
##ism
*
a
history
of
[SEP]
[CLS]
or
ongoing
bra
##dy
##ar
##r
##hy
##th
##mia
##s
*
a
history
of
un
##com
##pen
##sat
##ed
heart
failure
*
serum
calcium
,
ma
##gnesium
,
or
potassium
levels
below
the
lower
limits
of
normal
If
necessary
,
bed
##aq
##uil
##ine
treatment
[SEP]
[CLS]
initiation
could
be
considered
in
these
patients
after
a
favorable
benefit
risk
assessment
and
with
frequent
EC
##G
monitoring
.
[SEP]
[CLS]
The
increased
risk
of
su
##icidal
thoughts
with
A
##ED
##s
was
observed
as
early
as
1
week
after
starting
treatment
with
A
##ED
##s
and
persisted
for
the
duration
of
treatment
assessed
.
[SEP]
[CLS]
As
with
all
therapeutic
proteins
,
there
is
potential
for
im
##mu
##no
##genic
##ity
.
[SEP]
[CLS]
Co
##gni
##tive
d
##ys
##function
-
related
events
were
serious
in
0
.
2
%
of
AP
##TI
##OM
-
treated
patients
(
and
0
.
2
%
of
place
##bo
patients
)
and
led
to
disco
##ntin
##uation
in
1
%
of
AP
##TI
##OM
-
treated
patients
(
[SEP]
[CLS]
and
0
.
5
%
of
place
##bo
-
treated
patients
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
of
those
exposed
to
D
##UR
##E
##Z
##OL
occurring
in
5
-
10
%
of
subjects
included
blurred
vision
,
eye
irritation
,
eye
pain
,
headache
,
[SEP]
[CLS]
increased
I
##OP
,
i
##rit
##is
,
con
##junct
##ival
h
##yper
##emia
,
pu
##nc
##tate
k
##era
##titis
,
and
u
##ve
##itis
.
[SEP]
[CLS]
The
incidence
of
serious
adverse
events
was
30
.
6
%
in
the
place
##bo
group
and
34
.
6
%
in
the
Pro
##lia
group
.
[SEP]
[CLS]
More
than
half
(
55
%
)
of
the
population
was
male
;
46
%
were
White
,
50
%
were
Asian
,
and
3
%
were
Black
or
African
[SEP]
[CLS]
American
.
[SEP]
[CLS]
The
Q
##T
interval
should
be
monitored
when
P
##OT
##IG
##A
is
prescribed
with
medicines
known
to
increase
Q
##T
interval
and
in
patients
with
known
prolonged
Q
##T
interval
,
con
##ges
##tive
heart
failure
,
[SEP]
[CLS]
vent
##ric
##ular
h
##yper
##tro
##phy
,
h
##y
##po
##kal
##emia
,
or
h
##y
##po
##ma
##gne
##se
##mia
[
see
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
.
[SEP]
[CLS]
The
proportion
of
patients
with
trans
##ami
##nas
##e
elevations
>
=
3
times
U
##L
##N
(
at
End
##point
)
was
0
.
9
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
1
.
3
%
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Grade
3
/
4
h
##yper
##tens
##ion
was
observed
in
56
/
35
##9
patients
(
16
%
)
receiving
IN
##L
##Y
##TA
and
39
/
35
##5
patients
(
11
%
)
receiving
so
##ra
##fen
##ib
.
[SEP]
[CLS]
*
Risk
of
Card
##iac
A
##rr
##hy
##th
##mia
and
Su
##dden
Card
##iac
Death
during
General
An
##est
##hesia
for
Central
V
##eno
##us
Cat
##he
##ter
Place
##ment
:
C
##aut
##ion
should
be
used
when
administer
##ing
general
an
##est
##hesia
for
the
placement
of
[SEP]
[CLS]
a
central
ve
##nous
cat
##he
##ter
intended
for
al
##g
##lu
##cos
##idas
##e
al
##fa
in
##fusion
(
5
.
4
)
.
[SEP]
[CLS]
The
common
adverse
events
occurring
at
a
rate
of
10
%
or
greater
with
K
##y
##p
##rol
##is
mon
##otherapy
are
presented
in
Table
7
.
[SEP]
[CLS]
Additionally
,
serum
p
##hos
##phorus
should
be
measured
in
patients
at
risk
for
re
##nal
imp
##air
##ment
.
[SEP]
[CLS]
5
.
2
H
##y
##pot
##ens
##ion
in
Volume
-
or
Salt
-
De
##ple
##ted
Pat
##ients
In
patients
with
an
activated
re
##nin
-
an
##gio
##tens
##in
system
,
such
as
volume
-
and
/
or
salt
-
depleted
patients
(
e
.
g
.
,
those
being
treated
with
high
doses
[SEP]
[CLS]
of
di
##ure
##tics
)
,
s
##ym
##pt
##oma
##tic
h
##y
##pot
##ens
##ion
may
occur
after
initiation
of
treatment
with
Ed
##ar
##bi
.
[SEP]
[CLS]
Di
##zzi
##ness
led
to
withdrawal
in
1
%
of
patients
receiving
600
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
.
[SEP]
[CLS]
There
was
no
apparent
association
between
mean
or
peak
I
##g
##G
anti
##body
t
##iter
##s
and
the
occurrence
of
adverse
reactions
.
[SEP]
[CLS]
Do
not
use
BR
##E
##O
E
##LL
##IP
##TA
for
patients
whose
as
##th
##ma
is
adequately
controlled
on
low
-
or
medium
-
dose
inhaled
co
##rt
##ico
##ster
##oids
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
The
clinical
relevance
of
this
in
v
##it
##ro
in
##hibition
is
not
fully
understood
.
[SEP]
[CLS]
When
der
##mat
##itis
is
controlled
,
co
##rt
##ico
##ster
##oid
tape
##ring
should
occur
over
a
period
of
at
least
1
month
.
[SEP]
[CLS]
P
##sy
##chia
##tric
Di
##sor
##ders
:
Su
##icidal
idea
##tion
.
[SEP]
[CLS]
Program
include
the
following
:
E
##NT
##ER
##EG
is
available
only
for
short
-
term
(
15
doses
)
use
in
hospital
##ized
patients
.
[SEP]
[CLS]
There
were
48
##4
subjects
included
in
the
efficacy
and
safety
analyses
.
[SEP]
[CLS]
Across
the
clinical
development
program
of
Y
##ER
##VO
##Y
,
my
##ast
##hen
##ia
g
##ra
##vis
and
additional
cases
of
G
##uil
##lain
-
Barr
##e
syndrome
have
been
reported
.
[SEP]
[CLS]
In
many
cases
,
the
occurrence
of
these
adverse
reactions
led
to
disco
##ntin
##uation
of
therapy
.
[SEP]
[CLS]
There
were
many
adverse
events
associated
with
the
operative
procedure
in
the
clinical
studies
of
C
##lev
##ip
##re
##x
and
relatively
few
p
##laus
##ibly
related
to
the
drugs
used
to
lower
blood
pressure
.
[SEP]
[CLS]
5
.
9
Drug
-
drug
Inter
##actions
Due
to
significant
increases
in
exposure
of
ever
##oli
##mus
,
co
-
administration
with
strong
C
##YP
##3
##A
##4
/
P
##g
##P
inhibitor
##s
should
be
avoided
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
,
2
.
5
)
[SEP]
[CLS]
and
Drug
Inter
##actions
(
7
.
1
)
]
.
[SEP]
[CLS]
Re
##fer
to
Table
2
for
recommended
dose
modifications
for
adverse
reactions
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Do
not
disco
##ntin
##ue
therapy
with
le
##uc
##ovo
##rin
based
on
the
determination
of
a
single
met
##hot
##re
##xa
##te
concentration
below
the
le
##uc
##ovo
##rin
treatment
threshold
.
[SEP]
[CLS]
In
the
pool
of
place
##bo
-
and
active
-
controlled
trials
,
the
types
and
frequency
of
common
adverse
reactions
excluding
h
##y
##po
##gly
##ce
##mia
were
similar
to
those
listed
in
Table
1
.
[SEP]
[CLS]
For
patients
who
test
positive
for
H
##B
##V
infection
,
consultation
with
a
physician
with
expertise
in
the
treatment
of
he
##pa
##titis
B
is
recommended
.
[SEP]
[CLS]
V
##eno
##us
T
##hr
##omb
##oe
##mbo
##lis
##m
(
V
##TE
)
In
the
W
##H
##I
est
##rogen
-
alone
sub
##st
##ud
##y
,
the
risk
of
V
##TE
[
D
##V
##T
and
pulmonary
em
##bol
##ism
(
P
##E
)
]
was
increased
for
women
receiving
daily
[SEP]
[CLS]
con
##ju
##gated
est
##rogen
##s
(
0
.
625
mg
)
-
alone
compared
to
place
##bo
(
30
versus
22
per
10
,
000
women
-
years
)
,
although
only
the
increased
risk
of
D
##V
##T
reached
statistical
significance
(
[SEP]
[CLS]
23
versus
15
per
10
,
000
women
-
years
)
.
[SEP]
[CLS]
Testing
for
I
##g
##G
t
##iter
##s
may
also
be
considered
if
patients
develop
h
##yper
##sen
##si
##ti
##vity
reactions
,
other
immune
-
mediated
reactions
,
or
lose
clinical
response
.
[SEP]
[CLS]
(
5
.
1
)
*
An
##emia
-
The
addition
of
VI
##CT
##RE
##L
##IS
to
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
is
associated
with
an
additional
decrease
in
hem
##og
##lo
##bin
concentrations
compared
with
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
[SEP]
[CLS]
alone
.
[SEP]
[CLS]
Ad
##vise
female
patients
of
reproductive
potential
to
avoid
becoming
pregnant
and
to
use
highly
effective
con
##tra
##ception
while
using
A
##FI
##NI
##TO
##R
and
for
up
to
8
weeks
after
ending
treatment
[
see
[SEP]
[CLS]
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
I
##g
##G
anti
##body
formation
every
3
months
for
2
years
and
then
annually
thereafter
.
[SEP]
[CLS]
These
cases
were
reported
post
-
marketing
and
are
derived
from
a
variety
of
sources
including
re
##gis
##tries
and
spontaneous
post
-
marketing
reports
.
[SEP]
[CLS]
Red
##uction
of
Risk
of
St
##roke
and
System
##ic
Em
##bol
##ism
in
Pat
##ients
with
Non
##val
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
The
safety
of
E
##L
##I
##Q
##UI
##S
was
evaluated
in
the
AR
##IS
##TO
##TL
##E
and
A
##VE
##R
##RO
##ES
studies
[
see
##C
##lini
##cal
Studies
(
[SEP]
[CLS]
14
)
]
,
including
11
,
28
##4
patients
exposed
to
E
##L
##I
##Q
##UI
##S
5
mg
twice
daily
and
60
##2
patients
exposed
to
E
##L
##I
##Q
##UI
##S
2
.
5
mg
twice
daily
.
[SEP]
[CLS]
T
##AF
##IN
##LA
##R
when
used
in
combination
with
tram
##eti
##ni
##b
results
in
an
increased
incidence
of
basal
cell
car
##cin
##oma
.
[SEP]
[CLS]
Rare
cases
of
ne
##uro
##logical
disorders
,
including
seizure
disorder
,
op
##tic
ne
##uri
##tis
,
and
peripheral
ne
##uro
##pathy
have
been
reported
in
patients
treated
with
C
##IM
##Z
##IA
[
see
Ad
##verse
Re
##actions
(
6
.
1
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
The
incidence
of
anti
##body
development
in
patients
receiving
G
##RA
##NI
##X
has
not
been
adequately
determined
.
[SEP]
[CLS]
A
negative
image
does
not
rule
out
the
presence
of
re
##current
pro
##state
cancer
and
a
positive
image
does
not
confirm
the
presence
of
re
##current
cancer
.
[SEP]
[CLS]
The
conditions
and
duration
of
exposure
varied
greatly
and
included
single
-
and
multiple
-
dose
clinical
p
##har
##ma
##cology
studies
in
healthy
volunteers
and
two
double
-
blind
studies
in
patients
with
L
##GS
(
Study
1
[SEP]
[CLS]
and
2
)
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
PM
##L
is
usually
diagnosed
by
brain
imaging
,
c
##ere
##bro
##sp
##inal
fluid
(
CS
##F
)
testing
for
J
##C
viral
DNA
by
polymer
##ase
chain
reaction
(
PC
##R
)
,
and
/
or
brain
bio
##psy
.
[SEP]
[CLS]
A
reduction
of
the
A
##FI
##NI
##TO
##R
dose
is
recommended
when
co
-
administered
with
a
moderate
C
##YP
##3
##A
##4
/
P
##g
##P
inhibitor
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
,
2
.
5
)
and
Drug
Inter
##actions
(
7
.
1
[SEP]
[CLS]
)
]
.
[SEP]
[CLS]
5
.
10
I
##mm
##une
System
Effects
Following
G
##IL
##EN
##Y
##A
Disco
##ntin
##uation
Fin
##gol
##imo
##d
remains
in
the
blood
and
has
p
##har
##ma
##co
##dynamic
effects
,
including
decreased
l
##ymph
##oc
##yte
counts
,
for
up
to
2
months
following
the
last
[SEP]
[CLS]
dose
of
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
(
5
.
1
,
6
)
*
Use
with
C
##YP
##3
##A
induce
##rs
:
Con
##com
##ita
##nt
use
with
strong
C
##YP
##3
##A
induce
##rs
(
e
.
g
.
,
r
##if
##amp
##in
,
St
.
John
'
s
w
##ort
)
substantially
decreases
exposure
[SEP]
[CLS]
of
i
##va
##ca
##ft
##or
,
which
may
dim
##ini
##sh
effectiveness
.
[SEP]
[CLS]
*
Application
site
reactions
,
have
been
reported
.
[SEP]
[CLS]
It
is
important
to
emphasize
that
,
although
the
reactions
reported
occurred
during
treatment
with
FA
##NA
##P
##T
,
they
were
not
necessarily
caused
by
it
.
[SEP]
[CLS]
Non
-
acute
h
##yper
##sen
##si
##ti
##vity
reactions
including
r
##ash
,
nausea
,
fatigue
,
my
##al
##gia
,
headache
,
and
facial
ed
##ema
,
have
been
reported
and
typically
occurred
up
to
a
week
following
the
[SEP]
[CLS]
most
recent
in
##fusion
.
[SEP]
[CLS]
The
incidence
of
these
adverse
reactions
was
greater
in
the
patients
receiving
1
,
200
mg
per
day
.
[SEP]
[CLS]
Red
##uction
in
Heart
Rate
After
the
first
dose
of
G
##IL
##EN
##Y
##A
,
the
heart
rate
decrease
starts
within
an
hour
.
[SEP]
[CLS]
In
patients
treated
with
K
##y
##p
##rol
##is
,
the
incidence
of
serious
adverse
events
was
higher
in
those
>
=
65
years
old
and
in
those
>
=
75
years
old
[
[SEP]
[CLS]
see
G
##eria
##tric
Use
(
8
.
5
)
]
.
[SEP]
[CLS]
In
short
-
term
place
##bo
-
controlled
bi
##pol
##ar
man
##ia
adult
trials
,
the
incidence
of
EP
##S
-
related
events
,
excluding
events
related
to
aka
##thi
##sia
,
for
SA
##P
##H
##RI
##S
-
treated
patients
was
7
%
versus
2
%
for
[SEP]
[CLS]
place
##bo
;
and
the
incidence
of
aka
##thi
##sia
-
related
events
for
SA
##P
##H
##RI
##S
-
treated
patients
was
4
%
versus
2
%
for
place
##bo
.
[SEP]
[CLS]
Table
7
:
Most
Common
##ly
Report
##ed
Ad
##verse
Events
(
>
=
10
%
)
with
K
##y
##p
##rol
##is
Mon
##otherapy
a
P
##ne
##um
##onia
includes
the
preferred
terms
of
pneumonia
,
br
##on
##cho
##p
##ne
##um
##onia
.
[SEP]
[CLS]
One
patient
with
u
##rt
##ica
##ria
had
re
##cu
##rrence
when
IN
##VO
##KA
##NA
was
re
-
initiated
.
[SEP]
[CLS]
6
.
2
End
##ogen
##ous
An
##ter
##ior
U
##ve
##itis
A
total
of
200
subjects
participated
in
the
clinical
trials
for
end
##ogen
##ous
anterior
u
##ve
##itis
,
of
which
106
were
exposed
to
D
##UR
##E
##Z
##OL
.
[SEP]
[CLS]
Co
##gni
##tive
d
##ys
##function
events
were
also
observed
in
mon
##otherapy
trials
.
[SEP]
[CLS]
The
Q
##T
-
pro
##long
##ing
effect
occurred
within
3
hours
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
WA
##R
##NI
##NG
:
IN
##CR
##EA
##SE
##D
M
##OR
##TA
##L
##IT
##Y
IN
E
##LD
##ER
##L
##Y
PA
##TI
##EN
##TS
W
##IT
##H
DE
##ME
##NT
##IA
-
R
##EL
##AT
##ED
PS
##Y
##CH
##OS
##IS
Elder
##ly
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
treated
with
[SEP]
[CLS]
anti
##psy
##cho
##tic
drugs
are
at
an
increased
risk
of
death
.
[SEP]
[CLS]
*
Em
##b
##ryo
-
Fe
##tal
To
##xi
##city
:
Can
cause
f
##etal
harm
.
[SEP]
[CLS]
[
See
Clinical
Studies
(
14
.
1
,
14
.
2
.
)
]
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
Heart
F
##ail
##ure
In
place
##bo
-
controlled
and
open
-
label
r
##he
##uma
##to
##id
art
##hr
##itis
studies
,
cases
of
worse
##ning
heart
failure
have
been
reported
for
C
##IM
##Z
##IA
-
treated
patients
[SEP]
[CLS]
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
With
>
=
10
%
Inc
##iden
##ce
for
Any
Grade
or
>
=
5
%
Inc
##iden
##ce
for
Grade
3
or
Higher
(
N
=
212
)
Ad
##verse
Re
##action
Any
[SEP]
[CLS]
Grade
##G
##rading
based
on
NC
##I
Common
Te
##rm
##ino
##logy
C
##rite
##ria
for
Ad
##verse
Events
(
CT
##CA
##E
)
version
4
.
0
(
%
)
Grade
3
or
Higher
(
%
)
Blood
and
l
##ymph
##atic
system
disorders
[SEP]
[CLS]
Feb
##ril
##e
ne
##ut
##rop
##enia
An
##emia
N
##eu
##tro
##pen
##ia
T
##hr
##omb
##oc
##yt
##ope
##nia
Le
##uk
##ope
##nia
251
##8
##16
##11
##9
231
##31
##5
##8
##8
Gas
##tro
##int
##est
##inal
disorders
Na
##use
##a
Con
##st
##ip
##ation
Di
##ar
##r
##hea
##D
##iar
##r
##hea
includes
the
following
terms
:
co
##lit
##is
,
di
##ar
##r
##hea
,
enter
##itis
,
and
ne
##ut
##rop
##eni
##c
co
##lit
##is
.
[SEP]
[CLS]
The
incidence
of
XI
##AF
##LE
##X
-
associated
p
##ru
##rit
##us
was
similar
after
each
injection
regardless
of
the
number
of
injection
##s
administered
.
[SEP]
[CLS]
Studies
1
and
2
were
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trial
in
newly
diagnosed
patients
with
pulmonary
MD
##R
-
T
##B
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
>
=
25
%
)
are
increased
AS
##T
,
increased
AL
##T
,
l
##ymph
##ope
##nia
,
increased
al
##kal
##ine
p
##hos
##pha
##tase
,
h
##y
##po
##cal
##ce
##mia
,
ne
##ut
##rop
##enia
,
th
##rom
##bo
##cy
##top
##enia
,
[SEP]
[CLS]
h
##y
##pop
##hos
##phate
##mia
,
and
h
##yper
##bil
##ir
##ubi
##ne
##mia
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Z
##Y
##KA
##DI
##A
for
life
-
threatening
bra
##dy
##card
##ia
if
no
contributing
con
##com
##ita
##nt
medication
is
identified
;
however
,
if
associated
with
a
con
##com
##ita
##nt
medication
known
to
cause
bra
##dy
##card
##ia
or
h
##y
##pot
##ens
##ion
,
with
##hold
[SEP]
[CLS]
Z
##Y
##KA
##DI
##A
until
recovery
to
as
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
or
to
a
heart
rate
of
60
b
##pm
or
above
,
and
if
the
con
##com
##ita
##nt
medication
can
be
adjusted
or
discontinued
,
resume
Z
##Y
##KA
##DI
##A
[SEP]
[CLS]
at
a
reduced
dose
as
described
in
Table
1
upon
recovery
to
as
##ym
##pt
##oma
##tic
bra
##dy
##card
##ia
or
to
a
heart
rate
of
60
b
##pm
or
above
,
with
frequent
monitoring
[
see
[SEP]
[CLS]
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Women
of
reproductive
potential
should
be
advised
to
avoid
pregnancy
when
taking
Fe
##rri
##p
##ro
##x
[
see
Use
in
S
##pecific
Population
##s
(
8
.
1
)
and
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
Studies
have
shown
an
increased
risk
of
developing
he
##pa
##to
##cellular
car
##cin
##oma
in
long
-
term
(
>
8
years
)
CO
##C
users
.
[SEP]
[CLS]
Four
(
0
.
62
%
)
Fe
##rri
##p
##ro
##x
-
treated
subjects
discontinued
the
drug
due
to
increased
serum
AL
##T
levels
and
1
(
0
.
16
%
)
due
to
an
increase
in
both
AL
##T
.
[SEP]
[CLS]
5
.
8
B
##lee
##ding
I
##rre
##gu
##lar
##ities
Break
##th
##rough
bleeding
and
spot
##ting
sometimes
occur
in
patients
on
CO
##Cs
,
especially
during
the
first
three
months
of
use
.
[SEP]
[CLS]
Oral
con
##tra
##ceptive
-
related
ch
##ole
##sta
##sis
may
occur
in
women
with
a
history
of
pregnancy
-
related
ch
##ole
##sta
##sis
.
[SEP]
[CLS]
Ad
##re
##V
##ie
##w
safety
and
effectiveness
have
not
been
established
in
neon
##ates
(
p
##ediatric
patients
below
the
age
of
1
month
)
.
[SEP]
[CLS]
Forty
-
four
(
70
%
)
patients
with
moderate
der
##mat
##itis
were
reported
to
have
complete
resolution
,
7
(
11
%
)
improved
to
mild
(
Grade
1
)
severity
,
[SEP]
[CLS]
and
12
(
19
%
)
had
no
reported
improvement
.
[SEP]
[CLS]
Study
3
was
an
open
-
label
,
non
##com
##par
##ative
study
with
S
##IR
##TU
##RO
administered
as
part
of
an
individual
##ized
pulmonary
MD
##R
-
T
##B
treatment
regime
##n
in
previously
treated
patients
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Inc
##iden
##ce
in
Place
##bo
-
Control
##led
Ad
##junct
##ive
Trials
in
Adult
Pat
##ients
with
Part
##ial
-
On
##set
Se
##iz
##ures
(
Ad
##verse
reactions
in
at
least
2
%
of
patients
treated
with
P
##OT
##IG
##A
in
any
treatment
group
[SEP]
[CLS]
and
numerical
##ly
more
frequent
than
in
the
place
##bo
group
.
)
[SEP]
[CLS]
Across
all
Y
##ER
##VO
##Y
-
treated
patients
(
n
=
51
##1
)
,
5
(
1
%
)
patients
developed
in
##test
##inal
per
##fo
##ration
,
4
(
0
.
8
%
)
patients
died
as
a
result
of
complications
[SEP]
[CLS]
,
and
26
(
5
%
)
patients
were
hospital
##ized
for
severe
enter
##oc
##oli
##tis
.
[SEP]
[CLS]
5
.
11
Inter
##ference
with
Laboratory
Tests
The
use
of
CO
##Cs
may
change
the
results
of
some
laboratory
tests
,
such
as
co
##agu
##lation
factors
,
lip
##ids
,
glucose
tolerance
,
and
binding
[SEP]
[CLS]
proteins
.
[SEP]
[CLS]
(
5
.
6
)
*
Mac
##rov
##as
##cular
outcomes
:
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
FA
##R
##X
##IG
##A
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
Mali
##gna
##ncies
In
clinical
studies
of
C
##IM
##Z
##IA
,
the
overall
incidence
rate
of
ma
##li
##gna
##ncies
was
similar
for
C
##IM
##Z
##IA
-
treated
and
control
patients
.
[SEP]
[CLS]
(
5
.
5
)
*
Mac
##rov
##as
##cular
outcomes
:
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
NE
##SI
##NA
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
as
reasons
for
disco
##ntin
##uation
of
treatment
In
the
pre
-
marketing
pool
##ed
8
-
week
place
##bo
-
controlled
studies
in
patients
with
MD
##D
,
1
,
83
##4
patients
were
exposed
to
PR
##IS
##TI
##Q
(
50
to
[SEP]
[CLS]
400
mg
)
.
[SEP]
[CLS]
5
.
4
Ana
##phy
##la
##ctic
Re
##actions
and
Ang
##io
##ede
##ma
Rare
cases
of
an
##aph
##yla
##xi
##s
and
an
##gio
##ede
##ma
have
been
reported
in
patients
taking
AP
##TI
##OM
.
[SEP]
[CLS]
Across
clinical
trials
,
bra
##dy
##card
##ia
occurred
in
205
(
12
.
3
%
)
of
166
##9
patients
treated
with
X
##AL
##KO
##RI
.
[SEP]
[CLS]
Me
##as
##ure
liver
tests
promptly
in
patients
who
report
symptoms
that
may
indicate
liver
injury
,
including
fatigue
,
an
##ore
##xia
,
right
upper
abdominal
discomfort
,
dark
urine
or
j
##au
##ndi
##ce
.
[SEP]
[CLS]
Risk
factors
for
development
of
serious
der
##mat
##olo
##gic
reactions
with
AP
##TI
##OM
use
have
not
been
identified
.
[SEP]
[CLS]
5
.
4
F
##lus
##hing
T
##EC
##FI
##DE
##RA
may
cause
flush
##ing
(
e
.
g
.
,
warmth
,
red
##ness
,
it
##ching
,
and
/
or
burning
sensation
)
.
[SEP]
[CLS]
Before
in
##iti
##ating
treatment
with
T
##EC
##FI
##DE
##RA
,
a
CBC
including
l
##ymph
##oc
##yte
count
should
be
obtained
.
[SEP]
[CLS]
Red
##uction
of
Risk
of
St
##roke
and
System
##ic
Em
##bol
##ism
in
Non
-
v
##al
##vu
##lar
At
##rial
Fi
##bri
##lla
##tion
The
R
##E
-
L
##Y
(
Random
##ized
Evaluation
of
Long
-
term
Anti
##coa
##gu
##lant
Therapy
)
study
provided
safety
information
on
the
use
of
[SEP]
[CLS]
two
doses
of
PR
##AD
##A
##X
##A
and
war
##fari
##n
[
see
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
Use
with
caution
in
patients
with
known
card
##iovascular
or
c
##ere
##bro
##vas
##cular
disease
,
and
in
anti
##psy
##cho
##tic
-
naive
patients
.
[SEP]
[CLS]
These
application
site
reactions
.
[SEP]
[CLS]
SA
##P
##H
##RI
##S
is
not
approved
for
the
treatment
of
patients
with
dem
##ent
##ia
-
related
ps
##ych
##osis
[
see
##B
##ox
##ed
Warning
##and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
The
mean
change
from
base
##line
for
the
all
-
SA
##P
##H
##RI
##S
5
mg
or
10
mg
twice
daily
treated
group
was
comparable
to
place
##bo
in
each
of
the
rating
scale
scores
.
[SEP]
[CLS]
Other
accompanying
reactions
included
chest
discomfort
,
w
##hee
##zing
,
ta
##chy
##p
##nea
,
c
##yan
##osis
,
decreased
oxygen
sat
##uration
,
con
##vu
##ls
##ions
,
p
##ru
##rit
##us
,
r
##ash
,
h
##yper
##hi
##dr
##osis
,
nausea
,
di
##zzi
##ness
,
h
##yper
##tens
##ion
/
increased
[SEP]
[CLS]
blood
pressure
,
flush
##ing
/
feeling
hot
,
er
##yt
##hem
##a
,
p
##yre
##xia
,
p
##allo
##r
,
peripheral
cold
##ness
,
restless
##ness
,
nervous
##ness
,
headache
,
back
pain
,
and
par
##est
##hesia
.
[SEP]
[CLS]
The
most
common
cause
of
disco
##ntin
##uation
due
to
an
adverse
event
was
acute
re
##nal
failure
(
2
%
)
.
[SEP]
[CLS]
There
were
80
##8
subjects
included
in
the
efficacy
and
safety
analyses
.
[SEP]
[CLS]
System
Organ
Class
/
Pre
##ferred
Te
##rm
Place
##bo
N
=
166
%
SA
##P
##H
##RI
##S
5
mg
or
10
mg
twice
daily
*
N
=
158
%
Gas
##tro
##int
##est
##inal
disorders
D
##ys
##pe
##ps
##ia
2
3
Oral
h
##y
##po
##est
##hesia
0
5
General
disorders
Fat
##ig
##ue
2
[SEP]
[CLS]
4
Ed
##ema
peripheral
<
1
3
Investigation
##s
Inc
##reased
weight
0
3
N
##er
##vous
system
disorders
Di
##zzi
##ness
2
4
Other
extra
##py
##ram
##idal
symptoms
(
excluding
aka
##thi
##sia
)
5
6
So
##m
##no
##len
##ce
?
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
with
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
This
finding
with
sa
##lm
##eter
##ol
is
considered
a
class
effect
of
LA
##BA
.
[SEP]
[CLS]
5
.
5
In
##fusion
Re
##actions
In
the
controlled
clinical
trials
,
adverse
events
associated
with
the
in
##fusion
(
occurring
on
the
same
day
of
the
in
##fusion
)
were
reported
in
17
%
[SEP]
[CLS]
(
251
/
1
,
45
##8
)
of
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
15
%
(
99
/
67
##5
)
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Pat
##ients
should
be
monitored
for
signs
of
anti
##cho
##liner
##gic
C
##NS
effects
,
particularly
after
beginning
treatment
or
increasing
the
dose
.
[SEP]
[CLS]
Treatment
-
experienced
,
In
##te
##gra
##se
Strand
Transfer
In
##hibit
##or
-
naive
Sub
##jects
:
In
an
international
,
multi
##cent
##er
,
double
-
blind
trial
(
IN
##G
##11
##17
##6
##2
,
SA
##IL
##ING
)
,
71
##9
HIV
-
1
-
infected
,
anti
##ret
##rov
##ira
##l
treatment
-
experienced
adults
were
random
##ized
[SEP]
[CLS]
and
received
either
T
##I
##VI
##CA
##Y
50
mg
once
daily
or
r
##al
##te
##gra
##vir
400
mg
twice
daily
with
investigator
-
selected
background
regime
##n
consisting
of
up
to
2
agents
,
including
at
least
one
fully
[SEP]
[CLS]
active
agent
.
[SEP]
[CLS]
(
5
.
2
,
7
.
2
,
12
.
3
)
*
Cat
##ara
##cts
:
Non
-
con
##gen
##ital
lens
op
##ac
##ities
have
been
reported
in
p
##ediatric
patients
treated
with
K
##AL
##Y
##DE
##CO
.
[SEP]
[CLS]
Institute
medical
intervention
as
appropriate
for
management
of
severe
ne
##uro
##pathy
.
[SEP]
[CLS]
E
##NT
##ER
##EG
R
##EM
##S
Program
E
##NT
##ER
##EG
is
available
only
through
a
program
called
the
E
##NT
##ER
##EG
Access
Support
and
Education
(
E
.
A
.
S
.
E
.
)
[SEP]
[CLS]
Ad
##vise
females
of
the
potential
hazard
to
the
f
##etus
and
to
use
highly
effective
con
##tra
##ception
.
[SEP]
[CLS]
Pat
##ient
monitoring
may
help
detect
patients
at
risk
for
P
##VA
##N
.
[SEP]
[CLS]
O
##bt
##ain
frequent
blood
counts
to
monitor
for
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
In
clinical
trials
,
G
##IL
##EN
##Y
##A
was
discontinued
if
the
elevation
exceeded
5
times
the
U
##L
##N
.
[SEP]
[CLS]
As
PM
##L
has
been
associated
with
high
levels
of
overall
im
##mu
##nos
##up
##press
##ion
,
the
recommended
doses
and
frequency
of
N
##U
##L
##O
##J
##IX
and
con
##com
##ita
##nt
im
##mu
##nos
##up
##pressive
##s
,
including
M
##MF
,
should
not
be
exceeded
[SEP]
[CLS]
.
[SEP]
[CLS]
Pat
##ients
were
permitted
to
participate
se
##quential
##ly
in
both
place
##bo
-
controlled
trials
;
safety
data
collected
during
exposure
to
K
##AL
##BI
##TO
##R
was
attributed
to
treatment
with
K
##AL
##BI
##TO
##R
,
and
safety
data
collected
during
[SEP]
[CLS]
exposure
to
place
##bo
was
attributed
to
treatment
with
place
##bo
.
[SEP]
[CLS]
Healthcare
providers
should
follow
current
CD
##C
guidelines
both
to
evaluate
for
and
to
treat
possible
late
##nt
tuberculosis
infections
before
in
##iti
##ating
therapy
with
IL
##AR
##IS
.
[SEP]
[CLS]
Disco
##ntin
##uation
from
study
due
to
g
##eni
##tal
infection
occurred
in
0
%
of
place
##bo
-
treated
patients
and
0
.
2
%
of
patients
treated
with
either
J
##AR
##DI
##AN
##CE
10
or
25
mg
.
[SEP]
[CLS]
5
.
5
At
##y
##pical
Sub
##tro
##chan
##ter
##ic
and
Di
##aph
##ys
##eal
Fe
##mor
##al
Fr
##act
##ures
have
been
reported
in
patients
receiving
Pro
##lia
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
5
.
6
N
##eur
##olo
##gic
Re
##actions
Use
of
T
##NF
block
##ers
,
of
which
C
##IM
##Z
##IA
is
a
member
,
has
been
associated
with
rare
cases
of
new
onset
or
ex
##ace
##rb
##ation
of
clinical
symptoms
and
/
or
[SEP]
[CLS]
radio
##graphic
evidence
of
central
nervous
system
dem
##ye
##lina
##ting
disease
,
including
multiple
s
##cle
##rosis
,
and
with
peripheral
dem
##ye
##lina
##ting
disease
,
including
G
##uil
##lain
-
Barr
##e
syndrome
.
[SEP]
[CLS]
Ad
##verse
reactions
leading
to
permanent
treatment
disco
##ntin
##uation
occurred
in
33
%
of
patients
>
=
65
years
of
age
compared
to
17
%
in
patients
<
65
years
of
age
[SEP]
[CLS]
.
[SEP]
[CLS]
For
women
with
a
history
of
ch
##ole
##static
j
##au
##ndi
##ce
associated
with
past
est
##rogen
use
or
with
pregnancy
,
caution
should
be
exercised
;
and
in
the
case
of
re
##cu
##rrence
,
D
##U
##AV
##EE
[SEP]
[CLS]
should
be
discontinued
.
[SEP]
[CLS]
Mali
##gna
##ncies
One
case
of
ma
##li
##gna
##ncy
other
than
l
##ymph
##oma
and
N
##MS
##C
with
S
##IM
##PO
##NI
ARIA
was
reported
through
Week
24
during
the
controlled
phase
of
Trial
1
.
[SEP]
[CLS]
Most
patients
responded
to
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
Disco
##ntin
##uation
of
Co
##arte
##m
Table
##ts
due
to
adverse
drug
reactions
occurred
in
1
.
1
%
of
patients
treated
with
the
6
-
dose
regime
##n
overall
:
0
.
2
%
(
1
/
64
##7
)
in
adults
and
[SEP]
[CLS]
1
.
6
%
(
21
/
1
,
33
##2
)
in
children
.
[SEP]
[CLS]
Approximately
half
the
cases
were
l
##ymph
##oma
##s
,
including
non
-
Ho
##d
##g
##kin
'
s
l
##ymph
##oma
.
[SEP]
[CLS]
During
random
##ized
controlled
studies
,
trans
##ami
##nas
##e
elevations
greater
than
three
times
the
upper
limit
of
normal
(
U
##L
##N
)
were
observed
(
AS
##T
:
2
%
,
2
%
,
[SEP]
[CLS]
and
AL
##T
:
3
%
,
2
%
in
U
##L
##OR
##IC
and
all
##op
##uri
##no
##l
-
treated
patients
,
respectively
)
.
[SEP]
[CLS]
N
##eu
##tro
##phi
##ls
and
Plate
##lets
The
proportion
of
subjects
with
decreased
ne
##ut
##rop
##hil
and
plate
##let
counts
was
higher
in
subjects
treated
with
VI
##CT
##RE
##L
##IS
in
combination
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
to
subjects
receiving
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
[SEP]
[CLS]
.
[SEP]
[CLS]
Ad
##vise
patients
treated
with
M
##U
##LT
##A
##Q
to
report
immediately
symptoms
suggesting
he
##pa
##tic
injury
(
such
as
an
##ore
##xia
,
nausea
,
vomit
##ing
,
fever
,
ma
##lai
##se
,
fatigue
,
right
upper
q
##uad
##rant
[SEP]
[CLS]
pain
,
j
##au
##ndi
##ce
,
dark
urine
,
or
it
##ching
)
.
[SEP]
[CLS]
In
the
controlled
portions
of
clinical
trials
of
all
the
T
##NF
block
##ers
,
more
cases
of
l
##ymph
##oma
have
been
observed
among
patients
receiving
T
##NF
block
##ers
compared
to
control
patients
.
[SEP]
[CLS]
An
observation
##al
study
evaluated
whether
recent
use
of
PD
##E
##5
inhibitor
##s
,
as
a
class
,
was
associated
with
acute
onset
of
N
##A
##ION
.
[SEP]
[CLS]
For
patients
with
lesser
elevations
of
serum
AL
##T
or
bi
##li
##ru
##bin
and
with
an
alternate
probable
cause
,
treatment
with
U
##L
##OR
##IC
can
be
used
with
caution
.
[SEP]
[CLS]
If
CD
##AD
is
suspected
or
confirmed
,
anti
##ba
##cter
##ial
##s
not
directed
against
C
.
di
##ff
##ici
##le
should
be
discontinued
,
if
possible
.
[SEP]
[CLS]
The
effect
of
anti
##body
development
on
the
long
term
efficacy
of
al
##g
##lu
##cos
##idas
##e
al
##fa
is
not
fully
understood
.
[SEP]
[CLS]
(
5
.
1
)
*
C
##los
##tri
##dium
di
##ff
##ici
##le
-
associated
di
##ar
##r
##hea
(
CD
##AD
)
has
been
reported
with
nearly
all
systemic
anti
##ba
##cter
##ial
agents
,
including
Te
##f
##lar
##o
.
[SEP]
[CLS]
Neo
##p
##las
##ms
Ben
##ign
,
Mali
##gnant
,
and
Un
##sp
##ec
##ified
(
including
c
##ys
##ts
and
p
##oly
##ps
)
:
Skin
p
##ap
##illo
##ma
.
[SEP]
[CLS]
No
dose
-
effect
relationship
for
these
trans
##ami
##nas
##e
elevations
was
noted
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
In
the
controlled
and
un
##con
##tro
##lled
portions
of
Trial
1
,
in
S
##IM
##PO
##NI
ARIA
treated
patients
,
the
incidence
of
active
T
##B
per
100
patient
-
years
was
0
.
31
(
95
%
C
##I
[SEP]
[CLS]
:
0
.
06
;
0
.
92
)
and
the
incidence
of
other
op
##port
##uni
##stic
infections
per
100
patient
-
years
was
0
.
42
(
95
%
C
##I
:
0
.
11
,
1
.
07
)
.
[SEP]
[CLS]
Counsel
##ing
patients
about
the
protective
measures
necessary
to
guard
against
sexually
transmitted
diseases
,
including
Human
I
##mm
##uno
##de
##ficiency
V
##ir
##us
(
HIV
)
,
should
be
considered
.
[SEP]
[CLS]
5
.
7
G
##eria
##tric
Pat
##ients
In
the
random
##ized
advanced
hormone
receptor
-
positive
,
H
##ER
##2
-
negative
breast
cancer
study
,
the
incidence
of
deaths
due
to
any
cause
within
28
days
of
the
last
A
##FI
##NI
##TO
##R
[SEP]
[CLS]
dose
was
6
%
in
patients
>
=
65
years
of
age
compared
to
2
%
in
patients
<
65
years
of
age
.
[SEP]
[CLS]
Trans
##ient
decreases
in
absolute
ne
##ut
##rop
##hil
count
)
to
less
than
1
##x
##10
9
/
L
were
reported
in
3
patients
(
6
.
0
%
)
in
the
IL
##AR
##IS
group
compared
to
##1
patient
(
[SEP]
[CLS]
2
.
0
%
)
in
the
place
##bo
group
.
[SEP]
[CLS]
H
##y
##po
##gly
##ce
##mia
was
more
frequent
when
T
##AN
##Z
##E
##UM
was
added
to
su
##lf
##ony
##lu
##rea
or
insulin
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
.
[SEP]
[CLS]
Pat
##ients
were
treated
with
K
##AL
##BI
##TO
##R
30
mg
sub
##cut
##aneous
or
place
##bo
.
[SEP]
[CLS]
Physicians
should
consider
PM
##L
in
the
differential
diagnosis
in
patients
with
new
or
worse
##ning
ne
##uro
##logical
,
cognitive
,
or
behavioral
signs
or
symptoms
.
[SEP]
[CLS]
Most
Common
Ad
##verse
Re
##actions
in
an
L
##GS
Place
##bo
Control
##led
Clinical
Trial
(
Study
1
)
Table
3
lists
the
adverse
reactions
that
occurred
in
>
=
5
%
of
ON
##FI
treated
[SEP]
[CLS]
patients
(
at
any
dose
)
,
and
at
a
rate
greater
than
place
##bo
treated
patients
,
in
the
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
,
parallel
group
clinical
study
of
[SEP]
[CLS]
ad
##junct
##ive
A
##ED
therapy
for
15
weeks
(
Study
1
)
.
[SEP]
[CLS]
Ser
##um
trans
##ami
##nas
##e
levels
returned
to
normal
within
approximately
2
months
after
disco
##ntin
##uation
of
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
5
.
4
Use
in
Pat
##ients
with
Sick
##le
Cell
Disease
Se
##vere
and
sometimes
fatal
sick
##le
cell
c
##rises
can
occur
in
patients
with
sick
##le
cell
disease
receiving
human
g
##ran
##ulo
##cy
##te
colony
-
s
##ti
##mulating
factors
.
[SEP]
[CLS]
Anti
##body
t
##iter
##s
for
cellular
up
##take
in
##hibition
were
present
in
18
of
59
(
31
%
)
patients
by
Week
78
.
[SEP]
[CLS]
(
6
.
1
)
*
Most
common
non
-
hem
##ato
##log
##ic
adverse
reactions
for
NHL
(
frequency
>
=
15
%
)
are
nausea
,
fatigue
,
vomit
##ing
,
di
##ar
##r
##hea
,
p
##yre
##xia
,
[SEP]
[CLS]
con
##st
##ip
##ation
,
an
##ore
##xia
,
cough
,
headache
,
weight
decreased
,
d
##ys
##p
##nea
,
r
##ash
,
and
s
##tom
##ati
##tis
.
[SEP]
[CLS]
In
the
remaining
patients
,
symptoms
resolved
within
3
to
4
weeks
.
[SEP]
[CLS]
In
Study
2
,
1
patient
in
each
treatment
group
(
0
.
1
%
)
had
an
infection
resulting
in
death
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
Fe
##tal
To
##xi
##city
Use
of
drugs
that
act
on
the
re
##nin
-
an
##gio
##tens
##in
system
during
the
second
and
third
trim
##ester
##s
of
pregnancy
reduces
f
##etal
re
##nal
function
and
increases
[SEP]
[CLS]
neon
##ata
##l
m
##or
##bid
##ity
.
[SEP]
[CLS]
(
5
.
4
)
*
Post
##eri
##or
re
##versible
en
##ce
##pha
##lop
##athy
syndrome
(
PR
##ES
)
:
If
suspected
,
disco
##ntin
##ue
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
Da
##T
##sca
##n
can
not
be
directly
compared
to
rates
in
the
clinical
[SEP]
[CLS]
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Some
of
these
reactions
were
I
##g
##E
-
mediated
.
[SEP]
[CLS]
The
rates
of
adverse
reactions
were
higher
in
the
combined
controlled
and
open
-
label
experience
than
in
the
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
5
.
3
He
##pa
##to
##to
##xi
##city
More
he
##pa
##tic
-
related
adverse
reactions
were
reported
with
the
use
of
S
##IR
##TU
##RO
plus
other
drugs
used
to
treat
tuberculosis
compared
to
other
drugs
used
to
treat
tuberculosis
without
the
[SEP]
[CLS]
addition
of
S
##IR
##TU
##RO
.
[SEP]
[CLS]
A
total
of
72
##5
men
were
exposed
to
place
##bo
and
73
##1
men
were
exposed
to
Pro
##lia
administered
once
every
6
months
as
a
single
60
mg
sub
##cut
##aneous
dose
.
[SEP]
[CLS]
In
clinical
trials
,
SC
##C
was
observed
both
in
patients
receiving
V
##im
##iz
##im
and
patients
receiving
place
##bo
.
[SEP]
[CLS]
Grade
3
or
greater
infections
occurred
in
14
%
to
26
%
of
patients
.
[SEP]
[CLS]
Te
##mpo
##rar
##ily
su
##sp
##end
,
dose
reduce
,
or
permanently
disco
##ntin
##ue
X
##AL
##KO
##RI
as
described
in
Table
2
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
and
Ad
##verse
Re
##actions
(
6
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
In
controlled
ad
##junct
##ive
e
##pile
##psy
trials
,
these
events
were
reported
in
26
%
and
38
%
of
patients
random
##ized
to
receive
AP
##TI
##OM
at
doses
of
800
mg
and
1200
mg
/
day
[SEP]
[CLS]
,
respectively
,
compared
to
12
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
5
.
6
O
##ste
##one
##c
##rosis
of
the
J
##aw
O
##ste
##one
##c
##rosis
of
the
jaw
(
ON
##J
)
occurred
in
1
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
.
[SEP]
[CLS]
c
Includes
abdominal
discomfort
,
abdominal
pain
,
abdominal
pain
lower
,
abdominal
pain
upper
,
abdominal
tender
##ness
,
gas
##tro
##int
##est
##inal
pain
.
[SEP]
[CLS]
Because
XI
##AF
##LE
##X
contains
foreign
proteins
,
severe
all
##ergic
reactions
to
XI
##AF
##LE
##X
can
occur
.
[SEP]
[CLS]
5
.
10
Depression
Women
with
a
history
of
depression
should
be
carefully
observed
and
Nat
##azi
##a
discontinued
if
depression
re
##cu
##rs
to
a
serious
degree
.
[SEP]
[CLS]
Among
401
patients
in
Studies
1
and
2
treated
with
the
recommended
regime
##n
of
N
##U
##L
##O
##J
##IX
and
the
71
patients
in
Study
3
treated
with
a
very
similar
(
but
non
-
identical
[SEP]
[CLS]
)
N
##U
##L
##O
##J
##IX
regime
##n
,
there
were
5
cases
of
PT
##LD
:
3
in
E
##B
##V
se
##rop
##os
##itive
patients
and
2
in
E
##B
##V
se
##rone
##gat
##ive
patients
.
[SEP]
[CLS]
5
.
14
Po
##ten
##tial
for
Co
##gni
##tive
and
Motor
I
##mp
##air
##ment
FA
##NA
##P
##T
,
like
other
anti
##psy
##cho
##tics
,
has
the
potential
to
imp
##air
judgment
.
[SEP]
[CLS]
FA
##R
##X
##IG
##A
should
not
be
used
in
patients
with
active
bladder
cancer
and
should
be
used
with
caution
in
patients
with
a
prior
history
of
bladder
cancer
.
[SEP]
[CLS]
If
formation
of
anti
-
b
##lina
##tum
##oma
##b
antibodies
with
a
clinical
##ly
significant
effect
is
suspected
,
contact
Am
##gen
at
1
-
800
-
77
-
AM
##GE
##N
(
1
-
800
-
77
##2
-
64
##36
)
to
discuss
anti
##body
testing
.
[SEP]
[CLS]
In
both
treatment
arms
,
patients
received
S
##IR
##TU
##RO
or
place
##bo
in
combination
with
other
drugs
used
to
treat
MD
##R
-
T
##B
.
[SEP]
[CLS]
These
data
reflect
exposure
of
167
##0
patients
to
T
##R
##U
##L
##IC
##IT
##Y
and
a
mean
duration
of
exposure
to
T
##R
##U
##L
##IC
##IT
##Y
of
23
.
8
weeks
.
[SEP]
[CLS]
N
##eur
##ace
##q
,
like
all
radio
##pha
##rma
##ce
##utical
##s
,
contributes
to
a
patient
'
s
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
El
##eva
##tions
of
AS
##T
,
AL
##T
,
or
bi
##li
##ru
##bin
from
the
patient
'
s
base
##line
should
pro
##mpt
more
frequent
monitoring
.
[SEP]
[CLS]
(
5
.
15
)
*
Be
alert
to
h
##y
##po
##kal
##emia
and
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
No
new
safety
signals
were
identified
among
subjects
who
were
retreated
with
XI
##AF
##LE
##X
.
[SEP]
[CLS]
CT
##CA
##E
Grade
3
or
4
IL
##D
/
p
##ne
##um
##oni
##tis
was
reported
in
3
%
of
patients
,
and
fatal
IL
##D
/
p
##ne
##um
##oni
##tis
was
reported
in
1
patient
(
0
.
4
%
)
in
Study
1
.
[SEP]
[CLS]
No
deaths
clearly
related
to
Z
##Y
##TI
##GA
were
reported
due
to
he
##pa
##to
##to
##xi
##city
events
.
[SEP]
[CLS]
5
.
7
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
FA
##R
##X
##IG
##A
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
Gas
##tro
##int
##est
##inal
Ad
##verse
Re
##actions
In
the
four
pivotal
studies
,
patients
on
PR
##AD
##A
##X
##A
150
mg
had
a
similar
incidence
of
gas
##tro
##int
##est
##inal
adverse
reactions
(
24
.
7
%
vs
.
22
.
7
%
on
war
##fari
##n
[SEP]
[CLS]
)
.
[SEP]
[CLS]
(
5
.
7
)
*
Em
##b
##ryo
-
f
##etal
toxicity
:
may
cause
f
##etal
harm
.
[SEP]
[CLS]
The
period
of
time
necessary
to
disco
##ntin
##ue
any
specific
medication
prior
to
Ad
##re
##V
##ie
##w
dos
##ing
has
not
been
established
[
see
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
5
.
5
H
##yper
##gly
##ce
##mia
H
##yper
##gly
##ce
##mia
can
occur
in
patients
receiving
Z
##Y
##KA
##DI
##A
.
[SEP]
[CLS]
The
frequency
,
type
and
severity
of
adverse
drug
reactions
in
p
##ediatric
subjects
were
comparable
to
those
observed
in
adult
subjects
,
except
for
r
##ash
which
was
observed
more
frequently
[SEP]
[CLS]
in
p
##ediatric
subjects
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
PR
##AD
##A
##X
##A
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
,
(
B
)
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
WA
##R
##NI
##NG
:
(
A
)
PR
##EM
##AT
##UR
##E
[SEP]
[CLS]
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
PR
##AD
##A
##X
##A
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##S
,
(
B
)
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
(
A
)
PR
##EM
##AT
##UR
##E
D
##IS
##CO
##NT
##IN
##U
##AT
##ION
OF
PR
##AD
##A
##X
##A
IN
##CR
##EA
##SE
##S
THE
R
##IS
##K
OF
T
##H
##RO
##MB
##OT
##IC
E
##VE
##NT
##SP
##rem
##ature
disco
##ntin
##uation
of
[SEP]
[CLS]
any
oral
anti
##coa
##gu
##lant
,
including
PR
##AD
##A
##X
##A
,
increases
the
risk
of
th
##rom
##bot
##ic
events
.
[SEP]
[CLS]
In
##jection
of
XI
##AF
##LE
##X
into
co
##rp
##ora
cavern
##osa
of
the
penis
may
result
in
damage
to
those
structures
and
possible
injury
such
as
co
##rp
##oral
r
##up
##ture
(
pen
##ile
fracture
)
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
commonly
reported
adverse
reactions
were
injection
site
reactions
,
which
occurred
in
almost
all
patients
(
97
%
)
in
clinical
trials
.
[SEP]
[CLS]
T
##iss
##ue
culture
experiments
indicate
that
approximately
one
-
third
of
human
breast
cancer
##s
are
pro
##la
##ct
##in
-
dependent
in
v
##it
##ro
,
a
factor
of
potential
importance
if
the
prescription
of
these
drugs
is
contemplated
in
[SEP]
[CLS]
a
patient
with
previously
detected
breast
cancer
.
[SEP]
[CLS]
The
Study
1
population
included
patients
with
a
median
age
of
11
years
(
2
to
18
years
)
;
59
%
were
male
,
78
%
were
White
,
[SEP]
[CLS]
10
%
were
Black
/
African
American
,
5
%
were
Asian
,
and
7
%
were
other
or
unknown
.
[SEP]
[CLS]
Among
the
47
##7
patients
in
Studies
1
,
2
,
and
3
treated
with
the
N
##U
##L
##O
##J
##IX
regime
##n
of
higher
cumulative
dose
and
more
frequent
dos
##ing
than
recommended
,
there
were
[SEP]
[CLS]
8
cases
of
PT
##LD
:
2
in
E
##B
##V
se
##rop
##os
##itive
patients
and
6
in
E
##B
##V
se
##rone
##gat
##ive
or
se
##ros
##tat
##us
unknown
patients
.
[SEP]
[CLS]
(
6
.
1
)
E
##X
##CE
##RP
##T
:
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Jan
##ssen
The
##rap
##eu
##tics
,
Division
of
Jan
##ssen
Products
,
LP
at
1
-
800
-
J
##AN
##SS
##EN
(
1
-
800
-
52
##6
-
77
##36
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
[SEP]
[CLS]
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Pat
##ients
with
severe
ne
##ut
##rop
##enia
(
absolute
ne
##ut
##rop
##hil
count
<
1000
/
mm
3
)
should
disco
##ntin
##ue
FA
##NA
##P
##T
and
have
their
W
##BC
followed
until
recovery
.
[SEP]
[CLS]
These
patients
received
T
##RE
##AN
##DA
at
a
dose
of
120
mg
/
m
2
in
##tra
##ven
##ously
on
Days
1
and
2
for
up
to
eight
21
-
day
cycles
.
[SEP]
[CLS]
In
the
majority
of
patients
who
experienced
flush
##ing
,
it
was
mild
or
moderate
in
severity
.
[SEP]
[CLS]
high
tumor
burden
)
(
5
.
6
)
.
[SEP]
[CLS]
Depending
on
the
severity
of
h
##y
##po
##nat
##rem
##ia
,
the
dose
of
AP
##TI
##OM
may
need
to
be
reduced
or
discontinued
.
[SEP]
[CLS]
In
the
controlled
ad
##junct
##ive
e
##pile
##psy
trials
,
4
/
415
patients
(
1
.
0
%
)
treated
with
800
mg
and
6
/
410
(
1
.
5
%
)
patients
treated
with
1200
mg
of
AP
##TI
##OM
[SEP]
[CLS]
had
at
least
one
serum
sodium
value
less
than
125
m
##E
##q
/
L
,
compared
to
none
of
the
patients
assigned
to
place
##bo
.
[SEP]
[CLS]
Ad
##verse
Re
##action
Place
##bo
##N
=
64
##6
IN
##VO
##KA
##NA
100
mg
##N
=
83
##3
IN
##VO
##KA
##NA
300
mg
##N
=
83
##4
Female
g
##eni
##tal
my
##cot
##ic
infections
3
.
2
%
10
.
4
%
11
.
4
%
U
##rina
##ry
tract
infections
4
.
0
%
5
.
9
%
4
.
3
%
[SEP]
[CLS]
Inc
##reased
u
##rina
##tion
0
.
8
%
5
.
3
%
4
.
6
%
Male
g
##eni
##tal
my
##cot
##ic
infections
0
.
6
%
4
.
2
%
3
.
7
%
V
##ul
##vo
##va
##gin
##al
p
##ru
##rit
##us
0
.
0
%
1
.
6
%
3
.
0
%
T
##hir
##st
0
.
2
%
2
.
8
[SEP]
[CLS]
%
2
.
3
%
Con
##st
##ip
##ation
0
.
9
%
1
.
8
%
2
.
3
%
Na
##use
##a
1
.
5
%
2
.
2
%
2
.
3
%
Abd
##omi
##nal
pain
was
also
more
commonly
reported
in
patients
taking
IN
##VO
##KA
##NA
100
mg
[SEP]
[CLS]
(
1
.
8
%
)
,
300
mg
(
1
.
7
%
)
than
in
patients
taking
place
##bo
(
0
.
8
%
)
.
[SEP]
[CLS]
The
majority
(
95
%
)
of
these
patients
had
Grade
1
visual
adverse
reactions
.
[SEP]
[CLS]
In
patients
with
trans
##ami
##nas
##e
elevations
,
monitor
liver
enzymes
more
frequently
.
[SEP]
[CLS]
In
##hala
##tion
of
high
doses
of
beta
##2
-
ad
##rene
##rg
##ic
ago
##nist
##s
may
produce
increases
in
plasma
glucose
.
[SEP]
[CLS]
Ad
##vise
the
patient
to
r
##ins
##e
his
/
her
mouth
with
water
without
swallowing
after
in
##hala
##tion
to
help
reduce
the
risk
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
Leading
to
Disco
##ntin
##uation
in
All
Control
##led
Clinical
Studies
In
the
3
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
studies
,
199
of
81
##3
patients
(
25
%
)
receiving
P
##OT
##IG
##A
[SEP]
[CLS]
and
45
of
42
##7
patients
(
11
%
)
receiving
place
##bo
discontinued
treatment
because
of
adverse
reactions
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
[SEP]
[CLS]
exposure
:
eye
swelling
,
eye
##lid
ed
##ema
,
d
##ys
##pha
##gia
,
nausea
,
flu
-
like
symptoms
,
injection
site
pain
,
injection
site
reaction
,
all
##ergic
der
##mat
##itis
,
localized
all
##ergic
reactions
,
[SEP]
[CLS]
her
##pes
z
##ost
##er
,
muscular
weakness
,
muscle
spa
##sm
,
d
##ys
##art
##hr
##ia
,
my
##al
##gia
and
h
##yper
##sen
##si
##ti
##vity
.
[SEP]
[CLS]
*
When
pregnancy
is
detected
,
disco
##ntin
##ue
Ed
##ar
##bi
as
soon
as
possible
.
[SEP]
[CLS]
Monitor
for
symptoms
of
gas
##tro
##int
##est
##inal
per
##fo
##ration
or
fist
##ula
periodically
throughout
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
The
proportion
of
patients
with
trans
##ami
##nas
##e
elevations
>
=
3
times
upper
limit
of
normal
(
U
##L
##N
)
(
at
End
##point
)
was
2
.
5
%
for
SA
##P
##H
##RI
##S
-
treated
patients
versus
0
.
6
%
[SEP]
[CLS]
for
place
##bo
-
treated
patients
.
[SEP]
[CLS]
In
patients
with
P
##H
##N
receiving
H
##OR
##I
##Z
##AN
##T
twice
daily
,
the
dose
should
be
reduced
to
once
daily
for
1
week
prior
to
disco
##ntin
##uation
to
minimize
the
potential
of
withdrawal
seizure
[SEP]
[CLS]
,
see
Table
2
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
(
6
.
2
)
In
clinical
trials
,
the
most
common
adverse
reactions
,
headache
,
nausea
,
ve
##rt
##igo
,
dry
mouth
or
di
##zzi
##ness
occurred
in
<
1
%
of
subjects
[SEP]
[CLS]
.
[SEP]
[CLS]
Since
patients
who
develop
I
##g
##E
antibodies
to
al
##g
##lu
##cos
##idas
##e
al
##fa
appear
to
be
at
a
higher
risk
for
developing
an
##aph
##yla
##xi
##s
and
h
##yper
##sen
##si
##ti
##vity
reactions
,
these
patients
should
be
monitored
more
closely
[SEP]
[CLS]
during
administration
of
al
##g
##lu
##cos
##idas
##e
al
##fa
.
[SEP]
[CLS]
The
incidence
of
con
##st
##ip
##ation
was
2
%
in
those
taking
place
##bo
,
4
%
in
those
taking
4
mg
/
day
,
and
6
%
in
those
taking
8
mg
/
day
.
[SEP]
[CLS]
In
the
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
trial
in
late
-
onset
patients
,
all
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patients
with
available
samples
(
N
=
59
,
100
%
)
developed
I
##g
##G
antibodies
to
al
##g
##lu
##cos
##idas
##e
[SEP]
[CLS]
al
##fa
.
[SEP]
[CLS]
However
,
there
is
substantial
evidence
from
place
##bo
-
controlled
maintenance
studies
in
adults
with
depression
that
the
use
of
anti
##de
##press
##ants
can
delay
the
re
##cu
##rrence
of
depression
.
[SEP]
[CLS]
The
data
obtained
in
an
ass
##ay
are
highly
dependent
on
several
factors
including
ass
##ay
sensitivity
and
specific
##ity
,
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
[SEP]
[CLS]
medications
,
underlying
disease
,
and
the
number
of
patients
tested
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
and
Active
-
controlled
Trials
The
occurrence
of
adverse
reactions
was
also
evaluated
in
a
larger
pool
of
patients
with
type
2
diabetes
participating
in
7
place
##bo
-
and
active
-
controlled
[SEP]
[CLS]
trials
.
[SEP]
[CLS]
tooth
extraction
,
dental
imp
##lants
,
oral
surgery
)
,
diagnosis
of
cancer
,
con
##com
##ita
##nt
the
##rap
##ies
(
e
.
g
.
[SEP]
[CLS]
5
.
1
Su
##icidal
Thought
##s
and
Be
##ha
##vior
##s
in
Children
,
Ad
##ole
##scent
##s
and
Young
Adults
Pat
##ients
with
major
de
##pressive
disorder
(
MD
##D
)
,
both
adult
and
p
##ediatric
,
may
experience
worse
##ning
of
[SEP]
[CLS]
their
depression
and
/
or
the
emergence
of
su
##icidal
idea
##tion
and
behavior
(
su
##icidal
##ity
)
or
unusual
changes
in
behavior
,
whether
or
not
they
are
taking
anti
##de
##press
##ant
medications
,
and
this
[SEP]
[CLS]
risk
may
per
##sist
until
significant
re
##mission
occurs
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Au
##xi
##lium
Ph
##arma
##ce
##utical
##s
,
Inc
.
at
1
-
87
##7
-
66
##3
-
04
##12
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Pat
##ients
with
pre
##ex
##ist
##ing
liver
disease
may
be
at
increased
risk
of
developing
elevated
liver
enzymes
when
taking
G
##IL
##EN
##Y
##A
.
[SEP]
[CLS]
In
Trial
2
,
the
incidence
of
fever
(
serious
and
non
-
serious
)
was
71
%
(
39
/
55
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
and
26
[SEP]
[CLS]
%
(
14
/
53
)
in
patients
treated
with
T
##AF
##IN
##LA
##R
as
a
single
agent
.
[SEP]
[CLS]
If
feasible
,
D
##U
##AV
##EE
should
be
discontinued
at
least
4
to
6
weeks
before
surgery
of
the
type
associated
with
an
increased
risk
of
th
##rom
##boe
##mbo
##lis
##m
,
or
during
periods
of
[SEP]
[CLS]
prolonged
im
##mo
##bil
##ization
.
[SEP]
[CLS]
There
were
no
Grade
3
or
4
in
##fusion
-
related
reactions
reported
in
Studies
1
and
2
;
however
,
Grade
1
or
2
in
##fusion
-
related
reactions
were
reported
for
19
patients
(
[SEP]
[CLS]
12
%
)
.
[SEP]
[CLS]
Step
##wise
increase
in
alpha
-
block
##er
dose
may
be
associated
with
further
lowering
of
blood
pressure
when
taking
a
PD
##E
##5
inhibitor
.
[SEP]
[CLS]
5
.
9
He
##pa
##tic
I
##mp
##air
##ment
and
Past
History
of
Cho
##les
##tat
##ic
J
##au
##ndi
##ce
D
##U
##AV
##EE
has
not
been
studied
in
women
with
impaired
liver
function
or
past
history
of
ch
##ole
##static
j
##au
##ndi
##ce
.
[SEP]
[CLS]
In
##fusion
reactions
Two
cases
of
an
##aph
##yla
##xi
##s
were
reported
in
the
dose
-
finding
trials
.
[SEP]
[CLS]
Eight
patients
had
a
new
c
##yt
##ogen
##etic
abnormal
##ity
reported
on
therapy
,
including
5
patients
who
had
complex
changes
in
chromosome
7
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
are
nausea
(
11
%
)
,
vomit
##ing
(
7
%
)
,
abdominal
pain
(
6
%
)
,
[SEP]
[CLS]
gas
##tro
##int
##est
##inal
hem
##or
##r
##hage
(
4
%
)
,
an
##emia
(
2
%
)
,
and
ne
##ut
##rop
##enia
(
2
%
)
(
6
)
.
[SEP]
[CLS]
Because
im
##mo
##bil
##ization
increases
the
risk
for
ve
##nous
th
##rom
##boe
##mbo
##lic
events
independent
of
therapy
,
D
##U
##AV
##EE
should
be
discontinued
prior
to
and
during
prolonged
im
##mo
##bil
##ization
(
e
.
g
.
,
post
-
surgical
recovery
,
prolonged
[SEP]
[CLS]
bed
rest
)
and
D
##U
##AV
##EE
therapy
should
be
resumed
only
after
the
patient
is
fully
am
##bula
##tory
.
[SEP]
[CLS]
Treatment
with
anti
##ba
##cter
##ial
agents
alter
##s
the
normal
flora
of
the
co
##lon
and
may
permit
over
##gro
##wth
of
C
.
di
##ff
##ici
##le
.
[SEP]
[CLS]
Pat
##ients
with
RA
,
particularly
those
with
highly
active
disease
,
are
at
a
higher
risk
for
the
development
of
l
##ymph
##oma
.
[SEP]
[CLS]
(
5
.
3
)
*
H
##yper
##sen
##si
##ti
##vity
-
Ser
##ious
acute
h
##yper
##sen
##si
##ti
##vity
reactions
(
e
.
g
.
,
u
##rt
##ica
##ria
,
an
##gio
##ede
##ma
)
have
been
observed
during
combination
therapy
with
VI
##CT
##RE
##L
##IS
,
p
##eg
##int
##er
##fer
##on
al
##fa
and
rib
##avi
##rin
[SEP]
[CLS]
.
[SEP]
[CLS]
In
adults
,
the
most
frequently
reported
adverse
reactions
were
headache
,
an
##ore
##xia
,
di
##zzi
##ness
,
and
as
##the
##nia
.
[SEP]
[CLS]
In
##hibit
##ors
of
C
##YP
##3
##A
##4
may
reduce
ST
##EN
##DR
##A
clearance
and
increase
plasma
concentrations
of
a
##vana
##fi
##l
.
[SEP]
[CLS]
E
##SC
##AP
##E
-
1
E
##SC
##AP
##E
-
2
C
##L
##VN
=
53
(
%
)
P
##BO
##N
=
51
(
%
)
C
##L
##VN
=
61
(
%
)
P
##BO
##N
=
49
(
%
)
Any
common
adverse
event
27
(
51
%
)
21
(
41
[SEP]
[CLS]
%
)
32
(
53
%
)
24
(
49
%
)
A
##cute
re
##nal
failure
5
(
9
%
)
1
(
2
%
)
-
-
-
-
At
##rial
fi
##bri
##lla
##tion
-
-
[SEP]
[CLS]
-
-
13
(
21
%
)
6
(
12
%
)
Na
##use
##a
-
-
-
-
13
(
21
%
)
6
(
12
%
)
Three
random
##ized
,
parallel
,
open
-
label
[SEP]
[CLS]
studies
called
EC
##L
##IP
##SE
,
with
longer
exposure
in
cardiac
surgery
patients
define
the
adverse
reactions
for
patients
with
per
##io
##per
##ative
h
##yper
##tens
##ion
.
[SEP]
[CLS]
In
patients
with
mild
re
##nal
imp
##air
##ment
(
C
##r
##C
##l
51
-
80
m
##L
/
min
)
,
AM
##P
##Y
##RA
plasma
levels
may
approach
those
seen
at
a
dose
of
15
mg
twice
daily
,
a
dose
[SEP]
[CLS]
that
may
be
associated
with
an
increased
risk
of
seizure
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
5
.
5
U
##rina
##ry
T
##rac
##t
In
##fect
##ions
U
##rina
##ry
tract
infections
(
U
##TI
##s
)
were
reported
more
frequently
as
adverse
reactions
in
controlled
studies
in
patients
receiving
AM
##P
##Y
##RA
10
mg
twice
daily
(
12
[SEP]
[CLS]
%
)
as
compared
to
place
##bo
(
8
%
)
.
[SEP]
[CLS]
The
CA
##PS
clinical
studies
employed
the
bio
##sen
##sor
binding
ass
##ay
,
and
most
of
the
S
##J
##IA
clinical
studies
employed
the
br
##id
##ging
ass
##ay
.
[SEP]
[CLS]
Pat
##ients
should
be
advised
not
to
drive
a
car
or
operate
other
complex
machinery
until
they
have
gained
sufficient
experience
on
H
##OR
##I
##Z
##AN
##T
to
assess
whether
H
##OR
##I
##Z
##AN
##T
imp
##air
##s
their
ability
to
[SEP]
[CLS]
perform
these
tasks
.
[SEP]
[CLS]
For
patients
with
a
history
of
trans
##ami
##nas
##e
elevations
,
more
frequent
monitoring
of
liver
function
tests
should
be
considered
.
[SEP]
[CLS]
ST
##RI
##BI
##LD
is
not
approved
for
the
treatment
of
chronic
he
##pa
##titis
B
virus
(
H
##B
##V
)
infection
and
the
safety
and
efficacy
of
ST
##RI
##BI
##LD
have
not
been
established
in
patients
coin
##fected
[SEP]
[CLS]
with
H
##B
##V
and
HIV
-
1
.
[SEP]
[CLS]
The
rate
of
adverse
events
leading
to
disco
##ntin
##uation
was
4
%
of
subjects
at
Week
48
.
[SEP]
[CLS]
In
the
controlled
clinical
trials
,
ma
##li
##gna
##ncies
,
excluding
non
-
me
##lan
##oma
skin
cancer
##s
,
were
observed
in
0
.
2
%
(
3
/
1
,
45
##8
)
and
0
.
3
%
(
2
/
67
##5
)
of
patients
receiving
[SEP]
[CLS]
B
##EN
##L
##Y
##ST
##A
and
place
##bo
,
respectively
.
[SEP]
[CLS]
(
2
.
3
,
5
.
2
)
*
Inter
##st
##iti
##al
lung
disease
(
IL
##D
)
:
O
##cc
##urs
in
1
.
5
%
of
patients
.
[SEP]
[CLS]
The
median
age
of
these
patients
was
64
years
(
range
32
-
87
)
.
[SEP]
[CLS]
WA
##R
##NI
##NG
:
F
##ET
##AL
TO
##X
##IC
##IT
##Y
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
.
[SEP]
[CLS]
5
.
6
Use
with
Ana
##kin
##ra
Con
##current
administration
of
an
##aki
##n
##ra
(
an
inter
##le
##uki
##n
-
1
antagonist
)
and
another
T
##NF
-
block
##er
,
was
associated
with
a
greater
portion
of
serious
infections
and
ne
##ut
##rop
##enia
and
no
[SEP]
[CLS]
additional
benefits
compared
with
the
T
##NF
-
block
##er
alone
.
[SEP]
[CLS]
In
patients
whose
re
##nal
function
may
depend
on
the
activity
of
the
re
##nin
-
an
##gio
##tens
##in
system
(
e
.
g
.
,
patients
with
severe
con
##ges
##tive
heart
failure
,
re
##nal
artery
s
##ten
##osis
,
or
volume
[SEP]
[CLS]
de
##ple
##tion
)
,
treatment
with
an
##gio
##tens
##in
-
converting
enzyme
inhibitor
##s
and
an
##gio
##tens
##in
receptor
block
##ers
has
been
associated
with
o
##li
##gu
##ria
or
progressive
a
##zo
##tem
##ia
and
rarely
with
acute
re
##nal
failure
and
death
.
[SEP]
[CLS]
Grade
3
-
4
adverse
reactions
were
reported
in
44
%
of
X
##TA
##ND
##I
-
treated
patients
and
37
%
of
place
##bo
-
treated
patients
.
[SEP]
[CLS]
Table
3
shows
absolute
and
relative
risk
by
indication
for
all
evaluated
A
##ED
##s
.
[SEP]
[CLS]
Additionally
in
Pro
##lia
-
treated
men
with
non
##met
##ast
##atic
pro
##state
cancer
receiving
AD
##T
,
a
greater
incidence
of
cat
##ara
##cts
was
observed
(
1
.
2
%
place
##bo
vs
.
4
.
7
%
Pro
##lia
)
.
[SEP]
[CLS]
One
death
occurred
during
the
24
weeks
of
administration
of
S
##IR
##TU
##RO
.
[SEP]
[CLS]
*
Tu
##mor
L
##ys
##is
S
##yn
##drome
(
T
##LS
)
:
Monitor
patients
at
risk
for
T
##LS
(
e
.
g
.
[SEP]
[CLS]
If
super
-
infection
occurs
,
disco
##ntin
##ue
use
and
institute
alternative
therapy
.
[SEP]
[CLS]
(
24
weeks
)
N
=
197
N
=
212
N
=
196
Major
[
n
(
%
)
]
1
(
0
.
5
)
1
(
0
.
5
)
1
(
0
.
5
)
Minor
[
n
(
[SEP]
[CLS]
%
)
]
67
(
34
.
0
)
92
(
43
.
4
)
79
(
40
.
3
)
Gen
##ital
My
##cot
##ic
In
##fect
##ions
Gen
##ital
my
##cot
##ic
infections
were
more
frequent
with
FA
##R
##X
##IG
##A
treatment
.
[SEP]
[CLS]
5
.
9
H
##yper
##p
##rol
##act
##ine
##mia
As
with
other
drugs
that
ant
##agon
##ize
do
##pa
##mine
D
##2
receptors
,
FA
##NA
##P
##T
el
##eva
##tes
pro
##la
##ct
##in
levels
.
[SEP]
[CLS]
Upon
improvement
to
Grade
1
or
less
,
initiate
co
##rt
##ico
##ster
##oid
tape
##r
and
continue
to
tape
##r
over
at
least
1
month
.
[SEP]
[CLS]
Monitor
blood
pressure
prior
to
initiation
and
regularly
during
CO
##ME
##TR
##I
##Q
treatment
.
[SEP]
[CLS]
In
these
trials
,
which
had
a
median
treatment
duration
of
12
weeks
,
the
estimated
incidence
rate
of
su
##icidal
behavior
among
27
,
86
##3
A
##ED
treated
patients
was
0
.
43
%
,
[SEP]
[CLS]
compared
to
0
.
24
%
among
16
,
02
##9
place
##bo
treated
patients
,
representing
an
increase
of
approximately
one
case
of
su
##icidal
thinking
for
every
530
patients
treated
.
[SEP]
[CLS]
Ra
##sh
was
self
-
limiting
and
generally
resolved
within
1
week
on
continued
therapy
.
[SEP]
[CLS]
Treatment
of
h
##yper
##am
##mon
##emia
may
require
dial
##ys
##is
,
prefer
##ably
hem
##od
##ial
##ys
##is
,
to
remove
a
large
burden
of
am
##monia
.
[SEP]
[CLS]
ON
##FI
should
be
tape
##red
by
decreasing
the
dose
every
week
by
5
-
10
mg
/
day
until
disco
##ntin
##uation
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
CT
##CA
##E
Grade
3
-
4
elevations
of
lip
##ase
occurred
in
15
%
of
patients
receiving
Z
##Y
##KA
##DI
##A
in
Study
1
.
[SEP]
[CLS]
In
animal
studies
,
administration
of
def
##eri
##p
##rone
during
the
period
of
organ
##ogen
##esis
resulted
in
em
##b
##ryo
##fe
##tal
death
at
doses
lower
than
equivalent
human
clinical
doses
.
[SEP]
[CLS]
A
##vo
##id
concurrent
use
of
Z
##yd
##eli
##g
and
other
drugs
that
cause
di
##ar
##r
##hea
.
[SEP]
[CLS]
E
##rro
##rs
may
also
occur
in
cases
with
severe
brain
at
##rop
##hy
that
limits
the
ability
to
distinguish
gray
and
white
matter
on
the
N
##eur
##ace
##q
scan
.
[SEP]
[CLS]
N
##eur
##ace
##q
scan
results
are
in
##dicative
of
the
presence
of
brain
ne
##uri
##tic
beta
-
am
##yl
##oid
plaque
##s
only
at
the
time
of
image
acquisition
and
a
negative
scan
result
does
not
pre
##c
##lude
the
development
[SEP]
[CLS]
of
brain
ne
##uri
##tic
beta
-
am
##yl
##oid
plaque
##s
in
the
future
.
[SEP]
[CLS]
Table
1
:
Treatment
-
Em
##er
##gent
Ad
##verse
Re
##actions
##I
##nc
##lude
##s
adverse
reactions
at
least
possibly
,
probably
,
or
very
likely
related
to
the
drug
.
[SEP]
[CLS]
5
.
3
He
##pa
##to
##to
##xi
##city
In
the
two
random
##ized
clinical
trials
,
grade
3
or
4
AS
##T
increases
(
at
least
5
*
U
##L
##N
)
were
reported
in
4
%
of
patients
who
received
[SEP]
[CLS]
Z
##Y
##TI
##GA
,
typically
during
the
first
3
months
after
starting
treatment
.
[SEP]
[CLS]
Media
##n
time
to
resolution
ranged
between
1
week
and
1
month
across
trials
,
following
interrupt
##ion
of
Z
##yd
##eli
##g
therapy
and
in
some
instances
,
use
of
co
##rt
##ico
##ster
##oids
[
see
Do
##sa
##ge
[SEP]
[CLS]
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
The
adverse
reaction
profile
was
similar
for
each
injection
,
regardless
of
the
number
of
injection
##s
administered
.
[SEP]
[CLS]
Be
##si
##vance
is
for
topic
##al
op
##ht
##hal
##mic
use
only
,
and
should
not
be
injected
sub
##con
##junct
##ival
##ly
,
nor
should
it
be
introduced
directly
into
the
anterior
chamber
of
the
eye
.
[SEP]
[CLS]
Len
##ses
may
be
reins
##ert
##ed
after
10
minutes
following
administration
of
D
##UR
##E
##Z
##OL
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
The
following
serious
adverse
reactions
are
discussed
elsewhere
in
the
label
##ing
:
*
Inc
##reased
mortality
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
[SEP]
[CLS]
Q
##T
Pro
##long
##ation
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
and
Clinical
Ph
##arma
##cology
(
12
.
2
)
]
*
He
##pa
##to
##to
##xi
##city
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
3
)
]
*
Drug
[SEP]
[CLS]
Inter
##actions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
4
)
]
*
The
most
common
adverse
reactions
reported
in
10
%
or
more
of
patients
treated
with
S
##IR
##TU
##RO
were
nausea
,
[SEP]
[CLS]
art
##hra
##l
##gia
,
headache
,
hem
##op
##ty
##sis
and
chest
pain
.
[SEP]
[CLS]
In
s
##ym
##pt
##oma
##tic
patients
,
rule
out
infectious
et
##iol
##ogies
and
consider
end
##os
##copic
evaluation
for
persistent
or
severe
symptoms
.
[SEP]
[CLS]
Six
percent
(
6
%
)
of
T
##EC
##FI
##DE
##RA
patients
and
<
1
%
of
place
##bo
patients
experienced
l
##ymph
##oc
##yte
counts
<
0
.
5
##x
##10
9
/
L
(
lower
limit
of
normal
0
.
91
##x
##10
9
[SEP]
[CLS]
/
L
)
.
[SEP]
[CLS]
F
##lus
##hing
symptoms
generally
began
soon
after
in
##iti
##ating
T
##EC
##FI
##DE
##RA
and
usually
improved
or
resolved
over
time
.
[SEP]
[CLS]
Therefore
,
obtaining
a
liver
test
panel
and
assessing
the
patient
before
in
##iti
##ating
NE
##SI
##NA
therapy
is
recommended
.
[SEP]
[CLS]
Approximately
half
of
the
patients
(
49
%
)
were
male
.
[SEP]
[CLS]
6
.
1
O
##cular
Surgery
O
##cular
adverse
reactions
occurring
in
5
-
15
%
of
subjects
in
clinical
studies
with
D
##UR
##E
##Z
##OL
included
corn
##eal
ed
##ema
,
con
##junct
##ival
h
##yper
##emia
,
eye
pain
,
photo
##ph
##obia
,
[SEP]
[CLS]
posterior
capsule
op
##ac
##ification
,
anterior
chamber
cells
,
anterior
chamber
flare
,
con
##junct
##ival
ed
##ema
,
and
b
##le
##pha
##rit
##is
.
[SEP]
[CLS]
The
decrease
in
serum
potassium
is
usually
trans
##ient
,
not
requiring
supplement
##ation
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
Most
common
adverse
reactions
(
>
15
%
)
are
gas
##tri
##tis
-
like
symptoms
and
bleeding
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Bo
##eh
##ring
##er
In
##gel
##heim
Ph
##arma
##ce
##utical
##s
,
[SEP]
[CLS]
Inc
.
at
(
800
)
54
##2
-
625
##7
or
(
800
)
45
##9
-
99
##0
##6
T
##TY
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Heart
rates
below
40
beats
per
minute
were
rarely
observed
.
[SEP]
[CLS]
A
total
of
80
##1
patients
were
treated
for
at
least
6
months
,
58
##5
patients
were
treated
for
1
year
or
longer
,
and
311
patients
were
treated
for
at
[SEP]
[CLS]
least
2
years
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
H
##yper
##sen
##si
##ti
##vity
and
injection
site
reactions
have
been
reported
following
Da
##T
##sca
##n
administration
.
[SEP]
[CLS]
If
IN
##L
##Y
##TA
is
interrupted
,
patients
receiving
anti
##hy
##pert
##ens
##ive
medications
should
be
monitored
for
h
##y
##pot
##ens
##ion
[
see
##D
##osa
##ge
and
Administration
(
2
.
2
)
]
.
[SEP]
[CLS]
The
risks
and
benefits
of
re
-
administer
##ing
al
##g
##lu
##cos
##idas
##e
al
##fa
following
an
an
##aph
##yla
##ctic
or
h
##yper
##sen
##si
##ti
##vity
reaction
should
be
considered
.
[SEP]
[CLS]
In
these
trials
,
which
had
a
median
treatment
duration
of
12
weeks
,
the
estimated
incidence
rate
of
su
##icidal
behavior
among
27
,
86
##3
A
##ED
-
treated
patients
was
0
.
43
%
,
compared
[SEP]
[CLS]
with
0
.
24
%
among
16
,
02
##9
place
##bo
-
treated
patients
,
representing
an
increase
of
approximately
1
case
of
su
##icidal
thinking
for
every
530
patients
treated
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
incidence
>
=
50
%
)
were
decreased
hem
##og
##lo
##bin
,
h
##yper
##gly
##ce
##mia
,
al
##kal
##ine
p
##hos
##pha
##tase
increased
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
bi
##car
##bon
##ate
decreased
,
and
[SEP]
[CLS]
increased
as
##par
##tate
trans
##ami
##nas
##e
)
.
[SEP]
[CLS]
Therefore
,
the
use
of
c
##yt
##och
##rome
P
##45
##0
enzyme
induce
##rs
(
e
.
g
.
,
r
##if
##amp
##in
,
p
##hen
##ob
##ar
##bit
##al
,
car
##ba
##ma
##ze
##pine
,
p
##hen
##yt
##oi
##n
)
with
O
##TE
##Z
##LA
is
not
recommended
[
see
Drug
Inter
##actions
(
[SEP]
[CLS]
7
.
1
)
and
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
In
addition
to
the
reactions
shown
in
Table
##s
2
and
3
,
adverse
reactions
occurring
in
greater
than
or
equal
to
2
%
of
the
subjects
treated
with
BR
##E
##O
E
##LL
##IP
##TA
[SEP]
[CLS]
100
/
25
or
BR
##E
##O
E
##LL
##IP
##TA
200
/
25
for
12
months
included
p
##yre
##xia
,
back
pain
,
extra
##sy
##sto
##les
,
upper
abdominal
pain
,
respiratory
tract
infection
,
all
##ergic
r
##hin
##itis
,
p
##har
##yn
##git
##is
,
[SEP]
[CLS]
r
##hin
##itis
,
art
##hra
##l
##gia
,
su
##pra
##vent
##ric
##ular
extra
##sy
##sto
##les
,
vent
##ric
##ular
extra
##sy
##sto
##les
,
acute
sin
##us
##itis
,
and
pneumonia
.
[SEP]
[CLS]
A
reaction
was
considered
treatment
-
emerge
##nt
if
it
occurred
for
the
first
time
or
worse
##ned
while
receiving
therapy
following
base
##line
evaluation
.
[SEP]
[CLS]
I
##mm
##une
System
Di
##sor
##ders
H
##yper
##sen
##si
##ti
##vity
reactions
,
including
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
,
r
##ash
,
and
u
##rt
##ica
##ria
.
[SEP]
[CLS]
Table
1
lists
adverse
events
,
regardless
of
ca
##usal
##ity
,
that
were
reported
in
the
combined
Phase
3
,
random
##ized
,
place
##bo
-
controlled
trials
at
an
incidence
greater
than
place
##bo
and
[SEP]
[CLS]
in
1
%
or
more
of
patients
treated
with
To
##via
##z
4
or
8
mg
once
daily
for
up
to
12
weeks
.
[SEP]
[CLS]
Some
patients
who
tested
positive
for
al
##g
##lu
##cos
##idas
##e
al
##fa
-
specific
I
##g
##E
antibodies
and
experienced
h
##yper
##sen
##si
##ti
##vity
reactions
were
able
to
be
re
##chal
##len
##ged
with
al
##g
##lu
##cos
##idas
##e
al
##fa
using
a
slower
in
##fusion
rate
at
lower
starting
[SEP]
[CLS]
doses
and
have
continued
to
receive
treatment
under
close
clinical
supervision
[
see
##W
##ar
##ning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Includes
5
subjects
with
major
bleeding
events
that
occurred
before
the
first
dose
of
a
##pi
##xa
##ban
(
administered
12
to
24
hours
post
surgery
)
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
the
incidence
of
antibodies
to
can
##aki
##num
##ab
between
the
CA
##PS
and
S
##J
##IA
clinical
studies
or
with
the
incidence
of
antibodies
to
other
products
may
be
[SEP]
[CLS]
misleading
.
[SEP]
[CLS]
Because
it
takes
approximately
2
months
to
eliminate
G
##IL
##EN
##Y
##A
from
the
body
,
women
of
child
##be
##aring
potential
should
use
effective
con
##tra
##ception
to
avoid
pregnancy
during
and
for
2
months
after
[SEP]
[CLS]
stopping
G
##IL
##EN
##Y
##A
treatment
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
As
##tel
##las
Ph
##arma
US
,
Inc
.
at
1
-
800
-
72
##7
-
700
##3
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
If
con
##com
##ita
##nt
use
of
PR
##IS
##TI
##Q
with
other
se
##rot
##one
##rg
##ic
drugs
is
clinical
##ly
warrant
##ed
,
patients
should
be
made
aware
of
a
potential
increased
risk
for
se
##rot
##oni
##n
syndrome
,
particularly
during
treatment
[SEP]
[CLS]
initiation
and
dose
increases
(
5
.
2
)
.
[SEP]
[CLS]
5
.
3
Mali
##gnant
Neo
##p
##las
##ms
End
##ome
##tri
##al
Cancer
An
increased
risk
of
end
##ome
##tri
##al
cancer
has
been
reported
with
the
use
of
unopposed
est
##rogen
therapy
in
women
with
a
u
##ter
##us
.
[SEP]
[CLS]
Standard
international
guidelines
were
followed
for
infection
prop
##hyl
##ax
##is
for
her
##pes
simple
##x
virus
(
H
##SV
)
,
var
##ice
##lla
-
z
##ost
##er
virus
(
V
##Z
##V
)
,
and
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
(
PC
##P
)
post
-
auto
-
H
##SC
##T
[SEP]
[CLS]
.
[SEP]
[CLS]
5
.
15
D
##ys
##pha
##gia
E
##so
##pha
##ge
##al
d
##ys
##mot
##ility
and
as
##piration
have
been
associated
with
anti
##psy
##cho
##tic
drug
use
.
[SEP]
[CLS]
For
patients
taking
con
##com
##ita
##nt
moderate
C
##YP
##3
##A
##4
inhibitor
##s
(
including
er
##yt
##hr
##omy
##cin
,
am
##p
##rena
##vir
,
a
##p
##re
##pit
##ant
,
di
##lt
##ia
##ze
##m
,
flu
##cona
##zo
##le
,
f
##osa
##mp
##rena
##vir
,
and
ve
##rap
##ami
##l
)
,
the
maximum
recommended
dose
of
[SEP]
[CLS]
ST
##EN
##DR
##A
is
50
mg
,
not
to
exceed
once
every
24
hours
[
see
##D
##rug
Inter
##actions
(
7
.
2
)
]
.
[SEP]
[CLS]
Monitor
for
signs
and
symptoms
of
my
##oc
##ard
##ial
in
##far
##ction
(
MI
)
and
stroke
.
[SEP]
[CLS]
Contact
your
local
Gen
##zy
##me
representative
or
Gen
##zy
##me
Corporation
at
1
-
800
-
74
##5
-
44
##47
for
information
on
testing
and
to
obtain
a
sample
collection
box
.
[SEP]
[CLS]
5
.
3
Pro
##long
##ed
E
##re
##ction
Pro
##long
##ed
erection
greater
than
4
hours
and
p
##ria
##pis
##m
(
painful
erection
##s
greater
than
6
hours
in
duration
)
have
been
reported
with
other
PD
##E
##5
inhibitor
##s
.
[SEP]
[CLS]
(
5
.
5
)
5
.
1
Em
##b
##ryo
##fe
##tal
To
##xi
##city
(
Use
with
R
##iba
##vir
##in
and
P
##eg
##int
##er
##fer
##on
Alfa
)
R
##iba
##vir
##in
may
cause
birth
defects
and
/
or
death
of
the
exposed
f
##etus
.
[SEP]
[CLS]
5
.
3
He
##pa
##tic
Effects
There
have
been
post
##market
##ing
reports
of
fatal
and
non
-
fatal
he
##pa
##tic
failure
in
patients
taking
U
##L
##OR
##IC
,
although
the
reports
contain
insufficient
information
necessary
to
establish
the
probable
[SEP]
[CLS]
cause
.
[SEP]
[CLS]
Laboratory
Value
##s
Changes
in
selected
hem
##ato
##logical
parameters
during
treatment
of
adult
subjects
with
the
combination
of
VI
##CT
##RE
##L
##IS
with
P
##eg
##I
##nt
##ron
and
R
##E
##BE
##TO
##L
are
described
in
Table
4
.
[SEP]
[CLS]
5
.
5
Su
##dden
Hearing
Loss
Use
of
PD
##E
##5
inhibitor
##s
has
been
associated
with
loss
of
hearing
,
which
may
be
accompanied
by
tin
##ni
##tus
or
di
##zzi
##ness
.
[SEP]
[CLS]
A
number
of
reports
note
that
patients
were
also
receiving
treatment
with
g
##lu
##co
##cor
##tic
##oids
(
e
.
g
.
[SEP]
[CLS]
5
.
4
Ana
##phy
##lax
##is
AM
##P
##Y
##RA
can
cause
an
##aph
##yla
##xi
##s
and
severe
all
##ergic
reactions
.
[SEP]
[CLS]
5
.
12
H
##y
##po
##cal
##ce
##mia
E
##stro
##gen
therapy
should
be
used
with
caution
in
women
with
h
##y
##pop
##ara
##thy
##roid
##ism
as
est
##rogen
-
induced
h
##y
##po
##cal
##ce
##mia
may
occur
.
[SEP]
[CLS]
The
most
common
(
>
=
5
%
)
grade
3
-
4
adverse
reactions
in
patients
who
received
J
##E
##V
##TA
##NA
were
ne
##ut
##rop
##enia
,
le
##uk
##ope
##nia
,
an
##emia
,
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
di
##ar
##r
##hea
,
[SEP]
[CLS]
fatigue
,
and
as
##the
##nia
.
[SEP]
[CLS]
Because
of
the
nature
of
the
adverse
events
seen
with
this
combination
therapy
,
similar
toxic
##ities
may
also
result
from
the
use
of
C
##IM
##Z
##IA
in
this
combination
.
[SEP]
[CLS]
However
,
pre
##s
##cribe
##rs
and
patients
should
be
aware
that
patients
'
ability
to
assess
their
own
driving
competence
,
as
well
as
their
ability
to
assess
the
degree
of
so
##m
##no
##len
##ce
[SEP]
[CLS]
caused
by
H
##OR
##I
##Z
##AN
##T
,
can
be
imp
##er
##fect
.
[SEP]
[CLS]
In
the
event
of
a
serious
reaction
,
administration
of
B
##EN
##L
##Y
##ST
##A
must
be
discontinued
immediately
and
appropriate
medical
therapy
administered
.
[SEP]
[CLS]
In
those
patients
treated
with
1
,
200
mg
of
H
##OR
##I
##Z
##AN
##T
per
day
who
reported
so
##m
##no
##len
##ce
(
10
%
)
,
the
so
##m
##no
##len
##ce
persisted
during
treatment
in
about
27
%
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
laboratory
abnormal
##ities
(
incidence
>
=
3
%
)
were
h
##yper
##gly
##ce
##mia
,
l
##ymph
##ope
##nia
,
decreased
hem
##og
##lo
##bin
,
h
##y
##pop
##hos
##phate
##mia
,
increased
al
##kal
##ine
p
##hos
##pha
##tase
,
ne
##ut
##rop
##enia
,
[SEP]
[CLS]
increased
as
##par
##tate
trans
##ami
##nas
##e
)
,
potassium
decreased
,
and
th
##rom
##bo
##cy
##top
##enia
.
[SEP]
[CLS]
Ex
##ace
##rb
##ation
Trial
In
a
24
-
to
76
-
week
trial
,
subjects
received
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
(
n
=
1
,
00
##9
)
or
flu
##tica
##son
##e
fur
##oat
##e
100
m
##c
##g
(
n
=
1
,
01
##0
)
(
[SEP]
[CLS]
Trial
5
)
.
[SEP]
[CLS]
(
5
.
6
)
*
Not
recommended
in
pan
##cre
##atic
or
gas
##tric
an
##ast
##omo
##sis
.
[SEP]
[CLS]
Poole
##d
analyses
of
199
place
##bo
-
controlled
clinical
trials
(
mon
##otherapy
and
ad
##junct
##ive
therapy
)
of
11
different
A
##ED
##s
showed
that
patients
random
##ized
to
1
of
the
A
##ED
##s
had
approximately
twice
the
[SEP]
[CLS]
risk
[
adjusted
relative
risk
1
.
8
,
95
%
confidence
interval
(
C
##I
)
:
1
.
2
,
2
.
7
]
of
su
##icidal
thinking
compared
with
patients
random
##ized
to
place
##bo
.
[SEP]
[CLS]
C
##rea
##tine
Ki
##nas
##e
(
C
##K
)
:
The
proportion
of
adult
patients
with
C
##K
elevations
>
3
times
U
##L
##N
at
any
time
were
6
.
4
%
and
11
.
1
%
for
patients
treated
[SEP]
[CLS]
with
SA
##P
##H
##RI
##S
5
mg
twice
daily
and
10
mg
twice
daily
,
respectively
,
as
compared
to
6
.
7
%
for
place
##bo
-
treated
patients
in
short
-
term
,
fixed
-
dose
trials
in
s
##chi
##zophrenia
and
[SEP]
[CLS]
bi
##pol
##ar
man
##ia
.
[SEP]
[CLS]
Extra
##py
##ram
##idal
S
##ym
##pt
##oms
:
In
the
short
-
term
,
place
##bo
-
controlled
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
adult
trials
,
data
was
objective
##ly
collected
on
the
Simpson
Angus
Rat
##ing
Scale
for
extra
##py
##ram
##idal
symptoms
(
[SEP]
[CLS]
EP
##S
)
,
the
Barnes
A
##kat
##his
##ia
Scale
(
for
aka
##thi
##sia
)
and
the
Assessment
##s
of
In
##vo
##lu
##ntary
Movement
Scale
##s
(
for
d
##ys
##kin
##esi
##as
)
.
[SEP]
[CLS]
5
.
2
Arte
##rial
T
##hr
##omb
##oe
##mbo
##lic
Events
In
clinical
trials
,
art
##erial
th
##rom
##boe
##mbo
##lic
events
have
been
reported
,
including
deaths
.
[SEP]
[CLS]
The
patients
received
a
median
of
5
(
range
1
-
20
)
prior
regime
##ns
.
[SEP]
[CLS]
What
should
I
tell
my
healthcare
provider
before
taking
D
##U
##AV
##EE
?
[SEP]
[CLS]
The
clinical
significance
of
this
finding
is
unknown
.
[SEP]
[CLS]
Table
2
includes
adverse
reactions
reported
in
Study
2
that
occurred
at
a
>
=
2
%
higher
frequency
in
the
X
##TA
##ND
##I
arm
compared
to
the
place
##bo
arm
.
[SEP]
[CLS]
5
.
4
A
##vo
##id
Use
with
Other
Anti
##ret
##rov
##ira
##l
Products
ST
##RI
##BI
##LD
is
indicated
for
use
as
a
complete
regime
##n
for
the
treatment
of
HIV
-
1
infection
and
co
##ad
##mini
##stra
##tion
with
other
anti
##ret
##rov
##ira
##l
products
is
not
[SEP]
[CLS]
recommended
.
[SEP]
[CLS]
5
.
8
He
##mat
##olo
##gic
Cy
##top
##enia
##s
There
have
been
post
-
marketing
reports
of
pan
##cy
##top
##enia
,
le
##uk
##ope
##nia
,
ne
##ut
##rop
##enia
,
a
##p
##lastic
an
##emia
,
and
th
##rom
##bo
##cy
##top
##enia
in
patients
receiving
T
##NF
-
block
##ers
.
[SEP]
[CLS]
Medical
history
of
h
##yper
##tens
##ion
was
balanced
between
arms
.
[SEP]
[CLS]
5
.
6
Card
##iovascular
Effects
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
,
like
other
beta
##2
-
ago
##nist
##s
,
can
produce
a
clinical
##ly
significant
card
##iovascular
effect
in
some
patients
as
measured
by
increases
in
pulse
rate
,
or
symptoms
[SEP]
[CLS]
.
[SEP]
[CLS]
5
.
3
Ex
##cess
##ive
Use
of
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
and
Use
with
Other
Long
-
Acting
Beta
##2
-
A
##gon
##ists
As
with
other
inhaled
beta
##2
-
ad
##rene
##rg
##ic
drugs
,
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
should
not
be
used
more
often
,
at
higher
[SEP]
[CLS]
doses
than
recommended
,
or
in
conjunction
with
other
medications
containing
long
-
acting
beta
##2
-
ago
##nist
##s
,
as
an
over
##dos
##e
may
result
.
[SEP]
[CLS]
Table
1
contains
the
treatment
emerge
##nt
adverse
reactions
,
regardless
of
at
##tribution
,
that
were
reported
in
>
=
5
%
of
patients
in
either
treatment
group
in
the
random
##ized
[SEP]
[CLS]
C
##LL
clinical
study
.
[SEP]
[CLS]
5
.
2
Risk
of
A
##cute
Re
##sp
##ira
##tory
Co
##mp
##lication
##s
Pat
##ients
with
acute
f
##eb
##ril
##e
or
respiratory
illness
at
the
time
of
V
##im
##iz
##im
in
##fusion
may
be
at
higher
risk
of
life
-
threatening
complications
from
[SEP]
[CLS]
h
##yper
##sen
##si
##ti
##vity
reactions
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
Y
##ER
##VO
##Y
in
patients
with
severe
enter
##oc
##oli
##tis
and
initiate
systemic
co
##rt
##ico
##ster
##oids
at
a
dose
of
1
to
2
mg
/
kg
/
day
of
pre
##dn
##ison
##e
or
equivalent
.
[SEP]
[CLS]
The
data
described
below
reflect
a
median
exposure
to
CO
##ME
##TR
##I
##Q
for
204
days
.
[SEP]
[CLS]
Should
the
physician
decide
to
administer
anti
##coa
##gu
##lation
in
the
context
of
e
##pid
##ural
or
spinal
an
##est
##hesia
/
anal
##ges
##ia
or
l
##umba
##r
pu
##nc
##ture
,
monitor
frequently
to
detect
any
signs
or
symptoms
of
ne
##uro
##logical
imp
##air
##ment
[SEP]
[CLS]
,
such
as
mid
##line
back
pain
,
sensory
and
motor
deficit
##s
(
numb
##ness
,
tingling
,
or
weakness
in
lower
limbs
)
,
bow
##el
and
/
or
bladder
d
##ys
##function
.
[SEP]
[CLS]
Use
caution
when
treating
patients
whose
underlying
medical
conditions
might
be
compromised
by
increases
in
blood
pressure
,
h
##y
##po
##kal
##emia
or
fluid
retention
,
e
.
g
.
,
those
with
heart
failure
,
[SEP]
[CLS]
recent
my
##oc
##ard
##ial
in
##far
##ction
or
vent
##ric
##ular
a
##rr
##hy
##th
##mia
.
[SEP]
[CLS]
Approximately
81
%
of
these
local
reactions
resolved
without
intervention
within
4
weeks
of
XI
##AF
##LE
##X
injection
##s
.
[SEP]
[CLS]
Monitor
patients
closely
for
signs
of
peripheral
motor
and
sensory
ne
##uro
##pathy
.
[SEP]
[CLS]
Inter
##rup
##t
Fe
##rri
##p
##ro
##x
therapy
if
ne
##ut
##rop
##enia
develops
(
AN
##C
<
1
.
5
x
10
9
/
L
)
.
[SEP]
[CLS]
These
include
cases
of
Stevens
-
Johnson
syndrome
,
toxic
e
##pid
##er
##mal
ne
##c
##rol
##ys
##is
and
er
##yt
##hem
##a
multi
##form
##e
.
[SEP]
[CLS]
Sub
##ject
-
years
is
defined
as
cumulative
number
of
days
from
first
drug
intake
to
event
date
,
date
of
last
drug
intake
+
2
,
death
date
(
whatever
occurred
first
[SEP]
[CLS]
)
across
all
treated
subjects
divided
by
365
.
25
.
[SEP]
[CLS]
Anyone
considering
pre
##s
##cribing
ON
##FI
or
any
other
A
##ED
must
balance
the
risk
of
su
##icidal
thoughts
or
behavior
with
the
risk
of
un
##tre
##ated
illness
.
[SEP]
[CLS]
These
were
commonly
d
##ys
##pe
##ps
##ia
(
including
abdominal
pain
upper
,
abdominal
pain
,
abdominal
discomfort
,
and
e
##pi
##gas
##tric
discomfort
)
and
gas
##tri
##tis
-
like
symptoms
(
including
GE
##RD
,
es
##op
##ha
##git
##is
,
[SEP]
[CLS]
er
##os
##ive
gas
##tri
##tis
,
gas
##tric
hem
##or
##r
##hage
,
hem
##or
##r
##ha
##gic
gas
##tri
##tis
,
hem
##or
##r
##ha
##gic
er
##os
##ive
gas
##tri
##tis
,
and
gas
##tro
##int
##est
##inal
ul
##cer
)
.
[SEP]
[CLS]
Based
on
the
severity
of
the
adverse
drug
reaction
,
with
##hold
Z
##Y
##KA
##DI
##A
with
re
##sumption
at
a
reduced
dose
as
described
in
Table
1
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
[SEP]
[CLS]
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
Pat
##ients
with
al
##ani
##ne
amino
##tra
##ns
##fer
##ase
or
as
##par
##tate
amino
##tra
##ns
##fer
##ase
>
3
*
U
##L
##N
(
upper
limit
of
normal
)
experienced
a
higher
incidence
of
Grade
4
ne
##ut
##rop
##enia
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
than
patients
[SEP]
[CLS]
with
normal
amino
##tra
##ns
##fer
##ase
levels
.
[SEP]
[CLS]
Among
patients
in
Study
3
who
reported
no
prior
exposure
to
XI
##AF
##LE
##X
,
97
%
of
patients
had
antibodies
against
AU
##X
-
I
and
AU
##X
-
II
after
two
concurrent
doses
of
XI
##AF
##LE
##X
0
.
58
[SEP]
[CLS]
mg
(
total
dose
of
1
.
16
mg
)
in
the
same
hand
.
[SEP]
[CLS]
The
most
common
laboratory
abnormal
##ities
(
>
20
%
)
reported
in
the
two
random
##ized
clinical
trials
that
occurred
more
commonly
(
>
=
2
%
)
in
the
a
##bir
##ater
##one
ace
##tate
[SEP]
[CLS]
arm
were
an
##emia
,
elevated
al
##kal
##ine
p
##hos
##pha
##tase
,
h
##yper
##tri
##gly
##cer
##ide
##mia
,
l
##ymph
##ope
##nia
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
h
##yper
##gly
##ce
##mia
,
elevated
AS
##T
,
h
##y
##pop
##hos
##phate
##mia
,
elevated
AL
##T
and
h
##y
##po
##kal
##emia
.
[SEP]
[CLS]
Control
##led
Studies
with
R
##he
##uma
##to
##id
Art
##hr
##itis
C
##IM
##Z
##IA
was
studied
primarily
in
place
##bo
-
controlled
trials
and
in
long
-
term
follow
-
up
studies
.
[SEP]
[CLS]
Table
1
:
Change
in
Fast
##ing
G
##lu
##cos
##e
FA
##NA
##P
##T
Place
##bo
24
mg
/
day
Mean
Change
from
Basel
##ine
(
mg
/
d
##L
)
n
=
114
n
=
228
Ser
##um
G
##lu
##cos
##e
Change
from
Basel
##ine
-
0
.
5
6
.
6
Pro
##port
##ion
of
Pat
##ients
[SEP]
[CLS]
with
Shi
##fts
Ser
##um
G
##lu
##cos
##e
Normal
to
High
2
.
5
%
10
.
7
%
(
<
100
mg
/
d
##L
to
>
=
126
mg
/
d
##L
)
(
2
/
80
)
(
18
/
169
)
Poole
##d
analyses
of
glucose
[SEP]
[CLS]
data
from
clinical
studies
including
longer
term
trials
are
shown
in
Table
2
.
[SEP]
[CLS]
*
Palma
##r
-
plant
##ar
E
##ry
##th
##rod
##ys
##est
##hesia
syndrome
(
PP
##ES
)
:
Inter
##rup
##t
CO
##ME
##TR
##I
##Q
,
decrease
dose
.
[SEP]
[CLS]
A
##b
##rup
##t
disco
##ntin
##uation
or
dose
reduction
has
been
associated
with
the
appearance
of
new
symptoms
that
include
di
##zzi
##ness
,
nausea
,
headache
,
i
##rri
##ta
##bility
,
ins
##om
##nia
,
di
##ar
##r
##hea
,
anxiety
,
[SEP]
[CLS]
fatigue
,
abnormal
dreams
,
and
h
##yper
##hi
##dr
##osis
.
[SEP]
[CLS]
(
5
.
4
)
item
{
V
##ira
##l
infections
-
Employment
of
a
co
##rt
##ico
##ster
##oid
medication
in
the
treatment
of
patients
with
a
history
of
her
##pes
simple
##x
requires
great
caution
.
[SEP]
[CLS]
C
##aut
##ion
should
be
exercised
in
treating
patients
with
pre
-
existing
h
##yper
##tens
##ion
,
card
##iovascular
,
or
c
##ere
##bro
##vas
##cular
conditions
that
might
be
compromised
by
increases
in
blood
pressure
.
[SEP]
[CLS]
5
.
14
G
##lau
##com
##a
and
Cat
##ara
##cts
G
##lau
##com
##a
,
increased
in
##tra
##oc
##ular
pressure
,
and
cat
##ara
##cts
have
been
reported
in
patients
with
CO
##PD
or
as
##th
##ma
following
the
long
-
term
administration
of
inhaled
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
Ad
##vise
patients
with
my
##elo
##su
##pp
##ression
following
T
##RE
##AN
##DA
treatment
to
contact
a
physician
if
they
have
symptoms
or
signs
of
infection
.
[SEP]
[CLS]
(
6
.
1
)
*
Most
common
adverse
reactions
(
>
=
20
%
)
for
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
are
p
##yre
##xia
,
chill
##s
,
fatigue
,
r
##ash
,
nausea
,
[SEP]
[CLS]
vomit
##ing
,
di
##ar
##r
##hea
,
abdominal
pain
,
peripheral
ed
##ema
,
cough
,
headache
,
art
##hra
##l
##gia
,
night
sweat
##s
,
decreased
appetite
,
con
##st
##ip
##ation
,
and
my
##al
##gia
.
[SEP]
[CLS]
In
the
clinical
trials
,
blood
counts
were
monitored
every
week
initially
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Vale
##ant
Ph
##arma
##ce
##utical
##s
North
America
LLC
at
1
-
800
-
321
-
45
##7
##6
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
[SEP]
[CLS]
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
[SEP]
[CLS]
another
drug
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
Pat
##ients
were
random
##ized
to
three
treatment
groups
:
V
##im
##iz
##im
2
mg
/
kg
once
per
week
(
n
=
58
)
,
V
##im
##iz
##im
2
mg
/
kg
once
every
other
week
(
n
=
59
)
,
or
[SEP]
[CLS]
place
##bo
(
n
=
59
)
.
[SEP]
[CLS]
Approximately
50
%
of
the
subjects
were
male
and
the
ethnic
distribution
was
60
%
Caucasian
,
30
%
Asian
,
6
%
Hispanic
,
2
%
Black
,
and
[SEP]
[CLS]
3
%
patients
of
other
ethnic
groups
.
[SEP]
[CLS]
This
finding
with
sa
##lm
##eter
##ol
is
considered
a
class
effect
of
LA
##BA
,
including
in
##da
##cate
##rol
,
the
active
ingredient
in
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
.
[SEP]
[CLS]
(
2
.
4
,
5
.
10
)
*
He
##pa
##tic
To
##xi
##city
and
He
##pa
##tic
F
##ail
##ure
:
Monitor
liver
enzymes
.
[SEP]
[CLS]
(
5
.
9
)
*
Monitor
for
protein
##uria
before
initiation
of
,
and
periodically
throughout
,
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
Because
of
the
risk
of
seizure
associated
with
X
##TA
##ND
##I
use
,
patients
should
be
advised
of
the
risk
of
engaging
in
any
activity
where
sudden
loss
of
consciousness
could
cause
[SEP]
[CLS]
serious
harm
to
themselves
or
others
.
[SEP]
[CLS]
The
symptoms
are
consistent
with
the
mechanism
of
action
of
b
##ot
##ulin
##um
to
##xin
and
may
include
as
##the
##nia
,
generalized
muscle
weakness
,
dip
##lop
##ia
,
blurred
vision
,
p
##tosis
,
d
##ys
##pha
##gia
,
[SEP]
[CLS]
d
##ys
##phon
##ia
,
d
##ys
##art
##hr
##ia
,
u
##rina
##ry
in
##con
##tine
##nce
,
and
breathing
difficulties
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
for
example
age
>
60
years
,
h
##yper
##tens
##ion
or
diabetes
)
,
estimate
the
g
##lo
##mer
##ular
fi
##ltration
rate
(
G
##F
##R
)
[SEP]
[CLS]
through
laboratory
testing
(
5
.
1
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
has
occurred
in
patients
with
impaired
elimination
of
GB
##CA
##s
.
[SEP]
[CLS]
Of
the
14
patients
receiving
G
##IL
##EN
##Y
##A
,
7
patients
had
2
:
1
A
##V
block
(
5
patients
within
the
first
6
hours
post
##dos
##e
and
2
patients
after
6
hours
post
##dos
##e
)
[SEP]
[CLS]
.
[SEP]
[CLS]
In
Study
2
,
1
of
87
##1
(
0
.
1
%
)
ch
##em
##otherapy
-
naive
patients
treated
with
X
##TA
##ND
##I
and
1
of
84
##4
(
0
.
1
%
)
patients
treated
with
place
##bo
experienced
a
[SEP]
[CLS]
seizure
.
[SEP]
[CLS]
5
.
3
Con
##ges
##tive
Heart
F
##ail
##ure
Case
##s
of
worse
##ning
con
##ges
##tive
heart
failure
)
and
new
onset
CH
##F
have
been
reported
with
T
##NF
-
block
##ers
,
including
S
##IM
##PO
##NI
ARIA
.
[SEP]
[CLS]
Ad
##verse
events
that
led
to
treatment
disco
##ntin
##uation
and
occurred
in
more
than
1
%
of
patients
taking
G
##IL
##EN
##Y
##A
0
.
5
mg
were
serum
trans
##ami
##nas
##e
elevations
(
4
.
7
%
compared
to
1
[SEP]
[CLS]
%
on
place
##bo
)
and
basal
cell
car
##cin
##oma
(
1
%
compared
to
0
.
5
%
on
place
##bo
)
.
[SEP]
[CLS]
The
most
common
adverse
reactions
(
>
=
3
%
;
2
or
more
patients
)
observed
in
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patients
were
h
##yper
##sen
##si
##ti
##vity
reactions
and
included
an
##aph
##yla
##xi
##s
,
headache
,
[SEP]
[CLS]
nausea
,
u
##rt
##ica
##ria
,
di
##zzi
##ness
,
chest
discomfort
,
vomit
##ing
,
h
##yper
##hi
##dr
##osis
,
flush
##ing
/
feeling
hot
,
increased
blood
pressure
,
par
##est
##hesia
,
p
##yre
##xia
,
local
swelling
,
di
##ar
##r
##hea
,
[SEP]
[CLS]
p
##ru
##rit
##us
,
r
##ash
,
and
throat
tight
##ness
.
[SEP]
[CLS]
Eva
##lu
##ate
d
##ys
##p
##nea
to
exclude
card
##io
##pu
##lm
##ona
##ry
conditions
including
cardiac
failure
and
pulmonary
syndrome
##s
.
[SEP]
[CLS]
In
some
cases
of
an
##aph
##yla
##ctic
reactions
,
e
##pine
##ph
##rine
was
administered
.
[SEP]
[CLS]
b
Includes
di
##ar
##r
##hea
,
enter
##itis
,
enter
##oc
##oli
##tis
,
co
##lit
##is
,
def
##eca
##tion
urgency
,
and
s
##te
##ator
##r
##hea
.
[SEP]
[CLS]
5
.
5
Ke
##rat
##itis
Ke
##rat
##itis
,
characterized
as
worse
##ning
eye
inflammation
,
la
##c
##rima
##tion
,
light
sensitivity
,
blurred
vision
,
eye
pain
,
and
/
or
red
eye
occurred
in
0
.
8
%
of
patients
[SEP]
[CLS]
treated
with
G
##IL
##OT
##RI
##F
among
38
##65
patients
across
clinical
trials
.
[SEP]
[CLS]
No
cases
of
transmission
of
viral
diseases
or
C
##J
##D
have
ever
been
reported
for
album
##in
.
[SEP]
[CLS]
(
2
.
1
,
5
.
7
,
14
.
1
)
*
I
##mm
##uni
##zation
##s
:
avoid
use
of
live
vaccine
##s
during
treatment
.
[SEP]
[CLS]
If
T
##AF
##IN
##LA
##R
is
used
in
combination
with
tram
##eti
##ni
##b
,
do
not
modify
the
dose
of
T
##AF
##IN
##LA
##R
.
[SEP]
[CLS]
A
##vo
##id
use
of
PR
##AD
##A
##X
##A
and
P
-
g
##p
inhibitor
##s
in
patients
with
severe
re
##nal
imp
##air
##ment
(
C
##r
##C
##l
15
-
30
m
##L
/
min
)
[
see
Drug
Inter
##actions
(
7
.
1
)
and
Use
in
S
##pecific
Population
##s
[SEP]
[CLS]
(
8
.
6
)
]
.
[SEP]
[CLS]
S
##ym
##pt
##oma
##tic
treatment
employed
in
clinical
trials
included
s
##tero
##id
and
my
##dr
##ia
##tic
op
##ht
##hal
##mic
drops
.
[SEP]
[CLS]
In
Study
1
,
V
##OR
##A
##X
##A
##Z
##E
-
related
adverse
reactions
were
collected
on
a
flow
sheet
with
a
daily
log
of
adverse
reactions
characterized
as
`
`
g
##lu
##car
##pid
##ase
toxicity
.
'
'
[SEP]
[CLS]
(
5
.
6
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Post
-
Trans
##p
##lant
L
##ymph
##op
##rol
##ifer
##ative
Di
##sor
##der
(
PT
##LD
)
:
increased
risk
,
predominantly
involving
the
C
##NS
;
monitor
for
new
or
worse
##ning
[SEP]
[CLS]
ne
##uro
##logical
,
cognitive
,
or
behavioral
signs
and
symptoms
.
[SEP]
[CLS]
Table
2
:
Ad
##verse
Re
##actions
Report
##ed
in
Clinical
Trials
of
V
##iza
##my
##l
(
N
=
76
##1
subjects
)
Ad
##verse
Re
##action
N
(
percent
of
patients
)
F
##lus
##hing
16
(
2
%
[SEP]
[CLS]
)
Inc
##reased
blood
pressure
13
(
2
%
)
Head
##ache
10
(
1
%
)
Na
##use
##a
8
(
1
%
)
Di
##zzi
##ness
8
(
1
%
)
5
WA
##R
##NI
##NG
##S
AND
[SEP]
[CLS]
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
H
##yper
##sen
##si
##ti
##vity
reactions
:
Ask
patients
about
prior
reactions
to
V
##iza
##my
##l
.
[SEP]
[CLS]
These
two
trials
also
included
a
total
of
40
##3
patients
treated
with
a
N
##U
##L
##O
##J
##IX
regime
##n
of
higher
cumulative
dose
and
more
frequent
dos
##ing
than
recommended
[
see
Clinical
Studies
(
[SEP]
[CLS]
14
.
1
)
]
.
[SEP]
[CLS]
(
5
.
3
)
5
.
1
He
##pa
##tic
Dec
##om
##pen
##sation
in
Pat
##ients
with
Ch
##ronic
He
##pa
##titis
C
In
patients
with
chronic
he
##pa
##titis
C
,
PR
##OM
##AC
##TA
in
combination
with
inter
##fer
##on
and
rib
##avi
##rin
may
increase
the
risk
[SEP]
[CLS]
of
he
##pa
##tic
de
##com
##pen
##sation
.
[SEP]
[CLS]
In
patients
with
a
pre
-
existing
low
W
##BC
/
AN
##C
or
drug
-
induced
le
##uk
##ope
##nia
/
ne
##ut
##rop
##enia
,
perform
a
complete
blood
count
(
CBC
)
frequently
during
the
first
few
months
of
therapy
.
[SEP]
[CLS]
SP
##RI
##NT
-
2
(
subjects
who
were
previously
un
##tre
##ated
)
and
R
##ES
##PO
##ND
-
2
(
subjects
who
had
failed
previous
therapy
)
evaluated
the
use
of
VI
##CT
##RE
##L
##IS
800
mg
three
times
daily
in
combination
[SEP]
[CLS]
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
with
a
four
-
week
lead
-
in
period
with
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
compared
to
P
##eg
##I
##nt
##ron
/
R
##E
##BE
##TO
##L
alone
[
see
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
5
.
2
A
##cute
Pan
##cre
##ati
##tis
In
clinical
trials
,
acute
pan
##cre
##ati
##tis
has
been
reported
in
association
with
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
(
N
=
134
)
40
mg
daily
(
N
=
75
##7
)
80
mg
daily
(
N
=
127
##9
)
(
N
=
127
##7
)
Live
##r
Fun
##ction
A
##b
##nor
##mal
##ities
0
.
7
%
6
.
6
%
4
.
6
%
4
.
2
%
[SEP]
[CLS]
Na
##use
##a
0
.
7
%
1
.
1
%
1
.
3
%
0
.
8
%
Art
##hra
##l
##gia
0
%
1
.
1
%
0
.
7
%
0
.
7
%
Ra
##sh
0
.
7
%
0
.
5
%
1
.
6
%
1
.
6
%
The
most
common
[SEP]
[CLS]
adverse
reaction
leading
to
disco
##ntin
##uation
from
therapy
was
liver
function
abnormal
##ities
in
1
.
8
%
of
U
##L
##OR
##IC
40
mg
,
1
.
2
%
of
U
##L
##OR
##IC
80
mg
,
and
in
0
.
9
%
[SEP]
[CLS]
of
all
##op
##uri
##no
##l
-
treated
subjects
.
[SEP]
[CLS]
You
can
ask
your
p
##har
##ma
##cist
or
healthcare
provider
for
information
about
D
##U
##AV
##EE
that
is
written
for
health
professionals
.
[SEP]
[CLS]
Do
not
restart
if
confirmed
.
[SEP]
[CLS]
If
an
##emia
develops
during
or
after
treatment
with
Te
##f
##lar
##o
,
drug
-
induced
hem
##oly
##tic
an
##emia
should
be
considered
.
[SEP]
[CLS]
The
most
serious
adverse
reactions
reported
with
al
##g
##lu
##cos
##idas
##e
al
##fa
treatment
included
an
##aph
##yla
##xi
##s
and
acute
card
##ior
##es
##pi
##rator
##y
failure
.
[SEP]
[CLS]
Ren
##al
and
U
##rina
##ry
Di
##sor
##ders
:
Inter
##st
##iti
##al
ne
##ph
##rit
##is
.
[SEP]
[CLS]
He
##pa
##to
##to
##xi
##city
may
re
##oc
##cu
##r
if
PR
##OM
##AC
##TA
is
re
##ini
##tia
##ted
.
[SEP]
[CLS]
Risk
factors
for
art
##erial
vascular
disease
(
for
example
,
h
##yper
##tens
##ion
,
diabetes
me
##lli
##tus
,
tobacco
use
,
h
##yper
##cho
##les
##tero
##lem
##ia
,
and
o
##besity
)
and
/
or
V
##TE
(
for
example
,
personal
[SEP]
[CLS]
history
or
family
history
of
V
##TE
,
o
##besity
,
and
systemic
l
##up
##us
er
##yt
##hem
##ato
##sus
)
should
be
managed
appropriately
.
[SEP]
[CLS]
If
the
potential
benefit
for
re
##ini
##tia
##ting
treatment
with
PR
##OM
##AC
##TA
is
considered
to
out
##wei
##gh
the
risk
for
he
##pa
##to
##to
##xi
##city
,
then
consider
cautiously
re
##int
##rod
##uc
##ing
PR
##OM
##AC
##TA
and
measure
serum
liver
tests
weekly
during
[SEP]
[CLS]
the
dose
adjustment
phase
.
[SEP]
[CLS]
BR
##AF
V
##60
##0
##E
or
V
##60
##0
##K
Un
##res
##ec
##table
or
Met
##ast
##atic
Mel
##ano
##ma
:
The
safety
of
T
##AF
##IN
##LA
##R
in
combination
with
tram
##eti
##ni
##b
was
evaluated
in
Trial
2
and
other
trials
consisting
of
a
total
of
[SEP]
[CLS]
202
patients
with
BR
##AF
V
##60
##0
mutation
-
positive
un
##res
##ec
##table
or
meta
##static
me
##lan
##oma
who
received
T
##AF
##IN
##LA
##R
150
mg
oral
##ly
twice
daily
in
combination
with
tram
##eti
##ni
##b
2
mg
oral
##ly
once
daily
until
disease
progression
[SEP]
[CLS]
or
unacceptable
toxicity
.
[SEP]
[CLS]
Di
##ag
##nos
##tic
studies
including
a
direct
Co
##omb
##s
'
test
,
should
be
performed
.
[SEP]
[CLS]
Because
these
reactions
may
worse
##n
re
##nal
function
,
use
caution
when
in
##iti
##ating
or
es
##cal
##ating
doses
of
T
##AN
##Z
##E
##UM
in
patients
with
re
##nal
imp
##air
##ment
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
[SEP]
[CLS]
,
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
A
ca
##usal
relationship
to
ST
##EN
##DR
##A
is
uncertain
.
[SEP]
[CLS]
Ask
your
healthcare
provider
for
ways
to
lower
your
chances
of
getting
heart
disease
.
[SEP]
[CLS]
These
h
##yper
##sen
##si
##ti
##vity
reactions
included
:
an
##aph
##yla
##xi
##s
,
an
##gio
##ede
##ma
,
h
##y
##pot
##ens
##ion
,
ta
##chy
##card
##ia
,
swollen
tongue
,
d
##ys
##p
##nea
,
w
##hee
##zing
and
r
##ash
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
with
rates
in
the
clinical
trials
of
another
drug
,
and
may
not
reflect
the
rates
observed
in
medical
practice
.
[SEP]
[CLS]
*
In
##vasive
fun
##gal
infections
-
For
patients
who
develop
a
systemic
illness
on
S
##IM
##PO
##NI
ARIA
,
consider
em
##pi
##ric
anti
##fu
##nga
##l
therapy
for
those
who
reside
in
or
travel
to
regions
where
[SEP]
[CLS]
my
##cos
##es
are
endemic
(
5
.
1
)
.
[SEP]
[CLS]
Consider
tuberculosis
in
the
differential
diagnosis
in
patients
who
develop
a
new
infection
during
S
##IM
##PO
##NI
ARIA
treatment
,
especially
in
patients
who
have
previously
or
recently
traveled
to
countries
with
[SEP]
[CLS]
a
high
prevalence
of
tuberculosis
,
or
who
have
had
close
contact
with
a
person
with
active
tuberculosis
.
[SEP]
[CLS]
For
these
reasons
,
the
incidence
of
antibodies
to
al
##bi
##g
##lut
##ide
can
not
be
directly
compared
with
the
incidence
of
antibodies
of
other
products
.
[SEP]
[CLS]
Do
##ses
ranged
from
6
to
189
Units
/
kg
,
with
a
median
dose
of
50
Units
/
kg
.
[SEP]
[CLS]
Treatment
and
Red
##uction
in
the
Risk
of
Re
##cu
##rrence
of
Deep
V
##eno
##us
T
##hr
##omb
##osis
and
P
##ul
##mona
##ry
Em
##bol
##ism
A
##vo
##id
use
of
PR
##AD
##A
##X
##A
and
con
##com
##ita
##nt
P
-
g
##p
inhibitor
##s
in
patients
with
C
##r
##C
##l
<
50
m
##L
/
min
[SEP]
[CLS]
[
see
Drug
Inter
##actions
(
7
.
2
)
and
Use
in
S
##pecific
Population
##s
(
8
.
6
)
]
.
[SEP]
[CLS]
Per
##form
op
##ht
##hal
##mo
##logical
evaluation
at
any
time
a
patient
reports
visual
disturbance
##s
and
compare
with
base
##line
,
if
available
.
[SEP]
[CLS]
A
theoretical
risk
for
transmission
of
C
##re
##utz
##feld
##t
-
Jakob
disease
(
C
##J
##D
)
is
also
considered
extremely
remote
.
[SEP]
[CLS]
The
most
common
medical
interventions
required
during
A
##FI
##NI
##TO
##R
treatment
were
for
infections
,
an
##emia
,
and
s
##tom
##ati
##tis
.
[SEP]
[CLS]
C
##aut
##ion
is
warrant
##ed
when
pre
##s
##cribing
FA
##NA
##P
##T
with
drugs
that
in
##hibit
FA
##NA
##P
##T
metabolism
[
see
Drug
Inter
##action
s
(
7
.
1
)
]
,
and
in
patients
with
reduced
activity
of
C
##YP
##2
##D
##6
[SEP]
[CLS]
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
(
5
.
12
)
*
P
##ria
##pis
##m
:
Case
##s
have
been
reported
in
association
with
FA
##NA
##P
##T
treatment
.
[SEP]
[CLS]
In
patients
who
develop
severe
he
##pa
##tic
imp
##air
##ment
while
taking
G
##IL
##OT
##RI
##F
,
treatment
should
be
discontinued
.
[SEP]
[CLS]
c
Includes
p
##ne
##um
##oni
##tis
,
inter
##st
##iti
##al
lung
disease
,
pulmonary
fi
##bro
##sis
and
restrict
##ive
pulmonary
disease
.
[SEP]
[CLS]
Post
##eri
##or
re
##versible
en
##ce
##pha
##lop
##athy
syndrome
(
PR
##ES
)
,
formerly
termed
Rev
##ers
##ible
Post
##eri
##or
Le
##uk
##oe
##nce
##pha
##lop
##athy
S
##yn
##drome
(
R
##PL
##S
)
,
is
a
ne
##uro
##logical
disorder
which
can
present
with
seizure
,
headache
,
[SEP]
[CLS]
let
##har
##gy
,
confusion
,
blind
##ness
,
altered
consciousness
,
and
other
visual
and
ne
##uro
##logical
disturbance
##s
,
along
with
h
##yper
##tens
##ion
,
and
the
diagnosis
is
confirmed
by
ne
##uro
-
radio
##logical
imaging
(
MR
##I
[SEP]
[CLS]
)
.
[SEP]
[CLS]
No
association
between
anti
-
i
##cat
##iba
##nt
antibodies
and
efficacy
was
observed
.
[SEP]
[CLS]
AR
##CA
##P
##TA
NE
##OH
##AL
##ER
is
not
indicated
for
the
treatment
of
as
##th
##ma
[
See
B
o
##xed
Warning
and
W
a
##rn
##ing
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ad
##verse
reactions
observed
in
the
other
trials
were
similar
to
those
observed
in
the
confirm
##atory
trials
.
[SEP]
[CLS]
Before
in
##iti
##ating
therapy
with
Z
##ER
##BA
##X
##A
,
make
careful
inquiry
about
previous
h
##yper
##sen
##si
##ti
##vity
reactions
to
other
c
##ep
##hal
##os
##por
##ins
,
pen
##ici
##llin
##s
,
or
other
beta
-
la
##ct
##ams
.
[SEP]
[CLS]
Pat
##ients
experiencing
seizure
were
permanently
discontinued
from
therapy
and
all
seizure
events
resolved
.
[SEP]
[CLS]
System
Organ
Class
/
Pre
##ferred
Te
##rm
Place
##bo
N
=
203
%
SA
##P
##H
##RI
##S
5
mg
or
10
mg
twice
daily
*
N
=
37
##9
%
Gas
##tro
##int
##est
##inal
disorders
Dry
mouth
1
3
D
##ys
##pe
##ps
##ia
2
4
Oral
h
##y
##po
##est
##hesia
<
1
[SEP]
[CLS]
4
Too
##tha
##che
2
3
General
disorders
Fat
##ig
##ue
2
4
Investigation
##s
Inc
##reased
weight
<
1
5
Met
##ab
##olis
##m
disorders
Inc
##reased
appetite
1
4
Mu
##s
##cu
##los
##kel
##etal
and
connect
##ive
tissue
disorders
Art
##hra
##l
##gia
1
3
[SEP]
[CLS]
Pain
in
ex
##tre
##mity
<
1
2
N
##er
##vous
system
disorders
A
##kat
##his
##ia
2
4
Di
##zzi
##ness
3
11
D
##ys
##ge
##us
##ia
<
1
3
Head
##ache
11
12
Other
extra
##py
##ram
##idal
symptoms
(
excluding
aka
##thi
##sia
)
2
[SEP]
[CLS]
7
So
##m
##no
##len
##ce
?
[SEP]
[CLS]
In
place
##bo
-
controlled
trials
,
the
most
frequent
adverse
reactions
(
incidence
>
=
10
%
and
>
place
##bo
)
for
G
##IL
##EN
##Y
##A
0
.
5
mg
were
headache
,
liver
trans
##ami
##nas
##e
elevation
,
[SEP]
[CLS]
di
##ar
##r
##hea
,
cough
,
in
##fluenza
,
sin
##us
##itis
,
back
pain
,
abdominal
pain
,
and
pain
in
ex
##tre
##mity
.
[SEP]
[CLS]
(
2
.
1
)
Monitor
for
T
##LS
,
including
u
##ric
acid
levels
and
treat
promptly
.
[SEP]
[CLS]
The
data
described
below
reflect
exposure
to
a
6
-
dose
regime
##n
of
Co
##arte
##m
Table
##ts
in
1
,
97
##9
patients
including
64
##7
adults
(
older
than
16
years
)
and
1
,
33
##2
children
(
16
[SEP]
[CLS]
years
and
younger
)
.
[SEP]
[CLS]
(
5
.
6
)
5
.
1
Gas
##tro
##int
##est
##inal
To
##xi
##city
Di
##ar
##r
##hea
,
nausea
,
vomit
##ing
,
and
abdominal
pain
occur
with
B
##OS
##U
##L
##IF
treatment
.
[SEP]
[CLS]
Data
from
a
large
place
##bo
-
controlled
US
study
that
compared
the
safety
of
another
long
-
acting
beta
2
-
ad
##rene
##rg
##ic
ago
##nist
(
sa
##lm
##eter
##ol
)
or
place
##bo
added
to
usual
as
##th
##ma
therapy
showed
an
[SEP]
[CLS]
increase
in
as
##th
##ma
-
related
deaths
in
patients
receiving
sa
##lm
##eter
##ol
.
[SEP]
[CLS]
Table
4
identifies
the
clinical
##ly
relevant
or
severe
Grade
3
/
4
laboratory
test
abnormal
##ities
for
the
Phase
1
/
2
C
##ML
safety
population
.
[SEP]
[CLS]
All
patients
were
treated
with
anti
##his
##tamine
##s
prior
to
each
in
##fusion
.
[SEP]
[CLS]
Pat
##ients
with
h
##y
##po
##vo
##lem
##ia
may
be
more
susceptible
to
these
changes
.
[SEP]
[CLS]
The
data
described
[
see
##A
##d
##verse
Re
##actions
(
6
.
1
)
]
reflect
exposure
to
IN
##L
##Y
##TA
in
35
##9
patients
with
advanced
RC
##C
who
participated
in
a
random
##ized
clinical
study
versus
so
##ra
##fen
##ib
[
[SEP]
[CLS]
see
##C
##lini
##cal
Studies
(
14
)
]
.
[SEP]
[CLS]
In
the
event
of
treatment
-
related
my
##elo
##su
##pp
##ression
,
monitor
le
##uk
##ocytes
,
plate
##lets
,
hem
##og
##lo
##bin
(
H
##g
##b
)
,
and
ne
##ut
##rop
##hil
##s
frequently
.
[SEP]
[CLS]
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
>
=
25
%
)
in
patients
with
B
-
cell
ma
##li
##gna
##ncies
(
MC
##L
,
C
##LL
,
W
##M
)
were
th
##rom
##bo
##cy
##top
##enia
,
ne
##ut
##rop
##enia
,
[SEP]
[CLS]
di
##ar
##r
##hea
,
an
##emia
,
fatigue
,
m
##us
##cu
##los
##kel
##etal
pain
,
br
##ui
##sing
,
nausea
,
upper
respiratory
tract
infection
,
and
r
##ash
.
[SEP]
[CLS]
*
Du
##lag
##lut
##ide
causes
thy
##roid
C
-
cell
tumors
in
rats
.
[SEP]
[CLS]
5
.
7
Disco
##ntin
##uation
S
##yn
##drome
Disco
##ntin
##uation
symptoms
have
been
systematically
and
prospective
##ly
evaluated
in
patients
treated
with
PR
##IS
##TI
##Q
during
clinical
studies
in
Major
De
##pressive
Di
##sor
##der
.
[SEP]
[CLS]
V
##as
##cular
disorders
:
T
##hr
##omb
##op
##hl
##eb
##itis
,
v
##as
##cu
##lit
##is
.
[SEP]
[CLS]
Trial
1
included
197
control
-
treated
patients
and
46
##3
S
##IM
##PO
##NI
ARIA
-
treated
patients
(
which
includes
control
-
treated
patients
who
switched
to
S
##IM
##PO
##NI
ARIA
at
Week
16
)
.
[SEP]
[CLS]
Study
1
:
Met
##ast
##atic
CR
##PC
Following
Ch
##em
##otherapy
Study
1
enrolled
119
##5
patients
with
meta
##static
CR
##PC
who
had
received
prior
do
##ce
##ta
##xe
##l
ch
##em
##otherapy
.
[SEP]
[CLS]
Pat
##ients
with
bi
##li
##ru
##bin
>
1
.
5
*
U
##L
##N
also
had
a
higher
incidence
of
Grade
4
ne
##ut
##rop
##enia
and
f
##eb
##ril
##e
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
Monitor
and
manage
patients
using
standards
of
care
,
including
anti
-
di
##ar
##r
##hea
##ls
,
anti
-
em
##etics
,
or
fluid
replacement
,
as
indicated
.
[SEP]
[CLS]
These
data
reflect
exposure
of
233
##8
patients
to
FA
##R
##X
##IG
##A
with
a
mean
exposure
duration
of
21
weeks
.
[SEP]
[CLS]
Table
1
lists
adverse
reactions
that
occurred
in
>
=
2
%
of
patients
treated
with
AM
##P
##Y
##RA
10
mg
twice
daily
,
and
more
frequently
than
in
place
##bo
-
treated
patients
,
in
[SEP]
[CLS]
controlled
clinical
trials
.
[SEP]
[CLS]
b
##A
##nn
##ual
event
rate
per
100
p
##t
-
years
=
100
*
number
of
subjects
with
event
/
subject
-
years
.
[SEP]
[CLS]
5
.
3
He
##mat
##olo
##gic
To
##xi
##ci
##ties
Pro
##long
##ed
(
>
=
1
week
)
severe
ne
##ut
##rop
##enia
and
Grade
3
or
Grade
4
th
##rom
##bo
##cy
##top
##enia
or
an
##emia
can
occur
with
AD
##CE
##TR
##IS
.
[SEP]
[CLS]
Blood
and
l
##ymph
##atic
system
disorders
:
th
##rom
##bo
##cy
##tosis
,
pan
##cy
##top
##enia
.
[SEP]
[CLS]
Complete
blood
counts
should
be
monitored
prior
to
each
dose
of
AD
##CE
##TR
##IS
and
more
frequent
monitoring
should
be
considered
for
patients
with
Grade
3
or
4
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
5
.
3
Ra
##diation
Risk
##s
Cho
##line
C
11
In
##jection
contributes
to
a
patient
'
s
overall
long
-
term
cumulative
radiation
exposure
.
[SEP]
[CLS]
Do
##se
reduction
due
to
ne
##ut
##rop
##enia
was
required
in
12
%
(
62
/
50
##3
)
of
patients
and
disco
##ntin
##uation
was
required
in
<
1
%
of
patients
.
[SEP]
[CLS]
(
5
.
1
,
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
A
##po
##P
##har
##ma
Inc
.
at
:
Telephone
:
1
-
86
##6
-
94
##9
-
09
##9
##5
Em
##ail
:
medical
##safe
##ty
@
a
##pop
##har
##ma
.
com
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
[SEP]
[CLS]
}
}
6
.
1
Clinical
Trial
Experience
The
following
adverse
reactions
are
also
discussed
in
other
sections
of
the
label
##ing
:
A
##gra
##nu
##loc
##yt
##osis
/
N
##eu
##tro
##pen
##ia
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
A
##vo
##id
in
patients
with
con
##gen
##ital
long
Q
##T
syndrome
(
5
.
4
)
5
.
1
N
##eu
##tro
##pen
##ia
Se
##vere
ne
##ut
##rop
##enia
(
AN
##C
<
500
/
mm
3
)
lasting
more
than
one
week
occurred
in
12
%
[SEP]
[CLS]
(
62
/
50
##3
)
of
patients
in
Study
1
,
leading
to
disco
##ntin
##uation
in
<
1
%
of
patients
[
see
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
More
rapid
t
##it
##ration
would
be
expected
to
increase
the
rate
of
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
and
s
##ync
##ope
.
[SEP]
[CLS]
Media
##n
exposure
in
days
for
pool
##ed
studies
:
120
##3
for
N
##U
##L
##O
##J
##IX
recommended
regime
##n
and
116
##3
for
c
##y
##c
##los
##por
##ine
in
Studies
1
and
2
.
?
[SEP]
[CLS]
I
##mm
##une
-
mediated
end
##oc
##rino
##path
##ies
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
5
)
]
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Gil
##ead
Sciences
,
Inc
.
at
1
-
800
-
G
##IL
##EA
##D
-
5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
under
widely
[SEP]
[CLS]
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
and
may
[SEP]
[CLS]
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
The
protocol
included
provisions
for
patients
taking
place
##bo
to
receive
treatment
with
S
##IM
##PO
##NI
ARIA
at
Week
16
or
Week
24
either
by
patient
response
(
based
on
un
##con
##tro
##lled
disease
activity
[SEP]
[CLS]
)
or
by
design
,
so
that
adverse
events
can
not
always
be
un
##am
##bi
##guous
##ly
attributed
to
a
given
treatment
.
[SEP]
[CLS]
Two
patients
continued
treatment
with
P
##OT
##IG
##A
and
were
able
to
void
spontaneous
##ly
after
cat
##he
##ter
removal
.
[SEP]
[CLS]
Table
2
:
Change
in
G
##lu
##cos
##e
Mean
Change
from
Basel
##ine
(
mg
/
d
##L
)
3
-
6
months
6
-
12
months
>
12
months
FA
##NA
##P
##T
10
-
16
mg
/
day
1
.
8
(
N
=
77
##3
)
5
.
4
(
N
=
72
##3
[SEP]
[CLS]
)
5
.
4
(
N
=
425
)
FA
##NA
##P
##T
20
-
24
mg
/
day
-
3
.
6
(
N
=
34
)
-
9
.
0
(
N
=
31
)
-
18
.
0
(
N
=
20
)
D
##ys
##lip
##ide
##mia
Un
##des
##ira
##ble
alterations
in
lip
##ids
have
been
observed
in
patients
[SEP]
[CLS]
treated
with
at
##y
##pical
anti
##psy
##cho
##tics
.
[SEP]
[CLS]
H
##OR
##I
##Z
##AN
##T
in
the
treatment
of
R
##LS
was
studied
primarily
in
place
##bo
-
controlled
trials
(
n
=
64
##2
)
,
and
in
long
-
term
follow
-
up
studies
.
[SEP]
[CLS]
It
is
unknown
whether
T
##R
##U
##L
##IC
##IT
##Y
will
cause
thy
##roid
C
-
cell
tumors
,
including
me
##du
##llar
##y
thy
##roid
car
##cin
##oma
(
M
##TC
)
,
in
humans
,
as
the
human
relevance
of
du
##lag
##lut
##ide
-
induced
rode
##nt
[SEP]
[CLS]
thy
##roid
C
-
cell
tumors
has
not
been
determined
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
reported
include
an
##aph
##yla
##ctic
shock
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
]
,
my
##elo
##su
##pp
##ression
,
gas
##tro
##int
##est
##inal
toxicity
(
di
##ar
##r
##hea
)
,
fluid
retention
,
he
##pa
##to
##to
##xi
##city
and
r
##ash
.
[SEP]
[CLS]
Consider
measures
to
prevent
severe
reactions
,
including
anti
##his
##tamine
##s
,
anti
##py
##ret
##ics
and
co
##rt
##ico
##ster
##oids
in
subsequent
cycles
in
patients
who
have
experienced
Grade
1
or
2
in
##fusion
reactions
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
[SEP]
[CLS]
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
E
##X
##CE
##RP
##T
:
The
most
common
adverse
reactions
(
incidence
>
1
%
)
were
ing
##row
##n
toe
##nail
##s
,
application
site
der
##mat
##itis
,
application
site
ve
##si
##cles
,
and
[SEP]
[CLS]
application
site
pain
.
[SEP]
[CLS]
The
mean
base
##line
hem
##og
##lo
##bin
value
was
approximately
14
.
1
g
/
d
##L
across
treatment
groups
.
[SEP]
[CLS]
The
population
was
19
to
97
years
old
,
64
%
were
female
,
and
84
%
were
Caucasian
;
64
%
were
undergoing
a
surgery
that
included
bow
##el
re
##section
[SEP]
[CLS]
.
[SEP]
[CLS]
The
average
age
was
55
years
(
range
from
##1
week
to
93
years
)
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
were
reported
in
64
patients
(
37
.
2
%
)
treated
with
X
##AL
##KO
##RI
and
40
patients
(
23
.
4
%
)
in
the
ch
##em
##otherapy
arm
.
[SEP]
[CLS]
(
5
.
1
)
Growth
of
Re
##sist
##ant
Organ
##isms
with
Pro
##long
##ed
Use
.
[SEP]
[CLS]
5
.
2
S
##p
##read
of
To
##xin
Effect
Post
-
marketing
safety
data
from
D
##Y
##SP
##OR
##T
(
r
)
and
other
approved
b
##ot
##ulin
##um
to
##xin
##s
suggest
that
b
##ot
##ulin
##um
[SEP]
[CLS]
to
##xin
effects
may
,
in
some
cases
,
be
observed
beyond
the
site
of
local
injection
.
[SEP]
[CLS]
The
forms
specifically
requested
information
on
occurrence
of
all
##ergic
reactions
,
th
##rom
##bot
##ic
events
,
hem
##or
##r
##ha
##gic
events
,
he
##pa
##to
##bil
##iary
disorders
,
pan
##cre
##atic
disorders
,
and
h
##yper
##gly
##ce
##mia
.
[SEP]
[CLS]
Monitor
AL
##T
,
AS
##T
and
bi
##li
##ru
##bin
before
initiation
of
,
and
periodically
throughout
,
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
5
.
9
Mac
##rov
##as
##cular
Out
##come
##s
There
have
been
no
clinical
studies
establishing
con
##clusive
evidence
of
mac
##rov
##as
##cular
risk
reduction
with
IN
##VO
##KA
##NA
or
any
other
anti
##dia
##bet
##ic
drug
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
the
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Common
adverse
reactions
that
occurred
in
greater
than
or
equal
to
2
%
of
subjects
switching
to
ST
##RI
##BI
##LD
were
nausea
(
4
%
)
,
flat
##ule
##nce
(
2
%
)
[SEP]
[CLS]
,
and
headache
(
2
%
)
.
[SEP]
[CLS]
A
total
of
2
,
03
##4
subjects
with
CO
##PD
received
at
least
1
dose
of
BR
##E
##O
E
##LL
##IP
##TA
100
/
25
,
and
1
,
08
##7
subjects
received
a
higher
strength
of
flu
##tica
##son
##e
fur
##oat
##e
/
v
##ila
##nter
##ol
.
[SEP]
[CLS]
Treatment
with
anti
##ba
##cter
##ial
agents
alter
##s
the
normal
flora
of
the
co
##lon
and
may
permit
over
##gro
##wth
of
C
.
[SEP]
[CLS]
Ad
##mini
##ster
de
##xa
##met
##has
##one
prior
to
K
##y
##p
##rol
##is
to
reduce
the
incidence
and
severity
of
in
##fusion
reactions
[
see
Do
##sa
##ge
and
Administration
(
2
)
]
.
[SEP]
[CLS]
Table
3
:
Ad
##verse
Re
##actions
Report
##ed
in
>
=
1
%
of
Sub
##jects
on
O
##TE
##Z
##LA
and
With
Greater
Fr
##e
##que
##ncy
Than
in
Sub
##jects
on
Place
##bo
;
up
to
Day
112
(
Week
[SEP]
[CLS]
16
)
*
Two
subjects
treated
with
O
##TE
##Z
##LA
experienced
serious
adverse
reaction
of
abdominal
pain
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Z
##yler
##a
Ph
##arma
##ce
##utical
##s
,
LLC
.
[SEP]
[CLS]
Ex
##er
##cise
caution
in
patients
with
known
h
##yper
##sen
##si
##ti
##vity
to
beta
-
la
##ct
##am
anti
##ba
##cter
##ial
drugs
.
[SEP]
[CLS]
E
##L
##I
##Q
##UI
##S
can
cause
serious
,
potentially
fatal
bleeding
.
[SEP]
[CLS]
If
the
patient
is
known
or
strongly
suspected
of
having
had
a
h
##yper
##sen
##si
##ti
##vity
reaction
to
Da
##T
##sca
##n
,
the
decision
to
administer
Da
##T
##sca
##n
should
be
based
upon
an
assessment
of
the
[SEP]
[CLS]
expected
benefits
compared
to
the
potential
h
##yper
##sen
##si
##ti
##vity
risks
.
[SEP]
[CLS]
It
is
unknown
whether
T
##AN
##Z
##E
##UM
(
r
)
causes
thy
##roid
C
-
cell
tumors
,
including
me
##du
##llar
##y
thy
##roid
car
##cin
##oma
(
M
##TC
)
,
in
humans
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
[SEP]
[CLS]
)
,
Non
##c
##lini
##cal
To
##xi
##cology
(
13
.
1
)
]
.
[SEP]
[CLS]
If
anti
##coa
##gu
##lation
with
E
##L
##I
##Q
##UI
##S
is
discontinued
for
a
reason
other
than
path
##ological
bleeding
or
completion
of
a
course
of
therapy
,
consider
coverage
with
another
anti
##coa
##gu
##lant
[
see
Do
##sa
##ge
and
[SEP]
[CLS]
Administration
(
2
.
4
)
,
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
,
and
Clinical
Studies
(
14
.
1
)
]
.
[SEP]
[CLS]
These
studies
did
not
show
an
increase
in
the
risk
of
su
##icidal
thoughts
with
anti
##de
##press
##ant
use
in
patients
over
age
24
;
there
was
a
reduction
in
risk
with
anti
##de
##press
##ant
[SEP]
[CLS]
use
in
patients
aged
65
and
older
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
As
such
,
reliability
in
est
##imating
their
frequency
or
in
establishing
a
ca
##usal
relationship
to
drug
exposure
is
not
always
possible
.
[SEP]
[CLS]
Additional
safety
information
was
collected
from
clinical
records
submitted
by
treating
physicians
.
[SEP]
[CLS]
With
##hold
treatment
with
tram
##eti
##ni
##b
and
continue
T
##AF
##IN
##LA
##R
at
the
same
dose
if
absolute
L
##VE
##F
value
decreases
by
10
%
from
pre
##tre
##at
##ment
values
and
is
less
than
the
lower
limit
of
[SEP]
[CLS]
normal
.
[SEP]
[CLS]
If
an
infection
develops
,
monitor
carefully
,
and
stop
C
##IM
##Z
##IA
if
infection
becomes
serious
(
5
.
1
)
*
In
##vasive
fun
##gal
infections
-
for
patients
who
develop
a
systemic
illness
[SEP]
[CLS]
on
C
##IM
##Z
##IA
,
consider
em
##pi
##ric
anti
##fu
##nga
##l
therapy
for
those
who
reside
or
travel
to
regions
where
my
##cos
##es
are
endemic
(
5
.
1
)
*
Case
##s
of
l
##ymph
##oma
and
other
ma
##li
##gna
##ncies
have
[SEP]
[CLS]
been
observed
among
patients
receiving
T
##NF
block
##ers
(
5
.
2
)
*
Heart
failure
,
worse
##ning
may
occur
(
5
.
3
)
*
Ana
##phy
##lax
##is
or
serious
all
##ergic
reactions
may
occur
(
5
.
4
[SEP]
[CLS]
)
*
He
##pa
##titis
B
virus
react
##ivation
-
test
for
H
##B
##V
infection
before
starting
C
##IM
##Z
##IA
.
[SEP]
[CLS]
All
patients
also
received
b
##asi
##lix
##ima
##b
induction
,
my
##co
##phe
##no
##late
m
##of
##eti
##l
,
and
co
##rt
##ico
##ster
##oids
.
[SEP]
[CLS]
C
.
di
##ff
##ici
##le
produces
to
##xin
##s
A
and
B
which
contribute
to
the
development
of
CD
##AD
.
[SEP]
[CLS]
I
##mm
##uno
##genic
##ity
ass
##ay
results
are
highly
dependent
on
several
factors
including
ass
##ay
sensitivity
and
specific
##ity
,
ass
##ay
methodology
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
and
[SEP]
[CLS]
underlying
disease
.
[SEP]
[CLS]
St
##roke
In
the
W
##H
##I
est
##rogen
-
alone
sub
##st
##ud
##y
,
a
statistical
##ly
significant
increased
risk
of
stroke
was
reported
in
women
50
to
79
years
of
age
receiving
daily
con
##ju
##gated
est
##rogen
##s
(
CE
[SEP]
[CLS]
)
(
0
.
625
mg
)
-
alone
compared
to
women
in
the
same
age
group
receiving
place
##bo
(
45
versus
33
per
10
,
000
women
-
years
)
.
[SEP]
[CLS]
In
the
extension
trial
,
cat
##ara
##cts
developed
or
worse
##ned
in
4
%
of
patients
who
underwent
o
##cular
examination
prior
to
therapy
with
PR
##OM
##AC
##TA
.
[SEP]
[CLS]
5
.
10
H
##yper
##p
##rol
##act
##ine
##mia
Like
other
drugs
that
ant
##agon
##ize
do
##pa
##mine
D
##2
##re
##ceptor
##s
,
SA
##P
##H
##RI
##S
can
el
##eva
##te
pro
##la
##ct
##in
levels
,
and
the
elevation
can
per
##sist
during
chronic
administration
.
[SEP]
[CLS]
In
the
two
controlled
clinical
trials
in
patients
with
chronic
he
##pa
##titis
C
and
th
##rom
##bo
##cy
##top
##enia
,
cat
##ara
##cts
developed
or
worse
##ned
in
8
%
patients
treated
with
PR
##OM
##AC
##TA
and
5
%
patients
[SEP]
[CLS]
treated
with
place
##bo
.
[SEP]
[CLS]
If
hem
##og
##lo
##bin
is
less
than
10
g
per
d
##L
,
a
decrease
in
dos
##age
of
rib
##avi
##rin
is
recommended
;
and
if
hem
##og
##lo
##bin
is
less
than
8
.
5
g
per
d
##L
,
[SEP]
[CLS]
disco
##ntin
##uation
of
rib
##avi
##rin
is
recommended
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
and
Clinical
Studies
(
14
)
]
.
[SEP]
[CLS]
Less
Common
Ad
##verse
Re
##actions
In
Phase
2
and
3
clinical
studies
the
following
adverse
reactions
occurred
in
less
than
1
%
of
subjects
and
in
more
than
one
subject
treated
[SEP]
[CLS]
with
doses
ranging
from
40
mg
to
240
mg
of
U
##L
##OR
##IC
.
[SEP]
[CLS]
If
serum
ca
##l
##ci
##ton
##in
is
measured
and
found
to
be
elevated
,
the
patient
should
be
further
evaluated
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ser
##ious
skin
reactions
have
been
reported
with
g
##ly
##cope
##pt
##ide
anti
##ba
##cter
##ial
agents
,
including
D
##AL
##VA
##NC
##E
;
exercise
caution
in
patients
with
known
h
##yper
##sen
##si
##ti
##vity
to
g
##ly
##cope
##pt
##ides
[SEP]
[CLS]
.
[SEP]
[CLS]
Some
of
these
events
were
reported
in
patients
without
known
underlying
re
##nal
disease
.
[SEP]
[CLS]
Art
##hra
##l
##gia
##s
and
muscle
pain
have
also
been
reported
in
cases
of
pro
##ximal
re
##nal
tub
##ulo
##pathy
.
[SEP]
[CLS]
The
effect
of
anti
-
br
##ent
##ux
##ima
##b
ve
##do
##tin
antibodies
on
safety
and
efficacy
is
not
known
.
[SEP]
[CLS]
5
.
3
T
##hr
##omb
##otic
/
T
##hr
##omb
##oe
##mbo
##lic
Co
##mp
##lication
##s
In
two
controlled
clinical
trials
in
patients
with
chronic
he
##pa
##titis
C
and
th
##rom
##bo
##cy
##top
##enia
,
3
%
(
31
/
95
##5
)
treated
with
PR
##OM
##AC
##TA
experienced
a
th
##rom
##bot
##ic
event
(
[SEP]
[CLS]
1
%
in
patients
treated
with
PR
##OM
##AC
##TA
versus
less
than
1
%
for
place
##bo
)
.
[SEP]
[CLS]
If
drug
-
induced
hem
##oly
##tic
an
##emia
is
suspected
,
disco
##ntin
##uation
of
Te
##f
##lar
##o
should
be
considered
and
supportive
care
should
be
administered
to
the
patient
(
i
.
e
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
Op
##ht
##hal
##mo
##log
##ic
:
Non
-
art
##eri
##tic
anterior
is
##che
##mic
op
##tic
ne
##uro
##pathy
(
N
##A
##ION
)
,
a
cause
of
decreased
vision
including
permanent
loss
of
vision
,
has
been
reported
rarely
post
-
marketing
[SEP]
[CLS]
in
temporal
association
with
the
use
of
p
##hos
##ph
##odies
##tera
##se
type
5
(
PD
##E
##5
)
inhibitor
##s
.
[SEP]
[CLS]
The
detection
of
an
immune
response
is
highly
dependent
on
the
sensitivity
and
specific
##ity
of
the
ass
##ays
used
,
sample
handling
,
timing
of
sample
collection
,
con
##com
##ita
##nt
medications
,
[SEP]
[CLS]
and
underlying
disease
.
[SEP]
[CLS]
The
median
number
of
cycles
initiated
was
22
cycles
for
the
K
##R
##d
arm
and
14
cycles
for
the
Rd
arm
.
[SEP]
[CLS]
For
patients
at
risk
for
chronic
##ally
reduced
re
##nal
function
(
for
example
,
age
>
60
years
,
diabetes
me
##lli
##tus
or
chronic
h
##yper
##tens
##ion
)
,
estimate
the
G
##F
##R
through
laboratory
[SEP]
[CLS]
testing
.
[SEP]
[CLS]
5
.
7
P
##las
##mo
##dium
v
##iva
##x
In
##fect
##ion
Co
##arte
##m
Table
##ts
have
been
shown
in
limited
data
(
43
patients
)
to
be
effective
in
treating
the
er
##yt
##hr
##oc
##ytic
stage
of
P
.
v
##iva
##x
infection
.
[SEP]
[CLS]
Treatment
with
S
##IM
##PO
##NI
ARIA
should
not
be
initiated
in
patients
with
an
active
infection
,
including
clinical
##ly
important
localized
infections
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
A
##vo
##id
treatment
in
the
per
##io
##cular
area
.
[SEP]
[CLS]
For
the
purposes
of
assessing
Response
-
Guide
##d
Therapy
milestone
##s
,
a
confirmed
`
`
detect
##able
but
below
limit
of
q
##uant
##ification
'
'
HC
##V
-
RNA
result
should
not
be
considered
equivalent
to
an
`
`
und
##ete
##ct
##able
[SEP]
[CLS]
'
'
HC
##V
-
RNA
result
(
reported
as
`
`
Target
Not
Det
##ec
##ted
'
'
or
`
`
HC
##V
-
RNA
Not
Det
##ec
##ted
'
'
)
.
[SEP]
[CLS]
One
additional
patient
'
s
death
was
attributed
to
ne
##ut
##rop
##enia
without
a
documented
infection
.
[SEP]
[CLS]
Ad
##verse
reactions
are
listed
according
to
Me
##d
##DR
##A
version
15
.
0
system
organ
class
.
[SEP]
[CLS]
5
.
5
Effect
of
P
-
g
##p
In
##du
##cer
##s
and
In
##hibit
##ors
on
Da
##bi
##gat
##ran
Expo
##sure
The
con
##com
##ita
##nt
use
of
PR
##AD
##A
##X
##A
with
P
-
g
##p
induce
##rs
(
e
.
g
.
,
r
##if
##amp
##in
)
reduces
exposure
to
da
##bi
##gat
##ran
and
should
generally
[SEP]
[CLS]
be
avoided
[
see
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
(
5
.
3
)
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
?
[SEP]
[CLS]
at
1
-
86
##6
-
41
##6
-
96
##37
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
During
the
clinical
trials
,
0
.
1
%
(
1
/
130
##8
)
of
subjects
treated
with
O
##TE
##Z
##LA
discontinued
treatment
due
to
depression
compared
with
none
in
place
##bo
-
treated
subjects
(
0
/
50
##6
)
.
[SEP]
[CLS]
Of
the
1
,
03
##9
subjects
,
60
%
were
female
and
88
%
were
white
;
the
mean
age
was
46
years
.
[SEP]
[CLS]
Inc
##rease
##s
in
serum
c
##rea
##tin
##ine
occurred
within
the
first
4
weeks
of
treatment
and
remained
stable
through
48
to
96
weeks
.
[SEP]
[CLS]
These
reactions
can
occur
immediately
following
or
up
to
24
hours
after
administration
of
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
Ser
##ious
adverse
reactions
reported
with
al
##g
##lu
##cos
##idas
##e
al
##fa
included
an
##aph
##yla
##xi
##s
,
which
presented
as
an
##gio
##ede
##ma
,
throat
tight
##ness
and
chest
pain
.
[SEP]
[CLS]
Table
3
sum
##mar
##izes
the
most
common
adverse
reactions
that
occurred
in
at
least
3
%
of
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patients
and
with
a
higher
incidence
than
the
place
##bo
-
treated
patients
during
the
[SEP]
[CLS]
random
##ized
,
double
-
blind
,
place
##bo
-
controlled
study
described
above
.
[SEP]
[CLS]
With
##hold
K
##y
##p
##rol
##is
for
pulmonary
h
##yper
##tens
##ion
until
resolved
or
returned
to
base
##line
and
consider
whether
to
restart
K
##y
##p
##rol
##is
based
on
a
benefit
/
risk
assessment
[
see
Do
##sa
##ge
and
Administration
(
2
)
[SEP]
[CLS]
]
.
[SEP]
[CLS]
In
a
combined
analysis
of
Studies
115
and
121
,
the
frequency
of
adverse
reactions
(
all
grades
)
was
24
%
in
subjects
switching
to
ST
##RI
##BI
##LD
compared
to
6
[SEP]
[CLS]
%
of
subjects
in
either
group
who
stayed
on
their
base
##line
anti
##ret
##rov
##ira
##l
regime
##n
,
R
##TV
-
boost
##ed
P
##I
+
T
##R
##U
##VA
##DA
or
N
##NR
##TI
+
T
##R
##U
##VA
##DA
.
[SEP]
[CLS]
Pool
of
Place
##bo
-
Control
##led
Trials
The
data
in
Table
1
is
derived
from
four
26
-
week
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
La
##ryn
##ge
##al
attacks
:
Following
treatment
of
la
##ryn
##ge
##al
attacks
with
F
##IR
##A
##Z
##Y
##R
,
advise
patients
to
seek
immediate
medical
attention
.
[SEP]
[CLS]
V
##as
##cular
Di
##sor
##ders
superficial
p
##hl
##eb
##itis
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
WA
##R
##NI
##NG
:
NE
##P
##H
##RO
##GE
##NI
##C
S
##Y
##ST
##EM
##IC
F
##IB
##RO
##SI
##S
(
N
##SF
)
G
##ado
##lini
##um
-
based
contrast
agents
(
GB
##CA
##s
)
increase
[SEP]
[CLS]
the
risk
for
N
##SF
among
patients
with
impaired
elimination
of
the
drugs
.
[SEP]
[CLS]
S
##IM
##PO
##NI
ARIA
has
not
been
studied
in
patients
with
a
history
of
CH
##F
and
S
##IM
##PO
##NI
ARIA
should
be
used
with
caution
in
patients
with
CH
##F
.
[SEP]
[CLS]
B
##OX
##ED
WA
##R
##NI
##NG
:
WA
##R
##NI
##NG
:
E
##ND
##OM
##ET
##RI
##AL
CA
##NC
##ER
,
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
D
##IS
##OR
##DE
##RS
,
AND
PR
##O
##BA
##BL
##E
DE
##ME
##NT
##IA
WA
##R
##NI
##NG
:
E
##ND
##OM
##ET
##RI
##AL
CA
##NC
##ER
,
CA
##RD
##IO
##VA
##SC
##U
##LA
##R
D
##IS
##OR
##DE
##RS
,
AND
PR
##O
##BA
##BL
##E
DE
##ME
##NT
##IA
*
Women
taking
D
##U
##AV
##EE
should
[SEP]
[CLS]
not
take
additional
est
##rogen
##s
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
*
There
is
an
increased
risk
of
end
##ome
##tri
##al
cancer
in
a
woman
with
a
u
##ter
##us
who
uses
[SEP]
[CLS]
unopposed
est
##rogen
##s
.
[SEP]
[CLS]
In
most
cases
,
this
is
a
consequence
of
weakening
of
muscles
in
the
area
of
injection
that
are
involved
in
breathing
or
swallowing
.
[SEP]
[CLS]
The
incidence
of
non
-
hem
##ato
##log
##ic
,
non
-
infectious
,
adverse
events
(
all
Grades
)
in
Study
1
,
Study
2
,
and
the
E
##MT
##P
trial
is
provided
in
Table
1
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Ba
##us
##ch
&
Lo
##mb
Incorporated
at
1
-
800
-
32
##3
-
000
##0
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
Top
##ical
Op
##ht
##hal
##mic
[SEP]
[CLS]
Use
Only
.
[SEP]
[CLS]
The
most
frequent
serious
adverse
reactions
reported
in
patients
treated
with
X
##AL
##KO
##RI
were
pneumonia
(
4
.
1
%
)
,
pulmonary
em
##bol
##ism
(
3
.
5
%
)
,
d
##ys
##p
##nea
(
2
.
3
%
[SEP]
[CLS]
)
,
and
IL
##D
(
2
.
9
%
)
.
[SEP]
[CLS]
Among
the
patients
who
experienced
di
##ar
##r
##hea
,
the
median
number
of
episodes
of
di
##ar
##r
##hea
per
patient
during
treatment
with
B
##OS
##U
##L
##IF
was
3
(
range
1
-
221
)
.
[SEP]
[CLS]
(
5
.
2
)
*
L
##ymph
##ope
##nia
:
O
##bt
##ain
a
CBC
including
l
##ymph
##oc
##yte
count
before
in
##iti
##ating
T
##EC
##FI
##DE
##RA
,
after
6
months
,
and
every
6
to
12
months
thereafter
.
[SEP]
[CLS]
The
most
commonly
occurring
adverse
reactions
in
Study
1
and
Study
2
(
>
=
20
%
)
were
th
##rom
##bo
##cy
##top
##enia
,
ne
##ut
##rop
##enia
,
di
##ar
##r
##hea
,
an
##emia
,
fatigue
,
[SEP]
[CLS]
m
##us
##cu
##los
##kel
##etal
pain
,
upper
respiratory
tract
infection
,
r
##ash
,
nausea
,
and
p
##yre
##xia
.
[SEP]
[CLS]
S
##ym
##pt
##oms
include
fever
,
chill
##s
,
p
##ru
##rit
##us
and
r
##ash
.
[SEP]
[CLS]
7
)
]
E
##X
##CE
##RP
##T
:
Ce
##r
##vic
##al
D
##ys
##ton
##ia
Most
commonly
observed
adverse
reactions
(
>
5
%
of
patients
)
are
:
muscular
weakness
,
d
##ys
##pha
##gia
,
dry
mouth
,
[SEP]
[CLS]
injection
site
discomfort
,
fatigue
,
headache
,
neck
pain
,
m
##us
##cu
##los
##kel
##etal
pain
,
d
##ys
##phon
##ia
,
injection
site
pain
,
and
eye
disorders
.
[SEP]
[CLS]
G
##lu
##ca
##gon
-
like
p
##eptide
(
G
##LP
-
1
)
receptor
ago
##nist
##s
have
induced
thy
##roid
C
-
cell
ad
##eno
##mas
in
mice
and
rats
at
clinical
##ly
relevant
exposure
##s
.
[SEP]
[CLS]
Other
Ad
##verse
Re
##actions
The
most
commonly
occurring
adverse
reactions
in
controlled
trials
of
C
##ro
##hn
'
s
disease
were
described
above
.
[SEP]
[CLS]
B
##K
virus
-
associated
ne
##ph
##rop
##athy
was
reported
in
6
N
##U
##L
##O
##J
##IX
patients
(
4
of
which
resulted
in
g
##raft
loss
)
and
6
c
##y
##c
##los
##por
##ine
patients
(
none
of
which
resulted
in
g
##raft
loss
[SEP]
[CLS]
)
by
Year
3
.
[SEP]
[CLS]
(
5
.
9
)
5
.
1
Cy
##tok
##ine
Release
S
##yn
##drome
Cy
##tok
##ine
Release
S
##yn
##drome
(
CR
##S
)
,
which
may
be
life
-
threatening
or
fatal
,
occurred
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
Su
##mma
##ry
of
Clinical
Trials
in
Ch
##ronic
L
##ymph
##oc
##ytic
Le
##uke
##mia
The
safety
data
reflect
subject
exposure
to
Z
##yd
##eli
##g
from
Study
1
,
in
which
218
subjects
with
re
##lap
##sed
C
##LL
received
up
to
[SEP]
[CLS]
8
doses
of
r
##it
##ux
##ima
##b
with
or
without
Z
##yd
##eli
##g
150
mg
twice
daily
.
[SEP]
[CLS]
If
a
patient
is
exposed
to
me
##as
##les
,
prop
##hyl
##ax
##is
with
pool
##ed
in
##tra
##mus
##cular
im
##mu
##no
##g
##lo
##bul
##in
(
I
##G
)
may
be
indicated
.
[SEP]
[CLS]
Table
1
lists
adverse
reactions
that
occurred
in
>
=
0
.
1
%
of
subjects
treated
with
E
##O
##VI
##ST
.
[SEP]
[CLS]
During
the
initial
phase
of
combination
anti
##ret
##rov
##ira
##l
treatment
,
patients
whose
immune
system
responds
may
develop
an
inflammatory
response
to
in
##do
##lent
or
residual
op
##port
##uni
##stic
infections
(
such
as
[SEP]
[CLS]
My
##co
##ba
##cter
##ium
a
##vi
##um
infection
,
c
##yt
##ome
##gal
##ov
##ir
##us
,
P
##ne
##um
##oc
##ys
##tis
ji
##rove
##ci
pneumonia
(
PC
##P
)
or
tuberculosis
)
,
which
may
ne
##cess
##itate
further
evaluation
and
treatment
.
[SEP]
[CLS]
For
these
reasons
,
comparison
of
incidence
of
antibodies
to
co
##lla
##gen
##ase
c
##los
##tri
##dium
his
##to
##ly
##tic
##um
with
the
incidence
of
antibodies
to
other
products
may
be
misleading
.
[SEP]
[CLS]
The
most
frequent
serious
adverse
reactions
that
occurred
were
pneumonia
(
15
%
)
,
di
##ar
##r
##hea
(
11
%
)
,
and
p
##yre
##xia
(
9
%
)
.
[SEP]
[CLS]
These
patients
should
also
be
instructed
to
carry
a
warning
card
indicating
that
they
may
need
supplement
##ary
systemic
co
##rt
##ico
##ster
##oids
during
periods
of
stress
,
a
severe
CO
##PD
ex
##ace
##rb
##ation
,
or
[SEP]
[CLS]
a
severe
as
##th
##ma
attack
.
[SEP]
[CLS]
Grade
3
-
4
cardiac
failure
occurred
in
0
.
2
%
of
patients
taking
place
##bo
.
[SEP]
[CLS]
It
is
possible
that
systemic
co
##rt
##ico
##ster
##oid
effects
such
as
h
##yper
##cor
##tic
##ism
and
ad
##rena
##l
suppression
(
including
ad
##rena
##l
crisis
)
may
appear
in
a
small
number
of
patients
who
are
sensitive
to
[SEP]
[CLS]
these
effects
.
[SEP]
[CLS]
During
withdrawal
from
oral
co
##rt
##ico
##ster
##oids
,
some
patients
may
experience
symptoms
of
systemic
##ally
active
co
##rt
##ico
##ster
##oid
withdrawal
(
e
.
g
.
,
joint
and
/
or
muscular
pain
,
las
##si
##tude
,
depression
)
despite
maintenance
[SEP]
[CLS]
or
even
improvement
of
respiratory
function
.
[SEP]
[CLS]
Monitor
and
treat
promptly
per
standard
of
care
until
signs
and
symptoms
resolve
(
5
.
4
)
.
[SEP]
[CLS]
This
reflects
its
alpha
##1
-
ad
##rene
##rg
##ic
antagonist
properties
.
[SEP]
[CLS]
Ad
##verse
reactions
related
to
volume
de
##ple
##tion
(
including
reports
of
de
##hy
##dra
##tion
,
h
##y
##po
##vo
##lem
##ia
,
or
##th
##ost
##atic
h
##y
##pot
##ens
##ion
,
or
h
##y
##pot
##ens
##ion
)
are
shown
in
Table
2
for
the
12
-
study
and
13
-
study
[SEP]
[CLS]
,
short
-
term
,
place
##bo
-
controlled
pools
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
]
.
[SEP]
[CLS]
Ad
##verse
reactions
reported
within
48
weeks
of
treatment
and
in
at
least
1
%
of
subjects
treated
with
J
##U
##BL
##IA
and
those
reported
in
subjects
treated
with
the
vehicle
are
presented
[SEP]
[CLS]
in
Table
1
.
[SEP]
[CLS]
6
.
2
Post
##market
##ing
Experience
The
following
adverse
reactions
have
been
identified
during
the
post
##market
##ing
use
of
NE
##SI
##NA
.
[SEP]
[CLS]
Ce
##r
##vic
##al
D
##ys
##ton
##ia
The
data
described
below
reflect
exposure
to
D
##Y
##SP
##OR
##T
(
r
)
in
35
##7
c
##er
##vic
##al
d
##ys
##ton
##ia
patients
in
6
studies
.
[SEP]
[CLS]
[
see
Do
##sa
##ge
and
Administration
(
2
.
2
)
and
(
2
.
3
)
]
5
.
2
In
##fect
##ions
In
##fect
##ion
,
including
pneumonia
,
se
##psis
,
se
##ptic
shock
,
and
death
have
occurred
in
[SEP]
[CLS]
adult
and
p
##ediatric
patients
in
clinical
trials
and
in
post
##market
##ing
reports
.
[SEP]
[CLS]
The
most
common
adverse
reactions
in
children
(
>
12
%
)
are
p
##yre
##xia
,
cough
,
vomit
##ing
,
an
##ore
##xia
,
and
headache
.
[SEP]
[CLS]
If
skin
reactions
are
severe
or
progressive
,
with
##hold
or
disco
##ntin
##ue
T
##RE
##AN
##DA
.
[SEP]
[CLS]
The
data
described
below
reflect
exposure
to
Be
##si
##vance
in
approximately
1
,
000
patients
between
1
and
98
years
old
with
clinical
signs
and
symptoms
of
bacterial
con
##junct
##iv
##itis
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
compared
directly
[SEP]
[CLS]
with
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Laboratory
abnormal
##ities
are
described
separately
in
Table
11
.
[SEP]
[CLS]
This
drop
in
body
est
##rogen
levels
causes
the
`
`
change
of
life
'
'
or
men
##op
##aus
##e
(
the
end
of
monthly
men
##st
##ru
##al
periods
)
.
[SEP]
[CLS]
(
5
.
1
)
*
A
##cute
Ren
##al
F
##ail
##ure
:
Monitor
serum
c
##rea
##tin
##ine
regularly
(
5
.
2
)
*
Tu
##mor
L
##ys
##is
S
##yn
##drome
(
T
##LS
)
:
Ad
##mini
##ster
pre
-
treatment
h
##yd
##ration
.
[SEP]
[CLS]
(
5
.
13
)
*
Em
##b
##ryo
-
f
##etal
To
##xi
##city
:
K
##y
##p
##rol
##is
can
cause
f
##etal
harm
.
[SEP]
[CLS]
Monitor
for
signs
or
symptoms
of
cardiac
failure
throughout
treatment
with
IN
##L
##Y
##TA
.
[SEP]
[CLS]
At
the
first
sign
or
s
##ym
##pt
##om
suggest
##ive
of
PM
##L
,
with
##hold
G
##IL
##EN
##Y
##A
and
perform
an
appropriate
diagnostic
evaluation
.
[SEP]
[CLS]
If
une
##x
##plain
##ed
or
clinical
##ly
significant
weight
loss
occurs
,
evaluate
weight
loss
and
consider
disco
##ntin
##uation
of
O
##TE
##Z
##LA
(
5
.
2
)
*
Drug
Inter
##actions
:
Use
with
strong
c
##yt
##och
##rome
P
##45
##0
enzyme
[SEP]
[CLS]
induce
##rs
(
e
.
g
.
,
r
##if
##amp
##in
,
p
##hen
##ob
##ar
##bit
##al
,
car
##ba
##ma
##ze
##pine
,
p
##hen
##yt
##oi
##n
)
is
not
recommended
because
loss
of
efficacy
may
occur
(
5
.
3
,
7
.
1
)
5
.
1
Depression
Treatment
with
O
##TE
##Z
##LA
is
[SEP]
[CLS]
associated
with
an
increase
in
adverse
reactions
of
depression
.
[SEP]
[CLS]
Therefore
,
if
E
##NT
##ER
##EG
is
administered
to
these
patients
,
they
should
be
monitored
for
gas
##tro
##int
##est
##inal
adverse
reactions
.
[SEP]
[CLS]
The
proportion
of
subjects
who
discontinued
treatment
with
ST
##RI
##BI
##LD
,
the
R
##TV
-
boost
##ed
P
##I
,
or
the
N
##NR
##TI
due
to
adverse
events
,
was
2
%
,
3
%
and
1
[SEP]
[CLS]
%
,
respectively
.
[SEP]
[CLS]
Red
##uce
or
with
##hold
dose
as
appropriate
[
see
Do
##sa
##ge
and
Administration
(
2
)
and
Ad
##verse
Re
##actions
(
6
)
]
.
[SEP]
[CLS]
If
CD
##AD
is
confirmed
,
disco
##ntin
##ue
anti
##ba
##cter
##ial
##s
not
directed
against
C
.
di
##ff
##ici
##le
,
if
possible
.
[SEP]
[CLS]
5
.
8
V
##eno
##us
T
##hr
##omb
##osis
V
##eno
##us
th
##rom
##boe
##mbo
##lic
events
(
including
deep
ve
##nous
th
##rom
##bos
##is
and
pulmonary
em
##bol
##ism
)
have
been
observed
with
K
##y
##p
##rol
##is
.
[SEP]
[CLS]
Table
7
:
B
##lee
##ding
Results
in
the
AM
##PL
##IF
##Y
-
E
##XT
Study
E
##L
##I
##Q
##UI
##S
2
.
5
mg
bid
##N
=
84
##0
##n
(
%
)
E
##L
##I
##Q
##UI
##S
5
mg
bid
##N
=
81
##1
##n
(
%
)
Place
##bo
##N
=
82
##6
##n
(
%
)
*
CR
##N
##M
=
[SEP]
[CLS]
clinical
##ly
relevant
non
##ma
##jo
##r
bleeding
.
Events
associated
with
each
end
##point
were
counted
once
per
subject
,
but
subjects
may
have
contributed
events
to
multiple
end
##points
.
[SEP]
[CLS]
Pat
##ients
should
be
observed
for
an
appropriate
period
of
time
after
administration
of
K
##AL
##BI
##TO
##R
,
taking
into
account
the
time
to
onset
of
an
##aph
##yla
##xi
##s
seen
in
clinical
trials
.
[SEP]
[CLS]
*
In
##fect
##ions
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Across
8
Phase
III
clinical
trials
[
see
Clinical
Studies
(
14
)
]
,
M
##TC
was
diagnosed
in
1
patient
receiving
T
##AN
##Z
##E
##UM
and
1
patient
receiving
place
##bo
.
[SEP]
[CLS]
J
##C
virus
infection
resulting
in
PM
##L
and
death
can
occur
in
patients
receiving
AD
##CE
##TR
##IS
(
5
.
9
,
6
.
2
)
.
[SEP]
[CLS]
5
.
11
Se
##iz
##ures
Se
##iz
##ures
were
reported
in
0
%
and
0
.
3
%
(
0
/
57
##2
,
1
/
37
##9
)
of
adult
patients
treated
with
doses
of
5
mg
and
10
mg
twice
daily
[SEP]
[CLS]
of
SA
##P
##H
##RI
##S
,
respectively
,
compared
to
0
%
(
0
/
50
##3
,
0
/
203
)
of
patients
treated
with
place
##bo
in
short
-
term
s
##chi
##zophrenia
and
bi
##pol
##ar
man
##ia
trials
,
respectively
.
[SEP]
[CLS]
Monitor
H
##B
##V
carriers
during
and
several
months
after
therapy
.
[SEP]
[CLS]
R
##out
##ine
monthly
pregnancy
tests
must
be
performed
during
this
time
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Drug
Inter
##actions
(
7
)
]
.
[SEP]
[CLS]
(
5
.
4
)
*
Ren
##al
I
##mp
##air
##ment
:
Monitor
re
##nal
function
in
patients
with
re
##nal
imp
##air
##ment
reporting
severe
adverse
gas
##tro
##int
##est
##inal
reactions
.
[SEP]
[CLS]
In
addition
,
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
should
be
used
with
caution
in
patients
with
severe
h
##yper
##sen
##si
##ti
##vity
to
milk
proteins
.
[SEP]
[CLS]
*
Mali
##gna
##ncies
-
More
cases
of
l
##ymph
##oma
have
been
observed
among
patients
receiving
T
##NF
-
block
##ers
compared
with
patients
in
the
control
groups
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
1
)
and
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
In
##tensive
measures
may
be
required
for
severe
di
##ar
##r
##hea
and
electro
##ly
##te
im
##bal
##ance
.
[SEP]
[CLS]
Given
the
similar
structural
formula
of
at
##rop
##ine
to
a
##c
##lid
##ini
##um
,
patients
with
a
history
of
h
##yper
##sen
##si
##ti
##vity
reactions
to
at
##rop
##ine
should
be
closely
monitored
for
similar
h
##yper
##sen
##si
##ti
##vity
reactions
to
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
[SEP]
[CLS]
.
[SEP]
[CLS]
N
##SF
may
result
in
fatal
or
de
##bil
##itating
fi
##bro
##sis
affecting
the
skin
,
muscle
and
internal
organs
.
[SEP]
[CLS]
Oral
con
##tra
##ceptive
##s
containing
lower
doses
of
nor
##eth
##ind
##rone
and
other
forms
of
ho
##rmon
##al
con
##tra
##ception
have
not
been
studied
or
are
con
##tra
##ind
##ica
##ted
.
[SEP]
[CLS]
Eye
Di
##sor
##ders
:
vision
blurred
.
[SEP]
[CLS]
Long
-
term
Safety
Trials
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
was
studied
in
three
long
term
safety
trials
,
two
double
blind
and
one
open
label
,
ranging
from
40
to
52
weeks
in
patients
[SEP]
[CLS]
with
moderate
to
severe
CO
##PD
.
[SEP]
[CLS]
Consider
the
potential
for
an
increased
risk
of
th
##rom
##boe
##mbo
##lis
##m
when
administer
##ing
PR
##OM
##AC
##TA
to
patients
with
known
risk
factors
for
th
##rom
##boe
##mbo
##lis
##m
(
e
.
g
.
,
Factor
V
Leiden
,
AT
##II
##I
deficiency
,
[SEP]
[CLS]
anti
##ph
##os
##ph
##oli
##pid
syndrome
,
chronic
liver
disease
)
.
[SEP]
[CLS]
Both
patients
had
marked
##ly
elevated
serum
ca
##l
##ci
##ton
##in
levels
at
base
##line
.
[SEP]
[CLS]
If
react
##ivation
occurs
,
stop
C
##IM
##Z
##IA
and
begin
anti
-
viral
therapy
(
5
.
5
)
*
De
##my
##elin
##ating
disease
,
ex
##ace
##rb
##ation
or
new
onset
,
may
occur
(
5
.
6
)
*
Cy
##top
##enia
##s
,
[SEP]
[CLS]
pan
##cy
##top
##enia
-
advise
patients
to
seek
immediate
medical
attention
if
symptoms
develop
,
and
consider
stopping
C
##IM
##Z
##IA
(
5
.
7
)
*
Lu
##pus
-
like
syndrome
-
stop
C
##IM
##Z
##IA
if
syndrome
develops
(
[SEP]
[CLS]
5
.
9
)
5
.
1
Risk
of
Ser
##ious
In
##fect
##ions
[
see
Box
##ed
Warning
]
Pat
##ients
treated
with
C
##IM
##Z
##IA
are
at
an
increased
risk
for
developing
serious
infections
involving
various
organ
systems
and
[SEP]
[CLS]
sites
that
may
lead
to
hospital
##ization
or
death
.
[SEP]
[CLS]
5
.
4
H
##yper
##sen
##si
##ti
##vity
Re
##actions
Across
8
Phase
III
clinical
trials
[
see
Clinical
Studies
(
14
)
]
,
a
serious
h
##yper
##sen
##si
##ti
##vity
reaction
with
p
##ru
##rit
##us
,
r
##ash
,
and
d
##ys
##p
##nea
occurred
[SEP]
[CLS]
in
a
patient
treated
with
T
##AN
##Z
##E
##UM
.
[SEP]
[CLS]
Trans
##p
##lant
recipients
who
are
E
##B
##V
se
##rone
##gat
##ive
,
or
with
unknown
se
##ros
##tat
##us
,
should
not
receive
N
##U
##L
##O
##J
##IX
[
see
Box
##ed
Warning
and
Con
##tra
##ind
##ica
##tions
(
4
)
]
.
[SEP]
[CLS]
*
Em
##b
##ryo
-
f
##etal
toxicity
:
Fe
##tal
harm
can
occur
.
[SEP]
[CLS]
(
2
.
4
,
5
.
1
,
14
.
1
)
(
B
)
SP
##IN
##AL
/
EP
##ID
##UR
##AL
H
##EM
##AT
##OM
##A
:
spinal
hem
##ato
##mas
may
occur
in
patients
treated
with
E
##L
##I
##Q
##UI
##S
who
are
receiving
ne
##ura
##xial
an
##est
##hesia
or
undergoing
spinal
[SEP]
[CLS]
pu
##nc
##ture
.
[SEP]
[CLS]
Monitor
patients
for
visual
signs
and
symptoms
of
u
##ve
##itis
(
e
.
g
.
,
change
in
vision
,
photo
##ph
##obia
,
eye
pain
)
.
[SEP]
[CLS]
Non
-
infectious
p
##ne
##um
##oni
##tis
was
reported
in
up
to
19
%
of
patients
treated
with
A
##FI
##NI
##TO
##R
in
clinical
trials
.
[SEP]
[CLS]
Major
2
(
0
.
2
)
1
(
0
.
1
)
4
(
0
.
5
)
CR
##N
##M
*
25
(
3
.
0
)
34
(
4
.
2
)
19
(
2
.
3
)
Major
+
CR
##N
##M
27
[SEP]
[CLS]
(
3
.
2
)
35
(
4
.
3
)
22
(
2
.
7
)
Minor
75
(
8
.
9
)
98
(
12
.
1
)
58
(
7
.
0
)
All
94
(
11
.
2
)
121
[SEP]
[CLS]
(
14
.
9
)
74
(
9
.
0
)
Ad
##verse
reactions
occurring
in
>
=
1
%
of
patients
in
the
AM
##PL
##IF
##Y
-
E
##XT
study
are
listed
in
Table
8
.
[SEP]
[CLS]
Other
adverse
reactions
in
##dicative
of
h
##yper
##sen
##si
##ti
##vity
reactions
included
the
following
:
p
##ru
##rit
##us
(
5
%
)
,
r
##ash
(
3
%
)
,
and
u
##rt
##ica
##ria
(
2
%
)
.
[SEP]
[CLS]
P
##ne
##um
##onia
In
the
pool
of
7
place
##bo
-
and
active
-
controlled
trials
,
the
adverse
reaction
of
pneumonia
was
reported
more
frequently
in
patients
receiving
T
##AN
##Z
##E
##UM
(
1
.
8
%
)
than
in
[SEP]
[CLS]
patients
in
the
all
-
com
##par
##ators
group
(
0
.
8
%
)
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
B
##io
##gen
at
1
-
800
-
45
##6
-
225
##5
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
In
the
event
of
a
severe
reaction
,
disco
##ntin
##ue
D
##IF
##IC
##ID
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
T
##AF
##IN
##LA
##R
and
tram
##eti
##ni
##b
for
life
-
threatening
P
##E
.
[SEP]
[CLS]
The
youngest
al
##g
##lu
##cos
##idas
##e
al
##fa
-
treated
patient
was
16
years
of
age
,
and
the
youngest
place
##bo
-
treated
patient
was
10
years
of
age
.
[SEP]
[CLS]
In
the
combination
study
,
the
incidence
of
ve
##nous
th
##rom
##boe
##mbo
##lic
events
in
the
first
12
cycles
was
13
%
in
the
K
##y
##p
##rol
##is
combination
arm
versus
6
%
in
the
control
[SEP]
[CLS]
arm
.
[SEP]
[CLS]
The
proportion
of
patients
who
discontinued
treatment
due
to
any
adverse
reaction
during
the
controlled
clinical
trials
was
6
.
2
%
for
patients
receiving
B
##EN
##L
##Y
##ST
##A
and
7
.
1
%
for
patients
receiving
[SEP]
[CLS]
place
##bo
.
[SEP]
[CLS]
Of
the
2
,
254
subjects
,
70
%
were
male
and
84
%
were
white
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Therefore
,
co
-
administration
of
K
##AL
##Y
##DE
##CO
with
strong
C
##YP
##3
##A
induce
##rs
(
e
.
g
.
,
r
##if
##amp
##in
,
St
.
John
'
s
w
##ort
)
is
not
recommended
[
see
Drug
Inter
##actions
(
7
.
2
)
and
[SEP]
[CLS]
Clinical
Ph
##arma
##cology
(
12
.
3
)
]
.
[SEP]
[CLS]
While
receiving
study
drug
through
Week
144
,
an
additional
11
%
of
ST
##RI
##BI
##LD
subjects
were
started
on
lip
##id
lowering
agents
,
compared
to
13
%
of
AT
##RI
##PL
##A
and
12
[SEP]
[CLS]
%
of
AT
##V
+
R
##TV
+
T
##R
##U
##VA
##DA
subjects
.
[SEP]
[CLS]
The
patients
were
also
not
taking
any
im
##mu
##nos
##up
##pressive
or
im
##mu
##no
##mo
##du
##lator
##y
medications
con
##com
##ita
##ntly
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Forest
Laboratories
,
LLC
.
[SEP]
[CLS]
(
5
.
5
)
*
Gas
##tro
##int
##est
##inal
per
##fo
##ration
,
including
death
,
have
occurred
.
[SEP]
[CLS]
In
Study
1
and
Study
2
,
safety
information
was
prospective
##ly
and
systematically
collected
.
[SEP]
[CLS]
Two
subjects
(
0
.
13
%
)
tested
positive
for
binding
antibodies
at
base
##line
.
[SEP]
[CLS]
Pat
##ients
in
the
ch
##em
##otherapy
arm
received
p
##em
##et
##re
##xed
unless
they
had
received
p
##em
##et
##re
##xed
as
part
of
first
-
line
or
maintenance
treatment
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
5
.
2
Aero
##sol
##ization
of
Cap
##sai
##cin
Aero
##sol
##ization
of
caps
##aic
##in
can
occur
upon
rapid
removal
of
Q
##ute
##nza
patches
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Me
##rc
##k
Sharp
&
Do
##hm
##e
Corp
.
,
a
subsidiary
of
Me
##rc
##k
&
Co
.
,
Inc
.
,
at
1
-
87
##7
-
88
##8
-
42
##31
or
FDA
at
[SEP]
[CLS]
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
(
6
.
2
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Ser
##ious
Ad
##verse
Re
##actions
The
following
serious
and
otherwise
[SEP]
[CLS]
important
adverse
reactions
are
discussed
in
greater
detail
in
other
sections
of
label
##ing
:
*
H
##yper
##sen
##si
##ti
##vity
Re
##actions
[
see
Con
##tra
##ind
##ica
##tions
(
4
)
and
Ad
##verse
Re
##actions
(
6
.
3
)
]
[SEP]
[CLS]
.
[SEP]
[CLS]
5
.
6
Other
Mali
##gna
##ncies
There
are
reports
of
ma
##li
##gnant
diseases
that
have
developed
in
patients
who
have
been
treated
with
T
##RE
##AN
##DA
,
including
my
##elo
##dy
##sp
##lastic
syndrome
,
my
##elo
##p
##rol
##ifer
##ative
disorders
,
[SEP]
[CLS]
acute
my
##elo
##id
le
##uke
##mia
and
br
##on
##chia
##l
car
##cin
##oma
.
[SEP]
[CLS]
Laboratory
Tests
No
clinical
##ly
meaningful
changes
in
hem
##ato
##logy
,
serum
chemistry
or
u
##rina
##lysis
were
observed
in
patients
treated
with
NE
##SI
##NA
.
[SEP]
[CLS]
The
patient
had
no
other
identified
systemic
medical
conditions
resulting
in
compromised
immune
system
function
and
had
not
previously
been
treated
with
na
##tal
##iz
##uma
##b
,
which
has
a
known
association
with
[SEP]
[CLS]
PM
##L
.
[SEP]
[CLS]
Life
-
threatening
or
fatal
CR
##S
was
in
##f
##re
##quent
##ly
reported
in
patients
receiving
B
##L
##IN
##C
##Y
##TO
.
[SEP]
[CLS]
5
.
1
I
##OP
Inc
##rease
Pro
##long
##ed
use
of
co
##rt
##ico
##ster
##oids
may
result
in
g
##lau
##com
##a
with
damage
to
the
op
##tic
nerve
,
defects
in
visual
a
##cu
##ity
.
[SEP]
[CLS]
Fun
##gal
culture
should
be
taken
when
appropriate
.
[SEP]
[CLS]
Elder
##ly
patients
and
patients
with
impaired
re
##nal
function
were
more
susceptible
to
these
adverse
reactions
(
see
Table
4
)
.
[SEP]
[CLS]
Monitor
for
signs
or
symptoms
of
T
##LS
.
[SEP]
[CLS]
Ad
##verse
reactions
led
to
study
treatment
disco
##ntin
##uation
in
16
%
of
patients
receiving
CO
##ME
##TR
##I
##Q
and
in
8
%
of
patients
receiving
place
##bo
.
[SEP]
[CLS]
Table
2
Ad
##ju
##dicated
Major
B
##lee
##ding
Events
in
T
##reate
##d
Pat
##ients
##a
a
##P
##ati
##ents
during
treatment
or
within
2
days
of
stopping
study
treatment
.
[SEP]
[CLS]
However
,
by
the
end
of
the
third
year
,
the
cumulative
incidence
of
NO
##DA
##T
was
8
%
(
24
/
304
)
in
patients
treated
with
the
N
##U
##L
##O
##J
##IX
recommended
regime
##n
and
[SEP]
[CLS]
10
%
(
29
/
280
)
in
patients
treated
with
the
c
##y
##c
##los
##por
##ine
regime
##n
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
The
Medicine
##s
Company
at
1
-
88
##8
-
97
##7
-
MD
##CO
(
63
##26
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
Te
##f
##lar
##o
was
evaluated
in
four
controlled
comparative
Phase
3
clinical
trials
(
two
in
ABS
##SS
##I
and
two
in
CA
##B
##P
)
which
included
1300
adult
patients
treated
with
Te
##f
##lar
##o
(
600
[SEP]
[CLS]
mg
administered
by
IV
over
1
hour
every
12
##h
)
and
129
##7
patients
treated
with
com
##par
##ator
(
van
##com
##y
##cin
plus
a
##z
##tre
##ona
##m
or
c
##ef
##tri
##ax
##one
)
for
a
treatment
period
up
to
21
[SEP]
[CLS]
days
.
[SEP]
[CLS]
For
each
subject
in
whom
a
Week
12
sample
was
selected
,
the
corresponding
Week
6
,
18
,
24
,
and
52
samples
were
ass
##ay
##ed
if
they
were
also
[SEP]
[CLS]
binding
anti
##body
positive
.
[SEP]
[CLS]
6
.
1
Clinical
Studies
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trial
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
Per
##ip
##her
##al
N
##eur
##op
##athy
:
In
Study
1
,
17
%
of
enrolled
patients
had
Grade
1
peripheral
ne
##uro
##pathy
and
3
%
of
patients
had
Grade
2
peripheral
ne
##uro
##pathy
at
base
##line
.
[SEP]
[CLS]
Pat
##ients
with
liver
meta
##sta
##ses
were
excluded
if
AS
##T
and
/
or
AL
##T
>
5
*
U
##L
##N
.
[SEP]
[CLS]
If
an
##aph
##yla
##xi
##s
occurs
,
immediately
and
permanently
disco
##ntin
##ue
administration
of
AD
##CE
##TR
##IS
and
administer
appropriate
medical
therapy
.
[SEP]
[CLS]
Ad
##verse
Re
##actions
N
(
Per
##cent
of
patients
)
Head
##ache
10
(
1
.
8
%
)
Mu
##s
##cu
##los
##kel
##etal
pain
4
(
0
.
7
%
)
Blood
pressure
increased
a
4
(
0
.
7
%
)
[SEP]
[CLS]
Na
##use
##a
4
(
0
.
7
%
)
Fat
##ig
##ue
3
(
0
.
5
%
)
In
##jection
site
reaction
b
3
(
0
.
5
%
)
An
##xi
##ety
2
(
0
.
4
%
)
Back
pain
2
[SEP]
[CLS]
(
0
.
4
%
)
Claus
##tro
##ph
##obia
2
(
0
.
4
%
)
Di
##zzi
##ness
2
(
0
.
4
%
)
Feeling
cold
c
2
(
0
.
4
%
)
In
##so
##m
##nia
2
(
0
.
4
%
)
[SEP]
[CLS]
Neck
pain
2
(
0
.
4
%
)
Other
adverse
reactions
occurred
at
lower
frequencies
and
included
in
##fusion
site
r
##ash
,
d
##ys
##ge
##us
##ia
,
p
##ru
##rit
##is
,
u
##rt
##ica
##ria
,
and
flush
##ing
.
[SEP]
[CLS]
As
with
other
anti
##psy
##cho
##tics
,
FA
##NA
##P
##T
should
be
used
cautiously
in
patients
with
a
history
of
seizure
##s
or
with
conditions
that
potentially
lower
the
seizure
threshold
,
e
.
g
.
,
Alzheimer
[SEP]
[CLS]
'
s
dem
##ent
##ia
.
[SEP]
[CLS]
5
.
6
Fun
##gal
In
##fect
##ions
Fun
##gal
infections
of
the
corn
##ea
are
particularly
prone
to
develop
coincide
##ntal
##ly
with
long
-
term
local
s
##tero
##id
application
.
[SEP]
[CLS]
*
Per
##fo
##rations
and
Fi
##st
##ula
##s
:
Gas
##tro
##int
##est
##inal
per
##fo
##rations
occurred
in
3
%
and
fist
##ula
formation
in
1
%
of
CO
##ME
##TR
##I
##Q
-
treated
patients
.
[SEP]
[CLS]
Pat
##ients
with
a
history
of
g
##eni
##tal
my
##cot
##ic
infections
and
un
##ci
##rc
##um
##cise
##d
males
were
more
likely
to
develop
g
##eni
##tal
my
##cot
##ic
infections
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
Pre
-
me
##dicate
in
subsequent
cycles
for
mild
##er
reactions
.
[SEP]
[CLS]
He
##mat
##olo
##gic
na
##dir
##s
were
observed
predominantly
in
the
third
week
of
therapy
.
[SEP]
[CLS]
Monitor
EC
##G
##s
and
disco
##ntin
##ue
S
##IR
##TU
##RO
if
significant
vent
##ric
##ular
a
##rr
##hy
##th
##mia
or
Q
##T
##c
##F
interval
>
500
m
##s
develops
.
[SEP]
[CLS]
At
##y
##pical
Sub
##tro
##chan
##ter
##ic
and
Di
##aph
##ys
##eal
Fr
##act
##ures
In
the
o
##ste
##op
##oro
##sis
clinical
trial
program
,
at
##y
##pical
f
##em
##oral
fracture
##s
were
reported
in
patients
treated
with
Pro
##lia
.
[SEP]
[CLS]
N
*
*
=
Number
of
patients
at
risk
at
Basel
##ine
with
assessments
at
both
Basel
##ine
and
End
##point
.
[SEP]
[CLS]
The
changes
averaged
less
than
10
mm
H
##g
,
although
some
patients
had
greater
increases
and
these
changes
lasted
for
approximately
two
hours
after
patch
removal
.
[SEP]
[CLS]
System
Organ
Class
/
Pre
##ferred
Te
##rm
Place
##bo
N
=
37
##8
%
SA
##P
##H
##RI
##S
5
mg
twice
daily
N
=
27
##4
%
SA
##P
##H
##RI
##S
10
mg
twice
daily
N
=
208
%
All
SA
##P
##H
##RI
##S
S
5
mg
or
10
mg
[SEP]
[CLS]
twice
daily
N
=
57
##2
%
Gas
##tro
##int
##est
##inal
disorders
Con
##st
##ip
##ation
6
7
4
5
Dry
mouth
1
3
1
2
Oral
h
##y
##po
##est
##hesia
1
6
7
5
Sal
##iva
##ry
h
##yper
##se
##cre
##tion
0
<
1
4
2
[SEP]
[CLS]
St
##oma
##ch
discomfort
1
<
1
3
2
V
##omi
##ting
5
4
7
5
General
disorders
Fat
##ig
##ue
3
4
3
3
I
##rri
##ta
##bility
<
1
2
1
2
Investigation
##s
Inc
##reased
weight
<
1
[SEP]
[CLS]
2
2
3
Met
##ab
##olis
##m
disorders
Inc
##reased
appetite
<
1
3
0
2
N
##er
##vous
system
disorders
A
##kat
##his
##ia
*
3
4
11
6
Di
##zzi
##ness
4
7
3
5
Extra
##py
##ram
##idal
symptoms
(
excluding
[SEP]
[CLS]
aka
##thi
##sia
)
7
9
12
10
So
##m
##no
##len
##ce
?
[SEP]
[CLS]
Disco
##ntin
##uations
due
to
adverse
drug
reactions
(
AD
##R
##s
)
were
5
.
2
%
in
the
IN
##TE
##LE
##NC
##E
(
r
)
arm
and
2
.
6
%
in
the
place
##bo
arm
.
[SEP]
[CLS]
Permanent
##ly
disco
##ntin
##ue
X
##TA
##ND
##I
in
patients
who
develop
a
seizure
during
treatment
.
[SEP]
[CLS]
Anti
##psy
##cho
##tic
treatment
itself
,
however
,
may
suppress
(
or
partially
suppress
)
the
signs
and
symptoms
of
the
syndrome
and
thereby
may
possibly
mask
the
underlying
process
.
[SEP]
[CLS]
Because
these
reactions
are
reported
voluntarily
from
a
population
of
uncertain
size
,
it
is
not
always
possible
to
re
##lia
##bly
estimate
their
frequency
or
establish
a
ca
##usal
relationship
to
drug
[SEP]
[CLS]
exposure
:
de
##hy
##dra
##tion
,
th
##rom
##bot
##ic
th
##rom
##bo
##cy
##top
##eni
##c
pu
##rp
##ura
/
hem
##oly
##tic
u
##rem
##ic
syndrome
(
T
##TP
/
H
##US
)
,
tumor
l
##ys
##is
syndrome
including
fatal
outcomes
,
and
posterior
re
##versible
en
##ce
##pha
##lop
##athy
syndrome
(
PR
##ES
)
.
[SEP]
[CLS]
This
may
require
protective
drops
,
o
##int
##ment
,
therapeutic
soft
contact
lenses
,
or
closure
of
the
eye
by
patch
##ing
or
other
means
.
[SEP]
[CLS]
H
##yper
##sen
##si
##ti
##vity
reactions
and
acute
kidney
injury
are
described
in
other
sections
of
the
label
##ing
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
and
(
5
.
3
)
]
.
[SEP]
[CLS]
Do
not
exceed
the
recommended
dos
##age
and
frequency
of
administration
of
D
##Y
##SP
##OR
##T
(
r
)
.
[SEP]
[CLS]
Ke
##rat
##itis
was
reported
in
5
(
2
.
2
%
)
patients
in
Study
1
,
with
Grade
3
in
1
(
0
.
4
%
)
.
[SEP]
[CLS]
Sub
##jects
ranged
in
age
from
18
to
83
years
,
with
an
overall
median
age
of
46
years
.
[SEP]
[CLS]
If
the
diagnosis
is
suspected
,
stop
K
##y
##p
##rol
##is
and
evaluate
.
[SEP]
[CLS]
The
risks
and
benefits
of
treatment
should
be
considered
prior
to
pre
##s
##cribing
T
##NF
-
block
##ers
,
including
S
##IM
##PO
##NI
ARIA
,
to
patients
who
are
carriers
of
H
##B
##V
.
[SEP]
[CLS]
Primary
prop
##hyl
##ax
##is
with
G
-
CS
##F
should
be
considered
in
patients
with
high
-
risk
clinical
features
(
age
>
65
years
,
poor
performance
status
,
previous
episodes
of
f
##eb
##ril
##e
ne
##ut
##rop
##enia
,
extensive
[SEP]
[CLS]
prior
radiation
ports
,
poor
nutrition
##al
status
,
or
other
serious
com
##or
##bid
##ities
)
that
pre
##dis
##pose
them
to
increased
complications
from
prolonged
ne
##ut
##rop
##enia
.
[SEP]
[CLS]
(
6
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
Nova
##rt
##is
Ph
##arma
##ce
##utical
##s
Corporation
at
1
-
88
##8
-
66
##9
-
66
##8
##2
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
6
.
1
Clinical
Trial
Experience
Because
clinical
trials
are
conducted
[SEP]
[CLS]
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
to
rates
in
the
clinical
trials
of
another
drug
[SEP]
[CLS]
and
may
not
reflect
the
rates
observed
in
practice
.
[SEP]
[CLS]
If
symptoms
are
moderate
,
consider
interrupting
therapy
until
symptoms
improve
.
[SEP]
[CLS]
In
clinical
trials
,
121
patients
who
received
one
(
n
=
99
)
,
two
(
n
=
21
)
,
or
three
(
n
=
1
)
doses
of
V
##OR
##A
##X
##A
##Z
##E
were
evaluated
for
anti
-
g
##lu
##car
##pid
##ase
[SEP]
[CLS]
antibodies
.
[SEP]
[CLS]
If
signs
or
symptoms
of
spinal
hem
##ato
##ma
are
suspected
,
initiate
urgent
diagnosis
and
treatment
including
consideration
for
spinal
cord
de
##com
##press
##ion
even
though
such
treatment
may
not
prevent
or
reverse
[SEP]
[CLS]
ne
##uro
##logical
sequel
##ae
.
[SEP]
[CLS]
E
##B
##V
se
##rop
##os
##itive
patients
are
defined
as
having
evidence
of
acquired
immunity
shown
by
the
presence
of
I
##g
##G
antibodies
to
viral
caps
##id
anti
##gen
(
VC
##A
)
and
E
##B
##V
nuclear
anti
##gen
(
[SEP]
[CLS]
E
##B
##NA
)
.
[SEP]
[CLS]
In
these
trials
,
89
##1
patients
were
treated
with
T
##U
##D
##OR
##Z
##A
PR
##ES
##SA
##IR
at
the
recommended
dose
of
400
m
##c
##g
twice
daily
.
[SEP]
[CLS]
Card
##iac
Di
##sor
##ders
:
an
##gin
##a
p
##ector
##is
,
at
##rial
fi
##bri
##lla
##tion
,
cardiac
murmur
,
EC
##G
abnormal
,
p
##al
##pit
##ations
,
sin
##us
bra
##dy
##card
##ia
,
ta
##chy
##card
##ia
.
[SEP]
[CLS]
5
.
5
Ren
##al
I
##mp
##air
##ment
In
patients
treated
with
G
##LP
-
1
receptor
ago
##nist
##s
,
there
have
been
post
##market
##ing
reports
of
acute
re
##nal
failure
and
worse
##ning
of
chronic
re
##nal
failure
,
which
may
sometimes
[SEP]
[CLS]
require
hem
##od
##ial
##ys
##is
.
[SEP]
[CLS]
Pat
##ients
have
frequently
presented
with
di
##sse
##minated
rather
than
localized
disease
.
[SEP]
[CLS]
Rep
##rod
##uctive
System
and
B
##rea
##st
Changes
:
breast
pain
,
erect
##ile
d
##ys
##function
,
g
##yne
##com
##ast
##ia
.
[SEP]
[CLS]
The
trial
excluded
patients
with
abnormal
left
vent
##ric
##ular
e
##jection
fraction
or
cardiac
valve
morphology
(
>
=
Grade
2
)
,
corrected
Q
##T
interval
>
=
480
mill
##ise
##con
##ds
on
electro
##card
##io
##gram
,
or
[SEP]
[CLS]
a
known
history
of
glucose
-
6
-
phosphate
de
##hy
##dr
##ogen
##ase
deficiency
.
[SEP]
[CLS]
Monitor
##ing
of
or
##th
##ost
##atic
vital
signs
should
be
considered
in
all
such
patients
,
and
a
dose
reduction
should
be
considered
if
h
##y
##pot
##ens
##ion
occurs
.
[SEP]
[CLS]
Women
taking
D
##U
##AV
##EE
should
not
take
pro
##ges
##tin
##s
,
additional
est
##rogen
##s
or
additional
est
##rogen
ago
##nist
/
antagonist
##s
.
[SEP]
[CLS]
Ex
##cluded
from
this
list
are
those
events
that
were
minor
,
those
with
no
plausible
relation
to
drug
use
,
and
reports
too
imp
##re
##cise
to
be
meaningful
.
[SEP]
[CLS]
The
demographic
and
base
##line
characteristics
of
the
long
term
safety
trials
were
similar
to
those
of
the
place
##bo
-
controlled
trials
.
[SEP]
[CLS]
Con
##ju
##gated
est
##rogen
##s
are
a
mixture
of
sodium
est
##rone
su
##lf
##ate
and
sodium
e
##qui
##lin
su
##lf
##ate
and
other
components
,
including
sodium
su
##lf
##ate
con
##ju
##gate
##s
,
17
##al
##pha
-
di
##hy
##dr
##oe
##qui
##lin
,
17
##al
##pha
-
est
##rad
##iol
,
and
17
##bet
##a
-
di
##hy
##dr
##oe
##qui
##lin
.
[SEP]
[CLS]
P
##yre
##xia
,
chill
##s
,
and
nausea
were
the
most
common
reasons
cited
for
dose
reduction
##s
and
p
##yre
##xia
,
chill
##s
,
and
decreased
e
##jection
fraction
were
the
most
common
reasons
cited
[SEP]
[CLS]
for
dose
interrupt
##ions
of
T
##AF
##IN
##LA
##R
and
tram
##eti
##ni
##b
when
used
in
combination
.
[SEP]
[CLS]
Blood
and
L
##ymph
##atic
System
Di
##sor
##ders
:
an
##emia
,
id
##io
##pathic
th
##rom
##bo
##cy
##top
##eni
##c
pu
##rp
##ura
,
le
##uk
##oc
##yt
##osis
/
le
##uk
##ope
##nia
,
ne
##ut
##rop
##enia
,
pan
##cy
##top
##enia
,
s
##ple
##no
##me
##gal
##y
,
th
##rom
##bo
##cy
##top
##enia
.
[SEP]
[CLS]
The
risk
may
also
be
increased
by
traumatic
or
repeated
e
##pid
##ural
or
spinal
pu
##nc
##ture
.
[SEP]
[CLS]
These
hem
##ato
##mas
may
result
in
permanent
para
##lysis
.
[SEP]
[CLS]
5
.
8
Mu
##s
##cu
##los
##kel
##etal
Pain
In
post
-
marketing
experience
,
severe
and
occasionally
in
##cap
##ac
##itating
muscle
pain
has
been
reported
in
patients
taking
Pro
##lia
[
see
Ad
##verse
Re
##actions
(
6
.
2
)
]
.
[SEP]
[CLS]
Ad
##verse
reactions
for
F
##U
##L
##Y
##Z
##A
##Q
that
occurred
in
at
least
2
%
of
patients
and
at
a
higher
incidence
than
place
##bo
are
provided
in
Table
1
.
[SEP]
[CLS]
The
use
of
co
##rt
##ico
##ster
##oids
may
be
indicated
.
[SEP]
[CLS]
A
minority
of
patients
(
approximately
17
%
)
who
tested
positive
for
anti
-
al
##bi
##g
##lut
##ide
antibodies
also
trans
##ient
##ly
tested
positive
for
antibodies
to
human
album
##in
.
[SEP]
[CLS]
For
patients
who
test
positive
for
he
##pa
##titis
B
surface
anti
##gen
,
consultation
with
a
physician
with
expertise
in
the
treatment
of
he
##pa
##titis
B
is
recommended
before
in
##iti
##ating
T
##NF
-
block
##er
therapy
.
[SEP]
[CLS]
G
-
CS
##F
may
be
administered
to
reduce
the
risks
of
ne
##ut
##rop
##enia
complications
associated
with
J
##E
##V
##TA
##NA
use
.
[SEP]
[CLS]
They
had
a
mean
age
of
62
years
and
an
average
smoking
history
of
44
pack
-
years
,
with
54
%
identified
as
current
smoke
##rs
.
[SEP]
[CLS]
A
similar
trend
was
also
seen
in
the
c
##UT
##I
trial
.
[SEP]
[CLS]
With
##hold
G
##IL
##OT
##RI
##F
during
evaluation
of
patients
with
suspected
k
##era
##titis
,
and
if
diagnosis
of
ul
##cer
##ative
k
##era
##titis
is
confirmed
,
treatment
with
G
##IL
##OT
##RI
##F
should
be
interrupted
or
discontinued
[
see
Do
##sa
##ge
[SEP]
[CLS]
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
No
h
##yper
##sen
##si
##ti
##vity
or
an
##aph
##yla
##ctic
reactions
were
reported
with
F
##IR
##A
##Z
##Y
##R
.
[SEP]
[CLS]
The
most
common
Grade
3
-
4
laboratory
abnormal
##ities
(
incidence
>
=
3
%
)
were
l
##ymph
##ope
##nia
,
h
##yper
##gly
##ce
##mia
,
an
##emia
,
h
##y
##pop
##hos
##phate
##mia
,
and
h
##yper
##cho
##les
##tero
##lem
##ia
.
[SEP]
[CLS]
For
patients
who
develop
prolonged
Grade
2
cut
##aneous
adverse
reactions
lasting
more
than
7
days
,
into
##ler
##able
Grade
2
,
or
Grade
3
cut
##aneous
reactions
,
with
##hold
G
##IL
##OT
##RI
##F
until
the
[SEP]
[CLS]
adverse
reaction
resolve
##s
to
Grade
1
or
less
,
and
resume
G
##IL
##OT
##RI
##F
with
appropriate
dose
reduction
[
see
Do
##sa
##ge
and
Administration
(
2
.
3
)
]
.
[SEP]
[CLS]
Changes
from
base
##line
in
total
ch
##ole
##ster
##ol
,
HD
##L
-
ch
##ole
##ster
##ol
,
L
##D
##L
-
ch
##ole
##ster
##ol
,
and
t
##rig
##ly
##cer
##ides
are
presented
in
Table
5
.
[SEP]
[CLS]
Live
##r
chemistry
elevations
consistent
with
immune
re
##con
##st
##itution
syndrome
were
observed
in
some
subjects
with
he
##pa
##titis
B
and
/
or
C
at
the
start
of
therapy
with
T
##I
##VI
##CA
##Y
,
particularly
in
the
setting
[SEP]
[CLS]
where
anti
-
he
##pa
##titis
therapy
was
withdrawn
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
.
[SEP]
[CLS]
Pat
##ients
with
pre
-
existing
swallowing
or
breathing
difficulties
may
be
more
susceptible
to
these
complications
.
[SEP]
[CLS]
Ad
##verse
reactions
of
ve
##nous
th
##rom
##boe
##mbo
##lis
##m
were
reported
in
0
.
0
%
of
patients
treated
with
D
##U
##AV
##EE
and
0
.
1
%
of
patients
treated
with
place
##bo
.
[SEP]
[CLS]
5
.
2
Pan
##cre
##ati
##tis
Pan
##cre
##ati
##tis
has
been
reported
in
4
%
of
patients
in
clinical
trials
[
see
Ad
##verse
Re
##actions
(
6
.
1
)
]
.
[SEP]
[CLS]
[
see
Warning
##s
and
Pre
##ca
##ution
##s
(
5
.
2
)
]
WA
##R
##NI
##NG
:
D
##IS
##TA
##NT
SP
##RE
##AD
OF
TO
##X
##IN
E
##FF
##EC
##T
See
full
pre
##s
##cribing
information
for
complete
box
##ed
warning
The
effects
of
D
##Y
##SP
##OR
##T
(
r
[SEP]
[CLS]
)
and
all
b
##ot
##ulin
##um
to
##xin
products
may
spread
from
the
area
of
injection
to
produce
symptoms
consistent
with
b
##ot
##ulin
##um
to
##xin
effects
.
[SEP]
[CLS]
Ren
##al
ins
##uff
##iciency
adverse
events
(
re
##nal
imp
##air
##ment
,
acute
re
##nal
failure
,
re
##nal
failure
)
have
occurred
with
an
incidence
of
approximately
8
%
in
a
random
##ized
controlled
trial
.
[SEP]
[CLS]
Mean
changes
(
percent
changes
)
from
base
##line
in
non
-
HD
##L
-
C
relative
to
place
##bo
were
2
.
1
mg
/
d
##L
(
1
.
5
%
)
and
5
.
1
mg
/
d
##L
(
3
.
6
%
)
with
IN
##VO
##KA
##NA
100
[SEP]
[CLS]
mg
and
300
mg
,
respectively
.
[SEP]
[CLS]
6
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
*
The
following
serious
adverse
reactions
are
discussed
elsewhere
in
label
##ing
:
*
N
##ep
##hr
##ogenic
System
##ic
Fi
##bro
##sis
(
N
##SF
)
[
see
Box
##ed
Warning
and
Warning
##s
and
Pre
##ca
##ution
##s
[SEP]
[CLS]
(
5
.
1
)
]
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
trials
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
trials
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
trials
of
other
drugs
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
6
.
1
Clinical
Trials
Experience
Because
clinical
studies
are
conducted
under
widely
varying
conditions
,
adverse
reaction
rates
observed
in
the
clinical
studies
of
a
drug
can
not
be
directly
compared
[SEP]
[CLS]
to
rates
in
the
clinical
studies
of
another
drug
and
may
not
reflect
the
rates
observed
in
clinical
practice
.
[SEP]
[CLS]
There
are
no
adequate
and
well
-
controlled
studies
in
pregnant
women
using
J
##E
##V
##TA
##NA
.
[SEP]
[CLS]
The
adverse
reaction
most
commonly
(
>
=
1
%
on
AP
##TI
##OM
)
leading
to
disco
##ntin
##uation
was
h
##y
##po
##nat
##rem
##ia
.
[SEP]
[CLS]
Fat
##al
and
serious
cases
of
re
##nal
failure
have
occurred
with
I
##MB
##R
##U
##VI
##CA
therapy
.
[SEP]
[CLS]
(
6
.
1
)
Upper
Lim
##b
Spa
##stic
##ity
The
most
frequently
reported
adverse
reactions
(
>
=
2
%
)
are
:
u
##rina
##ry
tract
infection
,
na
##so
##pha
##ryn
##git
##is
,
muscular
weakness
,
[SEP]
[CLS]
m
##us
##cu
##los
##kel
##etal
pain
,
di
##zzi
##ness
,
fall
and
depression
.
[SEP]
[CLS]
(
6
.
1
)
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
P
##fi
##zer
,
Inc
at
1
-
800
-
43
##8
-
1985
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
[CLS]
5
WA
##R
##NI
##NG
##S
AND
PR
##EC
##A
##UT
##ION
##S
E
##X
##CE
##RP
##T
:
*
Ana
##phy
##lax
##is
and
an
##gio
##ede
##ma
:
Disco
##ntin
##ue
and
do
not
restart
T
##EC
##FI
##DE
##RA
if
these
occur
.
[SEP]
[CLS]
Pat
##ients
should
have
base
##line
op
##ht
##hal
##mo
##log
##ic
testing
by
an
op
##ht
##hal
##mic
professional
and
follow
-
up
testing
every
6
months
.
[SEP]
[CLS]
To
report
S
##US
##P
##EC
##TE
##D
AD
##VE
##RS
##E
R
##EA
##CT
##ION
##S
,
contact
##J
##ans
##sen
B
##iot
##ech
,
Inc
.
at
1
-
800
-
J
##AN
##SS
##EN
(
1
-
800
-
52
##6
-
77
##36
)
or
FDA
at
1
-
800
-
FDA
-
108
##8
or
www
.
f
##da
.
go
##v
/
me
##d
##watch
.
[SEP]
